Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
31900.0 | 2021-11-24 00:00:00 UTC | What To Expect From Medtronic's Q2? | ABT | https://www.nasdaq.com/articles/what-to-expect-from-medtronics-q2 | nan | nan | Medtronic stock (NYSE: MDT) is scheduled to report its fiscal second-quarter results on Tuesday, Nov 23. We expect Medtronic to likely post revenues and earnings largely in-line with the consensus estimates. The company is likely to benefit from an improved demand for medical devices with a rebound in the volume of elective surgeries, a trend seen with other medical device companies, as well. However, the rise of the delta variant, and its impact on overall healthcare services in some geographies, may impact the overall earnings growth.
Medtronic in its Q1earnings conference callstated that it is seeing a slowdown in total volume of procedures entering into Q2. That said, we expect the company to navigate well over the latest quarter led by economic recovery and rising demand for medical devices. Furthermore, Trefis’ forecast indicates that Medtronic’s valuation is $149 per share, which is 27% higher than the current market price of around $118, implying that the stock is undervalued, in our view. Our interactive dashboard analysis on Medtronic’s Pre-Earnings has additional details.
(1) Revenues expected to be in-line with the consensus estimate
Trefis estimates Medtronic’s Q2 fiscal 2022 total revenues to be around $8.0 billion, in-line with the consensus estimates. While medical devices sales were heavily impacted due to the Covid pandemic, the improved demand, with a rebound in volume of procedures, likely helped the company navigate well during the quarter. In Q1 fiscal 2022, the company reported a solid 23% y-o-y growth in revenue, led by a 29% growth in neuroscience as well as in medical surgical business, while cardiovascular segment sales were up 19%, and this trend could continue, albeit revenues growing at a slower pace given the impact of the delta variant on overall procedures volume. Our dashboard on Medtronic’s Revenues provides more details on segment-wise revenue breakup.
2) EPS likely to be in-line with the consensus estimates
Medtronic’s Q2 fiscal 2022 earnings per share (EPS) is expected to be $1.30 per Trefis analysis, in-line with the consensus estimate of $1.29. Medtronic’s Non-GAAP net income of $1.9 billion in Q1 fiscal 2022, reflected a sharp 2.3x growth from its $836 million profit in the prior year quarter, primarily due to growth in revenues as well as net margins expanding over 1000 bps, with operating expenses growing at a slower pace compared to the revenues. Looking at the full fiscal 2022, we expect a 30% y-o-y growth in EPS to $5.75, compared to $4.43 in fiscal 2021.
(3) Stock price estimate 27% above the current market price
Going by our Medtronic Valuation, with an EPS estimate of around $5.75 and P/E multiple of 26x in fiscal 2022, this translates into a price of $149, which is 27% above the current market price of around $118. In fact, at its current levels of $118, MDT stock is trading at 20x its forward full-year earnings, and this compares with levels of nearly 30x seen as recently as late 2020, implying that the stock has more room for growth.
Note: P/E Multiples are based on Share Price at the end of the year, and reported (or expected) Adjusted Earnings for the full year
While MDT stock looks like can gain, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Mettler vs Abbott.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Furthermore, Trefis’ forecast indicates that Medtronic’s valuation is $149 per share, which is 27% higher than the current market price of around $118, implying that the stock is undervalued, in our view. While medical devices sales were heavily impacted due to the Covid pandemic, the improved demand, with a rebound in volume of procedures, likely helped the company navigate well during the quarter. Medtronic’s Non-GAAP net income of $1.9 billion in Q1 fiscal 2022, reflected a sharp 2.3x growth from its $836 million profit in the prior year quarter, primarily due to growth in revenues as well as net margins expanding over 1000 bps, with operating expenses growing at a slower pace compared to the revenues. | (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q2 fiscal 2022 total revenues to be around $8.0 billion, in-line with the consensus estimates. 2) EPS likely to be in-line with the consensus estimates Medtronic’s Q2 fiscal 2022 earnings per share (EPS) is expected to be $1.30 per Trefis analysis, in-line with the consensus estimate of $1.29. (3) Stock price estimate 27% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.75 and P/E multiple of 26x in fiscal 2022, this translates into a price of $149, which is 27% above the current market price of around $118. | (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q2 fiscal 2022 total revenues to be around $8.0 billion, in-line with the consensus estimates. 2) EPS likely to be in-line with the consensus estimates Medtronic’s Q2 fiscal 2022 earnings per share (EPS) is expected to be $1.30 per Trefis analysis, in-line with the consensus estimate of $1.29. (3) Stock price estimate 27% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.75 and P/E multiple of 26x in fiscal 2022, this translates into a price of $149, which is 27% above the current market price of around $118. | (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q2 fiscal 2022 total revenues to be around $8.0 billion, in-line with the consensus estimates. In Q1 fiscal 2022, the company reported a solid 23% y-o-y growth in revenue, led by a 29% growth in neuroscience as well as in medical surgical business, while cardiovascular segment sales were up 19%, and this trend could continue, albeit revenues growing at a slower pace given the impact of the delta variant on overall procedures volume. (3) Stock price estimate 27% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.75 and P/E multiple of 26x in fiscal 2022, this translates into a price of $149, which is 27% above the current market price of around $118. |
31901.0 | 2021-11-23 00:00:00 UTC | 3 December Dividend Growers to Buy for 5.4% Yields, 40% Payout Growth | ABT | https://www.nasdaq.com/articles/3-december-dividend-growers-to-buy-for-5.4-yields-40-payout-growth | nan | nan | We've just hit the best time of the year to roll out one of our most potent dividend "hacks." Timed just right, it'll deliver us stout payouts yielding upwards of 5%--and growing triple-digits, too.
Best of all, we can "work" this proven dividend-growth system in just two quick steps, which we'll dive into now. Then I'll name three stocks you can buy today to give yourself a shot at "front running" double-digit payout hikes--and swift capital gains, too!
Step 1: Buy Just as a Dividend Hike Is Announced
We'll start by "timing" our buys just as dividend hikes are announced. That's a veteran move because a company's shares almost always rise with its payouts, and there's often a lag between the announcement of the hike and a rise in the stock.
You can see this set-your-watch-to-it pattern in shares of Texas Instruments (TXN), a holding of my Hidden Yields service that's delivered 138% price gains (and 168% total returns) since we bought it in June 2017.
You can see the pattern in action in the chart below, with a slight lag between when the dividend jumps and the stock price follows suit. That's our window to buy, just as first-level investors are catching on and bidding up the stock:
TXN's Dividend Telegraphs Its Next Price Move
This is Step 1 of our dividend-and-price-gain tango--buy shares of reliable dividend growers just before they announce hikes. And because management loves to reward investors near year-end, we have a raft of them to choose from--we'll look at three specific year-end dividend raisers below.
We're also perfectly set to profit here because we're entering three of the best months on the stock market.
According to 1950 to 2017 numbers from the Stock Trader's Almanac, November and December are the two best months for stock performance, with average gains of 1.5% and 1.6%, respectively. January is historically a strong month, too, with a 1% gain, tying it for fourth spot.
Step 2: Add a Low Payout Ratio for the Strongest Dividend (and Price) Gains
So we've got a predictable dividend-hike pattern and seasonality working in our favor. Next we want to look for a reasonable payout ratio, which is the percentage of free cash flow (FCF)--the best snapshot of the cash a company is generating that there is--that's absorbed by dividends. When it comes to dividend safety, I demand a ratio below 50%--and for maximum dividend growth, the lower, the better.
Now let's dive into three names that tick our boxes, with a strong likelihood of announcing big dividend hikes in December, plus the financial strength to double (or more!) their payouts in short order.
Abbott Dividends--and Shares--Set for a Second Big Pop
Medical device maker Abbott Laboratories (ABT) sent a message last December when it delivered the biggest payout hike in its history--a 25% boost that instantly bounced its stock to all-time highs last year:
December 10 Payout Raise Could Top Last Year's 25% Hike
Over the past five years, Abbott has inflated its dividend by 70%, driving the yield on a buy made then to 4.4% today, far higher than the 1.4% the stock yields now.
This year, you'll want to circle December 10 on your calendar, as it's the second Friday of the month--right when Abbott announced its double-digit hike last year. Because a second big boost is likely on the way.
I say that because the company posted solid third-quarter results, with total sales soaring 23.4% on double-digit gains across its divisions. The diagnostics business stole the show, thanks to healthy sales of its BinaxNow and Panbio at-home COVID-19 tests and its ID NOW COVID testing system for clinics and doctors' offices.
Even without COVID tests, sales still rose a healthy 11.7%. Free cash flow has also been soaring, another factor pacing the stock higher (and resulting in Abbott's extremely low FCF payout ratio of 33%):
FCF Powers the Share Price--and Our Dividends
Finally, don't be put off by Abbott's seemingly high P/E ratio of 31.9--it's actually a bargain in disguise! Last year at this time, the stock traded at a "nosebleed" 60-times trailing-12-month earnings and still delivered that big payout-driven pop we just saw. This year, with an even better valuation, I'm expecting more.
A Canadian Bank With a Pent-Up Payout Hike
Canada's banks are an untapped resource for many US investors, and I've always wondered why. For one, they tend to yield more than their American cousins--take Toronto Dominion Bank (TD), which yields 3.5% as I write this, compared to 2.4% for JPMorgan Chase & Co. (JPM) and a mere 1.6% for Wells Fargo (WFC).
TD is Canada's most "Americanized" bank, with roughly the same number of branches south of the border as in its own country (around 1,100 in the US, compared to 1,085 in Canada).
TD's Canadian and US businesses are also profiting both from higher trading volumes and strong loan originations. TD is also nicely positioned to profit on the gap between rising yields on the 10-year Treasury note (and in Canada the 5-year government bond), which dictates interest rates on loans it makes to customers, and near-zero overnight rates set by the Federal Reserve (and Bank of Canada), at which banks lend to each other.
The real catalyst is that TD and other Canadian banks have just been cleared by the Canadian government to resume dividend hikes as the worst of the COVID-19 crisis recedes. Given the bank's long dividend history (it's been paying dividends since 1857) and strong business performance, we can expect a hike to be announced any day--and it'll likely eclipse the 7% increase (in Canadian dollars) the bank last announced, pre-COVID.
Let's Gear Up for Our Progressive Special Payout
Our Hidden Yields members will know Progressive (PGR) well. The auto insurer uses a sneaky-smart strategy to discern, via an algorithm, if a new customer is worth insuring. If they're too risky, it tosses out a high quote, giving the company two ways to win: the customer either takes the quote or moves on to (and becomes a problem for!) one of its competitors.
The company applies the same strategy to its payout, yielding $0.10 per quarter, but paying the bulk of its dividend as a special payout that rolls out in early December (or thereabouts). Factor in last year's special payout and you get a hefty 5.4% trailing-12-month dividend yield. And with an FCF payout ratio of just 37%, Progressive has plenty of room to roll out another healthy "special" this year.
Finally, like TD, Progressive benefits from rising interest rates because it invests its "float" (or the premiums it collects) in safe interest-bearing securities, as claims will need to be paid out at some point.
Progressive's FCF Powers Its Payout
Finally, as you can see above, its cash flow has been growing strongly: FCF per share is up 242% over the past five years, and like dividend growth, is another strong driver of future share price increases.
These 23 Stocks Are Primed for Big Dividend Hikes (Starting Soon)
I'll give you my latest buy/sell/hold advice on Progressive and the other 22 dividend growers in my Hidden Yields portfolio when you take advantage of my special invitation to road test the service with no risk and no obligation!
Plenty of these stocks are on the verge of announcing their next big payout hike, and I don't want you to miss any of the action.
That's not all: I also want to give you my latest free investor report outlining the 7 dividend growers I've hand-picked to deliver you a steady 15%+ in gains and dividends a year, no matter what the market does.
These 7 dividend growers are especially critical to hold today, as their rising dividends keep your income stream ahead of inflation while powering their share prices higher, too!
Full details on all 7 are waiting for you now in your free investor report. Click here to get your copy, which includes their names, tickers, best-buy prices, current yields and complete dividend histories. And you'll get a chance to try Hidden Yields with no risk and no obligation, too!
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Dividends--and Shares--Set for a Second Big Pop Medical device maker Abbott Laboratories (ABT) sent a message last December when it delivered the biggest payout hike in its history--a 25% boost that instantly bounced its stock to all-time highs last year: December 10 Payout Raise Could Top Last Year's 25% Hike You can see this set-your-watch-to-it pattern in shares of Texas Instruments (TXN), a holding of my Hidden Yields service that's delivered 138% price gains (and 168% total returns) since we bought it in June 2017. Step 2: Add a Low Payout Ratio for the Strongest Dividend (and Price) Gains So we've got a predictable dividend-hike pattern and seasonality working in our favor. | Abbott Dividends--and Shares--Set for a Second Big Pop Medical device maker Abbott Laboratories (ABT) sent a message last December when it delivered the biggest payout hike in its history--a 25% boost that instantly bounced its stock to all-time highs last year: December 10 Payout Raise Could Top Last Year's 25% Hike Step 1: Buy Just as a Dividend Hike Is Announced We'll start by "timing" our buys just as dividend hikes are announced. You can see this set-your-watch-to-it pattern in shares of Texas Instruments (TXN), a holding of my Hidden Yields service that's delivered 138% price gains (and 168% total returns) since we bought it in June 2017. | Abbott Dividends--and Shares--Set for a Second Big Pop Medical device maker Abbott Laboratories (ABT) sent a message last December when it delivered the biggest payout hike in its history--a 25% boost that instantly bounced its stock to all-time highs last year: December 10 Payout Raise Could Top Last Year's 25% Hike Step 1: Buy Just as a Dividend Hike Is Announced We'll start by "timing" our buys just as dividend hikes are announced. These 23 Stocks Are Primed for Big Dividend Hikes (Starting Soon) I'll give you my latest buy/sell/hold advice on Progressive and the other 22 dividend growers in my Hidden Yields portfolio when you take advantage of my special invitation to road test the service with no risk and no obligation! | Abbott Dividends--and Shares--Set for a Second Big Pop Medical device maker Abbott Laboratories (ABT) sent a message last December when it delivered the biggest payout hike in its history--a 25% boost that instantly bounced its stock to all-time highs last year: December 10 Payout Raise Could Top Last Year's 25% Hike That's a veteran move because a company's shares almost always rise with its payouts, and there's often a lag between the announcement of the hike and a rise in the stock. Finally, as you can see above, its cash flow has been growing strongly: FCF per share is up 242% over the past five years, and like dividend growth, is another strong driver of future share price increases. |
31902.0 | 2021-11-18 00:00:00 UTC | 3 Reasons This Stock Could 10X in 10 Years | ABT | https://www.nasdaq.com/articles/3-reasons-this-stock-could-10x-in-10-years | nan | nan | The stock market has been on fire in the past year with the S&P 500 climbing more than 30%. And some stocks have actually performed a lot better. Case in point: shares of medical devices specialist DexCom (NASDAQ: DXCM) have soared by 86% in the trailing twelve-month period. That's a fantastic performance by any metric, but that could just be the beginning. There are excellent reasons to think DexCom could significantly outperform the market in the next decade. Here are three reasons why.
DXCM data by YCharts
1. A rapidly growing market
DexCom's goal is to improve the lives of diabetes patients. The company's flagship product is the G6 Continuous Glucose Monitoring (CGM) System. This device helps those with diabetes keep track of their blood glucose levels. CGM devices offer several advantages over the traditional method of measuring one's blood glucose levels. Key among them is that they don't require finger sticks that pierce the skin, so CGM devices are less painful.
Second, while finger sticks measure a patient's blood glucose level at a single point in time, CGM devices do so continuously. Hence the name. These nifty machines can automatically alert patients when they fall outside of their target glucose range thanks to the many measurements they make. DexCom's G6 records 288 per day -- or one every five minutes.
Third, CGMs lead to better outcomes for diabetes patients, including more time spent within their target glucose range and fewer hypoglycemic incidents, which happen when a patients' blood glucose level drops too low. It's no surprise then that there has been a sharp increase in the adoption of CGM devices among diabetes patients in recent years.
Image source: Getty Images.
Yet there remains a significant runway for growth in CGM use. In the U.S., DexCom believes there is less than 50% penetration among type 1 diabetes patients and less than 25% for type 2 diabetes patients. The U.S. is the worldwide leader in CGM adoption, which means the opportunity internationally is huge. And that's before factoring in the rapid increase in the number of diabetics over the past few decades, a trend that is expected to continue. In short, the opportunities for DexCom to grow its base of users are massive.
2. A solid market share
Naturally, DexCom isn't the only company looking to cash in on the CGM space. It competes with medical device giants such as Medtronic and Abbott Laboratories, among others. According to some estimates, the CGM market generated $4.7 billion in revenue in 2020. DexCom is unquestionably one of the leaders with an estimated 41% share of the total CGM market.
DexCom makes most of its money by selling its G6 CGM system along with its accessories (such as replaceable sensors). The rest of its revenue comes from previous versions of this device, such as the G4 and the G5. Last year, the company racked up $1.93 billion in revenue -- a 31% year-over-year increase -- and more than 90% of it came from sales of the G6 system.
The company is looking to maintain its solid position in this segment through innovation. The medical devices specialist is working on the G7, which it says will be smaller than its predecessor, among other upgrades.
3. Strong financial results
DexCom's results for the third quarter ended Sept. 30 were solid. Revenue jumped 30% year over year to $650.2 million while adjusted earnings per share (EPS) dropped to $0.89 from the adjusted EPS of $0.94 it recorded during the year-ago period, Still, that came out above the consensus analyst estimate of $0.64.
While a single quarter doesn't tell a whole lot about a company's general financial performances, DexCom's record speaks for itself. The company has generally recorded improving revenue, as the following graph shows. While the bottom line hasn't been as impressive as its top line, rising sales of the G6 over time should help improve earnings. DexCom's business model has, thus far, worked pretty well.
DXCM Revenue (Quarterly) data by YCharts
Should you pull the trigger?
Wall Street is currently not very bullish on DexCom. Its average price target of $636 implies a drop of a little over 2% from its current stock price of $651. Some analysts may feel that DexCom's shares have outpaced its intrinsic value in the past year -- with its stock having soared by more than 90% in the past 12 months -- and that it is likely to be volatile in the period ahead. Indeed, failure to meet sky-high expectations when it reports quarterly results could hit the company's shares hard. That's what happened when it released its first-quarter update.
The company's valuation is also through the roof with a price-to-earnings ratio of nearly 120, and so that is something else investors should consider. Further, DexCom will continue to compete with Medtronic, Abbott Laboratories, and others in this crowded space.
That said, I believe DexCom remains an attractive option. Lofty valuation metrics tend to be the norm for high-growth stocks and despite the competition, the company has managed to carve out a solid piece of this market for itself. Given how underpenetrated the CGM market is, there is enough space for multiple players.
In short, those focused on holding shares of great companies for the long-term should consider DexCom. The company's strong position in an industry ripe for growth, coupled with steadily improving revenue, makes it an excellent healthcare stock to add to your portfolio.
Find out why DexCom is one of the 10 best stocks to buy now
Our award-winning analyst team has spent more than a decade beating the market. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed their ten top stock picks for investors to buy right now. DexCom is on the list -- but there are nine others you may be overlooking.
Click here to get access to the full list!
*Stock Advisor returns as of November 10, 2021
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Case in point: shares of medical devices specialist DexCom (NASDAQ: DXCM) have soared by 86% in the trailing twelve-month period. Lofty valuation metrics tend to be the norm for high-growth stocks and despite the competition, the company has managed to carve out a solid piece of this market for itself. The company's strong position in an industry ripe for growth, coupled with steadily improving revenue, makes it an excellent healthcare stock to add to your portfolio. | Case in point: shares of medical devices specialist DexCom (NASDAQ: DXCM) have soared by 86% in the trailing twelve-month period. Second, while finger sticks measure a patient's blood glucose level at a single point in time, CGM devices do so continuously. While a single quarter doesn't tell a whole lot about a company's general financial performances, DexCom's record speaks for itself. | A solid market share Naturally, DexCom isn't the only company looking to cash in on the CGM space. DexCom is unquestionably one of the leaders with an estimated 41% share of the total CGM market. Some analysts may feel that DexCom's shares have outpaced its intrinsic value in the past year -- with its stock having soared by more than 90% in the past 12 months -- and that it is likely to be volatile in the period ahead. | Third, CGMs lead to better outcomes for diabetes patients, including more time spent within their target glucose range and fewer hypoglycemic incidents, which happen when a patients' blood glucose level drops too low. A solid market share Naturally, DexCom isn't the only company looking to cash in on the CGM space. While a single quarter doesn't tell a whole lot about a company's general financial performances, DexCom's record speaks for itself. |
31903.0 | 2021-11-18 00:00:00 UTC | Should You Be Adding Abbott Laboratories (NYSE:ABT) To Your Watchlist Today? | ABT | https://www.nasdaq.com/articles/should-you-be-adding-abbott-laboratories-nyse%3Aabt-to-your-watchlist-today | nan | nan | It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those businesses lose money. Unfortunately, high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson.
If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Abbott Laboratories (NYSE:ABT). Now, I'm not saying that the stock is necessarily undervalued today; but I can't shake an appreciation for the profitability of the business itself. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.
How Fast Is Abbott Laboratories Growing Its Earnings Per Share?
Over the last three years, Abbott Laboratories has grown earnings per share (EPS) like young bamboo after rain; fast, and from a low base. So I don't think the percent growth rate is particularly meaningful. Thus, it makes sense to focus on more recent growth rates, instead. Like the last firework on New Year's Eve accelerating into the sky, Abbott Laboratories's EPS shot from US$1.89 to US$4.08, over the last year. Year on year growth of 116% is certainly a sight to behold. The best case scenario? That the business has hit a true inflection point.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The good news is that Abbott Laboratories is growing revenues, and EBIT margins improved by 7.0 percentage points to 21%, over the last year. Ticking those two boxes is a good sign of growth, in my book.
You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image.
NYSE:ABT Earnings and Revenue History November 18th 2021
While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. So why not check this interactive chart depicting future EPS estimates, for Abbott Laboratories?
Are Abbott Laboratories Insiders Aligned With All Shareholders?
Since Abbott Laboratories has a market capitalization of US$231b, we wouldn't expect insiders to hold a large percentage of shares. But we do take comfort from the fact that they are investors in the company. Notably, they have an enormous stake in the company, worth US$1.7b. I would find that kind of skin in the game quite encouraging, if I owned shares, since it would ensure that the leaders of the company would also experience my success, or failure, with the stock.
Should You Add Abbott Laboratories To Your Watchlist?
Abbott Laboratories's earnings have taken off like any random crypto-currency did, back in 2017. That sort of growth is nothing short of eye-catching, and the large investment held by insiders certainly brightens my view of the company. At times fast EPS growth is a sign the business has reached an inflection point; and I do like those. So to my mind Abbott Laboratories is worth putting on your watchlist; after all, shareholders do well when the market underestimates fast growing companies. Even so, be aware that Abbott Laboratories is showing 2 warning signs in our investment analysis , you should know about...
Although Abbott Laboratories certainly looks good to me, I would like it more if insiders were buying up shares. If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NYSE:ABT Earnings and Revenue History November 18th 2021 While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Abbott Laboratories (NYSE:ABT). Over the last three years, Abbott Laboratories has grown earnings per share (EPS) like young bamboo after rain; fast, and from a low base. | If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Abbott Laboratories (NYSE:ABT). NYSE:ABT Earnings and Revenue History November 18th 2021 While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. The good news is that Abbott Laboratories is growing revenues, and EBIT margins improved by 7.0 percentage points to 21%, over the last year. | If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Abbott Laboratories (NYSE:ABT). NYSE:ABT Earnings and Revenue History November 18th 2021 While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. Over the last three years, Abbott Laboratories has grown earnings per share (EPS) like young bamboo after rain; fast, and from a low base. | If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Abbott Laboratories (NYSE:ABT). NYSE:ABT Earnings and Revenue History November 18th 2021 While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those businesses lose money. |
31904.0 | 2021-11-17 00:00:00 UTC | This Pharma Stock Appears To Be A Better Pick Over Abbott Labs | ABT | https://www.nasdaq.com/articles/this-pharma-stock-appears-to-be-a-better-pick-over-abbott-labs | nan | nan | We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock. Although both the companies saw a rise in revenue over the last year or so, with Covid-19 testing driving Abbott’s sales and market share gains for some of Eli Lilly’s drugs, including diabetes drug Trulicity, as well as its Covid-19 treatment, aiding its top-line expansion. ABT stock has been weighed down over the recent months owing to the rising vaccination rate, and subsequent decline anticipated for its Covid-19 related business.
For perspective, ABT stock is up just 10% over the last six months, underperforming the broader indices, with the S&P500 rising 12% over the same period. This compares with a 32% rise for LLY stock, partly aided by hopes for regulatory approval for its Alzheimer’s treatment – Donanemab – which, if approved, will be a multi-billion dollar opportunity for Eli Lilly. However, there is more to the comparison. Let’s step back to look at the fuller picture of the relative valuation of the two companies by looking at historical revenue growth as well as operating margin growth. Our dashboard Abbott vs Eli Lilly: Similar Market Cap; Which Stock Is A Better Bet? has more details on this. Parts of the analysis are summarized below.
1. Abbott’s Revenue Growth Has Been Stronger
Now, Abbott’s revenue grew at a faster pace of 28% compared to 16% for Eli Lilly during the last twelve month period, primarily driven by a very high demand for Covid-19 testing. If we were to look at the last three years, Abbott’s revenue grew at a CAGR of 8% slightly above the CAGR of 7% for Eli Lilly. Abbott’s revenue is expected to rise 22% in 2021, but decline in mid-single-digits next year, as the demand for Covid-19 testing declines gradually. However, Abbott’s other businesses, including Medical Devices, should pick up pace with economies opening up gradually. Our Abbott Revenue Comparison dashboard provides more insight on the company’s revenues and its comparison to that of its peers. Eli Lilly’s revenue is expected to rise 11% in 2021 and rise in low single-digits next year, aided by continued market share gains for drugs, such as Trulicty, Verzenio, Olumiant, and Bamlanivima, as well as its Covid-19 treatment. The company recently announced that it will supply another 614,000 doses of its Covid-19 cocktail (a combination of bamlanivimab and etesevimab) to the U.S. government for a total of $1.3 billion, bolstering its top-line growth over the coming quarters.
2. Eli Lilly Has Seen Better Margin Growth
Looking at profitability, unlike the trend seen in revenue growth, Eli Lilly’s operating margin of 21.6% over the last twelve month period is better than the 18.5% for Abbott. Even if we were to look at last three year average operating margin, Eli Lilly’s 20.8% figure is much better than 13.6% for Abbott. Eli Lilly’s operating margin of 21.6% over the last twelve month period compares with 21.8% in 2019, before the pandemic. The current operating margin of 18.5% for Abbott is lower compared to Eli Lilly, but it is better compared to the 14.0% figure in 2019. We expect margins for both companies to face some headwinds in the near term, given the inflationary pressure and supply chain constraints.
The Net of It All
Now that over half of the U.S. population is fully vaccinated against Covid-19, with overall economic activity picking up, the demand for Covid-19 testing is likely to slow going forward (compared to the surge seen over the last year or so), impacting the revenue growth for Abbott. However, with economic growth the demand for pharmaceuticals, as well as medical devices, is likely to rise.
Abbott’s current valuation is seemingly more attractive than that of Eli Lilly, with ABT stock trading at about 5.5x trailing revenues, versus 9.5x for LLY stock, and Abbott has also seen better revenue growth. However, Eli Lilly is much more profitable, partly explaining the difference in valuation of the two companies. Even if we were to look at financial risk, while Abbott’s 12% cash as percentage of assets is higher than 7% for Eli Lilly, Abbott’s 8% debt as a percentage of its equity is higher than the 7% figure for Eli Lilly, implying that Eli Lilly has a better debt position, while Abbott has a better cash cushion. This means that LLY stock does not appear to be at a higher financial risk compared to ABT stock.
Overall, with superior margins for Eli Lilly, and vast potential for Donanemab, with its peak sales estimated to top $10 billion (if approved), we think this gap in valuation between ABT and LLY is justified and LLY may continue to outperform ABT stock, going forward. In fact, going by our Abbott Valuation of $140 per share, there is an upside potential of only 9% from the current levels of around $128. On the other hand, if Donanemab is approved, LLY stock can see much higher levels from its current price of $258. That said, investors should weigh in the fact that Donanemab is not yet approved by any regulator. Eli Lilly has recently begun the process to get regulatory approval for its Alzheimer’s treatment. While its late stage clinical study data will be available only in 2023, the FDA will consider the accelerated approval application sometime in 2022.
While LLY stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Abbott vs. Vertex.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT stock has been weighed down over the recent months owing to the rising vaccination rate, and subsequent decline anticipated for its Covid-19 related business. We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock. | We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. Abbott’s current valuation is seemingly more attractive than that of Eli Lilly, with ABT stock trading at about 5.5x trailing revenues, versus 9.5x for LLY stock, and Abbott has also seen better revenue growth. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock. | We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. Abbott’s current valuation is seemingly more attractive than that of Eli Lilly, with ABT stock trading at about 5.5x trailing revenues, versus 9.5x for LLY stock, and Abbott has also seen better revenue growth. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock. | Abbott’s current valuation is seemingly more attractive than that of Eli Lilly, with ABT stock trading at about 5.5x trailing revenues, versus 9.5x for LLY stock, and Abbott has also seen better revenue growth. We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock. |
31905.0 | 2021-11-17 00:00:00 UTC | 1 Dividend Stock to Help You Fight Inflation | ABT | https://www.nasdaq.com/articles/1-dividend-stock-to-help-you-fight-inflation | nan | nan | Inflation is a problem in the U.S. The Consumer Price Index, a measure of the change in prices for some common goods and services, rose by 6.2% in the 12-month period ending Oct. 31. That's well above the U.S. Federal Reserve's long-term inflation target of 2%. Inflation chips away at our purchasing power, and that's why focusing solely on holding cash is not the best strategy. Investing in solid dividend-paying stocks can help counter the effects of inflation.
While partaking in the stock market has historically been one of the best ways to grow the average person's capital, dividend stocks take this to a whole new level. Here's one way of seeing this: In the past 10 years, the S&P 500 rose by 270.5%. The index's total return, which assumes that dividends are reinvested, was 352.9% over the same period. There are plenty of excellent dividend stocks on the market; one great option to consider is pharma giant AbbVie (NYSE: ABBV). Let's see why this drugmaker could be an excellent addition to your portfolio.
ABBV data by YCharts.
Looking at AbbVie's dividend record
AbbVie made its debut on the stock market in January 2013 when it split from its former parent company, Abbott Laboratories. Considering the time it spent under the wing of Abbott, AbbVie is a Dividend Aristocrat, having seen its payouts rise annually for 49 years in a row. Since 2013, the company's dividends have increased by 252.5%. That's an excellent record. The company currently offers a yield of 4.5%, much higher than the S&P 500's yield of 1.3%.
Furthermore, the company's current cash payout ratio of 41.7% is pretty conservative. AbbVie seems to have the means to sustain more dividend increases. The drugmaker will likely join the exclusive group of Dividend Kings next year, companies in the S&P 500 that have raised their payouts each year for 50 consecutive years. That makes it a solid option for income-oriented investors, provided, of course, it can continue posting solid financial results.
A strong business
AbbVie's shares significantly outperformed the broader market between 2013 and 2018, but things have been very different since. One of the reasons behind the drugmaker's lackluster showing in the past few years has been the loss of patent exclusivity of Humira in Europe in 2018. Sales of this rheumatoid arthritis medicine have been declining in international markets for the better part of the last three years. Also, given that the company expects biosimilar competition for Humira to enter the U.S. market in 2023, things don't look great on this front.
Image source: Getty Images.
Fortunately, AbbVie has the means to continue performing well for many years to come despite this problem. Several of the company's other drugs are performing exceptionally well. For instance, sales of the cancer medicine Venclexta came in at $492 million during the third quarter (ending Sept. 30), 40.1% higher than the year-ago period.
Revenue from Skyrizi, an immunosuppressant, was $796 million, an 83.3% year-over-year increase; sales of Rinvoq, another immunosuppressant, more than doubled year over year to $453 million. It is worth noting that Rinvoq could encounter some headwinds. It is part of a class of drugs known as JAK inhibitors, which have recently attracted the attention of health industry regulators.
In September, the Food and Drug Administration started requiring JAK inhibitors to come with a warning of an increased risk of cancer and cardiovascular events. The agency made that decision after a post-marketing study found that Xeljanz, a JAK inhibitor marketed by Pfizer, carried these risks. Despite this major caveat, AbbVie management expects Rinvoq to be a key growth driver for the company.
Then there was the company's decision to acquire Allergan back in May of 2020, in a cash and stock transaction valued at $63 billion. Thanks to this deal, the company got its hands on several exciting products, most notably Allergan's Botox franchise. In the third quarter, sales of Botox Cosmetics grew by 38.5% year over year to $545 million, while sales of Botox Therapeutics jumped by 23.4% year over year to $645 million. AbbVie's total revenue for the quarter was $14.3 billion, an 11.2% year-over-year increase.
One of the reasons AbbVie decided to acquire Allergan and its Botox franchise is that the company believes it would be extremely difficult to create a biosimilar version of Botox. This product will continue to contribute meaningfully to the company's performance. And given AbbVie's rich pipeline -- with 21 phase 3 studies and many more early-stage clinical trials -- the company is well-positioned to add more products to replace Humira.
AbbVie is here to stay
An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding dividend-paying stock to help you smooth out the harmful effects of inflation. And there's one more reason to pull the trigger right now. With a forward price-to-earnings (P/E) ratio of just 9.2 (compared to the pharma industry's overall forward P/E of 13.9 as of Nov. 10), AbbVie is attractively valued. At current levels, this pharma giant looks like a screaming buy.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 10, 2021
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In September, the Food and Drug Administration started requiring JAK inhibitors to come with a warning of an increased risk of cancer and cardiovascular events. And given AbbVie's rich pipeline -- with 21 phase 3 studies and many more early-stage clinical trials -- the company is well-positioned to add more products to replace Humira. AbbVie is here to stay An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding dividend-paying stock to help you smooth out the harmful effects of inflation. | There are plenty of excellent dividend stocks on the market; one great option to consider is pharma giant AbbVie (NYSE: ABBV). Revenue from Skyrizi, an immunosuppressant, was $796 million, an 83.3% year-over-year increase; sales of Rinvoq, another immunosuppressant, more than doubled year over year to $453 million. In the third quarter, sales of Botox Cosmetics grew by 38.5% year over year to $545 million, while sales of Botox Therapeutics jumped by 23.4% year over year to $645 million. | Looking at AbbVie's dividend record AbbVie made its debut on the stock market in January 2013 when it split from its former parent company, Abbott Laboratories. In the third quarter, sales of Botox Cosmetics grew by 38.5% year over year to $545 million, while sales of Botox Therapeutics jumped by 23.4% year over year to $645 million. AbbVie is here to stay An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding dividend-paying stock to help you smooth out the harmful effects of inflation. | Inflation is a problem in the U.S. There are plenty of excellent dividend stocks on the market; one great option to consider is pharma giant AbbVie (NYSE: ABBV). The drugmaker will likely join the exclusive group of Dividend Kings next year, companies in the S&P 500 that have raised their payouts each year for 50 consecutive years. |
31906.0 | 2021-11-17 00:00:00 UTC | Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows | ABT | https://www.nasdaq.com/articles/will-investors-win-with-johnson-johnsons-planned-spinoff-heres-what-history-shows | nan | nan | The biggest healthcare company in the world is preparing to shrink. Johnson & Johnson (NYSE: JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly traded entity.
J&J said that this move will unlock shareholder value and accelerate growth. But will investors really win with the planned spinoff? Here's what history shows.
Image source: Getty Images.
Three other spinoffs
Pfizer (NYSE: PFE) and GlaxoSmithKline established a joint venture for their consumer health units. However, the business won't spin off until next year so we don't know how the move will impact the companies. We can look at how a couple of Pfizer's other spinoffs have fared, though.
In February 2013, Pfizer spun off its animal health business, creating Zoetis (NYSE: ZTS). That transaction turned out to be tremendously successful for Pfizer shareholders who held onto their Zoetis stock. The animal health company went on to trounce the S&P 500. On the other hand, Pfizer lagged well behind the index.
ZTS data by YCharts
Zoetis was already delivering strong growth, though. J&J's consumer health unit isn't such a great growth driver. Perhaps a better comparison is Pfizer's spinoff and merger in November of last year of its biosimilars and generics business with Mylan to form Viatris (NASDAQ: VTRS). How has that deal rewarded investors? It's a much different story than the Zoetis spinoff.
PFE data by YCharts
In this case, the slower-growth Viatris has languished. Meanwhile, Pfizer has been on a tear thanks to success for its COVID-19 vaccine and tremendous potential for its experimental COVID-19 pill.
A third recent spinoff could also be instructive. Merck (NYSE: MRK) completed the divestiture of its women's health business in June, creating Organon (NYSE: OGN). Neither of the stocks has kept pace with the S&P 500 since.
MRK data by YCharts
The gold standard
We can't leave out what arguably deserves to be called the gold standard of spinoffs. In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). Abbott retained the established pharmaceuticals, diagnostics, medical devices, and nutrition businesses. AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star.
Shareholders were huge winners from this transaction. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years.
ABT data by YCharts
Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. Importantly, both Abbott and AbbVie have kept their streaks of dividend hikes going. Income investors who held onto their shares of both stocks have done very well.
Lessons from the past
Can we really learn anything from history about how Johnson & Johnson shareholders might fare with the spinoff of the consumer healthcare business? I think so.
Perhaps most importantly, a faster-growing business is likely to experience accelerated momentum after the spinoff of a slower-growing business. That's what happened with Zoetis, with Pfizer after the Viatris transaction, and to a lesser extent with Merck after spinning off Organon.
However, we can also see from the past that things don't always turn out as expected. For example, Some might have predicted that AbbVie would be the stronger performer after the separation. But Abbott's innovation has paid off in a huge way with products including FreeStyle Libre continuous glucose monitoring system and its BinaxNOW COVID-19 tests serving as key growth drivers.
In addition, companies that prioritized their dividends before a spinoff continued to do so afterward. Abbott and AbbVie are great examples of this. So is Pfizer. The big drugmaker still has an attractive dividend even after spinning off Zoetis and Viatris.
Of course, there are limits to how much we can extrapolate from past spinoffs and apply to Johnson & Johnson. The healthcare giant's deal won't be exactly like any of the transactions made by other companies in previous years.
But my prediction is that Johnson & Johnson shareholders will enjoy stronger growth once the consumer unit is a stand-alone entity. I also think that investors who have come to depend on J&J's dividend won't have any worries. This is definitely a surprising move by Johnson & Johnson, but it's one that I expect will pay off over the long term.
10 stocks we like better than Johnson & Johnson
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 10, 2021
Keith Speights owns shares of AbbVie, Pfizer, and Viatris. The Motley Fool owns shares of and recommends Zoetis. The Motley Fool recommends GlaxoSmithKline, Johnson & Johnson, and Viatris. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). ABT data by YCharts Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. Three other spinoffs Pfizer (NYSE: PFE) and GlaxoSmithKline established a joint venture for their consumer health units. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). ABT data by YCharts Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. In February 2013, Pfizer spun off its animal health business, creating Zoetis (NYSE: ZTS). | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). ABT data by YCharts Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. Johnson & Johnson (NYSE: JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly traded entity. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). ABT data by YCharts Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. That transaction turned out to be tremendously successful for Pfizer shareholders who held onto their Zoetis stock. |
31907.0 | 2021-11-16 00:00:00 UTC | Notable ETF Inflow Detected - VTI, XOM, PFE, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-vti-xom-pfe-abt | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.6 billion dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 1,183,922,203 to 1,194,563,534). Among the largest underlying components of VTI, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 0.6%, Pfizer Inc (Symbol: PFE) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average:
Looking at the chart above, VTI's low point in its 52 week range is $182.21 per share, with $243.56 as the 52 week high point — that compares with a last trade of $241.97. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 7%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTI, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 0.6%, Pfizer Inc (Symbol: PFE) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $182.21 per share, with $243.56 as the 52 week high point — that compares with a last trade of $241.97. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTI, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 0.6%, Pfizer Inc (Symbol: PFE) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $182.21 per share, with $243.56 as the 52 week high point — that compares with a last trade of $241.97. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of VTI, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 0.6%, Pfizer Inc (Symbol: PFE) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.6 billion dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 1,183,922,203 to 1,194,563,534). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $182.21 per share, with $243.56 as the 52 week high point — that compares with a last trade of $241.97. | Among the largest underlying components of VTI, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 0.6%, Pfizer Inc (Symbol: PFE) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.6 billion dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 1,183,922,203 to 1,194,563,534). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $182.21 per share, with $243.56 as the 52 week high point — that compares with a last trade of $241.97. |
31908.0 | 2021-11-12 00:00:00 UTC | Abbott's New Leadless Pacemaker System Meets Main Goal In Pivotal Trial | ABT | https://www.nasdaq.com/articles/abbotts-new-leadless-pacemaker-system-meets-main-goal-in-pivotal-trial-2021-11-12 | nan | nan | (RTTNews) - Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial.
The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms.
Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. The leadless pacemaker is currently being evaluated for the FDA approval.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial. The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms. Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. | (RTTNews) - Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial. The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms. Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. | (RTTNews) - Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial. The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms. Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. | (RTTNews) - Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial. The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms. Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed. |
31909.0 | 2021-11-11 00:00:00 UTC | 2 Dividend Aristocrats That Could Announce Generous Rate Hikes in December | ABT | https://www.nasdaq.com/articles/2-dividend-aristocrats-that-could-announce-generous-rate-hikes-in-december | nan | nan | Dividend increases aren't a guarantee. But for companies that have strong track records for making them, they're a safe bet to continue unless something goes disastrously wrong. And if a company continued raising dividends during the pandemic, that's a great sign that it can withstand significant adversity.
Both Abbott Laboratories (NYSE: ABT) and Enbridge (NYSE: ENB) raised their payouts last year and have done so for decades. And with the companies still doing well this year, investors should expect another round of rate hikes as early as next month.
Image source: Getty Images.
1. Abbott Laboratories
It was December 2020 when healthcare giant Abbott Labs last announced a rate hike. It was the 49th year in a row the company increased its payouts. It's not uncommon for a company with that long of a streak to make a modest 1% increase, just to keep the increases going. But Abbott Labs chose to reward its investors significantly, with a rate hike of 25%.
Although investors should never assume a rate is a guarantee, it's nearly that with Abbott Labs. One more increase to the dividend would make the company a Dividend King, solidifying its presence as one of the top dividend stocks in the world. And there are certainly no signs of danger for the business; Abbott Labs reported its third-quarter numbers in October, and sales of $10.9 billion for the period ending Sept. 30 were up 23.4% year over year. Although it benefited from COVID-19 testing volumes, even without that boost its sales grew by 11.7% when compared to its pre-pandemic numbers in 2019 for the same quarter.
Currently, the healthcare stock pays a yield of 1.4%, which is right around the S&P 500 average. But if you buy and hold shares of Abbott Labs, you're likely to be earning more on your investment over time as the dividend hikes boost your recurring income. Although I wouldn't suggest another 25% rate hike is coming next month, it would be surprising not to see another double-digit increase from the company.
2. Enbridge
Pipeline company Enbridge doesn't have nearly as long of a streak going as Abbott Labs has. But the oil and gas stock is no slouch, either. Last December, Enbridge increased its dividend for the 26th straight year, when it raised its payouts by 3%. On average, the Dividend Aristocrat has been increasing its recurring payments by a compound annual growth rate of 10%.
And now, with the oil and gas industry in better shape due to stronger demand for oil -- as is suggested with oil prices reaching multi-year highs -- that's led to better results all around. In the industry, companies use distributable cash flow (DCF) to assess their performance, which excludes non-operating items and can help assess whether a dividend is safe or not. For the period ending Sept. 30, Enbridge's DCF of 2.3 billion Canadian dollars was up 10% from the prior-year period. For the full year, it expects DCF per share to be between CA$4.70 and CA$5.
How big the company's rate hike is next month will likely depend on where within that range Enbridge believes it will finish the year. Enbridge targets a payout ratio that's no more than 70% of DCF. At CA$4.70, that would put its current annual dividend of CA$3.34 at just outside that range at 71%. However, if it finishes at CA$5, then the payout ratio will be slightly under 67%. In all likelihood, Enbridge will raise its payouts again, it's just a matter of how much they'll be. Given the strong demand for oil right now, I wouldn't be surprised if it's a higher rate hike than a year ago. And that makes its already high yield of 6.2% look even more attractive for income investors.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 10, 2021
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Enbridge. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Both Abbott Laboratories (NYSE: ABT) and Enbridge (NYSE: ENB) raised their payouts last year and have done so for decades. But if you buy and hold shares of Abbott Labs, you're likely to be earning more on your investment over time as the dividend hikes boost your recurring income. On average, the Dividend Aristocrat has been increasing its recurring payments by a compound annual growth rate of 10%. | Both Abbott Laboratories (NYSE: ABT) and Enbridge (NYSE: ENB) raised their payouts last year and have done so for decades. Abbott Laboratories It was December 2020 when healthcare giant Abbott Labs last announced a rate hike. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | Both Abbott Laboratories (NYSE: ABT) and Enbridge (NYSE: ENB) raised their payouts last year and have done so for decades. One more increase to the dividend would make the company a Dividend King, solidifying its presence as one of the top dividend stocks in the world. Enbridge Pipeline company Enbridge doesn't have nearly as long of a streak going as Abbott Labs has. | Both Abbott Laboratories (NYSE: ABT) and Enbridge (NYSE: ENB) raised their payouts last year and have done so for decades. It was the 49th year in a row the company increased its payouts. Enbridge Pipeline company Enbridge doesn't have nearly as long of a streak going as Abbott Labs has. |
31910.0 | 2021-11-08 00:00:00 UTC | IWB, ACN, PEP, ABT: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/iwb-acn-pep-abt%3A-etf-outflow-alert | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $856.3 million dollar outflow -- that's a 2.6% decrease week over week (from 123,450,000 to 120,200,000). Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.1%, PepsiCo Inc (Symbol: PEP) is off about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $196 per share, with $264.87 as the 52 week high point — that compares with a last trade of $264.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 7%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.1%, PepsiCo Inc (Symbol: PEP) is off about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $196 per share, with $264.87 as the 52 week high point — that compares with a last trade of $264.14. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.1%, PepsiCo Inc (Symbol: PEP) is off about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $196 per share, with $264.87 as the 52 week high point — that compares with a last trade of $264.14. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.1%, PepsiCo Inc (Symbol: PEP) is off about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $856.3 million dollar outflow -- that's a 2.6% decrease week over week (from 123,450,000 to 120,200,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $196 per share, with $264.87 as the 52 week high point — that compares with a last trade of $264.14. | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.1%, PepsiCo Inc (Symbol: PEP) is off about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $856.3 million dollar outflow -- that's a 2.6% decrease week over week (from 123,450,000 to 120,200,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $196 per share, with $264.87 as the 52 week high point — that compares with a last trade of $264.14. |
31911.0 | 2021-11-05 00:00:00 UTC | 10 S&P 500 Stocks to Buy After Winning in Q3 | ABT | https://www.nasdaq.com/articles/10-sp-500-stocks-to-buy-after-winning-in-q3-2021-11-05 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It has been an excellent third-quarter earnings season so far. Of the S&P 500 stocks that have reported earnings, a majority have beaten analyst estimates.
According to Factset Insight, 56% of the index companies have reported earnings so far in Q3 2021. Of those, 82% beat the consensus earnings per share (EPS). That’s higher than the five-year average of 76%. Further, not only are more companies beating estimates, but they’re also beating them by a wider margin. The five-year average beat is 8.4%. This year, it’s 190 basis points higher.
Which sectors are delivering the goods?
Real Estate is doing the best, with 93% of the companies reporting estimate beats. The next best is a tie between Communication Services and Healthcare at 91%. Finally, in the third spot, Financials have beaten estimates 88% of the time.
7 European Stocks to Buy to Diversify Your Portfolio
Who will be the winners in Q4 2021 and beyond? Here are the 10 S&P 500 stocks I believe will continue to beat the pros.
Abbott Laboratories (NYSE:ABT)
Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL)
Chevron (NYSE:CVX)
Delta Air Lines (NYSE:DAL)
Ford (NYSE:F)
Intel (NASDAQ:INTC)
MGM Resorts (NYSE:MGM)
Pfizer (NYSE:PFE)
SVB Financial (NASDAQ:SIVB)
Thomson Reuters (NYSE:TRI)
S&P 500 Stocks to Buy: Abbott Laboratories (ABT)
ABT) sign with lighting behind letters" width="300" height="169">
Source: testing / Shutterstock.com
First up on this list of S&P 500 stocks is Abbott Laboratories. If you were looking for bad news from Abbott’s Q3 2021 earnings report, you most likely didn’t find any. Instead, it was a flawless period with a 14% beat on revenue and a 49% beat on earnings.
Compared to last the year, the company’s revenues of $10.9 billion were 23.4% higher year-over-year (YOY). On the bottom line, it grew earnings per share 42.9% YOY to $1.40.
Covid-19 remains a moneymaker for the company. Its Covid-19 tests accounted for $1.9 billion or 20% of its overall sales. In addition, sales from all its segments grew by double digits during Q3.
Lastly, this company expects earnings in 2021 to be $5.05 per share at the midpoint of its guidance. That’s up from the previous guidance of $4.40 at the midpoint. That’s 32 times its 2021 earnings. Based on past valuations, this is a pretty reasonable figure for ABT stock.
Alphabet (GOOG)
Source: achinthamb / Shutterstock.com
Next up on this list of S&P 500 stocks to buy is Alphabet. Since the company reported Q3 results on Oct. 26, GOOG stock is up 8%. But given how it performed in the third quarter, you would have thought this would have been more.
On the bottom line, Alphabet reported earnings of $18.94 billion or $27.99 per share. There are a number of S&P 500 comanpies with share prices less than $27.99. But I digress. Alphabet’s EPS beat the consensus by some 18%. In terms of revenue, this company also delivered $65.1 billion on the top line, 41% higher YOY and 2.5% higher than analyst estimates.
A standout in the quarter was Google Cloud, which saw revenue increase 45% to $4.99 billion. That’s $20 billion on an annualized basis, but still remains a small part of the overall business. That said, as Alphabet seeks to grab a big chunk of business related to artificial intelligence (AI), more quarters like this will surely help it succeed.
7 Dividend Aristocrat Stocks That Should Grace Your Portfolio
Back in late 2016, I argued three reasons why GOOG stock was a must-own. Up about 280% since then, I bet there are at least six reasons the stock is a must-own now.
S&P 500 Stocks to Buy: Chevron (CVX)
Source: Denis Kuvaev / Shutterstock.com
To be an oil and gas company right now and not beat analyst estimates would have to be downright embarrassing. According to Factset Insight, up to Oct. 29, the energy sector S&P 500 stocks had reported $23.6 billion in earnings. That compares to a loss of $1.5 billion in Q3 2020.
Even though I’m not a fan of oil companies like Chevron, I also included CVX stock on a list of mega-cap stocks offering outsized returns back in February. Mainly, I felt that the company’s commitment to renewable energy to offset its carbon emissions was a responsible way to handle the transition away from fossil fuels.
It also didn’t hurt that its debt-to-EBITDA was one-third of Exxon Mobil’s (NYSE:XOM). Today, the stock is up 36% year-to-date (YTD) compared to 58% for XOM stock.
Moving forward, I expect the 34% earnings beat ($2.96 vs. $2.21 estimate) and 10% sales beat ($44.71 billion vs. $40.52 billion estimate) ought to help even the score for this pick of the S&P 500 stocks in Q4 and beyond.
Delta Air Lines (DAL)
DAL) plane flying through the clouds" width="300" height="169">
Source: NextNewMedia / Shutterstock.com
Next up on this list of S&P 500 stocks is DAL stock. Back in July 2020, I suggested that Delta shareholders would benefit long-term from the strong leadership of CEO Ed Bastian.
For one, I admired Bastian for keeping middle seats unoccupied while other airlines were stuffing their flights full of people. Sure, there was plenty of data suggesting — occupied or not occupied — the middle seat wasn’t a game-changer when it came to passenger safety from Covid-19. However, this decision did send a signal to travelers that Delta was serious about passenger health. Eventually, that would be rewarded with a higher share price. The stock is up 69% since that article.
Delta reported Q3 2021 results in mid-October. Revenue, earnings per share and load factor — the number of seats available filled with passengers — were all better than analyst expectations.
On the top line, revenues beat by $800 million or roughly 10%. Earnings per share beat by 5 cents or 20% as well. Finally, Delta’s load factor was 80%, 230 basis points higher than the consensus.
7 Best Tech Stocks to Buy for Q4 Earnings Season
Maybe most importantly, though, Q3 marked the airline’s “first quarterly profit since the start of the pandemic.” I am now looking for DAL stock to test $60 in 2022.
S&P 500 Stocks to Buy: Ford (F)
Source: JuliusKielaitis / Shutterstock.com
When CEO Jim Farley was hired at Ford back in August 2020, I wondered what took Executive Chairman Bill Ford so long. I wrote the following back in September 2020:
“In early March [2020], I stated that patient investors would be rewarded […] Now that Hackett’s moving aside, I hope for long-suffering shareholders that this COO promotion turns out better than the last one.”
It seems it has.
Ford reported Q3 2021 earnings on Oct. 27 — and they were off-the-charts good. For example, the company’s EPS of 51 cents was almost double analyst expectations. In addition, automotive revenue was $670 million higher than the consensus at $33.21 billion.
More importantly, though, Ford is going full-tilt on the electrification of its fleet. Initiatives include boosting production for the F-150 Lightning electric pickup to 80,000 yearly and spending more than $15 billion between now and 2025 on battery-electric vehicles (BEVs).
All in all, F stock is another solid pick on this list of S&P 500 stocks. I’d say CEO Jim Farley is doing his best to keep pace with General Motors (NYSE:GM) CEO Mary Barra.
Ford is back.
Intel (INTC)
Source: Kate Krav-Rude / Shutterstock.com
Next up on this list of S&P 500 stocks is INTC stock. Unfortunately, despite releasing good earnings in late October, Intel shares still fell on the news.
This chipmaker reported Q3 2021 results on Oct. 21. For starters, the EPS of $1.71 was 60 cents or 54% better than analyst expectations. However, because the company reported revenue that was $100 million less than the consensus of $18.2 billion, shares fell in after-hours trading.
While INTC has made back some of the post-earnings declines, the stock is still relatively flat for the year. By comparison, Nvidia (NASDAQ:NVDA) is up 133% YTD.
At this point, it doesn’t matter how enthusiastic CEO Pat Gelsinger is about the company’s plans for the future. Investors just don’t seem to be buying what Intel is selling. Gelsinger stated the following in the Q3 press release:
“We are still in the early stages of our journey, but I see the enormous opportunity ahead, and I couldn’t be prouder of the progress we are making towards that opportunity.”
I mean, the company even raised its 2021 EPS guidance to $5.28 per share. In 2022, it expects $74 billion in revenue, $900 million higher than analyst estimates according to Barron’s.
7 A-Rated Healthcare Stocks to Buy for the Long Haul
Intel remains an interesting play if you are a value investor, but there’s no question Nvidia is the better company.
S&P 500 Stocks to Buy: MGM Resorts (MGM)
Source: Jason Patrick Ross / Shutterstock.com
MGM Resorts reported a Q3 results beat on both the top and bottom line. For starters, the casino operator generated revenues of $2.71 billion during the quarter, about $240 million higher than the consensus estimate of $2.47 billion. Furthermore, its EPS in the quarter was 3 cents, 7 cents better than the 4 cent loss expected by analysts.
On top of this, revenues in China jumped 517% YOY to $289 million, while domestic operations saw sales climb by 187% YOY to $1.4 billion during the quarter. Essentially, the business on both sides of the Pacific continues to rebound to pre-pandemic numbers.
Of the major sports-betting stocks, MGM also appears to have had the best October, gaining 5.1%. Plus, now that DraftKings (NASDAQ:DKNG) has dropped its plans to make a bid for Entain (OTCMKTS:GMVHY), MGM can go back to working with its joint venture to grow BetMGM.
I’m sure MGM will revisit the idea of buying Entain and bringing BetMGM in-house once its existing markets get fully stabilized. All told, MGM stock is another solid name on this list of S&P 500 stocks.
Pfizer (PFE)
Source: photobyphm / Shutterstock.com
If there’s one of the S&P 500 stocks that’s a perennial underperformer, my vote would be on Pfizer.
Over the past 15 years, PFE stock has generated an annualized total return of 5.87%, about half the return of the entire U.S. market. Year-to-date, it’s got a total return of roughly 24%. That’s roughly equal to the U.S. markets on the whole.
It wouldn’t be so bad if Pfizer were merely sputtering along. However, that’s not the case. The company reported Q3 2021 earnings on Nov. 2. It beat on the top and bottom line and upped its guidance for all of 2021.
In Q3, Pfizer had earnings of $1.34, some 26 cents higher than the analyst estimate. Meanwhile, revenue was $24.09 billion, $1.51 billion higher than the consensus. CEO Albert Bourla stated the following in the company press release:
“More than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty [the Covid-19 vaccine] have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022.”
Recently, the Centers for Disease Control and Prevention (CDC) gave final approval for the Pfizer vaccine, marking it safe for kids between the ages of 5 and 11. As such, Canada’s health officials shouldn’t be too far behind.
7 Retail Stocks to Buy Regardless of Supply Shortages
And the rich get richer.
S&P 500 Stocks to Buy: SVB Financial (SIVB)
Source: Pavel Kapysh / Shutterstock.com
Next up on this list of S&P 500 stocks is one of my favorite banking plays, SIVB stock. This company remains one of the best-run financial institutions in the United States, serving a very appetizing financial services market segment.
Focused on providing banking and investment services for entrepreneurs and innovators, it consistently outperforms analyst estimates. In the third quarter, for example, SVB Financial had earnings of $7.26 per share, some $2.20 higher than the consensus or a roughly 44% surprise. In Q2 2021, the earnings surprise was also impressive at around 40%. Finally, on the top line, SVB had revenue of $1.53 billion, 17.2% higher than the estimate.
As far as its outlook goes, this company expects its net interest income and core fee income to grow, spurred on by increases in average loan balances and average deposits.
All I can say is I encourage all readers to check out this bank stock. SIVB is the real deal.
Thomson Reuters (TRI)
market newsglasses 1600" width="300" height="169" />
Source: Shutterstock
The last entry on this list of S&P 500 stocks is TRI stock. This Canadian media, business information and data company is having a quiet but excellent year in the markets, generating a YTD return of 49% so far. With almost two months left in the year, a more than 50% gain seems inevitable.
TRI stock has outperformed the U.S. markets over practically every period — both short and long-term. It’s sneaky good. On Nov. 2, the company reported its Q3 results.
For starters, Thomson Reuters beat on both the top and bottom line with sales of $1.52 billion, 6% higher than the previous year and slightly ahead of the analyst estimate. In addition, its EPS of 46 cents marked an 18% increase YOY, coming in 8 cents higher than the consensus estimate as well.
In 2021, this company expects 2021 free cash flow (FCF) of $1.15 billion at the midpoint of its guidance. Based on a market capitalization of $57.6 billion today, it has an FCF yield of around 2%.
7 Top Stocks to Buy On Any Dip If You Get the Chance in Q4
That’s not cheap, but you get what you pay for. Over the long haul, investors can make a healthy total return from Thomson Reuters’ business model.
On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.
The post 10 S&P 500 Stocks to Buy After Winning in Q3 appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE:ABT) Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) Chevron (NYSE:CVX) Delta Air Lines (NYSE:DAL) Ford (NYSE:F) Intel (NASDAQ:INTC) MGM Resorts (NYSE:MGM) Pfizer (NYSE:PFE) SVB Financial (NASDAQ:SIVB) Thomson Reuters (NYSE:TRI) S&P 500 Stocks to Buy: Abbott Laboratories (ABT) ABT) sign with lighting behind letters" width="300" height="169"> Source: testing / Shutterstock.com First up on this list of S&P 500 stocks is Abbott Laboratories. Based on past valuations, this is a pretty reasonable figure for ABT stock. I wrote the following back in September 2020: “In early March [2020], I stated that patient investors would be rewarded […] Now that Hackett’s moving aside, I hope for long-suffering shareholders that this COO promotion turns out better than the last one.” It seems it has. | Abbott Laboratories (NYSE:ABT) Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) Chevron (NYSE:CVX) Delta Air Lines (NYSE:DAL) Ford (NYSE:F) Intel (NASDAQ:INTC) MGM Resorts (NYSE:MGM) Pfizer (NYSE:PFE) SVB Financial (NASDAQ:SIVB) Thomson Reuters (NYSE:TRI) S&P 500 Stocks to Buy: Abbott Laboratories (ABT) ABT) sign with lighting behind letters" width="300" height="169"> Source: testing / Shutterstock.com First up on this list of S&P 500 stocks is Abbott Laboratories. Based on past valuations, this is a pretty reasonable figure for ABT stock. S&P 500 Stocks to Buy: MGM Resorts (MGM) Source: Jason Patrick Ross / Shutterstock.com MGM Resorts reported a Q3 results beat on both the top and bottom line. | Abbott Laboratories (NYSE:ABT) Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) Chevron (NYSE:CVX) Delta Air Lines (NYSE:DAL) Ford (NYSE:F) Intel (NASDAQ:INTC) MGM Resorts (NYSE:MGM) Pfizer (NYSE:PFE) SVB Financial (NASDAQ:SIVB) Thomson Reuters (NYSE:TRI) S&P 500 Stocks to Buy: Abbott Laboratories (ABT) ABT) sign with lighting behind letters" width="300" height="169"> Source: testing / Shutterstock.com First up on this list of S&P 500 stocks is Abbott Laboratories. Based on past valuations, this is a pretty reasonable figure for ABT stock. Moving forward, I expect the 34% earnings beat ($2.96 vs. $2.21 estimate) and 10% sales beat ($44.71 billion vs. $40.52 billion estimate) ought to help even the score for this pick of the S&P 500 stocks in Q4 and beyond. | Abbott Laboratories (NYSE:ABT) Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) Chevron (NYSE:CVX) Delta Air Lines (NYSE:DAL) Ford (NYSE:F) Intel (NASDAQ:INTC) MGM Resorts (NYSE:MGM) Pfizer (NYSE:PFE) SVB Financial (NASDAQ:SIVB) Thomson Reuters (NYSE:TRI) S&P 500 Stocks to Buy: Abbott Laboratories (ABT) ABT) sign with lighting behind letters" width="300" height="169"> Source: testing / Shutterstock.com First up on this list of S&P 500 stocks is Abbott Laboratories. Based on past valuations, this is a pretty reasonable figure for ABT stock. Of those, 82% beat the consensus earnings per share (EPS). |
31912.0 | 2021-11-04 00:00:00 UTC | December 23rd Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/december-23rd-options-now-available-for-abbott-laboratories-abt-2021-11-04 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 23rd contracts and identified one put and one call contract of particular interest.
The put contract at the $118.00 strike price has a current bid of 59 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $118.00, but will also collect the premium, putting the cost basis of the shares at $117.41 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $129.16/share today.
Because the $118.00 strike represents an approximate 9% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.50% return on the cash commitment, or 3.72% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $118.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $130.00 strike price has a current bid of $3.05. If an investor was to purchase shares of ABT stock at the current price level of $129.16/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $130.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.01% if the stock gets called away at the December 23rd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red:
Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.36% boost of extra return to the investor, or 17.58% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $129.16) to be 21%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 23rd expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 23rd contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 23rd contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 23rd contracts and identified one put and one call contract of particular interest. |
31913.0 | 2021-11-03 00:00:00 UTC | What's Happening With Dexcom Stock? | ABT | https://www.nasdaq.com/articles/whats-happening-with-dexcom-stock | nan | nan | [Updated: 11/1/2021] DXCM Stock Rise
The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen a rise of 10% last week, while it is up 14% in a month. The recent rise can be attributed to upbeat Q3 results. Dexcom reported revenues of $650 million and EPS of $0.89, comfortably above the $619 million sales and $0.65 EPS as per the consensus estimates. The company stated that sales growth was driven by new customer additions, amid rising awareness of CGM devices. Looking forward, the company expects to receive the CE mark for its new improved and smaller in size CGM device – G7 – in Q4 of this year. Dexcom also revised its full-year outlook upward with revenue now estimated to be in the range of $2.42-$2.45 billion, compared to its earlier guidance of $2.35-$2.40 billion. The company also revised its EBITDA margin outlook to 25% (vs. 24% earlier). A solid Q3 performance cheered investors and DXCM stock surged over 9% in a single day on Friday, October 29.
But now that DXCM stock has seen a 14% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of continued gains in DXCM stock over the next month. Out of 546 instances in the last ten years that DXCM stock saw a twenty-one day rise of 14% or more, 324 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 324 out of 546, or about a 59% chance of a rise in DXCM stock over the coming month, implying that the stock may continue to rise and make fresh highs in the near term. See our analysis on Dexcom Stock Chance of Rise for more details.
[Updated: 9/24/2021] DXCM Stock Update
A few months back we discussed that going by its historical performance Dexcom Stock (NASDAQ: DXCM) may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last one month close to its all-time high levels of $579. The company’s Q2 earnings of $0.76 per share on an adjusted basis were much better than $0.43 street estimate. The revenue growth of 32% during the quarter also reflected strong y-o-y growth. Dexcom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require finger prick and data can be self-monitored easily. Given the limited competition, and a wide pool of diabetic patients (over 34 million in the U.S. alone), the company is likely to see strong growth over the coming years. DXCM stock has also seen a large appreciation of 60% year-to-date, and more than 500% over the last five years.
But now that DXCM stock has seen a 11% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of continued gains in DXCM stock over the next month. Out of 702 instances in the last ten years that DXCM stock saw a twenty-one day rise of 11% or more, 414 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 414 out of 702, or about a 59% chance of a rise in DXCM stock over the coming month, implying that the stock may continue to rise and make fresh highs in the near term. See our analysis on Dexcom Stock Chance of Rise for more details.
Also, you can understand how Dexcom’s revenues have changed over the years along with trends in revenues for its closest peers in a separate dashboard analysis.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
After moving 1.3% or more over a five-day period, the stock rose in the next five days on 57% of the occasions.
After moving 3.6% or more over a ten-day period, the stock rose in the next ten days on 60% of the occasions
After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 59% of the occasions.
Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise
DexCom (DXCM) Stock Return (Recent) Comparison With Peers
Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7%
Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3%
Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1%
[Updated: 6/22/2021] DXCM Stock Rise
Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well. The Centers For Medicare & Medicaid Services (CMS) recently announced that there is no longer a requirement for a minimum of four self-monitoring blood glucose tests per day to have the continuous glucose monitoring (CGM) devices covered. This step will result in better patient access, and bode well for companies such as Dexcom and Abbott that develop CGM devices with no requirement of finger-pricking.
Furthermore, Dexcom expects to launch its newest CGM device – G7 – later this year, and given that the new device will use a new and improved application, while it will also be 60% smaller in size compared to the current G6, making it the smallest CGM device available in the market. It has several other benefits over the current version, such as, its transmitter and sensor will be combined, making it a single fully disposable unit. It is also expected to have a longer wear time. As such, the G7 CGM will likely be more attractive to customers, and bolster Dexcom’s sales growth after its launch.
However, now that DXCM stock has seen a rise of 23% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise in DXCM stock over the next month. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 99 out of 184, or about 54% chance of a rise in DXCM stock over the coming month. Also, despite the recent rally, DXCM stock is up only 4% from the levels it was trading at a year ago. See our analysis on Dexcom Stock Chances of Rise for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data
3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances
9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances
23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances
Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise
DexCom (DXCM) Stock Return (Recent) Comparison With Peers
Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1%
Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3%
Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4%
[Updated: 5/6/2021] DXCM Stock Decline
The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. The recent drop is surprising, given that the company last week reported its Q1 numbers, which were actually above the street estimates. Dexcom’s Q1 sales of $505 million was higher than the $482 million consensus estimate. Similarly, its adjusted EPS of $0.33 was ahead of the $0.31 consensus estimate. Looking at the company’s guidance for revenue to be between $2.26 billion and $2.36 billion in 2021 is also in-line with the $2.33 billion consensus estimates. It’s not that the stock had seen a large rally. DXCM stock is up just 1% year-to-date, and it is at the same levels it was at a year back.
While there have been rumors of Apple (NASDAQ:AAPL) coming up with a CGM feature in its Apple Watch, the company hasn’t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if the data collected by Apple Watch is fully reliable. However, it’s not easy to secure the U.S. FDA regulatory approval for a wearable CGM device given that it expects the data to be comparable to the regular CGM devices. It seems unlikely at this stage that Apple may come up with a CGM feature to match the level of accuracy on other CGM devices, such as that of Dexcom and Abbott.
Looking at the recent decline, the 11% drop for DXCM stock over the last five days compares with just a 0.7% decline seen in the broader S&P 500 index. Now, is DXCM stock poised to drop further? It doesn’t appears so. Given the large underperformance over the recent past, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 64% chance of a rise in DXCM stock over the next month (twenty-one trading days).
Out of 75 instances in the last ten years that Dexcom (DXCM) stock saw a five-day decline of 11% or more, 48 of them resulted in DXCM stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 48 out of 75, or about a 64% chance of gain in DXCM stock over the coming month. See our analysis on Dexcom Stock Chances of Rise for more details.
Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market
(3% likelihood event)
Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7%
A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years.
Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market
(11% likelihood event)
Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4%
A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years.
Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market
(44% likelihood event)
Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3%
A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years.
While DXCM stock may continue to rise, it is helpful to see how its peers stack up. Check out Dexcom Stock Comparison With Peers to see how DXCM stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Dexcom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days). | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. [Updated: 11/1/2021] DXCM Stock Rise The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen a rise of 10% last week, while it is up 14% in a month. |
31914.0 | 2021-11-02 00:00:00 UTC | This Stock Is Likely To Outperform Medtronic | ABT | https://www.nasdaq.com/articles/this-stock-is-likely-to-outperform-medtronic-2021-11-02 | nan | nan | We think that Intuitive Surgical stock (NASDAQ: ISRG) is currently is a better pick compared to Medtronic stock (NYSE: MDT), despite Intuitive Surgical being the more expensive of the two. ISRG trades at about 23x trailing revenues, compared to just 5x for Medtronic. Although both the companies have benefited from the rise in total procedure volume post-pandemic, Intuitive Surgical’s financial performance has been better over the recent years. However, there is more to the comparison. Let’s step back to look at the fuller picture of the relative valuation of the two companies by looking at historical revenue growth as well as operating margin growth. Our dashboard Medtronic vs Intuitive Surgical: Industry Peers; Which Stock Is A Better Bet? has more details on this. Parts of the analysis are summarized below.
1. Intuitive Surgical Revenue Growth Has Been Stronger
Now, Intuitive Surgical’s revenue growth over the last twelve month period was better than Medtronic (27% vs. 13%), given a sharp rebound in total procedure volume, resulting in more da Vinci system placements. Even if we were to look at a longer duration, Intuitive Surgical’s last three fiscal year CAGR of 12% is much higher than that of 0.2% CAGR for Medtronic. Note that the revenue base for Medtronic is much larger with $32 billion sales in the last twelve months compared to under $6 billion for Intuitive Surgical.
Looking forward, Intuitive Surgical is expected to see strong revenue growth with rising demand for robotic surgical systems. For Medtronic as well, a rebound in total procedure volume is likely to drive its revenue growth. For full-year 2021, Intuitive Surgical revenues are estimated to be north of $5.7 billion, reflecting a 25% growth over the 2019 sales. For Medtronic, total estimated sales of $33.2 billion in fiscal 2022 (fiscal ends in April), reflect 15% growth over its 2019 revenue of $28.9 billion. Our Medtronic Revenues dashboard provides more insight on the company’s revenues.
2. Intuitive Surgical Has Better Profitability
Unlike the pattern seen in revenue growth, Intuitive Surgical’s operating margin change of -8% over the last three years is worse than -6% for Medtronic. However, Intuitive Surgical’s operating margins have rebounded over the recent quarters, and it stood at 32.2% over the last twelve month period, compared to 30.6% in 2019, before the pandemic. The current operating margin of 14.7% for Medtronic is lower compared to Intuitive Surgical, and it compares with the 20.5% figure in 2019. Overall, Intuitive Surgical’s margins are much better than Medtronic and that has been the case even if we were to look at historical years. The margins for both companies are likely to be adversely impacted in the near term due to inflationary pressure, and supply chain headwinds, but rise in the long run.
The Net of It All
Now that over half of the U.S. population is fully vaccinated against Covid-19, with overall economic activity picking up, the demand for medical devices is likely to rise going forward, boding well for Medtronic. As the Covid-19 crisis winds down, the demand for medical devices sales will also normalize after the backlog of procedures is cleared. However, for Intuitive Surgical, its growth outlook is dependent on new placements for its da Vinci systems and it is likely to remain high over the coming years, given the limited competition, and rising procedure volume.
Covid-19 is proving more difficult to contain than initially thought, due to the spread of more contagious virus variants and infections in the U.S. are higher than what they were a few months back, despite them falling m-o-m in the October. This may directly impact the procedure volume in some of the geographies in the near term. That said, both the companies have seen a strong rebound in demand since the pandemic. While Medtronic’s current valuation is surely more attractive than that of Intuitive Surgical, with MDT stock trading at about 5x trailing revenues, versus 23x for Intuitive Surgical, the latter has demonstrated better revenue growth and better profitability over the last few years.
Not only that, even if we were to look at financial risk, Intuitive Surgical doesn’t have any significant debt, while its 63% cash as percentage of assets is also better than the 11% figure for Medtronic. Overall, Intuitive Surgical trumps Medtronic in most of the metrics that matter for investors and we think this gap in valuation between Intuitive Surgical and Medtronic is largely justified. In fact, looking forward, it is likely that the gap in valuation of these two companies will remain in the foreseeable future and Intuitive Surgical may continue to outperform with its better growth prospects and lower risk.
While ISRG stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Abbott vs. Corcept.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, for Intuitive Surgical, its growth outlook is dependent on new placements for its da Vinci systems and it is likely to remain high over the coming years, given the limited competition, and rising procedure volume. Covid-19 is proving more difficult to contain than initially thought, due to the spread of more contagious virus variants and infections in the U.S. are higher than what they were a few months back, despite them falling m-o-m in the October. In fact, looking forward, it is likely that the gap in valuation of these two companies will remain in the foreseeable future and Intuitive Surgical may continue to outperform with its better growth prospects and lower risk. | We think that Intuitive Surgical stock (NASDAQ: ISRG) is currently is a better pick compared to Medtronic stock (NYSE: MDT), despite Intuitive Surgical being the more expensive of the two. Intuitive Surgical Revenue Growth Has Been Stronger Now, Intuitive Surgical’s revenue growth over the last twelve month period was better than Medtronic (27% vs. 13%), given a sharp rebound in total procedure volume, resulting in more da Vinci system placements. While Medtronic’s current valuation is surely more attractive than that of Intuitive Surgical, with MDT stock trading at about 5x trailing revenues, versus 23x for Intuitive Surgical, the latter has demonstrated better revenue growth and better profitability over the last few years. | Intuitive Surgical Revenue Growth Has Been Stronger Now, Intuitive Surgical’s revenue growth over the last twelve month period was better than Medtronic (27% vs. 13%), given a sharp rebound in total procedure volume, resulting in more da Vinci system placements. Intuitive Surgical Has Better Profitability Unlike the pattern seen in revenue growth, Intuitive Surgical’s operating margin change of -8% over the last three years is worse than -6% for Medtronic. While Medtronic’s current valuation is surely more attractive than that of Intuitive Surgical, with MDT stock trading at about 5x trailing revenues, versus 23x for Intuitive Surgical, the latter has demonstrated better revenue growth and better profitability over the last few years. | Intuitive Surgical Revenue Growth Has Been Stronger Now, Intuitive Surgical’s revenue growth over the last twelve month period was better than Medtronic (27% vs. 13%), given a sharp rebound in total procedure volume, resulting in more da Vinci system placements. The current operating margin of 14.7% for Medtronic is lower compared to Intuitive Surgical, and it compares with the 20.5% figure in 2019. While Medtronic’s current valuation is surely more attractive than that of Intuitive Surgical, with MDT stock trading at about 5x trailing revenues, versus 23x for Intuitive Surgical, the latter has demonstrated better revenue growth and better profitability over the last few years. |
31915.0 | 2021-10-31 00:00:00 UTC | 2 Growth Stocks That Could Deliver 1,000% Returns | ABT | https://www.nasdaq.com/articles/2-growth-stocks-that-could-deliver-1000-returns-2021-10-31 | nan | nan | Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points.
Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? The cancer/rare disease specialist Mereo BioPharma Group (NASDAQ: MREO) and the diabetes-focused medical device company Senseonics Holdings (NYSEMKT: SENS) could both be gearing up for a monstrous run higher soon. In fact, these two low-pric | Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points. The cancer/rare disease specialist Mereo BioPharma Group (NASDAQ: MREO) and the diabetes-focused medical device company Senseonics Holdings (NYSEMKT: SENS) could both be gearing up for a monstrous run higher soon. | Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points. Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? | For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points. The cancer/rare disease specialist Mereo BioPharma Group (NASDAQ: MREO) and the diabetes-focused medical device company Senseonics Holdings (NYSEMKT: SENS) could both be gearing up for a monstrous run higher soon. In fact, these two low-pric | Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points. Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint? |
31916.0 | 2021-10-29 00:00:00 UTC | IWB, ACN, ABT, CVX: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/iwb-acn-abt-cvx%3A-etf-inflow-alert-2021-10-29 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $180.5 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 122,550,000 to 123,250,000). Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Chevron Corporation (Symbol: CVX) is up by about 0.6%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $180.78 per share, with $258.58 as the 52 week high point — that compares with a last trade of $257.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Chevron Corporation (Symbol: CVX) is up by about 0.6%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $180.78 per share, with $258.58 as the 52 week high point — that compares with a last trade of $257.23. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Chevron Corporation (Symbol: CVX) is up by about 0.6%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $180.78 per share, with $258.58 as the 52 week high point — that compares with a last trade of $257.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Chevron Corporation (Symbol: CVX) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $180.5 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 122,550,000 to 123,250,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $180.78 per share, with $258.58 as the 52 week high point — that compares with a last trade of $257.23. | Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Chevron Corporation (Symbol: CVX) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $180.5 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 122,550,000 to 123,250,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $180.78 per share, with $258.58 as the 52 week high point — that compares with a last trade of $257.23. |
31917.0 | 2021-10-29 00:00:00 UTC | Insiders at Abbott Laboratories (NYSE:ABT) sold US$2.8m worth of stock, possibly indicating weakness in the future | ABT | https://www.nasdaq.com/articles/insiders-at-abbott-laboratories-nyse%3Aabt-sold-us%242.8m-worth-of-stock-possibly-indicating | nan | nan | In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
The Last 12 Months Of Insider Transactions At Abbott Laboratories
Over the last year, we can see that the biggest insider sale was by the insider, Roger Bird, for US$1.2m worth of shares, at about US$122 per share. That means that an insider was selling shares at slightly below the current price (US$128). When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. It is worth noting that this sale was only 16% of Roger Bird's holding.
In total, Abbott Laboratories insiders sold more than they bought over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
NYSE:ABT Insider Trading Volume October 29th 2021
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
Insider Ownership of Abbott Laboratories
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Abbott Laboratories insiders own 0.7% of the company, currently worth about US$1.6b based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
So What Do The Abbott Laboratories Insider Transactions Indicate?
It doesn't really mean much that no insider has traded Abbott Laboratories shares in the last quarter. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the Abbott Laboratories insiders selling. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we found 2 warning signs for Abbott Laboratories that deserve your attention before buying any shares.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. NYSE:ABT Insider Trading Volume October 29th 2021 If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. At Simply Wall St, we found 2 warning signs for Abbott Laboratories that deserve your attention before buying any shares. | In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. NYSE:ABT Insider Trading Volume October 29th 2021 If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. In total, Abbott Laboratories insiders sold more than they bought over the last year. | In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. NYSE:ABT Insider Trading Volume October 29th 2021 If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. The Last 12 Months Of Insider Transactions At Abbott Laboratories Over the last year, we can see that the biggest insider sale was by the insider, Roger Bird, for US$1.2m worth of shares, at about US$122 per share. | In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. NYSE:ABT Insider Trading Volume October 29th 2021 If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. Insider Ownership of Abbott Laboratories Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. |
31918.0 | 2021-10-28 00:00:00 UTC | Why Investors Need to Pay Attention to the At-Home Diagnostics Market | ABT | https://www.nasdaq.com/articles/why-investors-need-to-pay-attention-to-the-at-home-diagnostics-market-2021-10-28 | nan | nan | T
he past few years have certainly emphasized the importance of health, both mental and physical, and on the diverse attitudes and economics of healthcare around the world. Here we look at how technology is reshaping healthcare and how it could improve the economics of the largest sector of the American economy.
According to WorldData.info, the average life expectancy for a male child born in the US in 2019 will be 76.3 years and 81.4 years for a female. Those numbers put the U.S. in 43rd place in the world for life expectancy for both genders, despite spending more than any other nation on healthcare per capita, at $10,624 in 2018. Comparing life expectancies around the world, we get an idea of just how poor of a return the U.S. is getting on its healthcare dollars:
The nation with the highest life expectancy was Hong Kong at 82.2 years for men and 88.1 for women, but data is not available on per capita healthcare spending.
Switzerland was in second place at 81.9 for men and in seventh place at 85.6 years for women and spent 93% ($9,870) of what the U.S. spent per capita.
Japan was in second place for women at 87.5 years and third place for men at 81.4 years and spent 39% ($4,267) of what the U.S. spent.
Singapore had the world’s fourth-highest life expectancy for men at 81.4 years and the sixth highest for women at 85.7 years and spent just 27% ($2,824) of what the U.S. spent.
Italy had the eighth highest life expectancy for men at 81.1 years and tenth for women at 85.4 years while spending 28% ($2,989) of what the U.S. spent.
Spain had the tenth highest life expectancy for men at 80.9 years and the fifth-highest for women at 86.2 years while spending 26% ($2,736) of what the U.S. spent.
Americans are clearly not getting their money’s worth, and that is saying an awful lot given that healthcare accounted for 17.8% of US GDP in 2019, and an estimated 18% of GDP in 2020. For other nations, the numbers look very different: Japan, 11% in 2019, for Spain 9.1%, for Italy 8.7%, and for Switzerland 11.3%. By 2028 it is expected that healthcare spending in the U.S. will reach nearly 20% of GDP, or roughly $6.2 trillion. This is a massive portion of the world’s largest economy to be delivering such poor results.
What can be done? That’s a very big question, unlikely to be solved through public policy alone, but if there is one force in this nation that seems to have the power to solve the unsolvable, it is innovation, and we are seeing an acceleration in healthcare innovation, unlike anything the world has seen in decades.
One arguably constructive thing the pandemic did was to alter the public policy for and improve consumer comfort with telemedicine. The various restrictions around the country and social distancing needs forced public policy to change, at least temporarily, but those changes are forcing a rethink of whether they even made sense in the first place. For example, the federal government changed the restrictions against provider telehealth services across state lines, and providers can now prescribe controlled substances via telehealth without the need for an in-person medical evaluation.
A huge beneficiary of this shift was Teladoc (TDOC), which saw its trailing twelve-month revenue jump from $553.3 million at the end of 2019 to $1.1 billion by the end of 2020 to $1.6 billion by June 30, 2021. The company just reported its third quarter results on Wednesday with an 81% YoY increase in revenue, which was 1% above estimates, and EBITDA that was also above forecasts.
Home testing, diagnostics, and access to telemedicine can give people more convenient, often more accurate, and more customized solutions. As consumers become more accustomed to the benefits of a faster and more personal approach, they are unlikely to want to give it up. It also makes economic sense. According to the Centers for Disease Control (CDC), preventative measures including screening and detection could dramatically reduce chronic diseases that were responsible for $1 trillion in healthcare costs in 2016. What better way to improve screening than to make it something that can be easily and quickly done in the privacy of one’s own home?
That brings us to the At Home Diagnostics Market, which refers to those tests that are performed on human body samples such as blood, saliva, and urine for the detection of disease or medical conditions. The market is currently estimated to grow by more than 30% over the next few years to $6.53 billion by 2025.
There is now a wide range of testing solutions for a variety of conditions that can be conducted at home, from cholesterol to fertility and sleep apnea to colon cancer. In fact, while colon cancer is among the most common causes of cancer deaths, it is the most preventable cancer, but the least prevented because only about 50% to 60% of people get screened as routinely as they ought. That’s not exactly shocking because a colonoscopy test is ... well, we don’t even need to say it. But there is hope on the horizon: Exact Sciences Corp (EXAS) has developed Colonguard, the first FDA-approved at-home colon cancer screening kit which simply requires a stool sample. Talk about a massive improvement in prevention/detection options.
One of the biggest health challenges in the U.S. is diabetes. Products like Abbot Labs (ABT) FreeStyle Libre 2 continuous glucose monitoring (iCGM) system is being used to not only help those with diabetes manage it better but is also being used to help others understand their body’s reactions to various foods and activities to prevent Type 2 diabetes. Integrity Applications’ (IGAP) GlucoTrack allows users to check their blood sugar levels just by clipping a sensor to their earlobe. No more finger pricks mean users are more likely to test more frequently, improving diabetes and prediabetes management.
One of the early players in the at-home market is the consumer genetics company 23andMe Holding Co (ME), which has been known for its at-home DNA testing kit that only requires customers to mail in a little tube of saliva in order to gain useful insight into their genetic predispositions. The company merged with VG Acquisitions Corp (VGAC) and began trading on the Nasdaq Global Select Market this past June. The company recently announced the acquisition of Lemonaid Health, an on-demand platform for accessing medical care and pharmacy services online. The acquisition is expected to close by the end of the year and gives 23andMe’s customers access to Lemonaid’s telemedicine and prescription drug delivery services.
Other private companies that are pushing the innovation edge and warrant watching include companies like Forward, which is a subscription-based service that combines DNA sequencing, AI, full-body scanning, and wearables for mobile health monitoring along with instant access to medical care via smartphone app.
Everlywell offers a wide range of at-home tests that are then physician-reviewed and delivered back to the consumer in days that include food sensitivity, allergy tests, thyroid function, STDs, heart health, B vitamin tests, and cholesterol and lipids tests.
The Miiskin app helps track changes in skin conditions such as moles over time, which can help head off more serious skin cancer problems. The Tytocare Medical Exam kit lets parents connect with a remote physician using a device that can check for heart and lung sounds, abnormal abdominal sounds, or give an ear or throat exam, all from home. A similar device is the MedWand from Medwand Solutions. It is a compact device that patients can connect to their computer, tablet, or mobile device via Bluetooth during a telehealth visit which can be used to provide their physician with a remote stethoscope, thermometer, oxygen sensor, heart rate monitor, EKG, and more. It also includes a high-definition camera that physicians can control remotely and use for multiple purposes, including ear exams.
The bottom line is that growth in at-home testing and services is accelerating, bringing consumers more convenient access and more control over their own health. A world with better tools for prevention leads to lower healthcare costs, greater life expectancies, and better quality of life. That is a world worth reimagining.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Products like Abbot Labs (ABT) FreeStyle Libre 2 continuous glucose monitoring (iCGM) system is being used to not only help those with diabetes manage it better but is also being used to help others understand their body’s reactions to various foods and activities to prevent Type 2 diabetes. That brings us to the At Home Diagnostics Market, which refers to those tests that are performed on human body samples such as blood, saliva, and urine for the detection of disease or medical conditions. But there is hope on the horizon: Exact Sciences Corp (EXAS) has developed Colonguard, the first FDA-approved at-home colon cancer screening kit which simply requires a stool sample. | Products like Abbot Labs (ABT) FreeStyle Libre 2 continuous glucose monitoring (iCGM) system is being used to not only help those with diabetes manage it better but is also being used to help others understand their body’s reactions to various foods and activities to prevent Type 2 diabetes. Home testing, diagnostics, and access to telemedicine can give people more convenient, often more accurate, and more customized solutions. The Tytocare Medical Exam kit lets parents connect with a remote physician using a device that can check for heart and lung sounds, abnormal abdominal sounds, or give an ear or throat exam, all from home. | Products like Abbot Labs (ABT) FreeStyle Libre 2 continuous glucose monitoring (iCGM) system is being used to not only help those with diabetes manage it better but is also being used to help others understand their body’s reactions to various foods and activities to prevent Type 2 diabetes. Comparing life expectancies around the world, we get an idea of just how poor of a return the U.S. is getting on its healthcare dollars: The nation with the highest life expectancy was Hong Kong at 82.2 years for men and 88.1 for women, but data is not available on per capita healthcare spending. Singapore had the world’s fourth-highest life expectancy for men at 81.4 years and the sixth highest for women at 85.7 years and spent just 27% ($2,824) of what the U.S. spent. | Products like Abbot Labs (ABT) FreeStyle Libre 2 continuous glucose monitoring (iCGM) system is being used to not only help those with diabetes manage it better but is also being used to help others understand their body’s reactions to various foods and activities to prevent Type 2 diabetes. The various restrictions around the country and social distancing needs forced public policy to change, at least temporarily, but those changes are forcing a rethink of whether they even made sense in the first place. In fact, while colon cancer is among the most common causes of cancer deaths, it is the most preventable cancer, but the least prevented because only about 50% to 60% of people get screened as routinely as they ought. |
31919.0 | 2021-10-28 00:00:00 UTC | December 10th Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/december-10th-options-now-available-for-abbott-laboratories-abt-2021-10-28 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 10th contracts and identified one put and one call contract of particular interest.
The put contract at the $128.00 strike price has a current bid of 92 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $128.00, but will also collect the premium, putting the cost basis of the shares at $127.08 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $128.78/share today.
Because the $128.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.72% return on the cash commitment, or 6.10% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $128.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $130.00 strike price has a current bid of 64 cents. If an investor was to purchase shares of ABT stock at the current price level of $128.78/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $130.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 1.44% if the stock gets called away at the December 10th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red:
Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.50% boost of extra return to the investor, or 4.21% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $128.78) to be 21%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 10th expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 10th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 10th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 10th contracts and identified one put and one call contract of particular interest. |
31920.0 | 2021-10-26 00:00:00 UTC | PREVIEW-Thermo Fisher set to benefit from demand for testing kits, vaccines | ABT | https://www.nasdaq.com/articles/preview-thermo-fisher-set-to-benefit-from-demand-for-testing-kits-vaccines-2021-10-26 | nan | nan | By Amruta Khandekar and Mrinalika Roy
Oct 26 (Reuters) - Thermo Fisher Scientific Inc's TMO.N third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said.
In July, when cases eased in the United States, the company cut its annual sales forecast for COVID-19 tests by $900 million. But the demand has again picked up pace in recent months amid a surge in Delta-led infections.
The world's largest maker of scientific instruments, which also supplies raw materials for COVID-19 vaccines and therapies, may see some benefit from the United States authorizing booster doses for some age-groups.
However, Thermo Fisher is unlikely to lift its testing forecast, according to Atlantic Equities analyst James Mainwaring, as it shifts its focus to its core business of making scientific instruments used in pharmaceutical and academic research.
The business took a hit last year as the pandemic disrupted research activities, but showed a strong recovery in the second quarter.
THE CONTEXT
** Thermo Fisher's COVID-19 response revenue, which consists of supply for vaccines and therapies as well as testing kits, helped cushion the hit to its mainstay business from COVID-19 curbs and beat profit expectations for the past few quarters.
** Demand for test kits from employers in the United States have surged in the past few months and has even resulted in a supply crunch as the U.S. government mandated big employers to inoculate their workers and test them every week.
** Last week, rival Abbott Laboratories ABT.N raised its 2021 profit forecast due to the recent uptick in testing demand. However, Quest Diagnostics DGX.N warned of a slowdown in demand through the rest of the year as infections decline.
THE FUNDAMENTALS
** Thermo Fisher is expected to report third-quarter revenue of $8.39 billion on Oct. 27, according to the mean estimate from 15 analysts, based on Refinitiv data
** Thermo Fisher reported overall second-quarter sales of $9.27 billion.
WALL STREET SENTIMENT
** The current average analyst rating on Thermo Fisher shares is "buy", with eight analysts rating it "strong buy", 12 "buy" and two "hold"
** Wall Street's median 12-month price target is $670
** The company's shares have risen about 30.5% so far this year
QUARTER ENDING
EPS ESTIMATE ($)
ACTUAL EPS($)
BEAT, MET, MISSED
July. 3 2021
$5.44
$5.60
BEAT
April. 3 2021
$6.65
$7.21
BEAT
Dec. 31 2020
$6.56
$7.09
BEAT
Sept. 26 2020
$4.31
$5.63
BEAT
June. 27 2020
$3.42
$3.89
BEAT
March. 28 2020
$2.79
$2.94
BEAT
Thermo Fisher overall revenue vs COVID-19 response revenuehttps://tmsnrt.rs/3vL4Qpn
Thermo Fisher overall revenue vs COVID-19 response revenuehttps://tmsnrt.rs/3Gp0Srl
(Reporting by Amruta Khandekar and Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)
((Amruta.Khandekar@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ** Last week, rival Abbott Laboratories ABT.N raised its 2021 profit forecast due to the recent uptick in testing demand. By Amruta Khandekar and Mrinalika Roy Oct 26 (Reuters) - Thermo Fisher Scientific Inc's TMO.N third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said. However, Thermo Fisher is unlikely to lift its testing forecast, according to Atlantic Equities analyst James Mainwaring, as it shifts its focus to its core business of making scientific instruments used in pharmaceutical and academic research. | ** Last week, rival Abbott Laboratories ABT.N raised its 2021 profit forecast due to the recent uptick in testing demand. ** Thermo Fisher's COVID-19 response revenue, which consists of supply for vaccines and therapies as well as testing kits, helped cushion the hit to its mainstay business from COVID-19 curbs and beat profit expectations for the past few quarters. ** The current average analyst rating on Thermo Fisher shares is "buy", with eight analysts rating it "strong buy", 12 "buy" and two "hold" ** Wall Street's median 12-month price target is $670 ** The company's shares have risen about 30.5% so far this year | ** Last week, rival Abbott Laboratories ABT.N raised its 2021 profit forecast due to the recent uptick in testing demand. By Amruta Khandekar and Mrinalika Roy Oct 26 (Reuters) - Thermo Fisher Scientific Inc's TMO.N third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said. ** Thermo Fisher's COVID-19 response revenue, which consists of supply for vaccines and therapies as well as testing kits, helped cushion the hit to its mainstay business from COVID-19 curbs and beat profit expectations for the past few quarters. | ** Last week, rival Abbott Laboratories ABT.N raised its 2021 profit forecast due to the recent uptick in testing demand. By Amruta Khandekar and Mrinalika Roy Oct 26 (Reuters) - Thermo Fisher Scientific Inc's TMO.N third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said. ** Thermo Fisher's COVID-19 response revenue, which consists of supply for vaccines and therapies as well as testing kits, helped cushion the hit to its mainstay business from COVID-19 curbs and beat profit expectations for the past few quarters. |
31921.0 | 2021-10-26 00:00:00 UTC | Got $5,000? These 2 Unstoppable Stocks Are No-Brainer Buys | ABT | https://www.nasdaq.com/articles/got-%245000-these-2-unstoppable-stocks-are-no-brainer-buys-2021-10-26 | nan | nan | If you have $5,000 that you can afford to invest, there are plenty of good options out there for you. But the safest approach is to invest in the long haul -- in businesses that have bright futures.
Abbott Laboratories (NYSE: ABT) and Palantir Technologies (NYSE: PLTR) are two suitable options for long-term investors. Their businesses are growing at impressive rates today and they don't look to be slowing down anytime soon.
Image source: Getty Images.
1. Abbott Laboratories
Healthcare giant Abbott Laboratories was a great buy before the pandemic and its business looks even better today. The company released its latest results on Oct. 20 and sales of $10.9 billion for the quarter ended Sept. 30 were up 23% over the same period last year. While diagnostics and COVID-19 test products were a big reason for the large spike in sales (that segment generated year-over-year growth of more than 48%), the company reported strong results across the board with its slowest-growing segment, nutrition, still up 10%.
The healthcare company is performing incredibly well and is on track to blow past last year's revenue of $34.6 billion as it already has sales of $31.6 billion through the first nine months of 2021. Plus, with multiple new products that the U.S. Food and Drug Administration has recently approved -- including Amplatzer Amulet for preventing blood clots -- Abbott is only adding to its portfolio.
On top of all that growth, Abbott is also a solid dividend stock, paying investors 1.5% annually -- slightly above the S&P 500 average of around 1.3%. Last year, the company boosted its dividend by a generous 25%. Given that its net earnings through the first three quarters of this year are more than double what they were a year ago, it wouldn't be surprising to see another solid rate hike before the end of the year. One more increase to the dividend would also make Abbott a Dividend King.
Whether you just want a safe dividend or a top business to invest in, Abbott Labs is a worthy investment to consider.
2. Palantir Technologies
Tech company Palantir doesn't pay a dividend, but investors likely won't mind given its attractive growth prospects. The company's analytics and data solutions utilize artificial intelligence to provide organizations with valuable decision-making information. And it has earned the trust of the government -- more than 60% of its revenue comes from a wide range of agencies and military customers such as the U.S. Army and the Centers for Disease Control and Prevention.
Commercial customers are also bullish on its software; for the second quarter ended June 30, U.S. commercial revenue grew 90% over the same period last year. And the number of commercial customers rose by 32%. All in all, through the first half of 2021, the company's revenue has totaled $717 million, which is a 49% increase from a year ago. Palantir expects that its business will grow by an annual rate of at least 30% through 2025.
The one knock on the business is that right now it isn't profitable. The company incurred losses of more than $1.2 billion over the trailing 12 months. However, that is skewed by the third quarter of last year when the company saw a net loss of $853 million, largely the result of $847 million in expenses due to stock-based compensation. In subsequent quarters, losses have been much smaller.
Investors will need to be patient with Palantir (especially if they're waiting for the company to turn a profit), but with the growth potential the stock possesses, this is another promising investment that long-term investors should consider adding to their portfolios.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of October 20, 2021
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Palantir Technologies Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) and Palantir Technologies (NYSE: PLTR) are two suitable options for long-term investors. Plus, with multiple new products that the U.S. Food and Drug Administration has recently approved -- including Amplatzer Amulet for preventing blood clots -- Abbott is only adding to its portfolio. The company's analytics and data solutions utilize artificial intelligence to provide organizations with valuable decision-making information. | Abbott Laboratories (NYSE: ABT) and Palantir Technologies (NYSE: PLTR) are two suitable options for long-term investors. On top of all that growth, Abbott is also a solid dividend stock, paying investors 1.5% annually -- slightly above the S&P 500 average of around 1.3%. Palantir Technologies Tech company Palantir doesn't pay a dividend, but investors likely won't mind given its attractive growth prospects. | Abbott Laboratories (NYSE: ABT) and Palantir Technologies (NYSE: PLTR) are two suitable options for long-term investors. Given that its net earnings through the first three quarters of this year are more than double what they were a year ago, it wouldn't be surprising to see another solid rate hike before the end of the year. Palantir Technologies Tech company Palantir doesn't pay a dividend, but investors likely won't mind given its attractive growth prospects. | Abbott Laboratories (NYSE: ABT) and Palantir Technologies (NYSE: PLTR) are two suitable options for long-term investors. The company released its latest results on Oct. 20 and sales of $10.9 billion for the quarter ended Sept. 30 were up 23% over the same period last year. Whether you just want a safe dividend or a top business to invest in, Abbott Labs is a worthy investment to consider. |
31922.0 | 2021-10-26 00:00:00 UTC | What's Next For Intuitive Surgical Stock? | ABT | https://www.nasdaq.com/articles/whats-next-for-intuitive-surgical-stock-2021-10-26 | nan | nan | [Updated: Oct 22, 2021] ISRG Q3 Update
The stock price of Intuitive Surgical (NASDAQ: ISRG) has seen a rise of around 3% over the last five tradings days after it announced its Q3 results, which were above the street estimates. The company reported revenues of $1.4 billion, up 30% y-o-y, and it compares with our forecast of $1.3 billion and $1.4 billion consensus estimate. The revenue growth was driven by a better than anticipated uptick in procedure volume (up 20% y-o-y), driving the company’s instrument & accessories (I&A) revenues. Note that while I&A revenue grew 20% on volume growth, the average I&A revenue per procedure has actually declined slightly to $1,900 in Q3 2021, compared to $1,910 in prior-year quarter and $1,940 in Q2 2021, due to an increase in extended use instruments usage. Our dashboard on Intuitive Surgical Revenues offers more details on the company’s segments. The company lowered its upper end of the range of procedure volume growth for the full-year 2021 to 27%-29% from 27%-30% earlier, owing to the impact of the delta variant.
Looking at the bottom-line, adjusted EPS of $1.19 per share (up 29% y-o-y) was slightly below our forecast of $1.22 but better than $1.17 consensus estimate. This can be attributed to higher revenues as well as margin expansion. Furthermore, the company said it expects gross margins to be 71%-71.5% for the full-year 2021, narrowing from the earlier provided range of 70.5% to 71.5%.
We have now revised our Intuitive Surgical Valuation to $361 per share (vs. $345 earlier) based on revised adjusted EPS forecast of $5.00 and a P/E multiple of 72x. This marks a small premium of around 6% from the current levels of $340 for ISRG.
While ISRG stock has some more room for growth, there are several peers in its sector that look like a better bet than Intuitive Surgical. Also, Intuitive Surgical Peer Comparison summarizes how the company fares against peers on metrics that matter.
[Updated: Oct 15, 2021] ISRG Q3 Earnings Preview
Intuitive Surgical (NASDAQ:ISRG), a fast growing robotic surgical platform company, is scheduled to report its Q3 2021 results on Tuesday, October 19. We expect Intuitive Surgical to likely to report mixed earnings with revenue slightly below and earnings to be above the consensus estimates. With the rise of the delta variant and Covid-19 cases in the U.S. over the last few months, it is likely that Intuitive Surgical’s sales were adversely impacted. That said, our forecast indicates that Intuitive Surgical’s valuation is around $345 per share, which is 6% above the current market price of $345, implying that ISRG stock still has some room for growth, in our view. Our interactive dashboard analysis on Intuitive Surgical Pre-Earnings has additional details.
(1) Revenues expected to fall short of the consensus estimate
Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. The ongoing vaccination programs and gradual opening up of economies has resulted in an increase in procedures volume over the recent quarter, and this should augur well for Intuitive Surgical’s top line growth, when compared to the prior year quarter. However, the recent surge in Covid-19 cases may have adversely impacted the overall revenue growth for the company. da Vinci procedure volume grew a stellar 68% in Q2 2021, driving total sales 72% higher to $1.46 billion. Sales growth reflect higher instruments & accessories sales, as well as an increase in system placements. Intuitive Surgical placed 328 systems last quarter, compared to 178 systems in the prior year quarter. Note that it was a favorable comparison to Q2 2020, which was significantly impacted from deferment of elective surgeries, amid the lockdowns. Our dashboard on Intuitive Surgical Revenues offers more details on the company’s segments.
2) EPS likely to be ahead of consensus estimates
Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. Intuitive Surgical’s adjusted net income of $477 million in Q2 2021 reflected a large 3.6x rise from its $132 million figure in the prior-year quarter. The rise in earnings was higher than revenues due to over 1700 bps expansion of net margins, driven by lower operating expenses (as a percentage of revenue) as well as lower taxes. We believe that margins will remain strong going forward, as the procedure volume increases. For the full-year 2021, we expect the adjusted EPS to be higher at $4.96 compared to $3.38 in 2020.
(3) Stock price estimate above the current market price
Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. Investors have assigned a high trading multiple for ISRG stock, given the strong revenue and earnings growth over the past years, and this trend is expected to continue going forward, as well. Note that Intuitive Surgical generates recurring revenues from every system placed, driven by the instruments and accessories sales, as well as services.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While ISRG stock may see more gains going forward, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company lowered its upper end of the range of procedure volume growth for the full-year 2021 to 27%-29% from 27%-30% earlier, owing to the impact of the delta variant. That said, our forecast indicates that Intuitive Surgical’s valuation is around $345 per share, which is 6% above the current market price of $345, implying that ISRG stock still has some room for growth, in our view. Investors have assigned a high trading multiple for ISRG stock, given the strong revenue and earnings growth over the past years, and this trend is expected to continue going forward, as well. | (1) Revenues expected to fall short of the consensus estimate Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | (1) Revenues expected to fall short of the consensus estimate Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. (3) Stock price estimate above the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. | The revenue growth was driven by a better than anticipated uptick in procedure volume (up 20% y-o-y), driving the company’s instrument & accessories (I&A) revenues. That said, our forecast indicates that Intuitive Surgical’s valuation is around $345 per share, which is 6% above the current market price of $345, implying that ISRG stock still has some room for growth, in our view. (3) Stock price estimate above the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. |
31923.0 | 2021-10-26 00:00:00 UTC | What To Expect From Boston Scientific Stock In Q3? | ABT | https://www.nasdaq.com/articles/what-to-expect-from-boston-scientific-stock-in-q3-2021-10-26 | nan | nan | Boston Scientific (NYSE:BSX) is scheduled to report its Q3 2021 results on Wednesday, Oct 27. We expect the company to report revenues and earnings in-line with the consensus estimates, driven by a rebound in volume of procedures performed. That said, a rise in Covid-19 cases in Q3, due to the spread of the delta variant, along with supply-chain constraints likely impacted the overall earnings growth for the company. While we don’t expect any earnings surprise from Boston Scientific, its stock has some more room for growth, in our view. Trefis’ forecast indicates that Boston Scientific’s valuation is $50 per share, which is 11% higher than the current market price of under $45. Our interactive dashboard analysis on Boston Scientific’s Pre-Earnings has additional details.
(1) Revenues expected to be in-line with the consensus estimates
Trefis estimates Boston Scientific’s Q3 2021 revenues to be around $2.94 billion, in-line with the consensus estimate. With a rise in overall vaccination rates across the globe, the healthcare institutions now have more resources to address the surgeries that were postponed earlier, implying a rebound for Boston Scientific’s medical devices business. In fact, the company’s overall sales surged 54% in Q2 this year. While MedSurg and Rhythm & Neuro segment sales were up 65% each (y-o-y), Cardiovascular segment sales grew 51%. The company’s Left Atrial Appendage Closure (LAAC) device – Watchman – continues to gain market share driven by higher physician utilization rate. Our dashboard on Boston Scientific Revenues offers more details on the company’s segments. Boston Scientific’s management in the Q2earnings callconference guided for a revenue growth of 11% to 13% in Q3, and we estimate the growth to be at the lower end of this range, given the disruption due to the spread of the delta variant.
2) EPS also likely to be in-line with the consensus estimates
Boston Scientific’s Q3 2021 adjusted earnings per share (EPS) is expected to be $0.37 per Trefis analysis, in-line with the consensus estimate. Boston Scientific’s adjusted net income of $577 million in Q2 2021 reflected a large 5x growth from its $120 million figure in the prior-year quarter. This can be attributed to higher revenues and over 1,200 bps rise in net margins. Note that Q2 2020 margins were significantly lower due to the impact of then imposed lockdowns. But now with a robust demand outlook, margins are expected to improve. That said, supply-chain constraints and inflationary pressure may impact the margins in the near term. For the full-year, we expect the adjusted EPS to be higher at $1.62 compared to $0.97 in 2020.
(3) Stock price estimate 11% higher than the current market price
Going by our Boston Scientific’s Valuation, with an EPS estimate of around $1.62 and a P/E multiple of around 31x in 2021, this translates into a price of $50, which is 11% above the current market price of under $45. At current levels of around $45, BSX is trading at under 28x its expected EPS of $1.62 in 2021, and the 28x figure compares with levels of 29x seen in 2018 and 37x as recently as late 2020, implying there is more room for growth in BSX stock.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While BSX stock has some more room for growth, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Mettler vs Abbott.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We expect the company to report revenues and earnings in-line with the consensus estimates, driven by a rebound in volume of procedures performed. With a rise in overall vaccination rates across the globe, the healthcare institutions now have more resources to address the surgeries that were postponed earlier, implying a rebound for Boston Scientific’s medical devices business. The company’s Left Atrial Appendage Closure (LAAC) device – Watchman – continues to gain market share driven by higher physician utilization rate. | 2) EPS also likely to be in-line with the consensus estimates Boston Scientific’s Q3 2021 adjusted earnings per share (EPS) is expected to be $0.37 per Trefis analysis, in-line with the consensus estimate. (3) Stock price estimate 11% higher than the current market price Going by our Boston Scientific’s Valuation, with an EPS estimate of around $1.62 and a P/E multiple of around 31x in 2021, this translates into a price of $50, which is 11% above the current market price of under $45. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | (1) Revenues expected to be in-line with the consensus estimates Trefis estimates Boston Scientific’s Q3 2021 revenues to be around $2.94 billion, in-line with the consensus estimate. 2) EPS also likely to be in-line with the consensus estimates Boston Scientific’s Q3 2021 adjusted earnings per share (EPS) is expected to be $0.37 per Trefis analysis, in-line with the consensus estimate. (3) Stock price estimate 11% higher than the current market price Going by our Boston Scientific’s Valuation, with an EPS estimate of around $1.62 and a P/E multiple of around 31x in 2021, this translates into a price of $50, which is 11% above the current market price of under $45. | While we don’t expect any earnings surprise from Boston Scientific, its stock has some more room for growth, in our view. 2) EPS also likely to be in-line with the consensus estimates Boston Scientific’s Q3 2021 adjusted earnings per share (EPS) is expected to be $0.37 per Trefis analysis, in-line with the consensus estimate. (3) Stock price estimate 11% higher than the current market price Going by our Boston Scientific’s Valuation, with an EPS estimate of around $1.62 and a P/E multiple of around 31x in 2021, this translates into a price of $50, which is 11% above the current market price of under $45. |
31924.0 | 2021-10-25 00:00:00 UTC | What Could These Clinical Results Mean for AbbVie's Shareholders? | ABT | https://www.nasdaq.com/articles/what-could-these-clinical-results-mean-for-abbvies-shareholders-2021-10-25 | nan | nan | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. But what impact could these clinical results have on pharma stock AbbVie in the years ahead?
Let's dive into the data studying Rinvoq's effect on patients with ankylosing spondylitis, as well as Rinvoq's U.S. sales potential to address this question.
Image source: Getty Images.
A highly effective treatment
Ankylosing spondylitis is a "rare type of arthritis that causes pain and stiffness in your spine," according to WebMD. Ankylosis refers to the fusion of bones or hard tissue, whereas spondylitis means inflammation in your vertebrae. While it often starts in the lower back, it can spread to the neck and damage other joints in the body as well.
Since ankylosing spondylitis can result in significant pain and mobility limitations, it is important for patients with the disease to develop and modify their treatment plan with the consultation of a medical professional. One biologic drug that could soon be a tool for doctors to treat refractory and severe cases of ankylosing spondylitis is Rinvoq, which was demonstrated to be beneficial in controlling it.
AbbVie enrolled 420 adult patients with ankylosing spondylitis who previously failed at least one biologic disease-modifying antirheumatic drug (bDMARD) into its phase 3 clinical trial to test the efficacy and safety of Rinvoq. The drug significantly reduced the symptoms of ankylosing spondylitis, which was demonstrated by the proportion of patients achieving an Assessment in SpondyloArthritis International Society (ASAS) 40 response.
An ASAS40 response means that a patient has experienced at least a 40% improvement in their ankylosing spondylitis. This includes patient measures, such as the severity of back pain and the duration of morning stiffness, as well as laboratory measures of inflammation levels. The higher the ASAS number, the more impactful a therapy was for a patient.
An astounding 45% of patients receiving 15 milligrams of Rinvoq each day achieved ASAS40 at week 14, which was more than double the 18% of patients receiving the placebo who achieved ASAS40 at week 14. And despite the U.S. Food and Drug Administration's (FDA) caution with Janus kinase (JAK) inhibitors as of late, Rinvoq was well tolerated. To this point, 0% of patients taking Rinvoq had adverse events that resulted in discontinuation of treatment, compared to 1.4% of patients receiving the placebo.
A large market with a need for more options
Rinvoq appears to be effective and well-tolerated by patients, which is why it was approved for use in the European Union in January for three rheumatic indications, including for ankylosing spondylitis. But what could that mean for the sales potential of an ankylosing spondylitis indication here in the United States?
Firstly, there are an estimated 300,000 Americans who have ankylosing spondylitis. And while the majority of patients find meaningful relief on their first DMARD, this isn't the case for all patients. In fact, 16.3% of ankylosing spondylitis patients in North America failed their first DMARD, which means the treatment was ineffective in managing the condition.
Based on this data, there are approximately 49,000 ankylosing spondylitis patients who have failed their first treatment and who could need another treatment. Since I believe that Rinvoq's efficacy makes up for the potential safety concerns associated with the JAK inhibitor drug class, the drug can reasonably capture 15%, or around 7,300, of these patients.
Rinvoq's annual list price for its rheumatoid arthritis indication in the U.S. is around $60,000. But since the Institute for Clinical and Economic Review (ICER) believes that a value-based price for the drug would be $45,000 annually, that likely is a more appropriate figure for list price. Conservatively accounting for insurance adjustments, the company probably would receive $40,000.
Factoring in 7,300 patients taking Rinvoq for ankylosing spondylitis in the U.S. at a net annual price of $40,000, the indication in the U.S. could realistically haul in nearly $300 million in annual revenue for AbbVie. This would be a nice revenue addition for AbbVie, which analysts already expect will generate $56.3 billion in revenue this year.
AbbVie is a soon-to-be Dividend King
By way of its roots dating back to when it was part of Abbott Laboratories, AbbVie is set to become a Dividend King. Its next dividend increase should be announced in the near future. This is despite the fact that AbbVie was spun off from Abbott Labs in 2013. But to its credit, AbbVie has raised its dividend each year since the spin-off.
AbbVie's dividend payout ratio is set to be in the low-40% range for this year, which is the reason for my confidence that AbbVie will soon raise its dividend and become a member of the highly respected Dividend Kings. And trading at less than nine times this year's non-GAAP earnings per share (EPS) forecast, AbbVie offers a market-crushing 4.8% dividend yield at an attractive price to income investors. With an already strong yield, the addition of this Rinvoq indication in the U.S. would provide more cushion for the company.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Kody Kester owns shares of AbbVie and Abbott Laboratories. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. AbbVie enrolled 420 adult patients with ankylosing spondylitis who previously failed at least one biologic disease-modifying antirheumatic drug (bDMARD) into its phase 3 clinical trial to test the efficacy and safety of Rinvoq. A large market with a need for more options Rinvoq appears to be effective and well-tolerated by patients, which is why it was approved for use in the European Union in January for three rheumatic indications, including for ankylosing spondylitis. | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. Let's dive into the data studying Rinvoq's effect on patients with ankylosing spondylitis, as well as Rinvoq's U.S. sales potential to address this question. A highly effective treatment Ankylosing spondylitis is a "rare type of arthritis that causes pain and stiffness in your spine," according to WebMD. | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. AbbVie enrolled 420 adult patients with ankylosing spondylitis who previously failed at least one biologic disease-modifying antirheumatic drug (bDMARD) into its phase 3 clinical trial to test the efficacy and safety of Rinvoq. Factoring in 7,300 patients taking Rinvoq for ankylosing spondylitis in the U.S. at a net annual price of $40,000, the indication in the U.S. could realistically haul in nearly $300 million in annual revenue for AbbVie. | Let's dive into the data studying Rinvoq's effect on patients with ankylosing spondylitis, as well as Rinvoq's U.S. sales potential to address this question. Since I believe that Rinvoq's efficacy makes up for the potential safety concerns associated with the JAK inhibitor drug class, the drug can reasonably capture 15%, or around 7,300, of these patients. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie and Abbott Laboratories. |
31925.0 | 2021-10-24 00:00:00 UTC | What's Next For Guardant Health Stock After An 18% Fall In A Month? | ABT | https://www.nasdaq.com/articles/whats-next-for-guardant-health-stock-after-an-18-fall-in-a-month-2021-10-24 | nan | nan | The stock price of Guardant Health (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen an 18% fall over the last twenty-one trading days. This can be attributed to its plans to acquire NeoGenomics (NYSE: NEO). Both the companies offer multiple diagnostics tests for cancer patients, but investors were concerned about the valuation for NeoGenomics. The market capitalization for NEO stock was around $6 billion, earlier this month, compared to around $10 billion for Guardant, and with an acquisition of such a size, Guardant would have to use a significant portion of its stock. As such, GH stock plummeted 14% in a single trading session on October 1. However, a few days later there were reports of Guardant deciding not to pursue NeoGenomics, and this led to some respite in GH stock, but it didn’t stage a rebound toward the $125 levels it was at before this development.
Now that GH stock has seen a fall of 18% in a month, will it continue its downward trajectory, or is a rise imminent? Going by historical performance, there is a strong chance of a rise in GH stock over the next month. Out of 67 instances in the last three years that GH stock saw a twenty-one-day fall of 18% or more, 50 of them resulted in GH stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 50 out of 67, or about 75% chance of a rise in GH stock over the coming month. See our analysis on Guardant Health Stock Chance of Rise for more details.
So, if this follows historical performance, it is likely that GH stock will rise to higher levels going forward. Also, Guardant Health Stock Return summarizes GH stock performance and chances of its rise or decline, among other metrics that matter.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last three years data
After moving 4.3% or lower over a five-day period, the stock rose in the next five days on 54% of the occasions.
After moving <1% or more over a ten-day period, the stock rose in the next ten days on 53% of the occasions
After moving -18% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 75% of the occasions.
How does Guardant Health (GH) stock return in the recent past compare with peers and the S&P 500?
Five-Day Return: TMO highest at 5.6%; S&P 500 lowest at 1.4%
Ten-Day Return: ILMN highest at 5.2%; S&P 500 lowest at 0.09%
Twenty-One Day Return: ^SPX highest at 4.2%; S&P 500 lowest at -18%
While GH stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Abbott vs. Qorvo. What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016. Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The stock price of Guardant Health (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen an 18% fall over the last twenty-one trading days. However, a few days later there were reports of Guardant deciding not to pursue NeoGenomics, and this led to some respite in GH stock, but it didn’t stage a rebound toward the $125 levels it was at before this development. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last three years data After moving 4.3% or lower over a five-day period, the stock rose in the next five days on 54% of the occasions. | The stock price of Guardant Health (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen an 18% fall over the last twenty-one trading days. Also, Guardant Health Stock Return summarizes GH stock performance and chances of its rise or decline, among other metrics that matter. Five-Day Return: TMO highest at 5.6%; S&P 500 lowest at 1.4% Ten-Day Return: ILMN highest at 5.2%; S&P 500 lowest at 0.09% Twenty-One Day Return: ^SPX highest at 4.2%; S&P 500 lowest at -18% While GH stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | Out of 67 instances in the last three years that GH stock saw a twenty-one-day fall of 18% or more, 50 of them resulted in GH stock rising over the subsequent one-month period (twenty-one trading days). Also, Guardant Health Stock Return summarizes GH stock performance and chances of its rise or decline, among other metrics that matter. Five-Day Return: TMO highest at 5.6%; S&P 500 lowest at 1.4% Ten-Day Return: ILMN highest at 5.2%; S&P 500 lowest at 0.09% Twenty-One Day Return: ^SPX highest at 4.2%; S&P 500 lowest at -18% While GH stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | The stock price of Guardant Health (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen an 18% fall over the last twenty-one trading days. Out of 67 instances in the last three years that GH stock saw a twenty-one-day fall of 18% or more, 50 of them resulted in GH stock rising over the subsequent one-month period (twenty-one trading days). How does Guardant Health (GH) stock return in the recent past compare with peers and the S&P 500? |
31926.0 | 2021-10-22 00:00:00 UTC | Why Senseonics Holdings Stock Popped This Week | ABT | https://www.nasdaq.com/articles/why-senseonics-holdings-stock-popped-this-week-2021-10-22 | nan | nan | What happened
Shares of Senseonics Holdings (NYSEMKT: SENS) rose by nearly 10% by the end of trading Thursday afternoon this week, according to data from S&P Global Market Intelligence. Senseonics is a small-cap player in the high-value and ultra-high growth continuous glucose monitoring (CGM) system market.
What sparked the stock's upswing this week? While the medical device company has so far maintained radio silence this week, investors are apparently piling into this stock in anticipation of a long-awaited approval for the 180-day version of the company's implantable Eversense device. Senseonics applied for a premarket approval to the U.S. Food and Drug Administration to extend the wearable life of the Eversense CGM system to 180 days on Sept. 30.
Image source: Getty Images.
So what
Senseonics might be targeting one of the fastest growing areas in all of healthcare. But its Eversense CGM devices are fighting for market share against entrenched competitors from the likes of Abbott Laboratories, DexCom, and Medtronic. As a direct result of this exceedingly intense competition, Wall Street only expects Senseonics to generate about $14 million in total sales this year. That's not a whole lot of revenue for a company with a market cap north of $1.59 billion at the time of writing. Investors, for their part, are hoping that this six-month version of the Eversense CGM system will make the company far more competitive against these industry giants in 2022 and beyond.
Now what
FDA PMA reviews can take around a year to complete. Armed with this insight, investors appear to be buying this small-cap biotech stock right now in the hopes of catching lightning in a bottle, so to speak. A six-month implantable CGM device, after all, could be a game changer for the company in terms of its top-line growth. Therefore, risk-tolerant investors may want to consider buying this speculative medical device stock ahead of this potentially explosive catalyst.
10 stocks we like better than Senseonics Holdings, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of October 20, 2021
George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Senseonics Holdings (NYSEMKT: SENS) rose by nearly 10% by the end of trading Thursday afternoon this week, according to data from S&P Global Market Intelligence. Senseonics applied for a premarket approval to the U.S. Food and Drug Administration to extend the wearable life of the Eversense CGM system to 180 days on Sept. 30. As a direct result of this exceedingly intense competition, Wall Street only expects Senseonics to generate about $14 million in total sales this year. | While the medical device company has so far maintained radio silence this week, investors are apparently piling into this stock in anticipation of a long-awaited approval for the 180-day version of the company's implantable Eversense device. Investors, for their part, are hoping that this six-month version of the Eversense CGM system will make the company far more competitive against these industry giants in 2022 and beyond. A six-month implantable CGM device, after all, could be a game changer for the company in terms of its top-line growth. | While the medical device company has so far maintained radio silence this week, investors are apparently piling into this stock in anticipation of a long-awaited approval for the 180-day version of the company's implantable Eversense device. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! See the 10 stocks *Stock Advisor returns as of October 20, 2021 George Budwell has no position in any of the stocks mentioned. | While the medical device company has so far maintained radio silence this week, investors are apparently piling into this stock in anticipation of a long-awaited approval for the 180-day version of the company's implantable Eversense device. 10 stocks we like better than Senseonics Holdings, Inc. That's right -- they think these 10 stocks are even better buys. |
31927.0 | 2021-10-21 00:00:00 UTC | Quest Diagnostics raises full-year forecast on strong COVID-19 test demand | ABT | https://www.nasdaq.com/articles/quest-diagnostics-raises-full-year-forecast-on-strong-covid-19-test-demand-2021-10-21 | nan | nan | Adds details on earnings, background, share movement
Oct 21 (Reuters) - U.S. laboratory Quest Diagnostics Inc DGX.N on Thursday raised its full-year forecast for profit and revenue and beat third-quarter estimates, on strong demand for its COVID-19 tests due to the spread of the virulent Delta variant in the United States.
COVID-19 testing volumes in the U.S. had slumped in the first half of this year, but demand rose once again in recent months due to the Delta variant, leading employers and schools to implement strict screening programs.
"We have raised our outlook for the remainder of the year based on higher than anticipated COVID-19 volumes," the company said.
Diagnostic companies like Abbott Laboratories ABT.N have said demand for COVID-19 tests rebounded during the quarter.
The company raised its full-year revenue forecast to between $10.45 billion and $10.60 billion, from $9.84 billion to $10.09 billion, and full-year profit outlook to $13.50 to $13.90, from $11.65 to $12.35.
Excluding items, Quest earned $3.96 per share, beating analysts' estimates of $2.88.
Net income attributable to the company fell to $505 million, or $4.02 per share, in the quarter ended Sept. 30, from $568 million, or $4.14 per share, a year earlier.
Shares of the company rose 3% before the bell.
(Reporting by Oishee Majumdar and Dania Nadeem in Bengaluru; Editing by Shailesh Kuber)
((oishee.majumdar@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Diagnostic companies like Abbott Laboratories ABT.N have said demand for COVID-19 tests rebounded during the quarter. Adds details on earnings, background, share movement Oct 21 (Reuters) - U.S. laboratory Quest Diagnostics Inc DGX.N on Thursday raised its full-year forecast for profit and revenue and beat third-quarter estimates, on strong demand for its COVID-19 tests due to the spread of the virulent Delta variant in the United States. COVID-19 testing volumes in the U.S. had slumped in the first half of this year, but demand rose once again in recent months due to the Delta variant, leading employers and schools to implement strict screening programs. | Diagnostic companies like Abbott Laboratories ABT.N have said demand for COVID-19 tests rebounded during the quarter. Adds details on earnings, background, share movement Oct 21 (Reuters) - U.S. laboratory Quest Diagnostics Inc DGX.N on Thursday raised its full-year forecast for profit and revenue and beat third-quarter estimates, on strong demand for its COVID-19 tests due to the spread of the virulent Delta variant in the United States. The company raised its full-year revenue forecast to between $10.45 billion and $10.60 billion, from $9.84 billion to $10.09 billion, and full-year profit outlook to $13.50 to $13.90, from $11.65 to $12.35. | Diagnostic companies like Abbott Laboratories ABT.N have said demand for COVID-19 tests rebounded during the quarter. Adds details on earnings, background, share movement Oct 21 (Reuters) - U.S. laboratory Quest Diagnostics Inc DGX.N on Thursday raised its full-year forecast for profit and revenue and beat third-quarter estimates, on strong demand for its COVID-19 tests due to the spread of the virulent Delta variant in the United States. The company raised its full-year revenue forecast to between $10.45 billion and $10.60 billion, from $9.84 billion to $10.09 billion, and full-year profit outlook to $13.50 to $13.90, from $11.65 to $12.35. | Diagnostic companies like Abbott Laboratories ABT.N have said demand for COVID-19 tests rebounded during the quarter. Adds details on earnings, background, share movement Oct 21 (Reuters) - U.S. laboratory Quest Diagnostics Inc DGX.N on Thursday raised its full-year forecast for profit and revenue and beat third-quarter estimates, on strong demand for its COVID-19 tests due to the spread of the virulent Delta variant in the United States. COVID-19 testing volumes in the U.S. had slumped in the first half of this year, but demand rose once again in recent months due to the Delta variant, leading employers and schools to implement strict screening programs. |
31928.0 | 2021-10-21 00:00:00 UTC | 3 Things Investors Should Love About Abbott's Q3 Results | ABT | https://www.nasdaq.com/articles/3-things-investors-should-love-about-abbotts-q3-results-2021-10-21 | nan | nan | Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. It's achieved market-leading positions with all of its businesses. The company has increased its dividend payout for 49 consecutive years.
Now there's even more to like. Abbott provided its third-quarter update before the market opened on Wednesday. Here are three things that investors should love about the healthcare-giant's Q3 results.
Image source: Getty Images.
1. Big revenue and earnings beats
Abbott's shares rose more than 2% on Wednesday after its Q3 earnings update. This gain was unsurprising, considering that Abbott beat Wall Street's top- and bottom-line estimates.
The consensus analyst estimate was for Abbott to generate revenue of $9.56 billion in the third quarter. The company blew past that estimate with Q3 revenue of $10.9 billion. This result reflected a 23.4% year-over-year increase on a reported basis and a 22.4% jump on an organic basis, adjusting for the impact of currency fluctuations.
Abbott announced Q3 diluted earnings per share (EPS) of $1.17, based on generally accepted accounting principles (GAAP). The company reported adjusted diluted EPS of $1.40, up 42.9% year over year and well above the $0.94 expected by Wall Street.
2. Strong non-COVID-19 growth
COVID-19 continued to serve as a huge growth driver for Abbott. The company reported sales of $1.9 billion in Q3 for its COVID-19 tests, which include the BinaxNOW, Panbio,and ID NOW rapid tests.
However, Abbott also saw strong growth that wasn't related to COVID-19. Excluding COVID testing-related sales, the company's Q3 sales jumped 11.7%, compared to the same quarter of 2019.
The company's Ensure, Pedialyte, and Glucerna nutrition products kept their sales momentum going in Q3. Abbott's molecular-diagnostics revenue rose 14.9% year over year, excluding all COVID-19 testing. Its generic drugs enjoyed solid growth, as well, especially in China, India, and Russia.
Medical-device sales were especially robust, soaring 18.5% from pre-pandemic levels in 2019. Abbott's FreeStyle Libre and Libre Sense diabetes management devices chalked up Q3 sales of $968 million, up 41.6% year over year.
3. Increased guidance
Investors like strong growth and better-than-expected revenue and earnings. But what they really love is when a company has more optimistic expectations for its future. Abbott gave investors what they wanted on this front, as well.
The company increased its full-year 2021 GAAP earnings guidance to a range of $3.55 to $3.65. It previously expected GAAP earnings for the year would be between $2.75 and $2.95.
Abbott also boosted its adjusted earnings guidance for the full year. It now looks for adjusted diluted earnings per share from continuing operations to be between $5 and $5.10, excluding specified items. The company's previous outlook projected that adjusted earnings per share from continuing operations would be between $4.30 and $4.50.
More good news on the way?
Several other recent developments could translate to even more good news for Abbott in the near future. The company won U.S. Food and Drug Administration (FDA) approval for its Amplatzer Amulet stroke-prevention device in August. In September, the FDA approved Abbott's Portico with FlexNav transcatheter aortic valve-replacement system in treating individuals with severe aortic stenosis (narrowing of the aortic valve opening) who have a high or extreme risk of requiring open-heart surgery.
Abbott also completed its acquisition of Walk Vascular in the third quarter. Walk Vascular markets medical devices used to remove peripheral blood clots, a great fit with the company's vascular medical-device business.
Abbott's financial fortunes could vary somewhat depending on the future demand for COVID-19 testing. However, it remains a seemingly unstoppable stock that's likely to be a winner for a long to come.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. This gain was unsurprising, considering that Abbott beat Wall Street's top- and bottom-line estimates. Abbott announced Q3 diluted earnings per share (EPS) of $1.17, based on generally accepted accounting principles (GAAP). | Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Big revenue and earnings beats Abbott's shares rose more than 2% on Wednesday after its Q3 earnings update. The company reported adjusted diluted EPS of $1.40, up 42.9% year over year and well above the $0.94 expected by Wall Street. | Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Big revenue and earnings beats Abbott's shares rose more than 2% on Wednesday after its Q3 earnings update. Abbott's molecular-diagnostics revenue rose 14.9% year over year, excluding all COVID-19 testing. | Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. The company reported adjusted diluted EPS of $1.40, up 42.9% year over year and well above the $0.94 expected by Wall Street. Excluding COVID testing-related sales, the company's Q3 sales jumped 11.7%, compared to the same quarter of 2019. |
31929.0 | 2021-10-20 00:00:00 UTC | US STOCKS-Futures flat on worries over supply chain disruptions; Netflix falls | ABT | https://www.nasdaq.com/articles/us-stocks-futures-flat-on-worries-over-supply-chain-disruptions-netflix-falls-2021-10-20-0 | nan | nan | By Devik Jain
Oct 20 (Reuters) - U.S. stock index futures struggled for direction on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report.
Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year.
Its shares, however, fell 2% after hitting a record high earlier this month and gaining 18.2% so far this year.
Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, while keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions.
"Investor response to the latest set of earnings reports has been a touch hit and miss with supply chain issues dogging both Procter and Gamble and Philip Morris," Danni Hewson, financial analyst at AJ Bell, said in a client note.
Other mega cap technology and communication names were mixed in premarket trading. Facebook FB.O, up 0.7%, is planning to rebrand itself with new name that focuses on metaverse, according to the Verge.
Tesla Inc TSLA.O edged 0.3% lower in the run up to its quarterly results after markets close, with investors awaiting details on its performance in China.
"People are waiting to see what the large tech companies are going to report. That is probably the real reason we're seeing individual stocks responding more than the broader market," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.
In quarterly reports, Verizon Communications Inc VZ.N gained 1.2% as it added more postpaid phone subscribers than expected in the third quarter, while oilfield firm Baker Hughes Co BKR.N slipped 3.2% on downbeat profit.
Abbott Laboratories ABT.N rose 3.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales.
Anthem Inc ANTM.N rose 1.6% and Biogen Inc BIIB.O gained 1.3% after both healthcare companies raised their full-year profit forecasts.
United Airlines Holdings UAL.O gained 1.6% after the carrier reported a smaller quarterly loss than a year ago on travel rebound.
The benchmark S&P 500 index .SPX is just 0.4% below its early September record close, while the Dow Jones Industrials average .DJI is 0.5% below its all-time high reached in mid-August.
U.S. stock indexes closed higher on Tuesday with the biggest boosts from the technology and healthcare sectors amid optimism about solid third-quarter earnings season.
At 08:52 a.m. ET, Dow e-minis 1YMcv1 were down 19 points, or 0.05%, S&P 500 e-minis EScv1 remained unchanged and Nasdaq 100 e-minis NQcv1 were up 15 points, or 0.1%.
Ford Motor F.N gained 0.5% after Credit Suisse upgraded the U.S. automaker's stock to 'outperform' on EV transition.
Oil majors Exxon Mobil XOM.N and Chevron Corp CVX.N slipped 0.6% and 0.3%, respectively, tracking crude prices. O/R/
(Reporting by Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Arun Koyyur)
((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780; +91 961 144 3740; Twitter: https://twitter.com/s_shreyashi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N rose 3.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures struggled for direction on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. | Abbott Laboratories ABT.N rose 3.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures struggled for direction on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Anthem Inc ANTM.N rose 1.6% and Biogen Inc BIIB.O gained 1.3% after both healthcare companies raised their full-year profit forecasts. | Abbott Laboratories ABT.N rose 3.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures struggled for direction on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, while keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions. | Abbott Laboratories ABT.N rose 3.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. Its shares, however, fell 2% after hitting a record high earlier this month and gaining 18.2% so far this year. |
31930.0 | 2021-10-20 00:00:00 UTC | US STOCKS-Wall Street closes higher as earnings reports soothe investor fears | ABT | https://www.nasdaq.com/articles/us-stocks-wall-street-closes-higher-as-earnings-reports-soothe-investor-fears-2021-10-20-0 | nan | nan | By Devik Jain, Shreyashi Sanyal and Sinéad Carew
Oct 20 (Reuters) - The S&P 500 and the Dow climbed on Wednesday with the Dow hitting an intraday record high as investors eyed better than expected third-quarter earnings from U.S. companies.
While the Nasdaq lagged as technology stocks took a breather, the Dow Jones Industrials Average .DJI surpassed its previous record reached in mid-August before paring gains during the session. The benchmark S&P 500 index .SPX came within five points of its early September record at its peak for the day.
The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which both gained ground on impressive financial forecasts.
The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week.
And while U.S. companies have been citing supply chain problems and higher costs during their earnings calls, investors have been relieved so far that they seem to be able to maintain profit margins by passing on costs to customers, according to Jack Janasiewicz, strategist and portfolio manager at Natixis Investment Managers Solutions.
"Earnings are what matter and thus far what we've seen have actually been better than expected. Margins are actually holding up, said Janasiewicz.
"The bar was set pretty low coming into (earnings season) so that makes things a little easier ... Things are coming out, so far, better than expected. That's putting upward pressure on stocks."
With just about 14% of S&P 500 third-quarter reports in, analysts were expecting earnings for the benchmark index to rise 33% from the year-ago quarter. More than 85% of earnings beat expectations, according to the latest Refinitiv data.
The Dow Jones Industrial Average .DJI rose 152.03 points, or 0.43%, to 35,609.34, the S&P 500 .SPX gained 16.56 points, or 0.37%, to 4,536.19 and the Nasdaq Composite .IXIC dropped 7.41 points, or 0.05%, to 15,121.68.
The CBOE volatility index .VIX, also known as Wall Street's fear gauge, closed at 15.49 after earlier hitting 15.29, its lowest level since Aug. 13.
Eight of the S&P's eleven major industry sectors indexes were advanced, led by utilities .SPLRCU and real estate .SPLRCR, both finishing up about 1.6% higher, and healthcare stocks .SPXHC, which closed up 1.5%.
The technology sector .SPLRCT was the S&P's biggest laggard, down 0.3%, as it snapped a five-day rally.
The S&P 500 Value index .IVX, which houses economically-sensitive stocks like energy and industrials, closed up 0.9% after hitting a fresh record high.
However, shares in IBM IBM.N were down around 5% in after the bell trading on Wednesday after it missed market estimates for third-quarter revenue due to a decline in orders at its managed infrastructure unit ahead of a spinoff.
Shares in Tesla Inc TSLA.O dipped slightly in late trade even after it beat Wall Street expectations for third-quarter revenue on the back of record deliveries, as the electric carmaker navigates through a prolonged global shortage of chips and raw materials.
Abbott Laboratories ABT.N had finished the regular trading session up 3.3% after raising its full-year profit forecast on a rebound in COVID-19 test sales.
Anthem Inc ANTM.N soared 7.7% after raising its full-year earnings forecasts. However, Biogen Inc BIIB.Oshares closed down 0.6% as it reported a much smaller-than-expected quarterly sales of its Alzheimer's drug while it raised its full year earnings forecast.
Verizon Communications Inc VZ.N gained 2.4% after it added more postpaid phone subscribers than expected in the third quarter.
Advancing issues outnumbered declining ones on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.37-to-1 ratio favored advancers.
The S&P 500 posted 63 new 52-week highs and no new lows; the Nasdaq Composite recorded 106 new highs and 41 new lows.
On U.S. exchanges 9.29 billion shares changed hands compared with the 10.26 billion average for the last 20 sessions.
(Reporting by Devik Jain and Shreyashi Sanyal in Bengaluru, Sinéad Carew in New York, Editing by Arun Koyyur)
((Sinead.carew@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which both gained ground on impressive financial forecasts. Abbott Laboratories ABT.N had finished the regular trading session up 3.3% after raising its full-year profit forecast on a rebound in COVID-19 test sales. The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which both gained ground on impressive financial forecasts. Abbott Laboratories ABT.N had finished the regular trading session up 3.3% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The S&P 500 and the Dow climbed on Wednesday with the Dow hitting an intraday record high as investors eyed better than expected third-quarter earnings from U.S. companies. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which both gained ground on impressive financial forecasts. Abbott Laboratories ABT.N had finished the regular trading session up 3.3% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The S&P 500 and the Dow climbed on Wednesday with the Dow hitting an intraday record high as investors eyed better than expected third-quarter earnings from U.S. companies. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which both gained ground on impressive financial forecasts. Abbott Laboratories ABT.N had finished the regular trading session up 3.3% after raising its full-year profit forecast on a rebound in COVID-19 test sales. With just about 14% of S&P 500 third-quarter reports in, analysts were expecting earnings for the benchmark index to rise 33% from the year-ago quarter. |
31931.0 | 2021-10-20 00:00:00 UTC | Why Abbott Laboratories Shot Higher Today | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-shot-higher-today-2021-10-20 | nan | nan | What happened
Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. The reason was the company's impressive third quarter, the results of which were published that morning.
So what
For the quarter, Abbott posted year-over-year sales growth of 23%, as its top line landed at $10.9 billion. Non-GAAP (adjusted) net income ballooned even more, expanding by 43% to just over $2.5 billion ($1.40 per share).
Image source: Getty Images.
Both headline figures were miles above the average analyst expectations. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93.
Not surprisingly, the most robust growth among the four Abbott business units was recorded by diagnostics. After all, the company has done very well with its COVID-19 testing products. Diagnostics' sales shot 48% higher during the quarter to take second place among the four with over $3.9 billion in revenue. Even without the COVID-19 tests, the unit would have done well, with a 14% rise in sales.
Two other divisions also posted double-digit increases at around the 15% mark -- medical devices and established pharmaceuticals (branded generics sold outside the U.S. market). The fourth unit, nutrition, enjoyed a nearly 10% gain, producing $2.1 billion in sales.
Now what
With such better-than-expected performance at its back, Abbott is confidently and significantly raising its profitability guidance. The company now expects that it will post a per-share, adjusted net profit of $5.00 to $5.10 for the entirety of 2021. Previously, it was guiding for $4.30 to $4.50. For comparison, that figure for 2020 was $3.65.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of October 20, 2021
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93. Two other divisions also posted double-digit increases at around the 15% mark -- medical devices and established pharmaceuticals (branded generics sold outside the U.S. market). | What happened Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. So what For the quarter, Abbott posted year-over-year sales growth of 23%, as its top line landed at $10.9 billion. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93. | What happened Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | What happened Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. So what For the quarter, Abbott posted year-over-year sales growth of 23%, as its top line landed at $10.9 billion. Even without the COVID-19 tests, the unit would have done well, with a 14% rise in sales. |
31932.0 | 2021-10-20 00:00:00 UTC | US STOCKS-Wall Street closes higher as earnings reports soothe investor fears | ABT | https://www.nasdaq.com/articles/us-stocks-wall-street-closes-higher-as-earnings-reports-soothe-investor-fears-2021-10-20 | nan | nan | By Devik Jain, Shreyashi Sanyal and Sinéad Carew
Oct 20 (Reuters) - The S&P 500 and the Dow closed higher on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies.
While the Nasdaq lagged as technology stocks took a breather, the Dow Jones Industrials Average .DJI briefly surpassed its previous record reached in mid-August during, while the benchmark S&P 500 index .SPX came within five points of its early September record during the session.
The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which gained on impressive financial forecasts.
The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week.
And while U.S. companies have been citing supply chain problems and higher costs during their earnings calls, investors have been relieved so far that they seem to be able to maintain profit margins by passing on costs to customers, according to Jack Janasiewicz, strategist and portfolio manager at Natixis Investment Managers Solutions.
"Earnings are what matter and thus far what we've seen have actually been better than expected. Margins are actually holding up, said Janasiewicz.
"The bar was set pretty low coming into (earnings season) so that makes things a little easier ... Things are coming out, so far, better than expected. That's putting upward pressure on stocks."
With just about 14% of S&P 500 third-quarter reports in, analysts were expecting earnings for the benchmark index to rise 33% from the year-ago quarter. More than 85% of those who reported beat expectations, according to the latest data from Refinitiv.
According to preliminary data, the S&P 500 .SPX gained 17.14 points, or 0.38%, to end at 4,536.77 points, while the Nasdaq Composite .IXIC lost 6.25 points, or 0.05%, to 15,121.68. The Dow Jones Industrial Average .DJI rose 157.95 points, or 0.45%, to 35,615.26.
During the session, the CBOE volatility index .VIX, also known as Wall Street's fear gauge, fell to its lowest level since Aug. 13.
The S&P 500 Value index .IVX, which houses economically-sensitive stocks like energy and industrials, hit a fresh record, during the session as investors eyed robust economic growth.
Abbott Laboratories ABT.Nadvanced after raising its full-year profit forecast on a rebound in COVID-19 test sales.
Anthem Inc ANTM.Nclimbed after raising its full-year earnings forecasts. However, Biogen Inc BIIB.Oshares had a choppier session as it reported a much smaller-than-expected quarterly sales of its Alzheimer's drug while it raised its full year earnings forecast.
Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. But its shares, fell after hitting a record high earlier this month.
Investors were watching anxiously for results from Tesla Inc TSLA.O after the close, with costs and margins in focus amid chip shortages and supply chain issues.
Verizon Communications Inc VZ.N gained ground as it added more postpaid phone subscribers than expected in the third quarter, while shares in Baker Hughes Co BKR.N fell as its profit missed expectations.
(Reporting by Devik Jain and Shreyashi Sanyal in Bengaluru, Sinéad Carew in New York, Editing by Arun Koyyur)
((Sinead.carew@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which gained on impressive financial forecasts. Abbott Laboratories ABT.Nadvanced after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The S&P 500 and the Dow closed higher on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which gained on impressive financial forecasts. Abbott Laboratories ABT.Nadvanced after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The S&P 500 and the Dow closed higher on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which gained on impressive financial forecasts. Abbott Laboratories ABT.Nadvanced after raising its full-year profit forecast on a rebound in COVID-19 test sales. While the Nasdaq lagged as technology stocks took a breather, the Dow Jones Industrials Average .DJI briefly surpassed its previous record reached in mid-August during, while the benchmark S&P 500 index .SPX came within five points of its early September record during the session. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which gained on impressive financial forecasts. Abbott Laboratories ABT.Nadvanced after raising its full-year profit forecast on a rebound in COVID-19 test sales. The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week. |
31933.0 | 2021-10-20 00:00:00 UTC | Health Care Sector Update for 10/20/2021: ABT,LMDX,ANTM,MITO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-10-20-2021%3A-abtlmdxantmmito-2021-10-20 | nan | nan | Health care stocks eased only slightly from their market-leading gains, with the NYSE Health Care Index rising 1.5% in late trade while the SPDR Health Care Select Sector ETF (XLV) was up 1.4%.
The Nasdaq Biotechnology index, however, was falling 0.1 this afternoon.
In company news, Abbott Laboratories (ABT) climbed 3.3% after reporting improved Q3 net income and revenue and raised its FY21 earnings forecast, with its top-line results benefitting by ongoing sales of its COVID-19 testing products. Excluding one-time items, the health care products company earned $1.40 per share, up from $0.98 per share during the same quarter last year, while net sales increased 23.5% to $10.93 billion. Analysts, on average, were expecting a $0.95 per share adjusted profit on $9.56 billion in sales.
LumiraDx (LMDX) rose almost 13% after Indian regulators approved emergency use of the company's SARS-CoV-2 antigen test. The 12-minute test demonstrated a 97.6% positive agreement and 96.6% negative agreement during clinical testing in patients within the first 12 days of symptom.
Anthem (ANTM) advanced 7.8% after reporting non-GAAP Q3 net income and revenue exceeding analyst forecasts and also raising its FY21 profit outlook. Excluding one-time items, the health care insurance carrier earned $6.79 per share on $35.82 billion in revenue during the three months ended Sept. 30 compared with the Capital IQ consensus expecting a $6.37 per share adjusted profit on $35.35 billion in revenue.
Stealth BioTherapeutics (MITO) fell over 10% after the US Food and Drug Administration declined to accept the new drug application for its Elamipretide drug candidate to treat Barth syndrome, saying the application did not include sufficient data to support a substantive review.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Abbott Laboratories (ABT) climbed 3.3% after reporting improved Q3 net income and revenue and raised its FY21 earnings forecast, with its top-line results benefitting by ongoing sales of its COVID-19 testing products. LumiraDx (LMDX) rose almost 13% after Indian regulators approved emergency use of the company's SARS-CoV-2 antigen test. Anthem (ANTM) advanced 7.8% after reporting non-GAAP Q3 net income and revenue exceeding analyst forecasts and also raising its FY21 profit outlook. | In company news, Abbott Laboratories (ABT) climbed 3.3% after reporting improved Q3 net income and revenue and raised its FY21 earnings forecast, with its top-line results benefitting by ongoing sales of its COVID-19 testing products. Excluding one-time items, the health care products company earned $1.40 per share, up from $0.98 per share during the same quarter last year, while net sales increased 23.5% to $10.93 billion. Anthem (ANTM) advanced 7.8% after reporting non-GAAP Q3 net income and revenue exceeding analyst forecasts and also raising its FY21 profit outlook. | In company news, Abbott Laboratories (ABT) climbed 3.3% after reporting improved Q3 net income and revenue and raised its FY21 earnings forecast, with its top-line results benefitting by ongoing sales of its COVID-19 testing products. Health care stocks eased only slightly from their market-leading gains, with the NYSE Health Care Index rising 1.5% in late trade while the SPDR Health Care Select Sector ETF (XLV) was up 1.4%. Excluding one-time items, the health care products company earned $1.40 per share, up from $0.98 per share during the same quarter last year, while net sales increased 23.5% to $10.93 billion. | In company news, Abbott Laboratories (ABT) climbed 3.3% after reporting improved Q3 net income and revenue and raised its FY21 earnings forecast, with its top-line results benefitting by ongoing sales of its COVID-19 testing products. Excluding one-time items, the health care products company earned $1.40 per share, up from $0.98 per share during the same quarter last year, while net sales increased 23.5% to $10.93 billion. Analysts, on average, were expecting a $0.95 per share adjusted profit on $9.56 billion in sales. |
31934.0 | 2021-10-20 00:00:00 UTC | US STOCKS-S&P 500, Dow near records as earnings reports soothe investor fears | ABT | https://www.nasdaq.com/articles/us-stocks-sp-500-dow-near-records-as-earnings-reports-soothe-investor-fears-2021-10-20 | nan | nan | By Devik Jain, Shreyashi Sanyal and Sinéad Carew
Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies.
While the Nasdaq lagged as technology stocks took a breather, the S&P's utility sector was gaining sharply and the healthcare index rallied for a second day in a row after strong forecasts from Anthem ANTM.K and Abbott ABT.N.
The Dow Jones Industrials Average .DJI briefly surpassed its previous record reached in mid-August, while the benchmark S&P 500 index .SPX at one point came within roughly five points of its early September record.
The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week.
And while U.S. companies were citing supply chain problems and higher costs during their earnings calls investors have been relieved so far that they seem to be able to maintain profit margins by passing on costs to customers, according to Jack Janasiewicz, strategist and portfolio manager at Natixis Investment Managers Solutions.
"Earnings are what matter and thus far what we've seen have actually been better than expected. Margins are actually holding up, said Janasiewicz.
"The bar was set pretty low coming into (earnings season) so that makes things a little easier ... Things are coming out, so far, better than expected. That's putting upward pressure on stocks."
With just about 14% of S&P 500 third-quarter reports in, analysts were expecting earnings for the benchmark index to rise 33% from the year-ago quarter. More than 85% of those who reported beat expectations, according to the latest data from Refinitiv.
By 2:49PM ET, the Dow Jones Industrial Average .DJI rose 148.19 points, or 0.42%, to 35,605.5, the S&P 500 .SPX gained 15.13 points, or 0.33%, to 4,534.76 and the Nasdaq Composite .IXIC dropped 13.52 points, or 0.09%, to 15,115.57.
Eight of the eleven major S&P 500 sector indexes were trading higher, led by healthcare stocks .SPXHC,up 1.6%, and utilities .SPLRCU, up 1.5%, while technology shares .SPLRCT were down 0.3% after rallying for the previous five sessions.
The S&P 500 Value index .IVX, which houses economically-sensitive stocks like energy and industrials, hit a fresh record, as investors eyed robust economic growth.
Abbott Laboratories ABT.N rose 3.6% after raising its full-year profit forecast on a rebound in COVID-19 test sales.
Anthem Inc ANTM.N was up 6.6% after raising its full-year earnings forecasts. However, Biogen Inc BIIB.O was down slightly as it reported a much smaller-than-expected quarterly sales of its Alzheimer's drug while it raised its full year earnings forecast.
Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year.
Its shares, however, were down 1.9% after hitting a record high earlier this month and gaining 18.2% so far this year.
Tesla Inc TSLA.O was barely higher ahead of its quarterly results, with costs and margins in focus amid chip shortages and supply chain issues.
The CBOE volatility index .VIX, also known as Wall Street's fear gauge, fell to its lowest level since Aug. 13.
Verizon Communications Inc VZ.N gained 2.4% as it added more postpaid phone subscribers than expected in the third quarter, while Baker Hughes Co BKR.N was down 5.9% as its profit missed expectations.
Advancing issues outnumbered declining ones on the NYSE by a 2.17-to-1 ratio; on Nasdaq, a 1.36-to-1 ratio favored advancers.
The S&P 500 posted 59 new 52-week highs and no new lows; the Nasdaq Composite recorded 90 new highs and 34 new lows.
(Reporting by Devik Jain and Shreyashi Sanyal in Bengaluru, Sinéad Carew in New York, Editing by Arun Koyyur)
((Sinead.carew@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While the Nasdaq lagged as technology stocks took a breather, the S&P's utility sector was gaining sharply and the healthcare index rallied for a second day in a row after strong forecasts from Anthem ANTM.K and Abbott ABT.N. Abbott Laboratories ABT.N rose 3.6% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. | While the Nasdaq lagged as technology stocks took a breather, the S&P's utility sector was gaining sharply and the healthcare index rallied for a second day in a row after strong forecasts from Anthem ANTM.K and Abbott ABT.N. Abbott Laboratories ABT.N rose 3.6% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. | While the Nasdaq lagged as technology stocks took a breather, the S&P's utility sector was gaining sharply and the healthcare index rallied for a second day in a row after strong forecasts from Anthem ANTM.K and Abbott ABT.N. Abbott Laboratories ABT.N rose 3.6% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. | While the Nasdaq lagged as technology stocks took a breather, the S&P's utility sector was gaining sharply and the healthcare index rallied for a second day in a row after strong forecasts from Anthem ANTM.K and Abbott ABT.N. Abbott Laboratories ABT.N rose 3.6% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. |
31935.0 | 2021-10-20 00:00:00 UTC | US STOCKS-S&P 500, Dow near record highs on solid forecasts from healthcare firms | ABT | https://www.nasdaq.com/articles/us-stocks-sp-500-dow-near-record-highs-on-solid-forecasts-from-healthcare-firms-2021-10-20 | nan | nan | By Devik Jain and Shreyashi Sanyal
Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather.
The Dow Jones Industrials Average .DJI was just short of all-time highs reached in mid-August, while the benchmark S&P 500 index .SPX traded 0.2% below its early September record.
Ten of the 11 major S&P 500 sector indexes were trading higher, led by healthcare stocks .SPXHC, while technology shares .SPLRCT were down 0.1%.
Financials .SPSY gained 0.5% to hit a record high. The S&P 500 Value index .IVX, which houses economy-sensitive stocks like energy and industrials, also scaled new peaks.
Abbott Laboratories ABT.N rose 2.9% after raising its full-year profit forecast on a rebound in COVID-19 test sales.
Anthem Inc ANTM.N jumped 7.2% and Biogen Inc BIIB.O added 0.3% after both healthcare companies raised their full-year earnings forecasts.
Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, as they kept a close eye on growth outlook from companies faced with rising costs, labor shortages and supply chain disruptions.
"Earnings is boosting sentiment and we'll know more in two weeks... we're going to hear more about supply chain issues, wage growth and costs, etc. So far we haven't heard too much of that yet," said Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago.
Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year.
Its shares, however, fell 0.8% after hitting a record high earlier this month and gaining 18.2% so far this year.
Facebook Inc FB.O added 0.6% after it said it is planning to rebrand itself with new name that focuses on metaverse, according to the Verge.
Tesla Inc TSLA.O edged 0.3% higher ahead of its quarterly results, with investors keeping a tab on costs and margins amid chip shortages and supply chain issues.
"People are waiting to see what the large tech companies are going to report. That is probably the real reason we're seeing individual stocks responding more than the broader market," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.
The CBOE volatility index .VIX, also known as Wall Street's fear gauge, fell to its lowest level since Aug. 13.
At 12:02 p.m. ET, the Dow Jones Industrial Average .DJI was up 163.79 points, or 0.46%, at 35,621.10, the S&P 500 .SPX was up 18.89 points, or 0.42%, at 4,538.52 and the Nasdaq Composite .IXIC was up 26.24 points, or 0.17%, at 15,155.33.
Verizon Communications Inc VZ.N gained 2.6% as it added more postpaid phone subscribers than expected in the third quarter, while Baker Hughes Co BKR.N slipped 6.7% on downbeat profit.
Advancing issues outnumbered decliners by a 2.66-to-1 ratio on the NYSE and by a 1.52-to-1 ratio on the Nasdaq.
The S&P index recorded 55 new 52-week highs and no new low, while the Nasdaq recorded 77 new highs and 25 new lows.
(Reporting by Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Arun Koyyur)
((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780; +91 961 144 3740; Twitter: https://twitter.com/s_shreyashi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N rose 2.9% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather. Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. | Abbott Laboratories ABT.N rose 2.9% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather. Ten of the 11 major S&P 500 sector indexes were trading higher, led by healthcare stocks .SPXHC, while technology shares .SPLRCT were down 0.1%. | Abbott Laboratories ABT.N rose 2.9% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather. Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, as they kept a close eye on growth outlook from companies faced with rising costs, labor shortages and supply chain disruptions. | Abbott Laboratories ABT.N rose 2.9% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather. The Dow Jones Industrials Average .DJI was just short of all-time highs reached in mid-August, while the benchmark S&P 500 index .SPX traded 0.2% below its early September record. |
31936.0 | 2021-10-20 00:00:00 UTC | S&P 500 Movers: OMC, ANTM | ABT | https://www.nasdaq.com/articles/sp-500-movers%3A-omc-antm-2021-10-20 | nan | nan | In early trading on Wednesday, shares of Anthem topped the list of the day's best performing components of the S&P 500 index, trading up 5.9%. Year to date, Anthem registers a 29.8% gain.
And the worst performing S&P 500 component thus far on the day is Omnicom Group, trading down 5.8%. Omnicom Group, is showing a gain of 15.6% looking at the year to date performance.
Two other components making moves today are Baker Hughes, trading down 4.1%, and Abbott Laboratories, trading up 4.1% on the day.
VIDEO: S&P 500 Movers: OMC, ANTM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And the worst performing S&P 500 component thus far on the day is Omnicom Group, trading down 5.8%. Omnicom Group, is showing a gain of 15.6% looking at the year to date performance. VIDEO: S&P 500 Movers: OMC, ANTM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In early trading on Wednesday, shares of Anthem topped the list of the day's best performing components of the S&P 500 index, trading up 5.9%. Year to date, Anthem registers a 29.8% gain. And the worst performing S&P 500 component thus far on the day is Omnicom Group, trading down 5.8%. | In early trading on Wednesday, shares of Anthem topped the list of the day's best performing components of the S&P 500 index, trading up 5.9%. And the worst performing S&P 500 component thus far on the day is Omnicom Group, trading down 5.8%. Two other components making moves today are Baker Hughes, trading down 4.1%, and Abbott Laboratories, trading up 4.1% on the day. | And the worst performing S&P 500 component thus far on the day is Omnicom Group, trading down 5.8%. Omnicom Group, is showing a gain of 15.6% looking at the year to date performance. VIDEO: S&P 500 Movers: OMC, ANTM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31937.0 | 2021-10-20 00:00:00 UTC | Best Health Care Stocks To Buy In Q4? 4 For Your Watchlist | ABT | https://www.nasdaq.com/articles/best-health-care-stocks-to-buy-in-q4-4-for-your-watchlist-2021-10-20 | nan | nan | 4 Health Care Stocks To Check Out In The Stock Market Today
Even with the focus on earnings season in the stock market this week, Covid continues to dominate the headlines. Because of this, health care stocks remain relevant regardless. After all, the health care industry is essentially the frontline of defense against the current pandemic. As countries across the globe ramp up their anti-pandemic measures, vaccine stocks, in particular, would gain traction. In fact, the White House announced plans to inoculate 5 to 11-year-olds once U.S. regulators approve vaccines for the group. Also, while upcoming names like Novavax (NASDAQ: NVAX) are reportedly facing hurdles in their approval processes, investors continue to watch anxiously.
At the same time, some industry titans in the health care space are also posting their earnings. Earlier today, leading biotech firm Biogen (NASDAQ: BIIB), posted solid figures in its latest quarterly earnings call. Notably, the company saw an earnings per share of $4.77 for the quarter, smashing consensus estimates of $4.11. Moreover, Biogen also beat projections on the top and bottom lines and is raising its full-year revenue outlook. Overall, the health care industry continues to power forward, regardless of the current situation with Covid. Should all this have you interested in the top health care stocks to watch, here are four in focus in the stock market now.
Top Health Care Stocks To Buy [Or Sell] This Week
Pfizer Inc. (NYSE: PFE)
Abbott Laboratories (NYSE: ABT)
LumiraDx (NASDAQ: LMDX)
Johnson & Johnson Inc. (NYSE: JNJ)
Pfizer Inc.
First on this list, we have Pfizer, a multinational pharmaceutical and biotechnology company with headquarters in New York City. The company has been at the forefront of the fight against the pandemic. With its vaccine that was co-developed with BioNTech (NASDAQ: BNTX), it is well on track to deliver over 2 billion doses of its life-saving vaccines by the end of this year. Shares of PFE stock are trading at $42.99 a piece as of 11:48 a.m. ET. Today, the White House outlined a plan to distribute doses of the company’s vaccines to kids aged between 5 to 11 as soon as it is authorized by U.S. drug regulators.
Accordingly, the Biden administration said it has procured enough vaccines to inoculate all 28 million 5- to 11-year-olds in the U.S. A key U.S. Food and Drug Administration (FDA) vaccine advisory group is scheduled to meet next week to discuss Pfizer’s data. This is then followed by a Centers for Disease Control and Prevention (CDC) meeting on November 2. The shots could be approved shortly after these meetings, depending on how quickly the FDA and CDC respond. A report by CNN has also indicated that booster shots could soon be recommended for people as young as 40 with Moderna (NASDAQ: MRNA) and Pfizer’s Covid-19 vaccine. All things considered, should investors be adding PFE stock to their portfolios?
Source: TD Ameritrade TOS
[Read More] Top Reddit Stocks To Buy Right Now? 5 For Your Late 2021 Watchlist
Abbott Laboratories
Another name to consider among health care stocks now would be Abbott Laboratories. In brief, Abbott is an Illinois-based medical device manufacturer. For a sense of scale, the company currently operates in over 160 countries across the globe. Through its vast array of medical tech, Abbott helps treat millions of patients around the world annually. In terms of end markets, the company’s offerings encompass the cardiovascular, Covid-testing, diabetes, nutrition, and neuromodulation industries. More importantly, ABT stock is now making waves in the stock market thanks to the company’s latest quarterly earnings report.
As it stands, the company’s shares now trade at $123.22 as of 11:49 a.m. ET after gaining by over 3% since today’s opening bell. Diving right in, Abbott reported an earnings per share of $1.40 on revenue of $10.93 billion. Comparatively, this is well over Wall Street’s estimates of $0.98 and $9.56 billion respectively. According to the company, its global diagnostics division saw a record growth of 48.2% year-over-year. This is, of course, attributed to the $1.9 billion in sales for its Covid-19 testing-related wares. With that in mind, would you be watching ABT stock?
Source: TD Ameritrade TOS
[Read More] Top Stocks To Buy Now? 4 Consumer Stocks To Consider
LumiraDx
LumiraDx is a next-generation point of care diagnostics company. It focuses on transforming community-based health care by providing critical diagnostic information to health care providers at the point of need, thereby enabling more informed medical decisions to improve health outcomes while lowering costs. LMDX stock currently trades at $9.32 a piece as of 11:49 a.m. ET and is up by over 10% on today’s opening bell. Investors seem to be responding positively to news from the company today.
Diving in, the company announced that it had received emergency use approval by India’s Central Drugs Standard Control Organization for its Covid-19 antigen test for use in India. The test detects antigen nucleocapsid protein from a nasal swab and provides a result in under 12 minutes from sample application.
Impressively, its clinical studies have shown a 97.6% positive agreement and a 96.6% negative agreement with the PCR test for patients within the first twelve days of symptom. This would make LumiraDx’s test one of the fastest and most sensitive antigen point of care tests that are currently available in the market. The test kits are also available in the U.S. and Europe after receiving their respective regulatory approvals last year. Given this exciting piece of news, should you consider LMDX stock a buy right now?
Source: TD Ameritrade TOS
[Read More] Best EV Stocks To Buy Right Now? 4 In Focus
Johnson & Johnson
Lastly, we have Johnson & Johnson. The company has been around for more than a century and is one of the largest and most broadly-based health companies in the world. Boasting over 130,000 employees worldwide, the company strives to improve access and affordability for the masses and continues to innovate tirelessly. JNJ stock trades at $164.52 as of 11:50 a.m. ET. On Tuesday, the company reported its third-quarter financials, beating analyst estimates.
Firstly, it reported that total sales grew by 10.7% to $23.3 billion. The company also reported a net earnings of $3.66 billion, or an earnings per share of $1.37. The company says that it saw solid performance across its business segments, driven by above-market results in Pharmaceuticals and ongoing recovery in Medical Devices. Furthermore, it also enjoyed strong growth in its Consumer Health segment. For this reason, will you add JNJ stock to your list of health care stocks?
Source: TD Ameritrade TOS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) Abbott Laboratories (NYSE: ABT) LumiraDx (NASDAQ: LMDX) Johnson & Johnson Inc. (NYSE: JNJ) Pfizer Inc. First on this list, we have Pfizer, a multinational pharmaceutical and biotechnology company with headquarters in New York City. More importantly, ABT stock is now making waves in the stock market thanks to the company’s latest quarterly earnings report. With that in mind, would you be watching ABT stock? | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) Abbott Laboratories (NYSE: ABT) LumiraDx (NASDAQ: LMDX) Johnson & Johnson Inc. (NYSE: JNJ) Pfizer Inc. First on this list, we have Pfizer, a multinational pharmaceutical and biotechnology company with headquarters in New York City. More importantly, ABT stock is now making waves in the stock market thanks to the company’s latest quarterly earnings report. With that in mind, would you be watching ABT stock? | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) Abbott Laboratories (NYSE: ABT) LumiraDx (NASDAQ: LMDX) Johnson & Johnson Inc. (NYSE: JNJ) Pfizer Inc. First on this list, we have Pfizer, a multinational pharmaceutical and biotechnology company with headquarters in New York City. More importantly, ABT stock is now making waves in the stock market thanks to the company’s latest quarterly earnings report. With that in mind, would you be watching ABT stock? | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) Abbott Laboratories (NYSE: ABT) LumiraDx (NASDAQ: LMDX) Johnson & Johnson Inc. (NYSE: JNJ) Pfizer Inc. First on this list, we have Pfizer, a multinational pharmaceutical and biotechnology company with headquarters in New York City. More importantly, ABT stock is now making waves in the stock market thanks to the company’s latest quarterly earnings report. With that in mind, would you be watching ABT stock? |
31938.0 | 2021-10-20 00:00:00 UTC | Health Care Sector Update for 10/20/2021: LMDX, ABT, TMO, XLV, IBB | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-10-20-2021%3A-lmdx-abt-tmo-xlv-ibb-2021-10-20 | nan | nan | Health care stocks were advancing pre-bell Wednesday. The Health Care SPDR (XLV) was 0.40% higher while the iShares NASDAQ Biotechnology Index (IBB) was flat in recent activity.
LumiraDx Limited (LMDX) was gaining over 22% in value as the company has received approval from India's Central Drugs Standard Control Organization for emergency use of its SARS-CoV-2 Antigen test in India.
Abbott Laboratories (ABT) was climbing past 4% as it reported adjusted Q3 earnings from continuing operations of $1.40 per diluted share, up from $0.98 a year earlier. Analysts polled by Capital IQ expected $0.95.
Thermo Fisher Scientific (TMO) was up more than 2% after it priced an offering of US dollar-denominated senior notes with a total principal amount of $5.85 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) was climbing past 4% as it reported adjusted Q3 earnings from continuing operations of $1.40 per diluted share, up from $0.98 a year earlier. The Health Care SPDR (XLV) was 0.40% higher while the iShares NASDAQ Biotechnology Index (IBB) was flat in recent activity. Thermo Fisher Scientific (TMO) was up more than 2% after it priced an offering of US dollar-denominated senior notes with a total principal amount of $5.85 billion. | Abbott Laboratories (ABT) was climbing past 4% as it reported adjusted Q3 earnings from continuing operations of $1.40 per diluted share, up from $0.98 a year earlier. Health care stocks were advancing pre-bell Wednesday. The Health Care SPDR (XLV) was 0.40% higher while the iShares NASDAQ Biotechnology Index (IBB) was flat in recent activity. | Abbott Laboratories (ABT) was climbing past 4% as it reported adjusted Q3 earnings from continuing operations of $1.40 per diluted share, up from $0.98 a year earlier. The Health Care SPDR (XLV) was 0.40% higher while the iShares NASDAQ Biotechnology Index (IBB) was flat in recent activity. LumiraDx Limited (LMDX) was gaining over 22% in value as the company has received approval from India's Central Drugs Standard Control Organization for emergency use of its SARS-CoV-2 Antigen test in India. | Abbott Laboratories (ABT) was climbing past 4% as it reported adjusted Q3 earnings from continuing operations of $1.40 per diluted share, up from $0.98 a year earlier. Health care stocks were advancing pre-bell Wednesday. The Health Care SPDR (XLV) was 0.40% higher while the iShares NASDAQ Biotechnology Index (IBB) was flat in recent activity. |
31939.0 | 2021-10-20 00:00:00 UTC | Abbott raises annual profit forecast after upbeat quarterly results | ABT | https://www.nasdaq.com/articles/abbott-raises-annual-profit-forecast-after-upbeat-quarterly-results-2021-10-20 | nan | nan | Adds details on forecast, background
Oct 20 (Reuters) - Abbott Laboratories ABT.N raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant.
The number of COVID-19 tests has reduced from the peak of the pandemic as more people get vaccinated in the United States, but their demand has increased in recent months as employers and schools implement screening programs.
The U.S. government has also announced policies aimed at pushing large employers to have their workers inoculated or tested weekly and has so far invested around $3 billion to procure rapid COVID-19 tests from Abbott and other manufacturers.
Third-quarter sales at Abbott's diagnostics business grew 48.2% to $3.91 billion, with coronavirus test-related sales at $1.9 billion, up from $1.3 billion in the second quarter.
The company raised its outlook for 2021 adjusted earnings from continuing operations to between $5.00 and $5.10 per share, compared with its previous forecast of $4.30 to $4.50 per share.
Revenue for the third quarter rose to $10.9 billion from $8.85 billion.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila and Shounak Dasgupta)
((mrinalika.roy@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds details on forecast, background Oct 20 (Reuters) - Abbott Laboratories ABT.N raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant. The number of COVID-19 tests has reduced from the peak of the pandemic as more people get vaccinated in the United States, but their demand has increased in recent months as employers and schools implement screening programs. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila and Shounak Dasgupta) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds details on forecast, background Oct 20 (Reuters) - Abbott Laboratories ABT.N raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant. Third-quarter sales at Abbott's diagnostics business grew 48.2% to $3.91 billion, with coronavirus test-related sales at $1.9 billion, up from $1.3 billion in the second quarter. The company raised its outlook for 2021 adjusted earnings from continuing operations to between $5.00 and $5.10 per share, compared with its previous forecast of $4.30 to $4.50 per share. | Adds details on forecast, background Oct 20 (Reuters) - Abbott Laboratories ABT.N raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant. The U.S. government has also announced policies aimed at pushing large employers to have their workers inoculated or tested weekly and has so far invested around $3 billion to procure rapid COVID-19 tests from Abbott and other manufacturers. Third-quarter sales at Abbott's diagnostics business grew 48.2% to $3.91 billion, with coronavirus test-related sales at $1.9 billion, up from $1.3 billion in the second quarter. | Adds details on forecast, background Oct 20 (Reuters) - Abbott Laboratories ABT.N raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant. The number of COVID-19 tests has reduced from the peak of the pandemic as more people get vaccinated in the United States, but their demand has increased in recent months as employers and schools implement screening programs. Third-quarter sales at Abbott's diagnostics business grew 48.2% to $3.91 billion, with coronavirus test-related sales at $1.9 billion, up from $1.3 billion in the second quarter. |
31940.0 | 2021-10-20 00:00:00 UTC | Abbott quarterly profit surges more than 70% | ABT | https://www.nasdaq.com/articles/abbott-quarterly-profit-surges-more-than-70-2021-10-20 | nan | nan | Oct 20 (Reuters) - Abbott Laboratories ABT.N reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus.
The company's net earnings rose to $2.1 billion, or $1.17 per share, in the third quarter ended Sept. 30, from $1.23 billion, or 69 cents per share, a year earlier.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila)
((mrinalika.roy@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 20 (Reuters) - Abbott Laboratories ABT.N reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus. The company's net earnings rose to $2.1 billion, or $1.17 per share, in the third quarter ended Sept. 30, from $1.23 billion, or 69 cents per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 20 (Reuters) - Abbott Laboratories ABT.N reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus. The company's net earnings rose to $2.1 billion, or $1.17 per share, in the third quarter ended Sept. 30, from $1.23 billion, or 69 cents per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 20 (Reuters) - Abbott Laboratories ABT.N reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus. The company's net earnings rose to $2.1 billion, or $1.17 per share, in the third quarter ended Sept. 30, from $1.23 billion, or 69 cents per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 20 (Reuters) - Abbott Laboratories ABT.N reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus. The company's net earnings rose to $2.1 billion, or $1.17 per share, in the third quarter ended Sept. 30, from $1.23 billion, or 69 cents per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31941.0 | 2021-10-20 00:00:00 UTC | Abbott Laboratories Q3 adjusted earnings Beat Estimates | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q3-adjusted-earnings-beat-estimates-2021-10-20 | nan | nan | (RTTNews) - Abbott Laboratories (ABT) released earnings for its third quarter that advanced from last year.
The company's earnings came in at $2.10 billion, or $1.17 per share. This compares with $1.23 billion, or $0.69 per share, in last year's third quarter.
Excluding items, Abbott Laboratories reported adjusted earnings of $2.52 billion or $1.40 per share for the period.
Analysts had expected the company to earn $0.94 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 23.5% to $10.93 billion from $8.85 billion last year.
Abbott Laboratories earnings at a glance:
-Earnings (Q3): $2.52 Bln. vs. $1.76 Bln. last year. -EPS (Q3): $1.40 vs. $0.98 last year. -Analysts Estimate: $0.94 -Revenue (Q3): $10.93 Bln vs. $8.85 Bln last year.
-Guidance: Full year EPS guidance: $5.00 to $5.10
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) released earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $2.52 billion or $1.40 per share for the period. Analysts had expected the company to earn $0.94 per share, according to figures compiled by Thomson Reuters. | (RTTNews) - Abbott Laboratories (ABT) released earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $2.52 billion or $1.40 per share for the period. Analysts' estimates typically exclude special items. | (RTTNews) - Abbott Laboratories (ABT) released earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $2.52 billion or $1.40 per share for the period. The company's revenue for the quarter rose 23.5% to $10.93 billion from $8.85 billion last year. | (RTTNews) - Abbott Laboratories (ABT) released earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $2.52 billion or $1.40 per share for the period. Abbott Laboratories earnings at a glance: -Earnings (Q3): $2.52 Bln. |
31942.0 | 2021-10-20 00:00:00 UTC | US STOCKS-Futures flat on worries over supply chain disruptions; Netflix falls | ABT | https://www.nasdaq.com/articles/us-stocks-futures-flat-on-worries-over-supply-chain-disruptions-netflix-falls-2021-10-20 | nan | nan | By Devik Jain
Oct 20 (Reuters) - U.S. stock index futures were flat on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report.
Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year.
Its shares, however, fell 2.7% after hitting a record high earlier this month and gaining 18.2% year-to-date.
Analysts expect S&P 500 earnings to rise 32.4% from a year earlier, according to Refinitiv data, while also keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions.
"Investor response to the latest set of earnings reports has been a touch hit and miss with supply chain issues dogging both Procter and Gamble and Philip Morris," wrote Danni Hewson, financial analyst at AJ Bell in a client note.
Other mega cap technology and communication names were mixed in premarket trading. Facebook FB.O, up 0.6%, is planning to rebrand itself with new name that focuses on metaverse, according to the Verge.
Tesla Inc TSLA.O edged 0.4% lower in the run up to its quarterly results after markets close, with investors awaiting details on its performance in China.
Anthem Inc ANTM.K rose 0.6% as the second largest health U.S. insurer raised its profit outlook for 2021 after beating third-quarter profit estimates.
United Airlines Holdings UAL.O gained 1.6% after the carrier reported a smaller quarterly loss than a year ago on travel rebound.
The benchmark S&P 500 index .SPX is just 0.4% below its early September record close, while the Dow Jones Industrials average .DJI is 0.5% below its all-time high reached in mid-August.
U.S. stock indexes closed higher on Tuesday with the biggest boosts from the technology and healthcare sectors amid optimism about solid third-quarter earnings season.
Verizon Communication VZ.N, Abbott Laboratories ABT.N, Tesla Inc TSLA.O, Kinder Morgan KMI.N and IBM IBM.N are set to report their earnings later in the day.
At 7:19 a.m. ET, Dow e-minis 1YMcv1 were down 8 points, or 0.02%, S&P 500 e-minis EScv1 were down 0.25 points, or 0.01%, and Nasdaq 100 e-minis NQcv1 were up 10 points, or 0.06%.
Ford Motor F.N gained 1.9% after Credit Suisse upgraded the U.S. automaker's stock to 'outperform' on EV transition.
Oil majors Exxon Mobil XOM.N and Chevron Corp CVX.N slipped 0.7% and 0.6%, respectively, tracking crude prices. O/R/
(Reporting by Devik Jain in Bengaluru; Editing by Arun Koyyur)
((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2062; ;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Verizon Communication VZ.N, Abbott Laboratories ABT.N, Tesla Inc TSLA.O, Kinder Morgan KMI.N and IBM IBM.N are set to report their earnings later in the day. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures were flat on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. | Verizon Communication VZ.N, Abbott Laboratories ABT.N, Tesla Inc TSLA.O, Kinder Morgan KMI.N and IBM IBM.N are set to report their earnings later in the day. Analysts expect S&P 500 earnings to rise 32.4% from a year earlier, according to Refinitiv data, while also keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions. U.S. stock indexes closed higher on Tuesday with the biggest boosts from the technology and healthcare sectors amid optimism about solid third-quarter earnings season. | Verizon Communication VZ.N, Abbott Laboratories ABT.N, Tesla Inc TSLA.O, Kinder Morgan KMI.N and IBM IBM.N are set to report their earnings later in the day. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures were flat on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Analysts expect S&P 500 earnings to rise 32.4% from a year earlier, according to Refinitiv data, while also keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions. | Verizon Communication VZ.N, Abbott Laboratories ABT.N, Tesla Inc TSLA.O, Kinder Morgan KMI.N and IBM IBM.N are set to report their earnings later in the day. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures were flat on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. |
31943.0 | 2021-10-20 00:00:00 UTC | Abbott Laboratories Q3 21 Earnings Conference Call At 9:00 AM ET | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q3-21-earnings-conference-call-at-9%3A00-am-et-2021-10-20 | nan | nan | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 20 , 2021, to discuss Q3 21 earnings results.
To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 20 , 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 20 , 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 20 , 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 20 , 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31944.0 | 2021-10-20 00:00:00 UTC | Will Abbott Stock Rise After Its Q3 Results? | ABT | https://www.nasdaq.com/articles/will-abbott-stock-rise-after-its-q3-results-2021-10-20 | nan | nan | Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. A rise in Covid-19 cases in Q3 due to the spread of the delta variant likely aided Covid-19 testing demand for the company. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. Trefis’ forecast indicates that Abbott’s valuation is $129 per share, which is 10% higher than the current market price of around $117. Our interactive dashboard analysis on Abbott’s Pre-Earnings has additional details.
(1) Revenues expected to be in-line with the consensus estimates
Trefis estimates Abbott’s Q3 2021 revenues to be around $9.58 billion, largely in-line with the $9.56 billion consensus estimate. With a rise in overall vaccination rates across the globe, the healthcare institutions now have more resources to address the surgeries that were postponed earlier, implying a rebound for Abbott’s medical devices business. In fact, Abbott’s medical devices sales surged 51% in Q2 this year.
Looking at the company’s diagnostics business, the sales are expected to moderate in Q3, after seeing a massive 90% rise in first half of this year. This can be attributed to high demand for Covid-19 testing. However, now that the Covid-19 vaccination rate is on a rise, the overall demand for testing is expected to come down over the coming quarters, and it will impact the overall sales growth of the company’s diagnostics business in the quarters to come. Our dashboard on Abbott Revenues offers more details on the company’s segments.
2) EPS likely to top the consensus estimates
Abbott’s Q3 2021 adjusted earnings per share (EPS) is expected to be $0.96 per Trefis analysis, just two cents above the consensus estimate of $0.94. Abbott’s adjusted net income of $2.1 billion in Q2 2021 reflected a large 2x growth from its $1.0 Bil figure in the prior-year quarter. This can be attributed to higher revenues and over 400 bps rise in operating margins. The company’s operating expenses, including R&D and SG&A grew at a slower pace compared to the revenue growth. This trend is expected to continue in Q3 as well, bolstering the overall earnings growth. For the full-year, we expect the adjusted EPS to be higher at $4.48 compared to $3.67 in 2020.
(3) Stock price estimate 11% higher than the current market price
Going by our Abbott’s Valuation, with an EPS estimate of around $4.48 and a P/E multiple of around 29x in 2021, this translates into a price of $129, which is 10% above the current market price of around $117. The 29x P/E multiple compares with levels of 30x seen as recently as late 2020, implying there is some more room for growth for ABT stock.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While ABT stock may be undervalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. The 29x P/E multiple compares with levels of 30x seen as recently as late 2020, implying there is some more room for growth for ABT stock. | Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. The 29x P/E multiple compares with levels of 30x seen as recently as late 2020, implying there is some more room for growth for ABT stock. | Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. The 29x P/E multiple compares with levels of 30x seen as recently as late 2020, implying there is some more room for growth for ABT stock. | Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. The 29x P/E multiple compares with levels of 30x seen as recently as late 2020, implying there is some more room for growth for ABT stock. |
31945.0 | 2021-10-20 00:00:00 UTC | US STOCKS-Wall St grinds higher on solid healthcare earnings; supply woes linger | ABT | https://www.nasdaq.com/articles/us-stocks-wall-st-grinds-higher-on-solid-healthcare-earnings-supply-woes-linger-2021-10-20 | nan | nan | By Devik Jain and Shreyashi Sanyal
Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings.
Abbott Laboratories ABT.N rose 4.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales.
Anthem Inc ANTM.N gained 5.7% and Biogen Inc BIIB.O added 2% after both healthcare companies raised their full-year profit forecasts.
Eight of the 11 major S&P 500 sector indexes were trading higher, led by healthcare stocks .SPXHC.
Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, while keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions.
"Investors are digesting earnings and the impact of supply chain disruptions on Corporate America," said Fiona Cincotta, senior financial markets analyst at City Index.
"The latest releases have helped to distract from stagflation fears but have diverted attention towards supply chain bottlenecks which look set to plague Q3 earnings."
Netflix's NFLX.O global sensation "Squid Game" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year.
Its shares, however, fell 2.3% after hitting a record high earlier this month and gaining 18.2% so far this year.
Other mega cap technology and communication names were mixed in premarket trading. Facebook FB.O, up 0.2%, is planning to rebrand itself with new name that focuses on metaverse, according to the Verge.
Tesla Inc TSLA.O edged 0.6% lower in the run up to its quarterly results after markets close, with investors awaiting details on its performance in China.
"People are waiting to see what the large tech companies are going to report. That is probably the real reason we're seeing individual stocks responding more than the broader market," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.
In quarterly reports, Verizon Communications Inc VZ.N gained 2.1% as it added more postpaid phone subscribers than expected in the third quarter, while oilfield firm Baker Hughes Co BKR.N slipped 4% on downbeat profit.
The benchmark S&P 500 index .SPX is just 0.3% below its early September record close, while the Dow Jones Industrials average .DJI is 0.3% below its all-time high reached in mid-August.
At 9:57 a.m. ET, the Dow Jones Industrial Average .DJI was up 83.61 points, or 0.24%, at 35,540.92, the S&P 500 .SPX was up 10.73 points, or 0.24%, at 4,530.36 and the Nasdaq Composite .IXIC was up 9.87 points, or 0.07%, at 15,138.96.
Ford Motor F.N gained 2.3% after Credit Suisse upgraded the U.S. automaker's stock to 'outperform' on EV transition.
Advancing issues outnumbered decliners by a 1.46-to-1 ratio on the NYSE. Declining issues outnumbered advancers for a 1.01-to-1 ratio on the Nasdaq.
The S&P index recorded 38 new 52-week highs and no new low, while the Nasdaq recorded 48 new highs and 12 new lows.
(Reporting by Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Arun Koyyur)
((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780; +91 961 144 3740; Twitter: https://twitter.com/s_shreyashi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N rose 4.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings. "Investors are digesting earnings and the impact of supply chain disruptions on Corporate America," said Fiona Cincotta, senior financial markets analyst at City Index. | Abbott Laboratories ABT.N rose 4.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings. Anthem Inc ANTM.N gained 5.7% and Biogen Inc BIIB.O added 2% after both healthcare companies raised their full-year profit forecasts. | Abbott Laboratories ABT.N rose 4.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings. Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, while keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions. | Abbott Laboratories ABT.N rose 4.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings. Anthem Inc ANTM.N gained 5.7% and Biogen Inc BIIB.O added 2% after both healthcare companies raised their full-year profit forecasts. |
31946.0 | 2021-10-19 00:00:00 UTC | Abbott Laboratories Breaks Above 200-Day Moving Average - Bullish for ABT | ABT | https://www.nasdaq.com/articles/abbott-laboratories-breaks-above-200-day-moving-average-bullish-for-abt-2021-10-19 | nan | nan | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $119.19, changing hands as high as $120.18 per share. Abbott Laboratories shares are currently trading up about 2.2% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $119.41. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com
Free Report: Top 7%+ Dividends (paid monthly)
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $119.19, changing hands as high as $120.18 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $119.41. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $119.19, changing hands as high as $120.18 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $119.41. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $119.19, changing hands as high as $120.18 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $119.41. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $119.19, changing hands as high as $120.18 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $119.41. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31947.0 | 2021-10-19 00:00:00 UTC | Pre-Market Earnings Report for October 20, 2021 : ASML, VZ, ABT, NEE, ANTM, CP, BIIB, NDAQ, NTRS, BKR, CFG, MTB | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-for-october-20-2021-%3A-asml-vz-abt-nee-antm-cp-biib-ndaq-ntrs-0 | nan | nan | The following companies are expected to report earnings prior to market open on 10/20/2021. Visit our Earnings Calendar for a full list of expected earnings releases.
ASML Holding N.V. (ASML)is reporting for the quarter ending September 30, 2021. The capital goods company's consensus earnings per share forecast from the 2 analysts that follow the stock is $4.68. This value represents a 58.11% increase compared to the same quarter last year. In the past year ASML has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5.19%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ASML is 49.39 vs. an industry ratio of 26.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Verizon Communications Inc. (VZ)is reporting for the quarter ending September 30, 2021. The wireless (national) company's consensus earnings per share forecast from the 16 analysts that follow the stock is $1.36. This value represents a 8.80% increase compared to the same quarter last year. In the past year VZ has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5.38%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for VZ is 9.79 vs. an industry ratio of 64.30.
Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2021. The medical products company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.92. This value represents a 6.12% decrease compared to the same quarter last year. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 26.43 vs. an industry ratio of -16.40, implying that they will have a higher earnings growth than their competitors in the same industry.
NextEra Energy, Inc. (NEE)is reporting for the quarter ending September 30, 2021. The electric power utilities company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.71. This value represents a 5.97% increase compared to the same quarter last year. In the past year NEE has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5.97%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for NEE is 32.14 vs. an industry ratio of 16.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Anthem, Inc. (ANTM)is reporting for the quarter ending September 30, 2021. The hmo company's consensus earnings per share forecast from the 21 analysts that follow the stock is $6.38. This value represents a 51.90% increase compared to the same quarter last year. ANTM missed the consensus earnings per share in the 4th calendar quarter of 2020 by -1.17%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ANTM is 15.13 vs. an industry ratio of 33.20.
Canadian Pacific Railway Limited (CP)is reporting for the quarter ending September 30, 2021. The transportation (rail) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.75. This value represents a 20.97% increase compared to the same quarter last year. Zacks Investment Research reports that the 2021 Price to Earnings ratio for CP is 23.53 vs. an industry ratio of 10.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Biogen Inc. (BIIB)is reporting for the quarter ending September 30, 2021. The biomedical (gene) company's consensus earnings per share forecast from the 28 analysts that follow the stock is $4.15. This value represents a 53.05% decrease compared to the same quarter last year. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2020 by -7.1%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BIIB is 14.45 vs. an industry ratio of -5.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Nasdaq, Inc. (NDAQ)is reporting for the quarter ending September 30, 2021. The securities exchange company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.72. This value represents a 12.42% increase compared to the same quarter last year. In the past year NDAQ has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 9.83%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for NDAQ is 27.76 vs. an industry ratio of 29.70.
Northern Trust Corporation (NTRS)is reporting for the quarter ending September 30, 2021. The bank company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.67. This value represents a 26.52% increase compared to the same quarter last year. Zacks Investment Research reports that the 2021 Price to Earnings ratio for NTRS is 17.44 vs. an industry ratio of 11.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Baker Hughes Company (BKR)is reporting for the quarter ending September 30, 2021. The oil (field services) company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.22. This value represents a 450.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BKR is 34.56 vs. an industry ratio of 2.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Citizens Financial Group, Inc. (CFG)is reporting for the quarter ending September 30, 2021. The savings & loan company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.19. This value represents a 63.01% increase compared to the same quarter last year. In the past year CFG has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for CFG is 9.30 vs. an industry ratio of 13.70.
M&T Bank Corporation (MTB)is reporting for the quarter ending September 30, 2021. The bank company's consensus earnings per share forecast from the 6 analysts that follow the stock is $3.52. This value represents a 27.08% increase compared to the same quarter last year. MTB missed the consensus earnings per share in the 2nd calendar quarter of 2021 by -6.76%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for MTB is 11.08 vs. an industry ratio of 11.80.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 26.43 vs. an industry ratio of -16.40, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 26.43 vs. an industry ratio of -16.40, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. | Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 26.43 vs. an industry ratio of -16.40, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 26.43 vs. an industry ratio of -16.40, implying that they will have a higher earnings growth than their competitors in the same industry. |
31948.0 | 2021-10-19 00:00:00 UTC | What's Next For Sarepta Stock After A 12% Fall? | ABT | https://www.nasdaq.com/articles/whats-next-for-sarepta-stock-after-a-12-fall-2021-10-19 | nan | nan | The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterday, while it is down 14% in the last five trading days. In comparison, the broader S&P500 index hasn’t seen any change over the same period. Sarepta saw its stock fall after releasing preliminary Q3 results with revenues expected to be $167 million and a cash balance of $1.6 billion. The revenue figure is just short of the nearly $168 million consensus estimate, while its cash balance compares with $1.7 billion at the end of Q2 this year. Our Sarepta Revenues dashboard offers more details. Furthermore, the company also announced a $500 million stock offering to support its clinical trials and other business activities. The recent developments didn’t sit well with the investors, resulting in a sharp decline in its stock. While the preliminary results are lower than the street estimates, they are short just less than 1% when it comes to revenues. That said, the amount of drop seems to already take the earnings miss as well as the offering into account.
Now, is SRPT stock poised to grow? Based on our machine learning analysis of trends in the stock price over the last ten years, there is a higher chance of a rise in SRPT stock in the near term. See our analysis on Sarepta Therapeutics Stock Return for more details.
5D: SRPT -14%, vs. S&P500 -0.03%; Underperformed market
(5% likelihood event; 56% probability of rise over next 5 days)
Sarepta Therapeutics stock declined 14% over the last five trading days (one week), compared to broader market (S&P500) decline of 0.03%
A change of -14% or more over five trading days (one week) is a 5% likelihood event, which has occurred 134 times out of 2516 in the last 10 years
Of these 134 instances, the stock has seen a positive movement over the next five trading days on 75 occasions
This points to a 56% probability for the stock rising over the next five trading days
21D: SRPT 3.7%, vs. S&P500 -2%; Outperformed market
(48% likelihood event; 58% probability of rise over next 21 days)
Sarepta Therapeutics stock rose 3.7% the last twenty-one trading days (one month), compared to broader market (S&P500) decline of 2.0%
A change of 3.7% or more over twenty-one trading days is a 48% likelihood event, which has occurred 1211 times out of 2516 in the last 10 years
Of these 1211 instances, the stock has seen a positive movement over the next twenty-one trading days on 699 occasions
This points to a 58% probability for the stock rising over the next twenty-one trading days
While SRPT stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Johnson & Johnson vs. Regeneron Pharmaceuticals.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sarepta saw its stock fall after releasing preliminary Q3 results with revenues expected to be $167 million and a cash balance of $1.6 billion. The revenue figure is just short of the nearly $168 million consensus estimate, while its cash balance compares with $1.7 billion at the end of Q2 this year. Furthermore, the company also announced a $500 million stock offering to support its clinical trials and other business activities. | The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterday, while it is down 14% in the last five trading days. 5D: SRPT -14%, vs. S&P500 -0.03%; Underperformed market (5% likelihood event; 56% probability of rise over next 5 days) Sarepta Therapeutics stock declined 14% over the last five trading days (one week), compared to broader market (S&P500) decline of 0.03% A change of -14% or more over five trading days (one week) is a 5% likelihood event, which has occurred 134 times out of 2516 in the last 10 years Of these 134 instances, the stock has seen a positive movement over the next five trading days on 75 occasions This points to a 56% probability for the stock rising over the next five trading days 21D: SRPT 3.7%, vs. S&P500 -2%; Outperformed market (48% likelihood event; 58% probability of rise over next 21 days) Sarepta Therapeutics stock rose 3.7% the last twenty-one trading days (one month), compared to broader market (S&P500) decline of 2.0% A change of 3.7% or more over twenty-one trading days is a 48% likelihood event, which has occurred 1211 times out of 2516 in the last 10 years Of these 1211 instances, the stock has seen a positive movement over the next twenty-one trading days on 699 occasions This points to a 58% probability for the stock rising over the next twenty-one trading days While SRPT stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterday, while it is down 14% in the last five trading days. Sarepta saw its stock fall after releasing preliminary Q3 results with revenues expected to be $167 million and a cash balance of $1.6 billion. 5D: SRPT -14%, vs. S&P500 -0.03%; Underperformed market (5% likelihood event; 56% probability of rise over next 5 days) Sarepta Therapeutics stock declined 14% over the last five trading days (one week), compared to broader market (S&P500) decline of 0.03% A change of -14% or more over five trading days (one week) is a 5% likelihood event, which has occurred 134 times out of 2516 in the last 10 years Of these 134 instances, the stock has seen a positive movement over the next five trading days on 75 occasions This points to a 56% probability for the stock rising over the next five trading days 21D: SRPT 3.7%, vs. S&P500 -2%; Outperformed market (48% likelihood event; 58% probability of rise over next 21 days) Sarepta Therapeutics stock rose 3.7% the last twenty-one trading days (one month), compared to broader market (S&P500) decline of 2.0% A change of 3.7% or more over twenty-one trading days is a 48% likelihood event, which has occurred 1211 times out of 2516 in the last 10 years Of these 1211 instances, the stock has seen a positive movement over the next twenty-one trading days on 699 occasions This points to a 58% probability for the stock rising over the next twenty-one trading days While SRPT stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | Sarepta saw its stock fall after releasing preliminary Q3 results with revenues expected to be $167 million and a cash balance of $1.6 billion. See our analysis on Sarepta Therapeutics Stock Return for more details. What if you’re looking for a more balanced portfolio instead? |
31949.0 | 2021-10-19 00:00:00 UTC | What To Expect From Intuitive Surgical's Q3? | ABT | https://www.nasdaq.com/articles/what-to-expect-from-intuitive-surgicals-q3-2021-10-19 | nan | nan | Intuitive Surgical (NASDAQ:ISRG), a fast growing robotic surgical platform company, is scheduled to report its Q3 2021 results on Tuesday, October 19. We expect Intuitive Surgical to likely to report mixed earnings with revenue slightly below and earnings to be above the consensus estimates. With the rise of the delta variant and Covid-19 cases in the U.S. over the last few months, it is likely that Intuitive Surgical’s sales were adversely impacted. That said, our forecast indicates that Intuitive Surgical’s valuation is around $345 per share, which is 6% above the current market price of $345, implying that ISRG stock still has some room for growth, in our view. Our interactive dashboard analysis on Intuitive Surgical Pre-Earnings has additional details.
(1) Revenues expected to fall short of the consensus estimate
Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. The ongoing vaccination programs and gradual opening up of economies has resulted in an increase in procedures volume over the recent quarter, and this should augur well for Intuitive Surgical’s top line growth, when compared to the prior year quarter. However, the recent surge in Covid-19 cases may have adversely impacted the overall revenue growth for the company. da Vinci procedure volume grew a stellar 68% in Q2 2021, driving total sales 72% higher to $1.46 billion. Sales growth reflect higher instruments & accessories sales, as well as an increase in system placements. Intuitive Surgical placed 328 systems last quarter, compared to 178 systems in the prior year quarter. Note that it was a favorable comparison to Q2 2020, which was significantly impacted from deferment of elective surgeries, amid the lockdowns. Our dashboard on Intuitive Surgical Revenues offers more details on the company’s segments.
2) EPS likely to be ahead of consensus estimates
Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. Intuitive Surgical’s adjusted net income of $477 million in Q2 2021 reflected a large 3.6x rise from its $132 million figure in the prior-year quarter. The rise in earnings was higher than revenues due to over 1700 bps expansion of net margins, driven by lower operating expenses (as a percentage of revenue) as well as lower taxes. We believe that margins will remain strong going forward, as the procedure volume increases. For the full-year 2021, we expect the adjusted EPS to be higher at $4.96 compared to $3.38 in 2020.
(3) Stock price estimate above the current market price
Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. Investors have assigned a high trading multiple for ISRG stock, given the strong revenue and earnings growth over the past years, and this trend is expected to continue going forward, as well. Note that Intuitive Surgical generates recurring revenues from every system placed, driven by the instruments and accessories sales, as well as services.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While ISRG stock may see more gains going forward, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That said, our forecast indicates that Intuitive Surgical’s valuation is around $345 per share, which is 6% above the current market price of $345, implying that ISRG stock still has some room for growth, in our view. Investors have assigned a high trading multiple for ISRG stock, given the strong revenue and earnings growth over the past years, and this trend is expected to continue going forward, as well. Note that Intuitive Surgical generates recurring revenues from every system placed, driven by the instruments and accessories sales, as well as services. | (1) Revenues expected to fall short of the consensus estimate Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | (1) Revenues expected to fall short of the consensus estimate Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. (3) Stock price estimate above the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. | Intuitive Surgical placed 328 systems last quarter, compared to 178 systems in the prior year quarter. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. (3) Stock price estimate above the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. |
31950.0 | 2021-10-17 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 10/17/2021 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-10-17-2021-2021-10-17 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
DAVITA INC (DVA) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: FAIL
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of DAVITA INC
Full Guru Analysis for DVA>
Full Factor Report for DVA>
ENSIGN GROUP INC (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ensign Group, Inc., through its operating subsidiaries, provides healthcare services. The Company's operating subsidiaries provide a spectrum of skilled nursing services, physical, occupational and speech therapies and other rehabilitative and healthcare services. The Company operates approximately 236 healthcare facilities, 24 of which also include assisted living operations across thirteen states. It operates the healthcare facilities across Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Through its skilled nursing operations, the Company provides short stay patients and long stay patients with a range of medical, nursing, rehabilitative, pharmacy and routine services, including daily dietary, social and recreational services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ENSIGN GROUP INC
Full Guru Analysis for ENSG>
Full Factor Report for ENSG>
INTUITIVE SURGICAL, INC. (ISRG) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Intuitive Surgical, Inc. develops, manufactures and markets the da Vinci surgical system and Ion endoluminal system. The Company's da Vinci products are offered in categories, including da Vinci Surgical Systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems (Firefly) and da Vinci Endoscopes. It also provides a comprehensive suite of services, training, and education programs. It manufactures a set of instruments, which incorporates EndoWrist technology with wristed joints for natural dexterity and tips customized for various surgical procedures. Its Ion endoluminal system is a robotic-assisted, catheter-based platform designed to navigate through very small lung airways to reach peripheral nodules for biopsies. The da Vinci Surgical System enables surgeons to operate while seated at an ergonomic console viewing a three-dimensional, high definition (3DHD) image of the surgical field.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of INTUITIVE SURGICAL, INC.
Full Guru Analysis for ISRG>
Full Factor Report for ISRG>
MEDIFAST INC (MED) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medifast, Inc. (Medifast) is a sellers of weight loss, weight management and healthy living products all based on its formulas under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The Company's operations are conducted through its subsidiaries Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Medifast Franchise Systems, Inc., Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD and OPTAVIA Health Consultation (Shanghai) Co., Ltd. The Company's product line includes approximately 137 consumable options, including, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of MEDIFAST INC
Full Guru Analysis for MED>
Full Factor Report for MED>
More details on Validea's John Neff strategy
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap value stock in the Healthcare Facilities industry. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap value stock in the Healthcare Facilities industry. Detailed Analysis of DAVITA INC Full Guru Analysis for DVA> Full Factor Report for DVA> ENSIGN GROUP INC (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap value stock in the Healthcare Facilities industry. The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap value stock in the Healthcare Facilities industry. The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. |
31951.0 | 2021-10-17 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Martin Zweig - 10/17/2021 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-10-17-2021-2021-10-17 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
MEDIFAST INC (MED) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medifast, Inc. (Medifast) is a sellers of weight loss, weight management and healthy living products all based on its formulas under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The Company's operations are conducted through its subsidiaries Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Medifast Franchise Systems, Inc., Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD and OPTAVIA Health Consultation (Shanghai) Co., Ltd. The Company's product line includes approximately 137 consumable options, including, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MEDIFAST INC
Full Guru Analysis for MED>
Full Factor Report for MED>
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Amedisys, Inc. is a healthcare services company, which is a multi-state provider of home health, hospice, and personal care services. The Company operates through three segments: Home Health, Hospice and Personal Care. The Home Health segment delivers a range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with important personal tasks. The Hospice segment provides palliative care and comfort to terminally ill patients and their families. The Personal Care segment provides patients with assistance with the essential activities of daily living. The Company owns and operates approximately 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and approximately 14 personal-care care centers in 39 states within the United States and the District of Columbia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AMEDISYS INC
Full Guru Analysis for AMED>
Full Factor Report for AMED>
MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medpace Holdings, Inc. is a provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MEDPACE HOLDINGS INC
Full Guru Analysis for MEDP>
Full Factor Report for MEDP>
QUEST DIAGNOSTICS INC (DGX) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of QUEST DIAGNOSTICS INC
Full Guru Analysis for DGX>
Full Factor Report for DGX>
More details on Validea's Martin Zweig strategy
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of AMEDISYS INC Full Guru Analysis for AMED> Full Factor Report for AMED> MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. Company Description: Amedisys, Inc. is a healthcare services company, which is a multi-state provider of home health, hospice, and personal care services. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. |
31952.0 | 2021-10-17 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Peter Lynch - 10/17/2021 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-10-17-2021-2021-10-17 | nan | nan | The following are the top rated Healthcare stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
QUEST DIAGNOSTICS INC (DGX) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of QUEST DIAGNOSTICS INC
Full Guru Analysis for DGX>
Full Factor Report for DGX>
EMERGENT BIOSOLUTIONS INC (EBS) is a mid-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of EMERGENT BIOSOLUTIONS INC
Full Guru Analysis for EBS>
Full Factor Report for EBS>
LABORATORY CORP. OF AMERICA HOLDINGS (LH) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company's business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The Company serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS
Full Guru Analysis for LH>
Full Factor Report for LH>
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services in the United States. The Company is focused on acquiring and developing behavioral healthcare facilities. It is engaged in developing and operating inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States and Puerto Rico. The Company operates approximately 229 behavioral healthcare facilities with approximately 10,100 beds in 40 states and Puerto Rico. Its properties are located in Alaska, Arizona, California, Delaware, Florida, Georgia and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ACADIA HEALTHCARE COMPANY INC
Full Guru Analysis for ACHC>
Full Factor Report for ACHC>
More details on Validea's Peter Lynch strategy
Peter Lynch Stock Ideas
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of EMERGENT BIOSOLUTIONS INC Full Guru Analysis for EBS> Full Factor Report for EBS> LABORATORY CORP. OF AMERICA HOLDINGS (LH) is a large-cap value stock in the Healthcare Facilities industry. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. | Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. |
31953.0 | 2021-10-17 00:00:00 UTC | 3 Solid Growth Stocks Perfect for Retirees | ABT | https://www.nasdaq.com/articles/3-solid-growth-stocks-perfect-for-retirees-2021-10-17 | nan | nan | Retired investors may recoil at the mere mention of the word "inflation," because it means the money they've accumulated in their portfolios will buy less and less of the services and items they need. That's one reason why it's important to have some exposure to growth stocks in your portfolio -- they can help counter inflation's erosive impact on the value of your nest egg.
To that end, we asked three savvy Motley Fool contributors to recommend growth stocks that they think would be smart additions to any retirement portfolio. Here's why they view Abbott Laboratories (NYSE: ABT), Facebook (NASDAQ: FB), and Rent-A-Center (NASDAQ: RCII) as great choices to consider buying now.
Image source: Getty Images.
A potent mix of income and growth
Eric Volkman (Abbott Laboratories): For a great retirement portfolio stock, let's duck into the laboratory -- Abbott Laboratories, that is.
A healthcare company with roots going back more than 130 years, Abbott has a bulging portfolio of products divided into four categories. In descending order of revenue, they are: medical devices; diagnostics; nutrition; and its outside-the-U.S. business, established (i.e., branded generic) pharmaceuticals. This mix gives the company numerous levers to pull for both growth and income.
Happily, sales in all four categories grew by double-digit percentages on a year-over-year basis in the second quarter (its most recently reported period). The standout segment was diagnostics, thanks to the company's popular COVID-19 testing products. All told, that unit took in nearly $3.25 billion to notch 63% growth.
The average overall age of Americans has been steadily rising for some time, and in the coming years, elderly people will form an increasingly larger share of the population (according to numerous demographic forecasts). COVID-19 aside, demand is growing organically for the many medicines, devices, and nutrition products in Abbott's catalog. Sales of its established pharmaceuticals grew by 16% in Q2, while revenues from its nutrition unit rose by 12%. And both of those results pale in comparison to the more than 51% growth it saw in device sales.
A long-established company like Abbott deserves a particular tip of the hat for managing such robust growth across the board.
Compared to many of its peers in the healthcare realm, Abbott doesn't spend as much capital on research and development or marketing -- but it doesn't need to. Its products generally have good reputations, and are purchased by individuals and institutions that have long relationships with the company. This helps Abbott deliver fairly consistent profits. It's only on rare occasions that it posts a bottom-line loss.
That habitual profitability provides plenty of cash for shareholder-pleasing moves such as paying a dividend. Abbott is one of the top healthcare-sector payers of such remuneration; in fact, with a dividend-raising streak of 49 straight years, it's just about to hit Dividend King status. Last month, it declared its 391st consecutive quarterly disbursement.
With the weight of that much history behind it, investors can be confident that the payouts will keep coming. At current share prices, the dividend yields 1.5%.
Abbott has been an important company in the U.S. healthcare sector for decades, and its positioned to remain one for many more. It can expect further revenue growth based on the demographic trends alone, and investors should anticipate more annual bumps to its ever-reliable payout.
Image source: Getty Images.
When opportunity knocks, open the door
Barbara Eisner Bayer (Facebook): If you're a retiree and depend significantly on your investment portfolio for income, it's natural that you'd want to be conservative about which assets you hold. Declining values will cut directly into your immediate ability to pay the bills.
But even cautious retirees need to have a portion of their portfolios in growth stocks. Sure, having all fixed-income holdings minimizes the risk that you'll lose money, but it also maximizes the risk that the growth of your portfolio won't keep up with inflation, and makes it more likely that you'll run out of money before you run out of time.
While no one has a guaranteed technique for detecting when a stock has hit a low or high, what one can often spot is when a company is going through a challenging period that has caused investors to give its share price a haircut. When you see opportunities like that, it's time to pounce.
Facebook is a growth stock that's currently under attack, but the tech giant will most likely survive and thrive -- which means now's a good time to add it to your retirement portfolio.
If we've learned anything from Facebook's hours-long global outage earlier this month, it's that most people can't live without at least one of the company's platforms. And when I say "most people," I mean the 3.51 billion monthly active users who flock to its family of apps, including its namesake social media site, Instagram, and What's App.
However, as most people are already aware, Congress recently heard a host of unflattering allegations about the social media powerhouse from whistleblower and former Facebook product manager Frances Haugen. That's very bad publicity, of course, and it appears to have triggered something of a sell-off of the stock -- which makes it an opportune time to buy. But remember: Every story has two sides, and while Facebook may look guilty in the court of public opinion, the company -- which has denied the allegations -- hasn't yet had its day in court (or in this case, Congress).
Facebook appears optimistic that it will overcome the challenges it faces, including regulatory issues and antitrust probes. It's also looking forward to its future in virtual reality and augmented reality. CEO Mark Zuckerberg plans to build what he calls a "metaverse" that will take advantage of those technologies. And while many people don't like the guy, it's hard to dispute that he's a visionary who has built quite an extraordinarily successful company.
Facebook is currently trading about 15% below the all-time high that it hit in August. If you're one of those 3.51 billion who has a habit of using one or more of the company's platforms -- or if you're just looking for a growth stock that will be there and continue growing and innovating through your entire retirement -- this seems like a good time to add the social media juggernaut to your retirement portfolio.
Image source: Getty Images.
A company that should do well in uncertain times
Chuck Saletta: (Rent-A-Center): The rent-to-own industry that Rent-A-Center competes in is one that people tend to turn to when their futures aren't all that certain or solid. After all, it offers people a way to get what they need even if they have "less than perfect" credit, or even no credit at all.
The way it works is that Rent-A-Center offers customers the opportunity to make seemingly reasonable weekly payments to buy appliances, furniture, or other somewhat high-dollar items. If you make all the payments on time, you get to keep the item. If you don't, Rent-A-Center takes it back.
The company makes its money by charging high prices for its wares, setting high interest rates and fees on its financing, and by re-renting items that get returned. For instance, picking a refrigerator at random off of its site, the Rent-A-Center "same as cash" price is $1,763.52, vs. $1,399 for an identical model at a familiar national retailer. For consumers not paying cash, the Rent-A-Center price is $29.99 per week for 98 weeks -- or $2,939.02 in total.
With inflation lately higher than it has been in many years, the most recent jobs report showing a surprisingly low number of jobs filled, and consumer confidence tumbling, the specter of stagflation is making a comeback. Add in the fact that it looks as if the Federal Reserve is preparing to start tightening credit again, and you have all the conditions for an almost perfect economic storm. And people on the financial brink are just the demographic that tends to use Rent-A-Center's services.
Analysts are expecting annualized earnings growth of more than 30% from Rent-A-Center over the next five years, compared with flattish earnings over the past five. The business is trading now at around 15 times its trailing earnings, a valuation that will look like a bargain if that forecast growth materializes.
The combination of a reasonable valuation, decent expected growth, and a business model that can do well in tough times makes Rent-A-Center a stock worth considering for retirees' portfolios.
10 stocks we like better than Facebook
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Facebook wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Barbara Eisner Bayer owns shares of Facebook. Chuck Saletta has no position in any of the stocks mentioned. Eric Volkman owns shares of Facebook. The Motley Fool owns shares of and recommends Facebook. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why they view Abbott Laboratories (NYSE: ABT), Facebook (NASDAQ: FB), and Rent-A-Center (NASDAQ: RCII) as great choices to consider buying now. The average overall age of Americans has been steadily rising for some time, and in the coming years, elderly people will form an increasingly larger share of the population (according to numerous demographic forecasts). When opportunity knocks, open the door Barbara Eisner Bayer (Facebook): If you're a retiree and depend significantly on your investment portfolio for income, it's natural that you'd want to be conservative about which assets you hold. | Here's why they view Abbott Laboratories (NYSE: ABT), Facebook (NASDAQ: FB), and Rent-A-Center (NASDAQ: RCII) as great choices to consider buying now. A potent mix of income and growth Eric Volkman (Abbott Laboratories): For a great retirement portfolio stock, let's duck into the laboratory -- Abbott Laboratories, that is. The way it works is that Rent-A-Center offers customers the opportunity to make seemingly reasonable weekly payments to buy appliances, furniture, or other somewhat high-dollar items. | Here's why they view Abbott Laboratories (NYSE: ABT), Facebook (NASDAQ: FB), and Rent-A-Center (NASDAQ: RCII) as great choices to consider buying now. A potent mix of income and growth Eric Volkman (Abbott Laboratories): For a great retirement portfolio stock, let's duck into the laboratory -- Abbott Laboratories, that is. If you're one of those 3.51 billion who has a habit of using one or more of the company's platforms -- or if you're just looking for a growth stock that will be there and continue growing and innovating through your entire retirement -- this seems like a good time to add the social media juggernaut to your retirement portfolio. | Here's why they view Abbott Laboratories (NYSE: ABT), Facebook (NASDAQ: FB), and Rent-A-Center (NASDAQ: RCII) as great choices to consider buying now. Retired investors may recoil at the mere mention of the word "inflation," because it means the money they've accumulated in their portfolios will buy less and less of the services and items they need. At current share prices, the dividend yields 1.5%. |
31954.0 | 2021-10-16 00:00:00 UTC | 3 Best Dividend Stocks for Retirement | ABT | https://www.nasdaq.com/articles/3-best-dividend-stocks-for-retirement-2021-10-16 | nan | nan | In a world where bank accounts pay low interest rates, dividend-paying stocks become a more appealing avenue for retiree income. Admittedly, the average cash yield for dividend stocks in the S&P 500 is only 1.3%, and companies can theoretically end payouts anytime. Such conditions may not appeal to income investors when advisors like Charles Schwab believe retirees should save enough to withdraw 4% of their account value per year in retirement.
However, some dividend stocks offer investors the confidence they seek because of a company's long track record of regular payouts. Three examples which fit that bill are AbbVie (NYSE: ABBV), STORE Capital (NYSE: STOR), and Verizon Communications (NYSE: VZ) -- and they also pay rising dividends that even exceed Schwab's 4% recommended return.
Image source: Getty Images
AbbVie
Drugmaker AbbVie offers its investors an annual payout of $5.20 per share. At its current stock price, that amounts to a dividend yield of about 4.8%. And thanks to its history as a part of Abbott Laboratories, the company holds Dividend Aristocrat status (for companies that have increased their dividend annually for at least 25 years).
Nonetheless, its longtime blockbuster drug Humira faces patent expirations across the world. While AbbVie has built a substantial development pipeline, its second-best-selling drug, Imbruvica, only drove $2.6 billion in sales in the first six months of 2021, well below Humira's revenue of $9.9 billion.
Still, some of Humira's U.S. patents will remain in place until the 2030s, giving AbbVie more time to develop alternative revenue sources. And the company generated $9.4 billion in free cash flow in the first six months of the year, positioning it to easily cover the $4.6 billion in dividend costs for that period.
Investors have taken notice as the stock has risen 26% over the past 12 months. Also, its price-to-earnings ratio (P/E) has climbed to 30 from 19 a year ago. AbbVie offers a burgeoning drug pipeline and billions in free cash flow, factors that should make it easier to fund a rising dividend for years to come.
STORE Capital
Scottsdale, Arizona-based STORE Capital pays a dividend of $1.54 per year, providing a cash return of around 4.6% -- and this payout has increased every year since the company's 2014 IPO.
STORE's name stands for "single tenant operational real estate" -- and what it owns are single-tenant buildings that include grocery stores, health clubs, and distribution facilities. With these assets, it has maintained a 99.6% occupancy rate for the past five years, and it typically has raised rent by 1.9% per year as an inflation hedge. Such factors have helped make STORE a reliable dividend stock.
Investors should note that it is a real estate investment trust (REIT). In exchange for paying no taxes on its operational income, STORE must pay dividends amounting to no less than 90% of its net income. This REIT designation makes it highly unlikely the company would cancel its dividend, and the property portfolio should keep that payout rising.
Over the past six months, STORE reported $261 million in adjusted funds from operations (AFFO), a measure of free cash flow for REITs. This cash allowed the company to pay $195 million in dividends to shareholders.
STORE has had more going for it than just its payout. Its stock rose by 17% over the past year. Although its P/E of 38 may seem high, its peer Duke Realty offers a comparable multiple with a much lower return on the dividend. That track record, along with STORE's ability to hold tenants at increasing rents, should help maintain a generous, growing cash return.
Verizon
Telecommunications giant Verizon just increased its dividend for the 15th consecutive year. Now with a $2.56 per share annual payout, investors can earn a 4.9% yield on its shares.
Although it operates in a competitive industry, Verizon is nevertheless only one of three nationwide 5G providers. With approximately $18 billion per year in capital expenditures in the previous two years, such expenses make the industry cost-prohibitive for new entrants, lessening the likelihood of additional competition.
Moreover, this spending has helped make Verizon the most-awarded company for network quality by J.D. Power 27 consecutive times. Further, on its most recent conference call, Verizon discussed the burgeoning network-as-a-service (NaaS), a data subscription business that can connect various devices and artificial-intelligence powered applications. Investors should take note because NaaS appears poised to give Verizon an additional revenue stream that did not exist before.
Verizon's focus on quality and innovation has allowed it to generate $11.7 billion in free cash flow (after capital expenditures) during the first half of 2021. With just $5.2 billion of that covering dividend costs, it should not face issues with future payout hikes.
Admittedly, the stock's 12% drop over the past year may deter some investors. Nonetheless, its 11 P/E ratio makes it an affordable choice for income investors who want rising cash returns and a new source of revenue helping to fund that payout well into the future.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Will Healy has no position in any of the stocks mentioned. The Motley Fool recommends STORE Capital and Verizon Communications. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie offers a burgeoning drug pipeline and billions in free cash flow, factors that should make it easier to fund a rising dividend for years to come. Further, on its most recent conference call, Verizon discussed the burgeoning network-as-a-service (NaaS), a data subscription business that can connect various devices and artificial-intelligence powered applications. Nonetheless, its 11 P/E ratio makes it an affordable choice for income investors who want rising cash returns and a new source of revenue helping to fund that payout well into the future. | Image source: Getty Images AbbVie Drugmaker AbbVie offers its investors an annual payout of $5.20 per share. AbbVie offers a burgeoning drug pipeline and billions in free cash flow, factors that should make it easier to fund a rising dividend for years to come. STORE Capital Scottsdale, Arizona-based STORE Capital pays a dividend of $1.54 per year, providing a cash return of around 4.6% -- and this payout has increased every year since the company's 2014 IPO. | And the company generated $9.4 billion in free cash flow in the first six months of the year, positioning it to easily cover the $4.6 billion in dividend costs for that period. AbbVie offers a burgeoning drug pipeline and billions in free cash flow, factors that should make it easier to fund a rising dividend for years to come. STORE Capital Scottsdale, Arizona-based STORE Capital pays a dividend of $1.54 per year, providing a cash return of around 4.6% -- and this payout has increased every year since the company's 2014 IPO. | STORE Capital Scottsdale, Arizona-based STORE Capital pays a dividend of $1.54 per year, providing a cash return of around 4.6% -- and this payout has increased every year since the company's 2014 IPO. STORE has had more going for it than just its payout. Nonetheless, its 11 P/E ratio makes it an affordable choice for income investors who want rising cash returns and a new source of revenue helping to fund that payout well into the future. |
31955.0 | 2021-10-14 00:00:00 UTC | ABT December 17th Options Begin Trading | ABT | https://www.nasdaq.com/articles/abt-december-17th-options-begin-trading-2021-10-14 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $115.00 strike price has a current bid of $3.05. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $115.00, but will also collect the premium, putting the cost basis of the shares at $111.95 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $117.42/share today.
Because the $115.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.65% return on the cash commitment, or 15.12% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $115.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $125.00 strike price has a current bid of $1.31. If an investor was to purchase shares of ABT stock at the current price level of $117.42/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $125.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.57% if the stock gets called away at the December 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $125.00 strike highlighted in red:
Considering the fact that the $125.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.12% boost of extra return to the investor, or 6.36% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $117.42) to be 22%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $125.00 strike highlighted in red: Considering the fact that the $125.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 17th expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $125.00 strike highlighted in red: Considering the fact that the $125.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 17th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $125.00 strike highlighted in red: Considering the fact that the $125.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 17th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $125.00 strike highlighted in red: Considering the fact that the $125.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 17th contracts and identified one put and one call contract of particular interest. |
31956.0 | 2021-10-13 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 14, 2021 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-for-october-14-2021-2021-10-13 | nan | nan | Abbott Laboratories (ABT) will begin trading ex-dividend on October 14, 2021. A cash dividend payment of $0.45 per share is scheduled to be paid on November 15, 2021. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABT has paid the same dividend. At the current stock price of $117.32, the dividend yield is 1.53%.
The previous trading day's last sale of ABT was $117.32, representing a -9.54% decrease from the 52 week high of $129.70 and a 13.76% increase over the 52 week low of $103.13.
ABT is a part of the Health Care sector, which includes companies such as Intuitive Surgical, Inc. (ISRG) and 3M Company (MMM). ABT's current earnings per share, an indicator of a company's profitability, is $3.55. Zacks Investment Research reports ABT's forecasted earnings growth in 2021 as 20.96%, compared to an industry average of 18.2%.
For more information on the declaration, record and payment dates, visit the abt Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares Evolved U.S. Healthcare Staples ETF (IEHS)
Invesco Dynamic Pharmaceuticals ETF (PJP)
Pacer BioThreat Strategy ETF (VIRS)
IQ Healthy Hearts ETF (HART)
iShares U.S. Medical Devices ETF (IHI).
The top-performing ETF of this group is IHI with an increase of 8.12% over the last 100 days. IEHS has the highest percent weighting of ABT at 7.7%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2021 as 20.96%, compared to an industry average of 18.2%. For more information on the declaration, record and payment dates, visit the abt Dividend History page. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. ABT's current earnings per share, an indicator of a company's profitability, is $3.55. Abbott Laboratories (ABT) will begin trading ex-dividend on October 14, 2021. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the abt Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares Evolved U.S. Healthcare Staples ETF (IEHS) Invesco Dynamic Pharmaceuticals ETF (PJP) Pacer BioThreat Strategy ETF (VIRS) IQ Healthy Hearts ETF (HART) iShares U.S. Medical Devices ETF (IHI). | ABT's current earnings per share, an indicator of a company's profitability, is $3.55. The following ETF(s) have ABT as a top-10 holding: iShares Evolved U.S. Healthcare Staples ETF (IEHS) Invesco Dynamic Pharmaceuticals ETF (PJP) Pacer BioThreat Strategy ETF (VIRS) IQ Healthy Hearts ETF (HART) iShares U.S. Medical Devices ETF (IHI). Abbott Laboratories (ABT) will begin trading ex-dividend on October 14, 2021. |
31957.0 | 2021-10-12 00:00:00 UTC | Notable ETF Outflow Detected - SPYG, AMD, ABT, LLY | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-spyg-amd-abt-lly-2021-10-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $335.9 million dollar outflow -- that's a 2.5% decrease week over week (from 210,350,000 to 205,150,000). Among the largest underlying components of SPYG, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Eli Lilly (Symbol: LLY) is lower by about 0.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $48.07 per share, with $68.59 as the 52 week high point — that compares with a last trade of $64.56. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 7%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Eli Lilly (Symbol: LLY) is lower by about 0.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $48.07 per share, with $68.59 as the 52 week high point — that compares with a last trade of $64.56. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Eli Lilly (Symbol: LLY) is lower by about 0.1%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $48.07 per share, with $68.59 as the 52 week high point — that compares with a last trade of $64.56. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SPYG, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Eli Lilly (Symbol: LLY) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $335.9 million dollar outflow -- that's a 2.5% decrease week over week (from 210,350,000 to 205,150,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $48.07 per share, with $68.59 as the 52 week high point — that compares with a last trade of $64.56. | Among the largest underlying components of SPYG, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Eli Lilly (Symbol: LLY) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $335.9 million dollar outflow -- that's a 2.5% decrease week over week (from 210,350,000 to 205,150,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $48.07 per share, with $68.59 as the 52 week high point — that compares with a last trade of $64.56. |
31958.0 | 2021-10-12 00:00:00 UTC | Ex-Dividend Reminder: Buckle, DTE Energy and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-buckle-dte-energy-and-abbott-laboratories-2021-10-12 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, Buckle, Inc. (Symbol: BKE), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.33 on 10/29/21, DTE Energy Co will pay its quarterly dividend of $0.7812 on 11/1/21, and Abbott Laboratories will pay its quarterly dividend of $0.45 on 11/15/21. As a percentage of BKE's recent stock price of $40.90, this dividend works out to approximately 0.81%, so look for shares of Buckle, Inc. to trade 0.81% lower — all else being equal — when BKE shares open for trading on 10/14/21. Similarly, investors should look for DTP to open 1.55% lower in price and for ABT to open 0.38% lower, all else being equal.
Below are dividend history charts for BKE, DTP, and ABT, showing historical dividends prior to the most recent ones declared.
Buckle, Inc. (Symbol: BKE):
DTE Energy Co (Symbol: DTP):
Abbott Laboratories (Symbol: ABT):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 3.23% for Buckle, Inc., 6.22% for DTE Energy Co, and 1.53% for Abbott Laboratories.
In Tuesday trading, Buckle, Inc. shares are currently up about 2.1%, DTE Energy Co shares are off about 1%, and Abbott Laboratories shares are up about 0.4% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, Buckle, Inc. (Symbol: BKE), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for DTP to open 1.55% lower in price and for ABT to open 0.38% lower, all else being equal. Below are dividend history charts for BKE, DTP, and ABT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, Buckle, Inc. (Symbol: BKE), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. (Symbol: BKE): DTE Energy Co (Symbol: DTP): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for DTP to open 1.55% lower in price and for ABT to open 0.38% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, Buckle, Inc. (Symbol: BKE), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. (Symbol: BKE): DTE Energy Co (Symbol: DTP): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for DTP to open 1.55% lower in price and for ABT to open 0.38% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, Buckle, Inc. (Symbol: BKE), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for DTP to open 1.55% lower in price and for ABT to open 0.38% lower, all else being equal. Below are dividend history charts for BKE, DTP, and ABT, showing historical dividends prior to the most recent ones declared. |
31959.0 | 2021-10-09 00:00:00 UTC | Abbott Laboratories (NYSE:ABT) Passed Our Checks, And It's About To Pay A US$0.45 Dividend | ABT | https://www.nasdaq.com/articles/abbott-laboratories-nyse%3Aabt-passed-our-checks-and-its-about-to-pay-a-us%240.45-dividend | nan | nan | It looks like Abbott Laboratories (NYSE:ABT) is about to go ex-dividend in the next 4 days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. Thus, you can purchase Abbott Laboratories' shares before the 14th of October in order to receive the dividend, which the company will pay on the 15th of November.
The company's next dividend payment will be US$0.45 per share, and in the last 12 months, the company paid a total of US$1.80 per share. Last year's total dividend payments show that Abbott Laboratories has a trailing yield of 1.5% on the current share price of $118.39. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. We need to see whether the dividend is covered by earnings and if it's growing.
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Abbott Laboratories paid out a comfortable 48% of its profit last year. A useful secondary check can be to evaluate whether Abbott Laboratories generated enough free cash flow to afford its dividend. It distributed 33% of its free cash flow as dividends, a comfortable payout level for most companies.
It's positive to see that Abbott Laboratories's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
NYSE:ABT Historic Dividend October 9th 2021
Have Earnings And Dividends Been Growing?
Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. For this reason, we're glad to see Abbott Laboratories's earnings per share have risen 16% per annum over the last five years. Earnings per share have been growing rapidly and the company is retaining a majority of its earnings within the business. This will make it easier to fund future growth efforts and we think this is an attractive combination - plus the dividend can always be increased later.
The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Abbott Laboratories's dividend payments are effectively flat on where they were 10 years ago.
Final Takeaway
Should investors buy Abbott Laboratories for the upcoming dividend? It's great that Abbott Laboratories is growing earnings per share while simultaneously paying out a low percentage of both its earnings and cash flow. It's disappointing to see the dividend has been cut at least once in the past, but as things stand now, the low payout ratio suggests a conservative approach to dividends, which we like. There's a lot to like about Abbott Laboratories, and we would prioritise taking a closer look at it.
In light of that, while Abbott Laboratories has an appealing dividend, it's worth knowing the risks involved with this stock. For example, we've found 2 warning signs for Abbott Laboratories that we recommend you consider before investing in the business.
A common investment mistake is buying the first interesting stock you see. Here you can find a list of promising dividend stocks with a greater than 2% yield and an upcoming dividend.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It looks like Abbott Laboratories (NYSE:ABT) is about to go ex-dividend in the next 4 days. NYSE:ABT Historic Dividend October 9th 2021 Have Earnings And Dividends Been Growing? Thus, you can purchase Abbott Laboratories' shares before the 14th of October in order to receive the dividend, which the company will pay on the 15th of November. | NYSE:ABT Historic Dividend October 9th 2021 Have Earnings And Dividends Been Growing? It looks like Abbott Laboratories (NYSE:ABT) is about to go ex-dividend in the next 4 days. It's positive to see that Abbott Laboratories's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. | It looks like Abbott Laboratories (NYSE:ABT) is about to go ex-dividend in the next 4 days. NYSE:ABT Historic Dividend October 9th 2021 Have Earnings And Dividends Been Growing? If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. | It looks like Abbott Laboratories (NYSE:ABT) is about to go ex-dividend in the next 4 days. NYSE:ABT Historic Dividend October 9th 2021 Have Earnings And Dividends Been Growing? It's positive to see that Abbott Laboratories's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. |
31960.0 | 2021-10-08 00:00:00 UTC | After Hours Most Active for Oct 8, 2021 : JWSM, VZ, CPUH, T, ABT, KKR^C | ABT | https://www.nasdaq.com/articles/after-hours-most-active-for-oct-8-2021-%3A-jwsm-vz-cpuh-t-abt-kkr%5Ec-2021-10-08 | nan | nan | The NASDAQ 100 After Hours Indicator is down -3.6 to 14,817.15. The total After hours volume is currently 62,252,456 shares traded.
The following are the most active stocks for the after hours session:
Jaws Mustang Acquisition Corp. (JWSM) is unchanged at $9.78, with 1,499,029 shares traded.
Verizon Communications Inc. (VZ) is +0.03 at $53.27, with 1,359,459 shares traded., following a 52-week high recorded in today's regular session.
Compute Health Acquisition Corp. (CPUH) is unchanged at $9.79, with 1,339,220 shares traded.
AT&T Inc. (T) is +0.0199 at $26.79, with 1,194,426 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2021. The consensus EPS forecast is $0.79. T's current last sale is 86.42% of the target price of $31.
Abbott Laboratories (ABT) is unchanged at $118.39, with 1,175,012 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
KKR & Co. Inc. (KKR^C) is +0.439 at $83.81, with 1,100,000 shares traded.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Abbott Laboratories (ABT) is unchanged at $118.39, with 1,175,012 shares traded. Verizon Communications Inc. (VZ) is +0.03 at $53.27, with 1,359,459 shares traded., following a 52-week high recorded in today's regular session. | Abbott Laboratories (ABT) is unchanged at $118.39, with 1,175,012 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The total After hours volume is currently 62,252,456 shares traded. | Abbott Laboratories (ABT) is unchanged at $118.39, with 1,175,012 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The total After hours volume is currently 62,252,456 shares traded. | Abbott Laboratories (ABT) is unchanged at $118.39, with 1,175,012 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The NASDAQ 100 After Hours Indicator is down -3.6 to 14,817.15. |
31961.0 | 2021-10-08 00:00:00 UTC | Noteworthy Friday Option Activity: PETS, ABT, EXAS | ABT | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-pets-abt-exas-2021-10-08 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PetMed Express Inc (Symbol: PETS), where a total of 1,542 contracts have traded so far, representing approximately 154,200 underlying shares. That amounts to about 44.4% of PETS's average daily trading volume over the past month of 347,220 shares. Particularly high volume was seen for the $20 strike put option expiring January 21, 2022, with 1,316 contracts trading so far today, representing approximately 131,600 underlying shares of PETS. Below is a chart showing PETS's trailing twelve month trading history, with the $20 strike highlighted in orange:
Abbott Laboratories (Symbol: ABT) options are showing a volume of 23,348 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44% of ABT's average daily trading volume over the past month, of 5.3 million shares. Especially high volume was seen for the $120 strike call option expiring June 17, 2022, with 5,294 contracts trading so far today, representing approximately 529,400 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $120 strike highlighted in orange:
And EXACT Sciences Corp. (Symbol: EXAS) options are showing a volume of 6,546 contracts thus far today. That number of contracts represents approximately 654,600 underlying shares, working out to a sizeable 43% of EXAS's average daily trading volume over the past month, of 1.5 million shares. Particularly high volume was seen for the $93 strike put option expiring October 15, 2021, with 1,633 contracts trading so far today, representing approximately 163,300 underlying shares of EXAS. Below is a chart showing EXAS's trailing twelve month trading history, with the $93 strike highlighted in orange:
For the various different available expirations for PETS options, ABT options, or EXAS options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $120 strike call option expiring June 17, 2022, with 5,294 contracts trading so far today, representing approximately 529,400 underlying shares of ABT. Below is a chart showing PETS's trailing twelve month trading history, with the $20 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 23,348 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44% of ABT's average daily trading volume over the past month, of 5.3 million shares. | Below is a chart showing PETS's trailing twelve month trading history, with the $20 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 23,348 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44% of ABT's average daily trading volume over the past month, of 5.3 million shares. Especially high volume was seen for the $120 strike call option expiring June 17, 2022, with 5,294 contracts trading so far today, representing approximately 529,400 underlying shares of ABT. | Below is a chart showing EXAS's trailing twelve month trading history, with the $93 strike highlighted in orange: For the various different available expirations for PETS options, ABT options, or EXAS options, visit StockOptionsChannel.com. Below is a chart showing PETS's trailing twelve month trading history, with the $20 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 23,348 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44% of ABT's average daily trading volume over the past month, of 5.3 million shares. | Especially high volume was seen for the $120 strike call option expiring June 17, 2022, with 5,294 contracts trading so far today, representing approximately 529,400 underlying shares of ABT. Below is a chart showing EXAS's trailing twelve month trading history, with the $93 strike highlighted in orange: For the various different available expirations for PETS options, ABT options, or EXAS options, visit StockOptionsChannel.com. Below is a chart showing PETS's trailing twelve month trading history, with the $20 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 23,348 contracts thus far today. |
31962.0 | 2021-10-06 00:00:00 UTC | U.S. to invest another $1 bln in rapid COVID-19 tests | ABT | https://www.nasdaq.com/articles/u.s.-to-invest-another-%241-bln-in-rapid-covid-19-tests-2021-10-06 | nan | nan | By Carl O'Donnell and Alexandra Alper
Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday.
The combined purchases will help quadruple the United States' test output by December to around 200 million tests per month, Jeff Zients, the White House coronavirus response coordinator, said during a press call.
"We'll continue to pull every lever to expand manufacturing production of tests which will have the impact of driving down the cost per test and making sure that tests are widely available and convenient," Zients said.
The government will also double the number of pharmacies it partners with to provide free COVID-19 tests to 20,000 pharmacies, Zients added.
Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs.
The White House in September said it plans to mandate weekly testing for unvaccinated staff at businesses with more than 100 employees.
The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests.
The U.S. government also has agreements to purchase tests from other manufacturers, including Quidel Corp. QDEL.O, OraSure Technologies, and Intrivo.
Earlier this week, U.S. regulators authorized another rapid test from Acon Technologies that can be taken at home. Zients said the test will retail for around $10 per test.
The average number of daily U.S. coronavirus cases dropped by 12% over the last seven days to nearly 98,000, and hospitalizations dropped 14% to 7,400, said U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky said during the briefing.
She cautioned that deaths remained constant at 1,400 per day.
(Reporting by Carl O'Donnell; Editing by Leslie Adler and Aurora Ellis)
((Carl.ODonnell@thomsonreuters.com; 646-223-6629;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests. By Carl O'Donnell and Alexandra Alper Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday. The White House in September said it plans to mandate weekly testing for unvaccinated staff at businesses with more than 100 employees. | The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests. By Carl O'Donnell and Alexandra Alper Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday. The combined purchases will help quadruple the United States' test output by December to around 200 million tests per month, Jeff Zients, the White House coronavirus response coordinator, said during a press call. | The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests. By Carl O'Donnell and Alexandra Alper Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday. "We'll continue to pull every lever to expand manufacturing production of tests which will have the impact of driving down the cost per test and making sure that tests are widely available and convenient," Zients said. | The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests. By Carl O'Donnell and Alexandra Alper Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday. The combined purchases will help quadruple the United States' test output by December to around 200 million tests per month, Jeff Zients, the White House coronavirus response coordinator, said during a press call. |
31963.0 | 2021-10-05 00:00:00 UTC | FOCUS-Rapid COVID-19 tests increasingly scarce, pricey as demand from employers jumps | ABT | https://www.nasdaq.com/articles/focus-rapid-covid-19-tests-increasingly-scarce-pricey-as-demand-from-employers-jumps-2021 | nan | nan | By Carl O'Donnell
Oct 5 (Reuters) - Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs, according to industry executives and state officials.
Testmakers including Abbott Laboratories ABT.N, Quidel Corp QDEL.O and LumiraDX Ltd LMDX.O are scaling up production to meet rising demand. But significantly boosting test output will take weeks to months, half a dozen industry executives told Reuters, making the tests harder to procure in the near term.
"Employer demand has gone crazy," said Quidel Chief Executive Doug Bryant. "We won't be able to meet all the requests that we're having."
Nearly a dozen state governments said they are grappling with shortages of rapid tests, which provide on-the-spot results within minutes and are crucial for COVID-19 surveillance programs.
In Missouri, limited supplies of Abbott's Binax Now rapid test, which typically sell to states for around $5 each, have forced it to consider other, more expensive options, a spokesperson for the states' public health agency said.
"We are exploring other rapid antigen tests and finding most are at least three times higher than Abbott’s rapid antigen test," the spokesperson said, adding that Missouri has not yet had to purchase the pricier tests.
Oklahoma has begun to pay higher prices for tests in recent weeks, said Michael DeRemer, the state's director of emergency preparedness and response services.
State governments have been struggling to acquire enough rapid tests for several months after a surge in COVID-19 cases fueled by the more contagious Delta variant.
And U.S. employers in recent weeks have been rushing to stockpile tests after the White House in September said it plans to mandate weekly testing for unvaccinated staff at businesses with more than 100 employees.
Emerald Packaging Inc, a plastic bag factory in San Francisco with 250 workers, sees the cost of complying with the government's testing mandate as a burden and is urging employees to get vaccinated.
Emerald may require vaccination once the federal rule goes into effect, said CEO Kevin Kelly. He said Emerald has spent about $50,000 testing its employees so far and is concerned weekly tests will further drive up costs.
Quidel has had to decline more than half of requests from employers seeking to stock up ahead of the mandate, expected to take effect in October, said CEO Bryant.
It has also had to postpone exports of rapid tests to some foreign governments until next year, Bryant said. Quidel is delivering on existing contracts with countries including Canada.
BIDDING WARS, SIGNIFICANT MARKUPS
U.S. testmakers manufacture more than 50 million rapid COVID-19 tests each month, not enough for regular surveillance testing at schools and workplaces across the country, said Evercore ISI analyst Vijay Kumar.
Rapid antigen tests can cost as little as $2 each to make, according to Mologic, one of the largest British testmakers. But in the United States, bidding wars between health systems, state governments, and employers have contributed to much higher prices.
South Carolina, for example, is paying as much as $130 each for some of its rapid tests, a state spokesperson said.
That contrasts sharply with the UK and European countries. In Germany, large government purchases allow it to offer rapid tests to residents for less than $1 each, and it is not experiencing severe shortages.
Abbott and Quidel said they do not plan to raise test prices for customers. However, retailers and test providers often purchase tests and resell them at significant markups.
Walgreens Boots Alliance Inc WBA.O and CVS Health Corp CVS.N sell Abbott's Binax Now rapid tests - which Abbott lists for around $5 - for $12 per test at pharmacies. Walmart Inc WMT.N, Kroger KR.N and Amazon.com Inc AMZN.O charge nearly $8 per test even after they slashed prices temporarily to cost.
States largely have been using the $10 billion the White House set aside primarily for school testing programs. Some states including Missouri said their federal aid is running out.
Meanwhile, employers and consumers must pay for rapid test purchases themselves.
In an effort to ramp up production, Abbott reopened a plant in Illinois it had shuttered earlier this year, putting it back on track to produce upwards of 50 million Binax Now tests per month by the end of October, a person familiar with the matter told Reuters.
Quidel is building a new plant that will boost its rapid test output from around 20 million per month to as much as 70 million, but it will not be operational until year-end, Bryant said. LumiraDX is planning to nearly double its test production by year end.
On Monday, U.S. regulators authorized a rapid test made by ACON Laboratories, which plans to produce as many as 100 million per month by the end of the year.
“There's definitely a supply chain squeeze on the rapid antigen side,” said Matthew McKnight, an executive at Ginkgo BioWorks, which manages surveillance testing programs for employers. "It will take a couple months (before) production catches up.”
(Reporting by Carl O'Donnell in New York, Additional reporting by Tim Aeppel in New York; Editing by Caroline Humer and Bill Berkrot)
((Carl.ODonnell@thomsonreuters.com; 646-223-6629;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Testmakers including Abbott Laboratories ABT.N, Quidel Corp QDEL.O and LumiraDX Ltd LMDX.O are scaling up production to meet rising demand. Oklahoma has begun to pay higher prices for tests in recent weeks, said Michael DeRemer, the state's director of emergency preparedness and response services. Emerald Packaging Inc, a plastic bag factory in San Francisco with 250 workers, sees the cost of complying with the government's testing mandate as a burden and is urging employees to get vaccinated. | Testmakers including Abbott Laboratories ABT.N, Quidel Corp QDEL.O and LumiraDX Ltd LMDX.O are scaling up production to meet rising demand. By Carl O'Donnell Oct 5 (Reuters) - Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs, according to industry executives and state officials. But significantly boosting test output will take weeks to months, half a dozen industry executives told Reuters, making the tests harder to procure in the near term. | Testmakers including Abbott Laboratories ABT.N, Quidel Corp QDEL.O and LumiraDX Ltd LMDX.O are scaling up production to meet rising demand. By Carl O'Donnell Oct 5 (Reuters) - Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs, according to industry executives and state officials. "We are exploring other rapid antigen tests and finding most are at least three times higher than Abbott’s rapid antigen test," the spokesperson said, adding that Missouri has not yet had to purchase the pricier tests. | Testmakers including Abbott Laboratories ABT.N, Quidel Corp QDEL.O and LumiraDX Ltd LMDX.O are scaling up production to meet rising demand. By Carl O'Donnell Oct 5 (Reuters) - Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs, according to industry executives and state officials. Quidel is building a new plant that will boost its rapid test output from around 20 million per month to as much as 70 million, but it will not be operational until year-end, Bryant said. |
31964.0 | 2021-09-30 00:00:00 UTC | 2 Unstoppable Stocks to Buy and Hold Forever | ABT | https://www.nasdaq.com/articles/2-unstoppable-stocks-to-buy-and-hold-forever-2021-09-30 | nan | nan | The stock market has been on a fantastic run in the past year and a half. Since bottoming out in late March 2020 following the coronavirus-fueled market crash, the S&P 500 has doubled in value. This performance underscores the power of the buy-and-hold strategy.
Even when the market is experiencing downturns, staying the course -- as opposed to panic selling -- is the right thing to do. The longer you hold onto shares of great companies, the juicier your returns will be. With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V).
ABT data by YCharts
1. Abbott Laboratories
The history of medical devices specialist Abbott Laboratories dates back more than 100 years. As a publicly-traded company, it has soundly outperformed the market over the past several decades. Of course, past performance isn't a guarantee of future success. But Abbott's long-standing habit of delivering solid results is a significant strength. Having been a major player in the medical devices space for a long time, the company benefits from a strong reputation.
Physicians, like most consumers, are inclined to stick to what they know works. In addition, with the healthcare sector having significant barriers to entry, the chances of new entrants with similar expertise and industry knowledge are minimal. Furthermore, the company's rich lineup of approved devices is protected by scores of patents and copyrights, which help insulate them from competition.
One of the company's key growth drivers is the FreeStyle Libre, a continuous glucose monitoring (CGM) system that helps diabetic patients track their blood glucose levels. CGMs significantly reduce the need for painful fingersticks, making them the more attractive option for patients. The increased adoption of this technology continues to spearhead sales growth for Abbott's crown jewel.
Image source: Getty Images.
During the second quarter ending June 30, Abbott's diabetes care revenue came in at $1.1 billion, 40% higher than the year-ago period. The company had the FreeStyle Libre to thank for this performance. And while it competes with several other companies in this space -- most notably Medtronic and DexCom (NASDAQ: DXCM) -- this market will only continue to grow. According to the U.S. Centers for Disease Control and Prevention, more than 34 million Americans have diabetes, a number that is set to increase drastically in the coming years.
This trend is unfortunate, but it underscores the need for innovative technologies to help diabetes patients manage this illness. Note that in 2020, sales of Abbott's Freestyle Libre came in at $2.6 billion, compared to DexCom's total revenue of $1.9 billion (DexCom generates revenue from the sale of its G6 CGM System as well as instruments and accessories that go along with it). Abbott looks well-placed to remain a key player in this market which, in my view, is more than enough to accommodate two or more big players.
The company does have other devices that can drive growth, including the MitraClip, which treats mitral regurgitation (a condition in which blood doesn't flow from the heart properly), and its Tricuspid Repair System, a non-invasive device to help repair the tricuspid valve. Lastly, Abbott's business extends beyond its medical devices unit. The company's nutritional products and established pharmaceuticals segments add diversification.
Abbott Laboratories is trading at 26.8 times forward earnings, compared to the average forward price to earnings (PE) ratio of 17.3 in the healthcare sector. That makes shares of the medical devices company expensive, but in my view, it is worth paying a premium for the company. Business is still booming for this established healthcare giant, and it will be tough for competitors to knock it off its pedestal anytime soon. That makes Abbott Laboratories' stock worth parking in your portfolio for many years to come.
2. Visa
Visa is one of those companies whose services people use daily. Many of us carry around debit or credit cards that proudly display its logo. Visa helps facilitate transactions between consumers and merchants. It does not issue credit or debit cards itself -- that's what banks are for. Rather, Visa provides the transaction processing network that supports debit and credit card purchases. The company charges fees for every transaction conducted with a card that bears its name.
Visa's stock has performed exceptionally well since its IPO in 2008, easily beating the market from then to now. There are two main reasons why the company can continue to perform well. First, Visa's business benefits from the network effect. That is, the value of its services increases as more people use it. The company's payment network becomes more attractive to merchants as more consumers join in. And as the number of merchants increases, more consumers are likely to use Visa for payment.
This dynamic ensures that it will be challenging to eat into Visa's market share. Meanwhile, Visa's network will only continue to grow. This brings us to the second reason why the company will continue to beat the market: Exciting opportunities ahead. According to a report published by the management consulting company McKinsey, cash transactions accounted for about 28% of total transactions by volume in the U.S. in 2020.
This figure is more or less in line with that of other developed nations, but cash is still king for developing countries. The digital payments market is projected to continue expanding rapidly.
Image source: Getty Images.
With one of the largest payment networks in the world, Visa is well-equipped to benefit. And as the financial services industry continues to evolve, it is looking to expand its reach. In June, the company announced the acquisition of Sweden-based fintech start-up Tink, which allows banks and other institutions to access financial data to build personalized banking and financial tools for consumers. The acquisition is valued at 1.8 billion Euros (roughly $2.1 billion).
Visa's shares aren't cheap either -- they currently trade for 46.05 past and 39.13 times forward earnings. But note that Visa's closest competitor, Mastercard (NYSE: MA), has a PE and forward PE ratio of 49.34 and 43.62, respectively. While those two companies dominate the industry, Visa holds the edge. For the fiscal year 2019, Visa had a higher payment volume ($8.9 billion vs. $4.8 billion), higher total transactions (207 billion vs 122 billion), and more cards to its name (3.4 million vs. 2.2 million).
Visa also generates higher revenue and profits. For their latest reported quarters, Visa's top line came in at $6.13 billion -- higher than Mastercard's $4.53 billion. Visa's shares aren't that expensive when put into context. And given the company's competitive advantage and growth prospects, it will continue delivering strong financial results, thereby pushing its share price ever higher.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Mastercard and Visa. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT data by YCharts 1. In addition, with the healthcare sector having significant barriers to entry, the chances of new entrants with similar expertise and industry knowledge are minimal. | With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT data by YCharts 1. One of the company's key growth drivers is the FreeStyle Libre, a continuous glucose monitoring (CGM) system that helps diabetic patients track their blood glucose levels. | With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT data by YCharts 1. Visa Visa is one of those companies whose services people use daily. | With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT data by YCharts 1. Note that in 2020, sales of Abbott's Freestyle Libre came in at $2.6 billion, compared to DexCom's total revenue of $1.9 billion (DexCom generates revenue from the sale of its G6 CGM System as well as instruments and accessories that go along with it). |
31965.0 | 2021-09-29 00:00:00 UTC | LGLV's Underlying Holdings Could Mean 10% Gain Potential | ABT | https://www.nasdaq.com/articles/lglvs-underlying-holdings-could-mean-10-gain-potential-2021-09-29 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— SSGA US Large Cap Low Volatility Index ETF (Symbol: LGLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $148.43 per unit.
With LGLV trading at a recent price near $134.41 per unit, that means that analysts see 10.44% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of LGLV's underlying holdings with notable upside to their analyst target prices are Roper Technologies Inc (Symbol: ROP), Duke Energy Corp (Symbol: DUK), and Abbott Laboratories (Symbol: ABT). Although ROP has traded at a recent price of $452.91/share, the average analyst target is 11.37% higher at $504.43/share. Similarly, DUK has 10.77% upside from the recent share price of $97.05 if the average analyst target price of $107.50/share is reached, and analysts on average are expecting ABT to reach a target price of $131.38/share, which is 10.65% above the recent price of $118.74. Below is a twelve month price history chart comparing the stock performance of ROP, DUK, and ABT:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
SPDR— SSGA US Large Cap Low Volatility Index ETF LGLV $134.41 $148.43 10.44%
Roper Technologies Inc ROP $452.91 $504.43 11.37%
Duke Energy Corp DUK $97.05 $107.50 10.77%
Abbott Laboratories ABT $118.74 $131.38 10.65%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SPDR— SSGA US Large Cap Low Volatility Index ETF LGLV $134.41 $148.43 10.44% Roper Technologies Inc ROP $452.91 $504.43 11.37% Duke Energy Corp DUK $97.05 $107.50 10.77% Abbott Laboratories ABT $118.74 $131.38 10.65% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of LGLV's underlying holdings with notable upside to their analyst target prices are Roper Technologies Inc (Symbol: ROP), Duke Energy Corp (Symbol: DUK), and Abbott Laboratories (Symbol: ABT). Similarly, DUK has 10.77% upside from the recent share price of $97.05 if the average analyst target price of $107.50/share is reached, and analysts on average are expecting ABT to reach a target price of $131.38/share, which is 10.65% above the recent price of $118.74. | Three of LGLV's underlying holdings with notable upside to their analyst target prices are Roper Technologies Inc (Symbol: ROP), Duke Energy Corp (Symbol: DUK), and Abbott Laboratories (Symbol: ABT). SPDR— SSGA US Large Cap Low Volatility Index ETF LGLV $134.41 $148.43 10.44% Roper Technologies Inc ROP $452.91 $504.43 11.37% Duke Energy Corp DUK $97.05 $107.50 10.77% Abbott Laboratories ABT $118.74 $131.38 10.65% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Similarly, DUK has 10.77% upside from the recent share price of $97.05 if the average analyst target price of $107.50/share is reached, and analysts on average are expecting ABT to reach a target price of $131.38/share, which is 10.65% above the recent price of $118.74. | Similarly, DUK has 10.77% upside from the recent share price of $97.05 if the average analyst target price of $107.50/share is reached, and analysts on average are expecting ABT to reach a target price of $131.38/share, which is 10.65% above the recent price of $118.74. Three of LGLV's underlying holdings with notable upside to their analyst target prices are Roper Technologies Inc (Symbol: ROP), Duke Energy Corp (Symbol: DUK), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of ROP, DUK, and ABT: Below is a summary table of the current analyst target prices discussed above: | SPDR— SSGA US Large Cap Low Volatility Index ETF LGLV $134.41 $148.43 10.44% Roper Technologies Inc ROP $452.91 $504.43 11.37% Duke Energy Corp DUK $97.05 $107.50 10.77% Abbott Laboratories ABT $118.74 $131.38 10.65% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of LGLV's underlying holdings with notable upside to their analyst target prices are Roper Technologies Inc (Symbol: ROP), Duke Energy Corp (Symbol: DUK), and Abbott Laboratories (Symbol: ABT). Similarly, DUK has 10.77% upside from the recent share price of $97.05 if the average analyst target price of $107.50/share is reached, and analysts on average are expecting ABT to reach a target price of $131.38/share, which is 10.65% above the recent price of $118.74. |
31966.0 | 2021-09-29 00:00:00 UTC | Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors | ABT | https://www.nasdaq.com/articles/heres-why-abbvie-is-a-great-healthcare-stock-for-long-term-investors-2021-09-29 | nan | nan | Pharmaceutical giant AbbVie (NYSE: ABBV) is best known for its mega-blockbuster drug Humira, which raked in more revenue than any other medicine in the world in yet another year of successive growth in 2020. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Brian Withers and Rachel Warren discuss what makes AbbVie such a stalwart choice for the long-term investor's portfolio.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. I'm not a big healthcare guy, [laughs] but interestingly enough, I worked for Allergan. When I left corporate world in 2019, Allergan was the last company I worked for, and AbbVie recently purchased Allergan. I know a little bit about the inner workings and some of the products, but I didn't know a ton about AbbVie and I just wanted to share what I found is super-interesting. For those who don't know, AbbVie started out, it was a split off from Abbott, and Abbott has been just over a century-old company that is focused on healthcare research and producing products that makes people's lives better.
In 2013, it was formed and spun out as ABBV. What's interesting is I looked at the initial announcement letter and they talked about how Abbott has been transformative in its 125-year history and enduring success, reinventing our times, reinventing ourselves. The bottom line of the announcement, it talked about a total of 10 programs that are currently in phase 3 clinical development.
The thing that came out most for me as I looked at AbbVie is these guys are an innovation machine. They used to be just focused on this immunology piece, but with the Allergan purchase, both aesthetics here, some neuroscience, Ubrelvy and Botox are both Allergan tools.
But they've expanded beyond their immunology routes into a number of other segments. I hadn't gotten to the R&D pipeline yet. But since 2013, solid growth on the top and the bottom line, shareholder return, and oh, yeah, dividends, big-time dividends, 225% increase in the quarterly dividend since 2013. Look at this pipeline, it is just amazing.
A number of different healthcare areas, as well as stuff throughout the pipeline in phases ready to go or even just early stage is just amazing. Then not only is this pipeline huge and continually growing, they have upcoming key events in the next one and two years that should result in real revenue for the company as they go forward in the next couple of years. Pretty exciting. As you cover healthcare, Rachel, I imagine this name comes up quite often.
Rachel Warren: Oh, yeah. I love writing about the healthcare industry. I think it has a lot of great investment opportunities for long-term buy-and-hold retail investors. I think AbbVie was definitely an easy pick for me in terms of the long list of healthcare stocks that are out there.
You were talking about its dividend. Because of the spin-off with Abbott, it maintained Abbott's dividend history. It qualifies as a Dividend Aristocrat. To be a Dividend Aristocrat, you have to have 20 years of consecutive dividend increases or more. AbbVie also has an incredibly above-average dividend yield. I believe, based on current share prices, it's in the ballpark of 4.9% -- that may have changed since I logged on -- which is quite a bit higher. I believe the average stock trading on the S&P 500 right about now, it's about 1.3% dividend yield. So, it's got a super high dividend.
I think the other thing, as with these very large pharmaceutical companies, is you're buying into a company that has a really stable track record of growth and it's definitely accomplished that. Then like you were saying, it's really going outside of these areas like immunology that it's really known for and expanding. I know one thing that's been a concern for some investors is that it's going to be losing U.S. patent exclusivity for Humira, which is the world's top-selling drug. I think it raked in like $20 billion in revenue for the company last year.
But I would say that AbbVie's product portfolio, like you were mentioning has grown so much in recent years, and with its acquisition of Allergan has really changed direction and spanning so many different healthcare areas that are really raking in more and more profits for the company. I don't think the Humira concern is a huge one, and I think that that particular acquisition of Allergan was a really good step in the right direction.
Brian Withers has no position in any of the stocks mentioned. Rachel Warren owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pharmaceutical giant AbbVie (NYSE: ABBV) is best known for its mega-blockbuster drug Humira, which raked in more revenue than any other medicine in the world in yet another year of successive growth in 2020. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Brian Withers and Rachel Warren discuss what makes AbbVie such a stalwart choice for the long-term investor's portfolio. But I would say that AbbVie's product portfolio, like you were mentioning has grown so much in recent years, and with its acquisition of Allergan has really changed direction and spanning so many different healthcare areas that are really raking in more and more profits for the company. | In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Brian Withers and Rachel Warren discuss what makes AbbVie such a stalwart choice for the long-term investor's portfolio. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. When I left corporate world in 2019, Allergan was the last company I worked for, and AbbVie recently purchased Allergan. | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. For those who don't know, AbbVie started out, it was a split off from Abbott, and Abbott has been just over a century-old company that is focused on healthcare research and producing products that makes people's lives better. But I would say that AbbVie's product portfolio, like you were mentioning has grown so much in recent years, and with its acquisition of Allergan has really changed direction and spanning so many different healthcare areas that are really raking in more and more profits for the company. | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. You were talking about its dividend. But I would say that AbbVie's product portfolio, like you were mentioning has grown so much in recent years, and with its acquisition of Allergan has really changed direction and spanning so many different healthcare areas that are really raking in more and more profits for the company. |
31967.0 | 2021-09-28 00:00:00 UTC | RSI Alert: Abbott Laboratories Now Oversold | ABT | https://www.nasdaq.com/articles/rsi-alert%3A-abbott-laboratories-now-oversold-2021-09-28 | nan | nan | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $118.06 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Abbott Laboratories, the RSI reading has hit 28.8 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 47.5. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, ABT's recent annualized dividend of 1.8/share (currently paid in quarterly installments) works out to an annual yield of 1.49% based upon the recent $120.58 share price.
A bullish investor could look at ABT's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
Click here to find out what 9 other oversold dividend stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABT's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $118.06 per share. | Indeed, ABT's recent annualized dividend of 1.8/share (currently paid in quarterly installments) works out to an annual yield of 1.49% based upon the recent $120.58 share price. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $118.06 per share. | Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $118.06 per share. | Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $118.06 per share. |
31968.0 | 2021-09-28 00:00:00 UTC | ABT Makes Notable Cross Below Critical Moving Average | ABT | https://www.nasdaq.com/articles/abt-makes-notable-cross-below-critical-moving-average-2021-09-28 | nan | nan | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $118.48, changing hands as low as $118.06 per share. Abbott Laboratories shares are currently trading down about 1.7% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $118.55. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com
Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $118.48, changing hands as low as $118.06 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $118.55. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $118.48, changing hands as low as $118.06 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $118.55. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $118.48, changing hands as low as $118.06 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $118.55. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $118.48, changing hands as low as $118.06 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $118.55. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31969.0 | 2021-09-28 00:00:00 UTC | Will Dexcom Stock Continue To Make Fresh Highs? | ABT | https://www.nasdaq.com/articles/will-dexcom-stock-continue-to-make-fresh-highs-2021-09-28 | nan | nan | [Updated: 9/24/2021] DXCM Stock Update
A few months back we discussed that going by its historical performance Dexcom Stock (NASDAQ: DXCM) may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last one month close to its all-time high levels of $579. The company’s Q2 earnings of $0.76 per share on an adjusted basis were much better than $0.43 street estimate. The revenue growth of 32% during the quarter also reflected strong y-o-y growth. Dexcom is one of the few players, along with Abbott, which has secured the regulatory approvals for its wearable continuous glucose monitoring (CGM) device. There is a high demand for CGM devices that do not require finger prick and data can be self-monitored easily. Given the limited competition, and a wide pool of diabetic patients (over 34 million in the U.S. alone), the company is likely to see strong growth over the coming years. DXCM stock has also seen a large appreciation of 60% year-to-date, and more than 500% over the last five years.
But now that DXCM stock has seen a 11% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is still a higher chance of continued gains in DXCM stock over the next month. Out of 702 instances in the last ten years that DXCM stock saw a twenty-one day rise of 11% or more, 414 of them resulted in DXCM stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 414 out of 702, or about a 59% chance of a rise in DXCM stock over the coming month, implying that the stock may continue to rise and make fresh highs in the near term. See our analysis on Dexcom Stock Chance of Rise for more details.
Also, you can understand how Dexcom’s revenues have changed over the years along with trends in revenues for its closest peers in a separate dashboard analysis.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
After moving 1.3% or more over a five-day period, the stock rose in the next five days on 57% of the occasions.
After moving 3.6% or more over a ten-day period, the stock rose in the next ten days on 60% of the occasions
After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 59% of the occasions.
Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise
DexCom (DXCM) Stock Return (Recent) Comparison With Peers
Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7%
Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3%
Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1%
[Updated: 6/22/2021] DXCM Stock Rise
Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well. The Centers For Medicare & Medicaid Services (CMS) recently announced that there is no longer a requirement for a minimum of four self-monitoring blood glucose tests per day to have the continuous glucose monitoring (CGM) devices covered. This step will result in better patient access, and bode well for companies such as Dexcom and Abbott that develop CGM devices with no requirement of finger-pricking.
Furthermore, Dexcom expects to launch its newest CGM device – G7 – later this year, and given that the new device will use a new and improved application, while it will also be 60% smaller in size compared to the current G6, making it the smallest CGM device available in the market. It has several other benefits over the current version, such as, its transmitter and sensor will be combined, making it a single fully disposable unit. It is also expected to have a longer wear time. As such, the G7 CGM will likely be more attractive to customers, and bolster Dexcom’s sales growth after its launch.
However, now that DXCM stock has seen a rise of 23% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise in DXCM stock over the next month. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 99 out of 184, or about 54% chance of a rise in DXCM stock over the coming month. Also, despite the recent rally, DXCM stock is up only 4% from the levels it was trading at a year ago. See our analysis on Dexcom Stock Chances of Rise for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data
3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances
9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances
23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances
Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise
DexCom (DXCM) Stock Return (Recent) Comparison With Peers
Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1%
Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3%
Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4%
[Updated: 5/6/2021] DXCM Stock Decline
The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. The recent drop is surprising, given that the company last week reported its Q1 numbers, which were actually above the street estimates. Dexcom’s Q1 sales of $505 million was higher than the $482 million consensus estimate. Similarly, its adjusted EPS of $0.33 was ahead of the $0.31 consensus estimate. Looking at the company’s guidance for revenue to be between $2.26 billion and $2.36 billion in 2021 is also in-line with the $2.33 billion consensus estimates. It’s not that the stock had seen a large rally. DXCM stock is up just 1% year-to-date, and it is at the same levels it was at a year back.
While there have been rumors of Apple (NASDAQ:AAPL) coming up with a CGM feature in its Apple Watch, the company hasn’t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if the data collected by Apple Watch is fully reliable. However, it’s not easy to secure the U.S. FDA regulatory approval for a wearable CGM device given that it expects the data to be comparable to the regular CGM devices. It seems unlikely at this stage that Apple may come up with a CGM feature to match the level of accuracy on other CGM devices, such as that of Dexcom and Abbott.
Looking at the recent decline, the 11% drop for DXCM stock over the last five days compares with just a 0.7% decline seen in the broader S&P 500 index. Now, is DXCM stock poised to drop further? It doesn’t appears so. Given the large underperformance over the recent past, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 64% chance of a rise in DXCM stock over the next month (twenty-one trading days).
Out of 75 instances in the last ten years that Dexcom (DXCM) stock saw a five-day decline of 11% or more, 48 of them resulted in DXCM stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 48 out of 75, or about a 64% chance of gain in DXCM stock over the coming month. See our analysis on Dexcom Stock Chances of Rise for more details.
Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market
(3% likelihood event)
Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7%
A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years.
Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market
(11% likelihood event)
Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4%
A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years.
Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market
(44% likelihood event)
Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3%
A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years.
While DXCM stock can see a rebound, it is helpful to see how its peers stack up. Check out Dexcom Stock Comparison With Peers to see how DXCM stock compares against peers on metrics that matter. You can find more such useful comparisons on Peer Comparisons.
Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Given the limited competition, and a wide pool of diabetic patients (over 34 million in the U.S. alone), the company is likely to see strong growth over the coming years. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. This step will result in better patient access, and bode well for companies such as Dexcom and Abbott that develop CGM devices with no requirement of finger-pricking. |
31970.0 | 2021-09-27 00:00:00 UTC | Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health? | ABT | https://www.nasdaq.com/articles/is-abbott-laboratories-nyse%3Aabt-stocks-recent-performance-a-reflection-of-its-financial | nan | nan | Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.5% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Abbott Laboratories' ROE today.
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
How To Calculate Return On Equity?
Return on equity can be calculated by using the formula:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for Abbott Laboratories is:
19% = US$6.4b ÷ US$34b (Based on the trailing twelve months to June 2021).
The 'return' is the profit over the last twelve months. That means that for every $1 worth of shareholders' equity, the company generated $0.19 in profit.
Why Is ROE Important For Earnings Growth?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
A Side By Side comparison of Abbott Laboratories' Earnings Growth And 19% ROE
To start with, Abbott Laboratories' ROE looks acceptable. On comparing with the average industry ROE of 10% the company's ROE looks pretty remarkable. Probably as a result of this, Abbott Laboratories was able to see an impressive net income growth of 37% over the last five years. However, there could also be other causes behind this growth. Such as - high earnings retention or an efficient management in place.
Next, on comparing with the industry net income growth, we found that Abbott Laboratories' growth is quite high when compared to the industry average growth of 14% in the same period, which is great to see.
NYSE:ABT Past Earnings Growth September 27th 2021
Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is ABT fairly valued? This infographic on the company's intrinsic value has everything you need to know.
Is Abbott Laboratories Making Efficient Use Of Its Profits?
Abbott Laboratories' significant three-year median payout ratio of 76% (where it is retaining only 24% of its income) suggests that the company has been able to achieve a high growth in earnings despite returning most of its income to shareholders.
Besides, Abbott Laboratories has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders. Existing analyst estimates suggest that the company's future payout ratio is expected to drop to 36% over the next three years. Accordingly, the expected drop in the payout ratio explains the expected increase in the company's ROE to 24%, over the same period.
Summary
Overall, we are quite pleased with Abbott Laboratories' performance. Especially the high ROE, Which has contributed to the impressive growth seen in earnings. Despite the company reinvesting only a small portion of its profits, it still has managed to grow its earnings so that is appreciable. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.5% over the past three months. NYSE:ABT Past Earnings Growth September 27th 2021 Earnings growth is a huge factor in stock valuation. Is ABT fairly valued? | Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.5% over the past three months. NYSE:ABT Past Earnings Growth September 27th 2021 Earnings growth is a huge factor in stock valuation. Is ABT fairly valued? | Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.5% over the past three months. NYSE:ABT Past Earnings Growth September 27th 2021 Earnings growth is a huge factor in stock valuation. Is ABT fairly valued? | Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.5% over the past three months. NYSE:ABT Past Earnings Growth September 27th 2021 Earnings growth is a huge factor in stock valuation. Is ABT fairly valued? |
31971.0 | 2021-09-26 00:00:00 UTC | 3 Winning Stocks to Buy No Matter What the Market Is Doing | ABT | https://www.nasdaq.com/articles/3-winning-stocks-to-buy-no-matter-what-the-market-is-doing-2021-09-26 | nan | nan | Right now is the perfect time to think about stocks to buy during any market environment. Why? Because we've had a recent example of how quickly things can change. Concerns about the economy and the pandemic weighed on the market -- after months of solid gains. The Dow Jones Industrial Average climbed more than 15% from the start of the year through Aug. 31. Then it slipped 4% in the first three weeks of September.
So, what makes an all-around winning stock to hold onto during good times and bad times? I look for companies with a strong sales and/or profit track record. I also like companies that sell essential goods or services. And finally, I'll go for companies that have built a strong brand and relationship with customers. Let's look at three stocks that fit the bill.
Image source: Getty Images.
1. Target
Target (NYSE: TGT) posted an exceptional performance during the worst of the pandemic. The company's recipe for success? First, its array of essential items -- available in store and online. Add to that its options for contactless pickup and delivery. The result? Target's sales last year grew by $15 billion -- that's more than in the previous 11 years combined.
But here's the best part. The company continued to post sales growth -- and growth of its pickup and delivery services -- even after shoppers returned to usual shopping habits. By that, I mean going to physical stores and buying items beyond the essentials. In fact, in the most recent quarter, sales in all product categories climbed. The high-margin category of apparel even posted double-digit sales growth.
Target makes shopping easy for consumers who like to shop in store and those who prefer an online platform. That means the retailer can attract both kinds of customers. Importantly, a lot of guests opt for both -- and Target says these multi-channel guests end up spending four times more than store-only customers and ten times more than online-only shoppers.
The company's plans should keep customers coming back: Target is investing $4 billion annually to remodel stores and strengthen fulfillment and the supply chain.
Target shares are trading at about 18 times forward earnings. That's a steal considering Target's revenue growth -- and potential for more on the horizon.
2. Abbott Labs
I like Abbott Laboratories (NYSE: ABT) for the diversity of its businesses -- and their growth. Abbott's nutrition, diagnostics, medical devices, and pharmaceuticals businesses each posted double-digit revenue gains in the most recent quarter. And Abbott's annual revenue and net income both have been on the rise for the past few years.
Since the early days of the pandemic, diagnostics have led to even more revenue for Abbott. That's because the company sells several coronavirus detection tests -- including the rapid BinaxNOW. These tests generated $2.4 billion in sales in the fourth quarter of last year, for example.
Of course, testing demand may ebb and flow. But that's OK. I look at COVID testing as a plus for the company -- not something that will determine Abbott's overall success. Here's why: Medical devices generally contribute the most to Abbott's revenue. Abbott's star product is the FreeStyle Libre continuous glucose monitoring system. It is the No. 1 such system worldwide. And it's the most prescribed in the U.S. The FreeStyle Libre brought in more than $900 million in the most recent quarter. Total medical device revenue topped $3.6 billion.
Abbott has already shown it can outperform the market over the long term.
ABT data by YCharts
Thanks to the strength and diversity of its product portfolio, I think this performance can continue.
3. Lululemon Athletica
During the worst of the pandemic, most clothing retailers suffered. But Lululemon Athletica (NASDAQ: LULU) actually managed to grow. The maker of yoga-inspired clothing built a strong brand prior to the health crisis. Lululemon sets itself apart through its innovation. The company uses fabrics that create particular sensations: The clothing feels weightless or comfortably body-hugging, for example.
Lululemon stayed connected with customers through its online community during lockdowns. Customers also flocked to Lululemon online for comfort clothing as they worked from home.
Since then, people have returned to offices. Yet things aren't slowing for Lululemon. The company expects to beat its 2023 revenue target by the end of this year. It's ahead on other 2023 goals too: Last year, Lululemon doubled its e-commerce business. And this year, the company is on track to double its men's business. Lululemon said it also may reach the goal of quadrupling its international business earlier than the 2023 target.
Lululemon shares have gained more than 20% so far this year. I don't expect double-digit gains every year. But overall, the stock has what it takes to head higher over the long term. Lululemon has proven it can grow during even the worst of times. So, it's a stock we can be confident about -- no matter what the market is doing.
10 stocks we like better than Target
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Target wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Lululemon Athletica. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs I like Abbott Laboratories (NYSE: ABT) for the diversity of its businesses -- and their growth. ABT data by YCharts Thanks to the strength and diversity of its product portfolio, I think this performance can continue. The company's plans should keep customers coming back: Target is investing $4 billion annually to remodel stores and strengthen fulfillment and the supply chain. | Abbott Labs I like Abbott Laboratories (NYSE: ABT) for the diversity of its businesses -- and their growth. ABT data by YCharts Thanks to the strength and diversity of its product portfolio, I think this performance can continue. The company continued to post sales growth -- and growth of its pickup and delivery services -- even after shoppers returned to usual shopping habits. | Abbott Labs I like Abbott Laboratories (NYSE: ABT) for the diversity of its businesses -- and their growth. ABT data by YCharts Thanks to the strength and diversity of its product portfolio, I think this performance can continue. The company continued to post sales growth -- and growth of its pickup and delivery services -- even after shoppers returned to usual shopping habits. | Abbott Labs I like Abbott Laboratories (NYSE: ABT) for the diversity of its businesses -- and their growth. ABT data by YCharts Thanks to the strength and diversity of its product portfolio, I think this performance can continue. The company continued to post sales growth -- and growth of its pickup and delivery services -- even after shoppers returned to usual shopping habits. |
31972.0 | 2021-09-24 00:00:00 UTC | Should You Take the "Basket Approach" to Investing in Tech Stocks? | ABT | https://www.nasdaq.com/articles/should-you-take-the-basket-approach-to-investing-in-tech-stocks-2021-09-24 | nan | nan | Thanks to technology, large industries are being remade for the 21st century and growing at a rapid pace. Picking the right stock from a very large segment of the economy can be tough, though. That's where the "basket approach" comes into play. In this video from the Motley Fool Live program "The 5," recorded Sept. 16, Fool.com contributors Jason Hall, Clay Bruning, and Nicholas Rossolillo discuss this investment style.
10 stocks we like better than Walmart
When our award-winning analyst team has an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
Stock Advisor returns as of 6/15/21
Jason Hall: Richard O., this is good. I like what he's saying and I think it applies pretty broadly, he says, "Gotta love medical devices, basket approach, Intuitive Surgical, ShockWave Medical, DexCom" -- the huge winner in diabetes testing -- "InMode, Inari Medical" -- getting into some that are a little more up-and-comers -- "Stryker, Medtronic, Abbott Laboratories, riding the wave." Sometimes one of the great ways to invest is to find trends. We talked about the aging trend, talked about the middle-class trend internationally. For healthcare, it's a great opportunity. But I think for a lot of these cloud companies, that basket approach works really well, too, Clay.
Clay Bruning: This is how I operate in my portfolio rather than buying an ETF in a theme that I really like. I looked at that ETF or I do some research of those underlying names and I try to find the ones that I think has the highest probability of placing in terms of being one of those top two, top three players. I'm with you there, and I do that in multiple themes and multiple industries. Personally, it's the way I attack it so obviously I think it's a good way to go about.
Hall: Sometimes your biased and you are also right. That's OK. Nick, what are your thoughts here?
Rossolillo: Yes, I do the same thing as Clay does. Especially if it's a new company or a new industry that I'm not super familiar with, one of the first things I like to do is, see who they compete with, what's the competitive landscape look like? Oftentimes you find multiple companies that have these great growth stories. Rather than picking, which one is going to be the best growth story over the next two decades, the basket purchase, fantastic. It allows you some leeway because if a couple of them don't work out, you still have those few that are the real gems that maybe early on you couldn't tell which one was going to ultimately come out on top.
Hall: I think the important thing to remember here too, is that a lot of time as you see a big trend and there are a lot of moving parts to it. You think about the Cloud, for example, or just determine like SaaS. You might have 50 companies that do 45 different things and trying to pick one or two or 10 out of that group that are going to be the ones to perform best out of all of these companies benefiting from a larger, secular tailwind. Sometimes it's just like I call it the precision fallacy here. There's no bonus points for getting too cute and picking the perfect company. Sometimes you just want a margin of safety.
Rossolillo: Yes, absolutely. Especially if a movement like the Cloud, like you said, if it's that big, we're talking about hundreds of billions of dollars in incremental spending every year. For years to come there's not going to be just one winner. In fact, some of those companies that are going to ultimately be the biggest winners, they're still going to have their down-year. Taking the basket approach helps get you some more consistent growth year-in and year-out from these really massive secular growth trends.
Hall: Right. You can have individual companies that went in particular areas, so you might have like a Zscaler that's showing itself is like the dominance in zero-trust and the kind of area that they live in, but then a related area of Cloud security, you've got another big winner like CrowdStrike. They're not really going head-to-head on a lot of stuff. There's some overlap. But you find all the horses in all the races, and you bet broadly and you can do pretty well.
Clay Bruning owns shares of Abbott Laboratories and CrowdStrike Holdings, Inc. Jason Hall owns shares of Intuitive Surgical and Zscaler. Nicholas Rossolillo owns shares of CrowdStrike Holdings, Inc. and Intuitive Surgical. The Motley Fool owns shares of and recommends CrowdStrike Holdings, Inc., InMode Ltd., Intuitive Surgical, ShockWave Medical, and Zscaler. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In this video from the Motley Fool Live program "The 5," recorded Sept. 16, Fool.com contributors Jason Hall, Clay Bruning, and Nicholas Rossolillo discuss this investment style. Especially if a movement like the Cloud, like you said, if it's that big, we're talking about hundreds of billions of dollars in incremental spending every year. The Motley Fool owns shares of and recommends CrowdStrike Holdings, Inc., InMode Ltd., Intuitive Surgical, ShockWave Medical, and Zscaler. | I like what he's saying and I think it applies pretty broadly, he says, "Gotta love medical devices, basket approach, Intuitive Surgical, ShockWave Medical, DexCom" -- the huge winner in diabetes testing -- "InMode, Inari Medical" -- getting into some that are a little more up-and-comers -- "Stryker, Medtronic, Abbott Laboratories, riding the wave." Clay Bruning owns shares of Abbott Laboratories and CrowdStrike Holdings, Inc. Jason Hall owns shares of Intuitive Surgical and Zscaler. The Motley Fool owns shares of and recommends CrowdStrike Holdings, Inc., InMode Ltd., Intuitive Surgical, ShockWave Medical, and Zscaler. | I like what he's saying and I think it applies pretty broadly, he says, "Gotta love medical devices, basket approach, Intuitive Surgical, ShockWave Medical, DexCom" -- the huge winner in diabetes testing -- "InMode, Inari Medical" -- getting into some that are a little more up-and-comers -- "Stryker, Medtronic, Abbott Laboratories, riding the wave." Clay Bruning owns shares of Abbott Laboratories and CrowdStrike Holdings, Inc. Jason Hall owns shares of Intuitive Surgical and Zscaler. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. | See the 10 stocks Stock Advisor returns as of 6/15/21 Jason Hall: Richard O., this is good. But I think for a lot of these cloud companies, that basket approach works really well, too, Clay. Oftentimes you find multiple companies that have these great growth stories. |
31973.0 | 2021-09-23 00:00:00 UTC | Top Stocks To Buy Today? 4 Health Care Stocks For Your Watchlist | ABT | https://www.nasdaq.com/articles/top-stocks-to-buy-today-4-health-care-stocks-for-your-watchlist-2021-09-23 | nan | nan | Top Health Care Stocks To Watch Right Now
In a world where a global pandemic has been overshadowing our daily lives, health care stocks would often be top picks in the stock market. After a year and a half, many people would expect that we could return to our normal lives. However, the reality is, COVID-19 has caused tremendous pain and loss to many people around the world and continues to be a threat even today. This is why testing and diagnosing for COVID-19 remains a priority.
We saw the U.S. government agreeing to purchase point-of-care COVID-19 tests from Abbott Laboratories (NYSE: ABT) and Celltrion earlier today. These tests are to be shipped to nursing homes and other high-risk populations. This is part of the government’s broader plan to purchase $2 billion in rapid coronavirus tests. Besides, vaccine companies such as Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) played significant roles to get us to where we are today. Nevertheless, health care services will always be a necessity even in post-pandemic times. With that in mind, here is a list of the top four health care stocks to watch in thestock market today
Best Health Care Stocks To Watch Before October 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Inotiv Inc (NASDAQ: NOTV)
Bausch Health Companies Inc (NYSE: BHC)
Inmode Ltd (NASDAQ: INMD)
Regeneron Pharmaceuticals
Regeneron is a biotechnology company that specializes in medicines for the treatment of serious diseases. In detail, the company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It has been a bullish year for the company stock thus far, increasing more than 30% since the start of the year.
Last week, the company announced that the U.S. government has agreed to purchase an additional 1.4 million doses of REGEN-COV (casirivimab and imdevimab). This new agreement will bring the total dose purchased by the U.S. government to nearly 3 million doses. This antibody cocktail is currently authorized to treat certain infected patients to reduce the risk of hospitalization or death from COVID-19. Although vaccination has been proven to be effective, there are still many people who are suffering from the virus. So treatment for COVID-19 is still a necessity at this point.
In addition, the company and Sanofi (NASDAQ: SNY) will be presenting its new Dupixent® (dupilumab) analyses in patients as young as six years old with moderate-to-severe atopic dermatitis at the 14th World Congress of Pediatric Dermatology Annual Congress (WCPD) and the 30th European Academy of Dermatology and Venereology Congress (EADV). The results will provide insight into the clinical and real-world experience of the drug on disease measures including itch, disease severity, sleep, and anxiety. Given these new developments, would you add REGN stock to your watchlist?
[Read More] What Stocks To Buy Today? 5 Tech Stocks To Watch
Inotiv
Following that, we have the international contract research company, Inotiv. Essentially, the company provides drug discovery and development services, and analytical instruments. It does so by focusing on providing drug developers with scientific research and analytical instrumentation. It would be an understatement to say that NOTV stock has had a fantastic year so far. Even though it is taking a breather today, NOTV stock has risen by around 50% just this month.
In fact, the company has recently announced that it has entered into an agreement to purchase Envigo. The combined company will enable drug developers to access products and services for the entirety of discovery and nonclinical development within one organization. The merger will also indirectly strengthen Inotiv’s presence in North America and add several locations in Western Europe to bolster the company’s global service delivery.
On top of that, the company’s financials are also trending in the right direction. In August, the company reported an increase of 45.2% to $22.9 million for its third quarter. Also, there was an increase in operating expenses that reflects higher strategic investment to support additional future revenue growth. With the weakness in NOTV stock today, would it be an opportune time to load up?
[Read More] Best Artificial Intelligence Stocks To Buy Right Now? 5 To Watch
Bausch Health Companies
Another top health care stock in focus today would be Bausch. For those unaware, the Canada-based company develops and markets a range of branded and generic pharmaceuticals, medical devices, and over-the-counter products. However, it primarily focuses on the therapeutic areas of eye health, gastroenterology, and dermatology.
The recent climb is likely due to a bullish recommendation from JPMorgan Chase’s analyst, Chris Schott. He pointed out that the sum-of-the-parts calculation of the company could be worth more than $40. Well, a large portion of his estimate consists of the Bausch & Lomb eye care division assumed to be $30 while the Solta dermatology-device unit supports the additional $7 per share of value. So, it appears that this analysis was sufficient to move the hearts of prospective investors.
After all, the company’s fundamentals have also been relatively stable over the years. For instance, the company reported revenues of $ 2.1 billion for its second quarter, representing an increase of 26% year-over-year. Bausch also launched expanded parameters for Bausch+Lomb Ultra® Multifocal for Astigmatism contact lenses during the quarter. Considering this information, will BHC stock make your list of top health care stocks to buy now?
[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist
Inmode
Inmode is an Israel-based company that specializes in energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians in a variety of procedures. This includes fat reduction with simultaneous skin tightening, face and body contouring, and ablative skin rejuvenation treatments. Therefore, the company’s area of expertise in today’s world is often in high demand.
For starters, Inmode recently announced the launch of the EvolveX platform with Transform technology. The EvolveX is a hands-free, zero downtime full-body transforming solution. Inmode believes that EvolveX is the only all-in-one system equipped with clinically proven technologies to remodel skin, treat fat and sculpt muscles.
Hence, the versatility of EvolveX multi-modalities will allow physicians to focus on individual patient needs by selectively delivering procedures that produce consistent transformative results. Investors are also responding positively to the announced plans for a 2-for-1 stock split last week. So much so that INMD stock has risen over 17% just within the past week. Given all this, will INMD stock enter your list of health care stocks to watch before October 2021?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We saw the U.S. government agreeing to purchase point-of-care COVID-19 tests from Abbott Laboratories (NYSE: ABT) and Celltrion earlier today. The merger will also indirectly strengthen Inotiv’s presence in North America and add several locations in Western Europe to bolster the company’s global service delivery. Well, a large portion of his estimate consists of the Bausch & Lomb eye care division assumed to be $30 while the Solta dermatology-device unit supports the additional $7 per share of value. | We saw the U.S. government agreeing to purchase point-of-care COVID-19 tests from Abbott Laboratories (NYSE: ABT) and Celltrion earlier today. With that in mind, here is a list of the top four health care stocks to watch in thestock market today Best Health Care Stocks To Watch Before October 2021 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Inotiv Inc (NASDAQ: NOTV) Bausch Health Companies Inc (NYSE: BHC) Inmode Ltd (NASDAQ: INMD) Regeneron Pharmaceuticals Regeneron is a biotechnology company that specializes in medicines for the treatment of serious diseases. Essentially, the company provides drug discovery and development services, and analytical instruments. | We saw the U.S. government agreeing to purchase point-of-care COVID-19 tests from Abbott Laboratories (NYSE: ABT) and Celltrion earlier today. Top Health Care Stocks To Watch Right Now In a world where a global pandemic has been overshadowing our daily lives, health care stocks would often be top picks in the stock market. With that in mind, here is a list of the top four health care stocks to watch in thestock market today Best Health Care Stocks To Watch Before October 2021 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Inotiv Inc (NASDAQ: NOTV) Bausch Health Companies Inc (NYSE: BHC) Inmode Ltd (NASDAQ: INMD) Regeneron Pharmaceuticals Regeneron is a biotechnology company that specializes in medicines for the treatment of serious diseases. | We saw the U.S. government agreeing to purchase point-of-care COVID-19 tests from Abbott Laboratories (NYSE: ABT) and Celltrion earlier today. With that in mind, here is a list of the top four health care stocks to watch in thestock market today Best Health Care Stocks To Watch Before October 2021 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Inotiv Inc (NASDAQ: NOTV) Bausch Health Companies Inc (NYSE: BHC) Inmode Ltd (NASDAQ: INMD) Regeneron Pharmaceuticals Regeneron is a biotechnology company that specializes in medicines for the treatment of serious diseases. 5 To Watch Bausch Health Companies Another top health care stock in focus today would be Bausch. |
31974.0 | 2021-09-22 00:00:00 UTC | 7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink | ABT | https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-now-as-the-pandemic-forces-a-rethink-2021-09-22 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Given all the talk surrounding the novel coronavirus and its multiple variants, it’s quite clear that Americans are suffering not only from the global health crisis but also from pandemic fatigue. As the concept of retail revenge demonstrates, people don’t want to live in fear anymore. Nevertheless, what may be a permanent impact of Covid-19 is attitude changes that affect healthcare stocks.
A few months after the coronavirus first breached our borders, the National Health Council reported that a survey conducted in early May of last year revealed that 72% of U.S. consumers changed their usage of traditional healthcare services. Not surprisingly, 41% of respondents delayed health-related services, while 38% stated that they intended to delay future care. Obviously, that imposed a dark cloud on many healthcare stocks.
At the same time, this dynamic represented a boon — albeit a cynical one — for companies levered to the burgeoning telehealth market. In fact, a McKinsey & Company report in June of this year acknowledged that care providers must provide options to prospective patients as people will delay medical service if they don’t feel comfortable or safe. Therefore, integration of telehealth will be a relevant component of healthcare stocks overall.
But it’s not just telehealth that’s benefitting from a broader rethink. McKinsey also reported that the “crisis has had an impact on how consumers think about the healthcare plans they are using and purchasing.” Some of the thought processes that are going on are not necessarily positive, so there’s an incentive for insurance providers to up their game. This too will affect investments in healthcare stocks.
7 Short-Interest Stocks That Could Be Bull Traps
Further, health doesn’t just revolve around physical needs. Alarmingly, self-harm increased during the pandemic in some instances, particularly among the Black population, according to a report from Johns Hopkins Medicine. Thus, demand for healthcare stocks stems from holistic needs, hence the diversity of names below that can rise in the post-pandemic period.
Pfizer (NYSE:PFE)
CVS Health (NYSE:CVS)
Abbott Laboratories (NYSE:ABT)
Talkspace (NASDAQ:TALK)
American Well (NYSE:AMWL)
Ginkgo Bioworks (NYSE:DNA)
Welltower (NYSE:WELL)
While there’s a temptation to think that the coronavirus impact is a one-off deal, this time really might be different. The Covid-19 crisis is still an ongoing threat — and we’re unlikely to forget it anytime soon. Therefore, these healthcare stocks could have remarkably long legs.
Healthcare Stocks to Buy: Pfizer (PFE)
PFE) logo on Pfizer building. Pfizer is an American pharmaceutical corporation." width="300" height="169">
Source: Manuel Esteban / Shutterstock.com
In the immediate term, Pfizer isn’t exactly having the best time in the market. Since closing at a high of $50.42 on Aug. 17 of this year, shares have slipped 13% heading into the third weekend of September. Based on the technical volatility, it’s very possible that PFE could have further to fall. Nevertheless, Pfizer has been one of the biggest winners among healthcare stocks.
Obviously, it has been the go-to name in terms of the vaccination rollout. However, I think it’s more than that. As one of the pioneers in nucleic-acid-based technologies — specifically the use of messenger RNA — Pfizer and its biotechnology partners have proven the efficacy of groundbreaking vaccine research and development. Best of all, Pfizer along with partner BioNTech (NASDAQ:BNTX), received approval for its solution by the Food and Drug Administration — a first for an mRNA vaccine.
Is PFE therefore a buy on the possible continuation of the Covid-19 crisis? Possibly but that specific narrative for healthcare stocks could be waning. Instead, I like the forward-looking potential for Pfizer to respond to the next global health threat. Certainly, the company has the tech to do so.
CVS Health (CVS)
Source: Jonathan Weiss / Shutterstock.com
Back in November 2018, CVS Health — one of the top retail pharmacy and healthcare stocks — made the announcement that it completed its acquisition of insurance provider Aetna. At the time, CVS stated that through the combined enterprise, its “Care delivery will have a local focus that will make a complicated system simpler for all, helping people achieve better health at lower cost.”
While an appealing concept on paper, the market wasn’t exactly pleased with the move. By the following spring, CVS stock was mired in the doldrums. But because of the Covid-19 crisis, the Aetna acquisition has proven to be either prescient or fortuitous.
7 Stocks to Buy Following Vaccine Victories
Either way, StockMarket.com contributor Jonathan Phillip had the following to say about CVS’ future ambitions:
“In August, it announced an innovative health care solution, Aetna Virtual Primary Care. It is designed to revolutionize the primary care experience and make it easier and more accessible for people to get their health services. Eligible members will have access to a panel of board-certified physicians and coordinated care based on their health needs. With this now available, consumers will be able to balance the demands of work and health more effectively.”
Because people are reconsidering their coverage options, CVS could be a long-term beneficiary among healthcare stocks.
Healthcare Stocks to Buy: Abbott Laboratories (ABT)
Source: Sundry Photography/Shutterstock.com
One of the quiet beneficiaries out of the healthcare stocks that received a Covid-boost, Abbott Laboratories is currently stuck in an extremely awkward situation, to put it mildly. In August, an unflattering New York Times piece described how the company’s Covid-19 testing kit division requested employees to trash the products they worked hard to create.
In some ways, the about-face is understandable: Covid cases plummeted in the spring, leading Abbott to take drastic measures to avoid being stuck with unsellable inventory. As the Times stated, this move is proving to be untimely, “hobbling efforts to expand screening as the highly contagious Delta variant rages across the country.”
Still, you can also look at the situation as a glass half-full. Demand has skyrocketed for Abbott’s 15-minute antigen test, demonstrating its popularity. Should another similar crisis emerge — or if we have additional variants of the SARS-CoV-2 virus — Abbott’s testing and diagnostics acumen should prove valuable to investors.
Also, the company has other non-Covid-related catalysts, such as its continuous glucose monitoring devices for diabetes patients. ABT’s generally steady rise higher provides confidence for prospective buyers to hold true to shares.
Talkspace (TALK)
Source: Ben__Stevens / Shutterstock.com
As one of the most speculative healthcare stocks, I want to be very clear about the risks betting on Talkspace. The underlying volatility of its equity unit is unpredictable and if anything, TALK stock is tilted in a decidedly negative trend at the moment. So you should only invest what you can afford to lose.
That said, mental health has always been an important topic, especially recently due to myriad societal and economic pressures. Even before the Covid-19 crisis became a thing, academic institutions reported on the worrying decline in U.S. life expectancy. Of course, this dynamic represents a perplexing contradiction: we’re the richest nation in the world yet our citizenry is dying at an unexpectedly high rate.
But with the pandemic, this circumstance has worsened significantly. In February 2021, Nature.com reported on scientists tracking a surge in depression with the crisis taking a mental health toll. Moreover, the situation isn’t limited to the U.S. but across the globe.
7 Undervalued Stocks to Keep an Eye on as We Head Towards October
That’s why Talkspace offers a vital business model, providing mental health support and services for individuals, couples and teens. Additionally, the company provides psychiatric services. Best of all, people can reach out on their phones, thereby providing convenience and a physically safe environment.
Healthcare Stocks to Buy: American Well (AMWL)
AMWL) displayed on a smartphone screen. The smartphone rests on top of a keyboard." width="300" height="169">
Source: Stephanie L Sanchez / Shutterstock.com
At the start of the pandemic, multiple healthcare stocks took a hit for understandable reasons. Frankly, visiting a clinic or hospital was the last thing anyone wanted to do unless they had a life-or-death emergency. Making matters worse was that the SARS-CoV-2 virus targeted people who were immunocompromised. This circumstance put those who suffered from chronic disease in between a rock and a hard place.
The one bright spot in this mess? The rise of the telehealth industry, which blossomed thanks to its ability to receive contactless medical guidance without the need to visit a possibly compromised facility. In addition, let’s not forget about the medical doctors who have championed telehealth during this crisis. It’s not like they want to expose themselves to Covid either.
However, with the gradual acclimatization to the pandemic, the narrative for telehealth-related healthcare stocks took a massive blow. Still, over the long run, this could turn out to be a long-term bullish opportunity. According to aforementioned data, telehealth may become a permanently relevant component of our care infrastructure moving forward.
That’s why if you can stomach volatility risk, you should check out American Well. With both its telehealth services combined with contactless psychiatric care, AMWL is attractively positioned to rise in the post-Covid environment.
Ginkgo Bioworks (DNA)
Source: Connect world / Shutterstock.com
One of the recent initial public offerings that I covered in my work for Benzinga, Ginkgo Bioworks specializes in a paradigm-shattering innovation called synthetic biology. Essentially, this practice increases the efficiency and speed of biochemical processes in a cell, offering radical and unprecedented solutions for biologics-related endeavors.
For instance, spider silk has always been a revered commodity for its ultra-thin profile and incredible strength. However, through synthetic biology, it’s possible for bioengineers to instruct specialized microbes to manufacture spider silk in quantities which would otherwise be impossible. Certainly, it’s a more palatable option than collecting a bunch of spiders to do their business.
Better yet, Ginkgo’s specialty doesn’t revolve around science-fiction-sounding aspirations. As I mentioned for my Benzinga piece, the company already played a pivotal role in protecting Americans. While most attention is paid to Moderna (NASDAQ:MRNA) for developing its Covid-19 vaccine, Ginkgo helped optimize enzyme production to accelerate said vaccine’s production.
Finally, Ginkgo has a biosecurity business, which involves using advanced analytics to “help flag genetic sequences with manmade signatures while leveraging artificial intelligence to distinguish between unnatural and organically evolved viruses.”
7 Buffett Stocks Trading at a Steep Discount You Need To Keep an Eye On
Yes, it’s an IPO based off a reverse merger with a special purpose acquisition company, but this could be one of the most important healthcare stocks in the biotech realm moving forward.
Healthcare Stocks to Buy: Welltower (WELL)
Source: Shutterstock
On a technical level, Welltower might not appear on many lists regarding healthcare stocks because the company is structured as a real estate investment trust. Nevertheless, it’s very much a healthcare play, specializing in senior housing facilities and post-acute care provider services. Already relevant from demographic dynamics, the pandemic has forced a rethink in elderly care.
Because the SARS-CoV-2 virus has been a particularly pernicious threat to older folks, a harsh spotlight fell on the senior housing industry. Following various controversies of mismanagement and neglect, the sector should improve for the better due to public outrage. It’s about time because let’s face it — there’s nothing in the world that can prevent aging.
Further, Welltower’s underlying market will benefit from an unprecedented demand surge. The latest data shows that more than 75 million baby boomers are planning to retire sooner rather than later, which will have a profound impact on multiple social segments, particularly the workforce.
Of course, as those boomers enter their twilight years, many will enter senior care facilities. Therefore, WELL has a very attractive long-term catalyst.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post 7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pfizer (NYSE:PFE) CVS Health (NYSE:CVS) Abbott Laboratories (NYSE:ABT) Talkspace (NASDAQ:TALK) American Well (NYSE:AMWL) Ginkgo Bioworks (NYSE:DNA) Welltower (NYSE:WELL) While there’s a temptation to think that the coronavirus impact is a one-off deal, this time really might be different. Healthcare Stocks to Buy: Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com One of the quiet beneficiaries out of the healthcare stocks that received a Covid-boost, Abbott Laboratories is currently stuck in an extremely awkward situation, to put it mildly. ABT’s generally steady rise higher provides confidence for prospective buyers to hold true to shares. | Pfizer (NYSE:PFE) CVS Health (NYSE:CVS) Abbott Laboratories (NYSE:ABT) Talkspace (NASDAQ:TALK) American Well (NYSE:AMWL) Ginkgo Bioworks (NYSE:DNA) Welltower (NYSE:WELL) While there’s a temptation to think that the coronavirus impact is a one-off deal, this time really might be different. Healthcare Stocks to Buy: Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com One of the quiet beneficiaries out of the healthcare stocks that received a Covid-boost, Abbott Laboratories is currently stuck in an extremely awkward situation, to put it mildly. ABT’s generally steady rise higher provides confidence for prospective buyers to hold true to shares. | Pfizer (NYSE:PFE) CVS Health (NYSE:CVS) Abbott Laboratories (NYSE:ABT) Talkspace (NASDAQ:TALK) American Well (NYSE:AMWL) Ginkgo Bioworks (NYSE:DNA) Welltower (NYSE:WELL) While there’s a temptation to think that the coronavirus impact is a one-off deal, this time really might be different. Healthcare Stocks to Buy: Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com One of the quiet beneficiaries out of the healthcare stocks that received a Covid-boost, Abbott Laboratories is currently stuck in an extremely awkward situation, to put it mildly. ABT’s generally steady rise higher provides confidence for prospective buyers to hold true to shares. | Pfizer (NYSE:PFE) CVS Health (NYSE:CVS) Abbott Laboratories (NYSE:ABT) Talkspace (NASDAQ:TALK) American Well (NYSE:AMWL) Ginkgo Bioworks (NYSE:DNA) Welltower (NYSE:WELL) While there’s a temptation to think that the coronavirus impact is a one-off deal, this time really might be different. Healthcare Stocks to Buy: Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com One of the quiet beneficiaries out of the healthcare stocks that received a Covid-boost, Abbott Laboratories is currently stuck in an extremely awkward situation, to put it mildly. ABT’s generally steady rise higher provides confidence for prospective buyers to hold true to shares. |
31975.0 | 2021-09-21 00:00:00 UTC | U.S. government to buy rapid COVID-19 tests from Abbott, Celltrion -official | ABT | https://www.nasdaq.com/articles/u.s.-government-to-buy-rapid-covid-19-tests-from-abbott-celltrion-official-2021-09-21 | nan | nan | By Jeff Mason
Sept 21 (Reuters) - The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday.
The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the official said.
The White House announced earlier this month that it will mandate staff at all large employers to either get vaccinated or submit to weekly testing. As part of that announcement, the administration said it would purchase around $2 billion worth of rapid tests.
The U.S. government also has agreements to purchase tests from other manufacturers including Quidel Corp. QDEL.O, OraSure Technologies, and Intrivo.
Demand for tests has been spurred in recent months by the emergence of the contagious Delta variant of COVID-19, reopenings of K-12 schools, and an earlier mandate by the White House that will require most U.S. federal employees to either get vaccinated or receive weekly tests.
(Reporting by Jeff Mason and Carl O'Donnell Editing by Chris Reese and Richard Pullin)
((Carl.ODonnell@thomsonreuters.com; 646-223-6629;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jeff Mason Sept 21 (Reuters) - The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday. The White House announced earlier this month that it will mandate staff at all large employers to either get vaccinated or submit to weekly testing. The U.S. government also has agreements to purchase tests from other manufacturers including Quidel Corp. QDEL.O, OraSure Technologies, and Intrivo. | By Jeff Mason Sept 21 (Reuters) - The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday. The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the official said. The White House announced earlier this month that it will mandate staff at all large employers to either get vaccinated or submit to weekly testing. | By Jeff Mason Sept 21 (Reuters) - The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday. The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the official said. Demand for tests has been spurred in recent months by the emergence of the contagious Delta variant of COVID-19, reopenings of K-12 schools, and an earlier mandate by the White House that will require most U.S. federal employees to either get vaccinated or receive weekly tests. | By Jeff Mason Sept 21 (Reuters) - The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday. The White House announced earlier this month that it will mandate staff at all large employers to either get vaccinated or submit to weekly testing. The U.S. government also has agreements to purchase tests from other manufacturers including Quidel Corp. QDEL.O, OraSure Technologies, and Intrivo. |
31976.0 | 2021-09-20 00:00:00 UTC | Abbott Reports FDA Approval For Portico With FlexNav TAVR System - Quick Facts | ABT | https://www.nasdaq.com/articles/abbott-reports-fda-approval-for-portico-with-flexnav-tavr-system-quick-facts-2021-09-20 | nan | nan | (RTTNews) - Abbott (ABT) announced FDA approval for Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. Portico is a self-expanding TAVR valve with intra-annular leaflets that help provide optimal blood flow when placed inside a patient's natural valve. The Portico device is implanted using Abbott's FlexNav delivery system.
"With the approval of our TAVR therapy in the U.S., physicians now have access to an even more robust set of solutions to treat structural heart disease," said Michael Dale, senior vice president of Abbott's structural heart business.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced FDA approval for Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Portico device is implanted using Abbott's FlexNav delivery system. "With the approval of our TAVR therapy in the U.S., physicians now have access to an even more robust set of solutions to treat structural heart disease," said Michael Dale, senior vice president of Abbott's structural heart business. | (RTTNews) - Abbott (ABT) announced FDA approval for Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Portico device is implanted using Abbott's FlexNav delivery system. "With the approval of our TAVR therapy in the U.S., physicians now have access to an even more robust set of solutions to treat structural heart disease," said Michael Dale, senior vice president of Abbott's structural heart business. | (RTTNews) - Abbott (ABT) announced FDA approval for Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. "With the approval of our TAVR therapy in the U.S., physicians now have access to an even more robust set of solutions to treat structural heart disease," said Michael Dale, senior vice president of Abbott's structural heart business. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced FDA approval for Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. Portico is a self-expanding TAVR valve with intra-annular leaflets that help provide optimal blood flow when placed inside a patient's natural valve. The Portico device is implanted using Abbott's FlexNav delivery system. |
31977.0 | 2021-09-20 00:00:00 UTC | Intuitive Surgical Stock To Bounce Back After A 3% Fall In A Week? | ABT | https://www.nasdaq.com/articles/intuitive-surgical-stock-to-bounce-back-after-a-3-fall-in-a-week-2021-09-20 | nan | nan | [Updated: Sep 16, 2021] ISRG Stock Decline
Last month we discussed that the stock price of Intuitive Surgical (NASDAQ:ISRG) is likely to see higher levels going by its historical performance, despite it being richly valued at levels of over $1,000. The stock continued to make new highs with levels of $1,087 seen as recently as last Wednesday. However, the stock has since declined over 3% to levels of $1,045 currently. Much of this decline came after bearish commentary from the company’s executives at an event. The rise of Covid-19 cases is likely to again impact the overall procedure volume in the near term, while there are also concerns over increasing costs for the company. Despite the recent decline, ISRG stock is up 31% year-to-date, outperforming the broader indices with the S&P500 rising 21%. But will ISRG stock continue its downward trajectory over the coming weeks, or is a recovery in the stock imminent?
According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ISRG stock average around 4.2% in the next one-month (twenty-one trading days) period after experiencing a 3.4% drop over the previous week (five trading days), implying that the stock will likely rebound in the near term. ISRG stock is also likely to see increased trading activity with its upcoming 3-to-1 stock split on October 6. But how would the returns fare if you are interested in holding ISRG stock for a shorter or a longer time period? You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Intuitive Surgical stock chances of a rise after a fall. You can test the chance of recovery over different time intervals of a quarter, month, or even just 1 day!
MACHINE LEARNING ENGINE – try it yourself:
If ISRG stock moved by -5% over five trading days, then over the next twenty-one trading days ISRG stock moves an average of 4%, with a good 64% probability of a positive return over this period.
Some Fun Scenarios, FAQs & Making Sense of Intuitive Surgical Stock Movements:
Question 1: Is the average return for Intuitive Surgical stock higher after a drop?
Answer: Consider two situations,
Case 1: Intuitive Surgical stock drops by -5% or more in a week
Case 2: Intuitive Surgical stock rises by 5% or more in a week
Is the average return for Intuitive Surgical stock higher over the subsequent month after Case 1 or Case 2?
ISRG stock fares better after Case 1, with an average return of 4.4% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 0.5% for Case 2.
In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise.
Try the Trefis machine learning engine above to see for yourself how Intuitive Surgical stock is likely to behave after any specific gain or loss over a period.
Question 2: Does patience pay?
Answer: If you buy and hold Intuitive Surgical stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong.
Overall, according to data and Trefis machine learning engine’s calculations, patience absolutely pays for most stocks!
For ISRG stock, the returns over the next N days after a -5% change over the last five trading days is detailed in the table below, along with the returns for the S&P500:
You can try the engine to see what this table looks like for Intuitive Surgical after a larger loss over the last week, month, or quarter.
Question 3: What about the average return after a rise if you wait for a while?
Answer: The average return after a rise is understandably lower than after a fall as detailed in the previous question. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks.
It’s pretty powerful to test the trend for yourself for Intuitive Surgical stock by changing the inputs in the charts above.
[Updated: Aug 9, 2021] ISRG Stock Rise
The stock price of Intuitive Surgical (NASDAQ:ISRG) has seen a rise of over 8% over the last twenty-one trading days, and it is also up a solid 51% over the last twelve month period. The recent rise can be attributed to the announcement of a 3-to-1 stock split. ISRG stock is now trading at its all-time high of around $1030. The stock appreciation is also backed by solid Q2 results it reported last month. The company’s sales grew a large 72%, driven by a 68% surge in procedure volume, while its earnings of $3.92 per share reflected a massive 3.5x y-o-y growth. While the Q2 2021 figures compare favorably with the prior year quarter, which saw fewer elective surgeries, amid the lockdowns, the company has guided for a solid 27-30% procedure volume growth for the full-year 2021.
But now that ISRG stock has moved to its all-time high levels past $1,000, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a good chance of a rise in ISRG stock over the next month. Out of 468 instances in the last ten years that ISRG stock saw a twenty-one day rise of 8% or more, 291 of them resulted in ISRG stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 291 out of 568, or about 61% chance of a rise in ISRG stock over the coming month. See our analysis on Intuitive Surgical Stock Chances of A Rise for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
After moving 3.9% or more over a five-day period, the stock rose in the next five days on 51% of the occasions.
After moving 5.5% or more over a ten-day period, the stock rose in the next ten days on 51% of the occasions
After moving 8.2% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 62% of the occasions.
Predict average return on Intuitive Surgical (ISRG) Stock Return: AI Predicts ISRG Average and Excess Return After a Fall or Rise
Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers
Five-Day Return: ISRG highest at 3.9%; BDX lowest at -5.8%
Ten-Day Return: ISRG highest at 5.5%; BDX lowest at -4%
Twenty-One Days Return: ISRG highest at 8.2%; BDX lowest at -4%
While the historical performance suggests even higher levels are likely for ISRG stock, we continue to believe that it is richly valued. Our Intuitive Surgical Valuation of $953 is based on expected EPS of $13.91 and a 68x P/E multiple, reflecting a discount of around 7% to the current market price of $1030.
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">Going by historical performance, while ISRG stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.
————————————————————————————– Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates ————————————————————————————–
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Answer: If you buy and hold Intuitive Surgical stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong. While the Q2 2021 figures compare favorably with the prior year quarter, which saw fewer elective surgeries, amid the lockdowns, the company has guided for a solid 27-30% procedure volume growth for the full-year 2021. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data After moving 3.9% or more over a five-day period, the stock rose in the next five days on 51% of the occasions. | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ISRG stock average around 4.2% in the next one-month (twenty-one trading days) period after experiencing a 3.4% drop over the previous week (five trading days), implying that the stock will likely rebound in the near term. Predict average return on Intuitive Surgical (ISRG) Stock Return: AI Predicts ISRG Average and Excess Return After a Fall or Rise Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: ISRG highest at 3.9%; BDX lowest at -5.8% Ten-Day Return: ISRG highest at 5.5%; BDX lowest at -4% Twenty-One Days Return: ISRG highest at 8.2%; BDX lowest at -4% While the historical performance suggests even higher levels are likely for ISRG stock, we continue to believe that it is richly valued. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">Going by historical performance, while ISRG stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ISRG stock average around 4.2% in the next one-month (twenty-one trading days) period after experiencing a 3.4% drop over the previous week (five trading days), implying that the stock will likely rebound in the near term. Answer: Consider two situations, Case 1: Intuitive Surgical stock drops by -5% or more in a week Case 2: Intuitive Surgical stock rises by 5% or more in a week Is the average return for Intuitive Surgical stock higher over the subsequent month after Case 1 or Case 2? Predict average return on Intuitive Surgical (ISRG) Stock Return: AI Predicts ISRG Average and Excess Return After a Fall or Rise Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: ISRG highest at 3.9%; BDX lowest at -5.8% Ten-Day Return: ISRG highest at 5.5%; BDX lowest at -4% Twenty-One Days Return: ISRG highest at 8.2%; BDX lowest at -4% While the historical performance suggests even higher levels are likely for ISRG stock, we continue to believe that it is richly valued. | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ISRG stock average around 4.2% in the next one-month (twenty-one trading days) period after experiencing a 3.4% drop over the previous week (five trading days), implying that the stock will likely rebound in the near term. MACHINE LEARNING ENGINE – try it yourself: If ISRG stock moved by -5% over five trading days, then over the next twenty-one trading days ISRG stock moves an average of 4%, with a good 64% probability of a positive return over this period. [Updated: Aug 9, 2021] ISRG Stock Rise The stock price of Intuitive Surgical (NASDAQ:ISRG) has seen a rise of over 8% over the last twenty-one trading days, and it is also up a solid 51% over the last twelve month period. |
31978.0 | 2021-09-20 00:00:00 UTC | Is A Fall Imminent For Quidel Stock After A 22% Rise In A Month? | ABT | https://www.nasdaq.com/articles/is-a-fall-imminent-for-quidel-stock-after-a-22-rise-in-a-month-2021-09-20 | nan | nan | [Updated: Sep 16, 2021] Quidel Stock Update
A few months back we discussed that Quidel (NASDAQ:QDEL) stock looks undervalued at levels of around $108, based on the testing demand and the company’s future growth prospects. QDEL stock has since rallied 36% to $147 currently. Quidel’s stock has rallied 6% over the last five trading days, and it is up a strong 22% over the last month. This can be attributed to rising Covid-19 cases in the U.S. resulting in higher demand for testing. Furthermore, the Biden administration recently announced that employers with more than 100 employees will have to mandate vaccines or require weekly testing for the staff. This will again result in an increased demand for Covid-19 testing, boding well for companies, such as Quidel and Abbott.
But now that QDEL stock has seen a 22% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a decline in QDEL stock over the next month. Out of 152 instances in the last ten years that QDEL stock saw a twenty-one day rise of 22% or more, 91 of them resulted in QDEL stock falling over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 91 out of 152, or about a 60% chance of a decline in QDEL stock over the coming month. See our analysis on Quidel Stock Chances of Decline for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
After moving 5% or more over a five-day period, the stock rose in the next five days on 53% of the occasions.
After moving 14% or more over a ten-day period, the stock rose in the next ten days on 45% of the occasions
After moving 22% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 40% of the occasions.
Predict average return on Quidel (QDEL) Stock Return: AI Predicts QDEL Average and Excess Return After a Fall or Rise
Quidel (QDEL) Stock Return (Recent) Comparison With Peers
Five-Day Return: VIVO highest at 11%; OPGN lowest at -36%
Ten-Day Return: QDEL highest at 14%; OPGN lowest at -29%
Twenty-One Day Return: QDEL highest at 22%; OPGN lowest at -13%
[Updated: Jun 4, 2021] QDEL Stock Rise
We believe that the stock price of Quidel (NASDAQ:QDEL), a clinical genetic testing company, looks undervalued at current levels near $108. QDEL stock is actually up just 22% from levels of around $88 it was at on March 23, 2020, when broader markets made a bottom. This compares to the S&P which has risen 87% over the same period. The underperformance can be attributed to the mounting concerns of a decline in Covid-19 testing demand, given the large scale vaccination programs undertaken by several governments. But now that the stock has seen a large drop (down 33% in the last one year) despite revenue growing 232% y-o-y over the last four quarters, we believe QDEL stock is oversold, and it will likely see a rebound in the near term. Our dashboard ‘Buy Or Fear Quidel Stock‘ provides the key numbers behind our thinking.
Looking at a longer time period, QDEL stock is up 122% from levels of under $50 seen toward the end of 2018. The rise in the stock price over the last two years or so can be attributed to favorable changes in the company’s EPS. The company’s revenues surged 218% to $1.7 billion in 2020, compared to $0.5 billion in 2018. Much of the growth came in 2020, driven by Covid-19 tests. Quidel’s net margins also expanded 243% to 49% in 2020, compared to 14% in 2018, given the company’s operating expenses grew at a much slower pace, compared to its revenues. The company’s shares outstanding increased 11% over the same period due to share issuances. This means that on a per share basis, the company’s earnings grew a whopping 9x to $19.24 in 2020, compared to $1.95 in 2018.
Despite a stellar growth in EPS, the company’s P/E multiple contracted from levels of over 25x in 2018 to 9x in 2020. Furthermore, given the sharp decline in QDEL stock over the recent months following the increased vaccination rate, the P/E multiple has now plunged to 6x, and we believe that the P/E multiple will likely rise going forward.
Outlook
Quidel has seen strong growth in 2020, primarily due to a very high demand for Covid-19 testing. The company’s Sofia and QuickVue antigen tests have already secured the emergency use authorization by the U.S. FDA, while its Lyra test is still pending for the regulatory approval. These tests have helped Quidel’s sales skyrocket in 2020, and this trend continued in Q1 2021, as well. Quidel reported a 2x jump in revenues in Q1, while its EPS surged 4x to $4.09, compared to $0.93 in the prior year quarter.
Given the kind of numbers the company has reported, the stock should have been skyrocketing, but that is not what is really happening. QDEL stock did surge from levels of under $90 to levels of around $250 as recently as end of January 2021. However, the stock plummeted 57% to levels of around $108 now. Why? Because Covid-19 testing led the company’s sales higher and now with several countries working fast on vaccination, the demand for testing is bound to decline. More than 40% of the U.S. population is fully vaccinated, and the numbers will keep getting higher. This essentially means the demand for testing will decline. That said, the keyword being “decline,” as we believe the demand is not going to fade away anytime soon.
There may be negative test report requirement for in-person activities, possibly schools, and for air travel. Quidel’s QuickVue, an at-home Covid-19 test, has already secured the emergency use authorization from the U.S. FDA, and it can address this demand. The company also has QuickVue SARS antigen test to meet the requirement of testing for asymptomatic people. It’s not just 2021, the demand is likely to stay for the next few years. There is no denying that Qudiel’s sales will see a decline as the Covid-19 crisis winds down, and impact its earnings. But is the impact on earnings as big as it has been on its stock? We don’t think so.
The consensus estimates for Quidel EPS indicate an 8% drop in 2021, and roughly a 42% drop (y-o-y) in 2022. Since the stock is being sold based on the decline in future earnings, it is best to look at 2022 figures for QDEL stock. So, at the current levels of $108, QDEL stock is trading at 10x its expected EPS of around $10.55 in 2022. This compares with levels of 16x seen in 2018.
In terms of Covid-19 testing, Quidel can be compared with Abbott, which is trading at 22x its 2022 expected EPS of $4.86. Although Abbott is far more diversified and it has multiple businesses to support its earnings, that does not justify such a large valuation gap in the two companies. Furthermore, Quidel is sitting on a cash balance of close to $1.0 billion, and it does not have any debt. It won’t be surprising if the company were to explore other companies to boost its long-term revenue growth.
Lastly, the average analyst price estimate for QDEL stock is around $173, reflecting a large 60% premium to the current market price of $108, and we also believe that Quidel is significantly undervalued at the current levels.
While QDEL stock looks undervalued, 2020 has also created many pricing discontinuities that can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Mettler vs. Abbott
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Furthermore, the Biden administration recently announced that employers with more than 100 employees will have to mandate vaccines or require weekly testing for the staff. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data After moving 5% or more over a five-day period, the stock rose in the next five days on 53% of the occasions. The underperformance can be attributed to the mounting concerns of a decline in Covid-19 testing demand, given the large scale vaccination programs undertaken by several governments. | [Updated: Sep 16, 2021] Quidel Stock Update A few months back we discussed that Quidel (NASDAQ:QDEL) stock looks undervalued at levels of around $108, based on the testing demand and the company’s future growth prospects. Predict average return on Quidel (QDEL) Stock Return: AI Predicts QDEL Average and Excess Return After a Fall or Rise Quidel (QDEL) Stock Return (Recent) Comparison With Peers Five-Day Return: VIVO highest at 11%; OPGN lowest at -36% Ten-Day Return: QDEL highest at 14%; OPGN lowest at -29% Twenty-One Day Return: QDEL highest at 22%; OPGN lowest at -13% [Updated: Jun 4, 2021] QDEL Stock Rise We believe that the stock price of Quidel (NASDAQ:QDEL), a clinical genetic testing company, looks undervalued at current levels near $108. Lastly, the average analyst price estimate for QDEL stock is around $173, reflecting a large 60% premium to the current market price of $108, and we also believe that Quidel is significantly undervalued at the current levels. | [Updated: Sep 16, 2021] Quidel Stock Update A few months back we discussed that Quidel (NASDAQ:QDEL) stock looks undervalued at levels of around $108, based on the testing demand and the company’s future growth prospects. Out of 152 instances in the last ten years that QDEL stock saw a twenty-one day rise of 22% or more, 91 of them resulted in QDEL stock falling over the subsequent one-month period (twenty-one trading days). Predict average return on Quidel (QDEL) Stock Return: AI Predicts QDEL Average and Excess Return After a Fall or Rise Quidel (QDEL) Stock Return (Recent) Comparison With Peers Five-Day Return: VIVO highest at 11%; OPGN lowest at -36% Ten-Day Return: QDEL highest at 14%; OPGN lowest at -29% Twenty-One Day Return: QDEL highest at 22%; OPGN lowest at -13% [Updated: Jun 4, 2021] QDEL Stock Rise We believe that the stock price of Quidel (NASDAQ:QDEL), a clinical genetic testing company, looks undervalued at current levels near $108. | This will again result in an increased demand for Covid-19 testing, boding well for companies, such as Quidel and Abbott. So, at the current levels of $108, QDEL stock is trading at 10x its expected EPS of around $10.55 in 2022. Lastly, the average analyst price estimate for QDEL stock is around $173, reflecting a large 60% premium to the current market price of $108, and we also believe that Quidel is significantly undervalued at the current levels. |
31979.0 | 2021-09-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Martin Zweig - 9/19/2021 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-martin-zweig-9-19-2021-2021-09-19 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
MEDIFAST INC (MED) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medifast, Inc. produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company's product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins. Its business units include Optavia, Medifast Direct, Franchise Medifast Weight Control Centers (MWCC) and Medifast Wholesale. Optavia is a personal coaching division of the Company that consists of Optavia Coaches, who provides coaching and support to clients utilizing the Optavia platform. Medifast Direct is its direct-to-consumer business unit that allows customers to order Medifast products directly through its Website or its in-house call center. The MWCC business unit sells product through franchise and reseller locations, which offers structured programs and a team of professionals to help customers achieve weight-loss and weight-management success at center locations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MEDIFAST INC
Full Guru Analysis for MED>
Full Factor Report for MED>
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Amedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. The Company owns and operates approximately 524 centers in 39 states and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness, such as heart disease, pulmonary disease, Alzheimer's and Human Immunodeficiency Virus (HIV)/Acquired Immuno Deficiency Syndrome (AIDS). The Personal care segment provides patients with assistance with the essential activities of daily living.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AMEDISYS INC
Full Guru Analysis for AMED>
Full Factor Report for AMED>
INMODE LTD (INMD) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of INMODE LTD
Full Guru Analysis for INMD>
Full Factor Report for INMD>
MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MEDPACE HOLDINGS INC
Full Guru Analysis for MEDP>
Full Factor Report for MEDP>
More details on Validea's Martin Zweig strategy
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of MEDPACE HOLDINGS INC Full Guru Analysis for MEDP> Full Factor Report for MEDP> More details on Validea's Martin Zweig strategy About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. Company Description: Medifast, Inc. produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. | Detailed Analysis of MEDIFAST INC Full Guru Analysis for MED> Full Factor Report for MED> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The following are the top rated Healthcare stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. |
31980.0 | 2021-09-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Peter Lynch - 9/19/2021 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-9-19-2021-2021-09-19 | nan | nan | The following are the top rated Healthcare stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
QUEST DIAGNOSTICS INC (DGX) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of QUEST DIAGNOSTICS INC
Full Guru Analysis for DGX>
Full Factor Report for DGX>
EMERGENT BIOSOLUTIONS INC (EBS) is a mid-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of EMERGENT BIOSOLUTIONS INC
Full Guru Analysis for EBS>
Full Factor Report for EBS>
LABORATORY CORP. OF AMERICA HOLDINGS (LH) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company's business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The Company serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS
Full Guru Analysis for LH>
Full Factor Report for LH>
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities. The Company is engaged in operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. Its U.S. Facilities include approximately 224 behavioral healthcare facilities with approximately 9,500 beds in 40 states and Puerto Rico. The Company's U.K. Facilities include approximately 361 behavioral healthcare facilities with approximately 8,700 beds in the United Kingdom. The Company operates a network of approximately 588 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the United Kingdom and Puerto Rico.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ACADIA HEALTHCARE COMPANY INC
Full Guru Analysis for ACHC>
Full Factor Report for ACHC>
More details on Validea's Peter Lynch strategy
Peter Lynch Stock Ideas
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of EMERGENT BIOSOLUTIONS INC Full Guru Analysis for EBS> Full Factor Report for EBS> LABORATORY CORP. OF AMERICA HOLDINGS (LH) is a large-cap value stock in the Healthcare Facilities industry. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. | Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. |
31981.0 | 2021-09-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 9/19/2021 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-9-19-2021-2021-09-19 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
DAVITA INC (DVA) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: FAIL
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of DAVITA INC
Full Guru Analysis for DVA>
Full Factor Report for DVA>
THE ENSIGN GROUP, INC. (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ensign Group, Inc., through its operating subsidiaries, provides healthcare services. The Company's operating subsidiaries provide a spectrum of skilled nursing services, physical, occupational and speech therapies and other rehabilitative and healthcare services. The Company operates approximately 236 healthcare facilities, 24 of which also include assisted living operations across thirteen states. It operates the healthcare facilities across Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Through its skilled nursing operations, the Company provides short stay patients and long stay patients with a range of medical, nursing, rehabilitative, pharmacy and routine services, including daily dietary, social and recreational services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of THE ENSIGN GROUP, INC.
Full Guru Analysis for ENSG>
Full Factor Report for ENSG>
ICON PLC (ICLR) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ICON PLC
Full Guru Analysis for ICLR>
Full Factor Report for ICLR>
INMODE LTD (INMD) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of INMODE LTD
Full Guru Analysis for INMD>
Full Factor Report for INMD>
More details on Validea's John Neff strategy
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap growth stock in the Healthcare Facilities industry. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap growth stock in the Healthcare Facilities industry. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of DAVITA INC Full Guru Analysis for DVA> Full Factor Report for DVA> THE ENSIGN GROUP, INC. (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap growth stock in the Healthcare Facilities industry. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> DAVITA INC (DVA) is a large-cap growth stock in the Healthcare Facilities industry. The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. |
31982.0 | 2021-09-17 00:00:00 UTC | Notable ETF Inflow Detected - VTI, KO, VZ, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-vti-ko-vz-abt-2021-09-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $4.4 billion dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 1,148,426,434 to 1,167,308,153). Among the largest underlying components of VTI, in trading today Coca-Cola Co (Symbol: KO) is off about 0.6%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average:
Looking at the chart above, VTI's low point in its 52 week range is $162.85 per share, with $234.65 as the 52 week high point — that compares with a last trade of $229.64. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 7%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTI, in trading today Coca-Cola Co (Symbol: KO) is off about 0.6%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $162.85 per share, with $234.65 as the 52 week high point — that compares with a last trade of $229.64. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTI, in trading today Coca-Cola Co (Symbol: KO) is off about 0.6%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $162.85 per share, with $234.65 as the 52 week high point — that compares with a last trade of $229.64. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of VTI, in trading today Coca-Cola Co (Symbol: KO) is off about 0.6%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $4.4 billion dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 1,148,426,434 to 1,167,308,153). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $162.85 per share, with $234.65 as the 52 week high point — that compares with a last trade of $229.64. | Among the largest underlying components of VTI, in trading today Coca-Cola Co (Symbol: KO) is off about 0.6%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $4.4 billion dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 1,148,426,434 to 1,167,308,153). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $162.85 per share, with $234.65 as the 52 week high point — that compares with a last trade of $229.64. |
31983.0 | 2021-09-16 00:00:00 UTC | 3 Top Growth Stocks You Can Buy and Hold Forever | ABT | https://www.nasdaq.com/articles/3-top-growth-stocks-you-can-buy-and-hold-forever-2021-09-16 | nan | nan | Do you want an investment that you can just buy and forget about, regardless of what's happening in the stock market every day? You don't have to settle for boring old dividend stocks to fit that purpose. There are plenty of good growth investments that are not only safe but also likely to continue increasing in value over the years as their financials get stronger. And some of them even pay dividends, too.
Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). These businesses have been generating strong results and make for safe long-term investments.
Image source: Getty Images.
1. Abbott Laboratories
Abbott Laboratories is a robust healthcare business that makes for an ideal set-and-forget investment. While COVID-19 testing has given its top line some added growth, the company is diverse. That's one of the big reasons you can safely hang on to the stock for years or even decades.
When Abbott last reported earnings on July 22, its sales for the period ending June 30 topped $10.2 billion, up by nearly 40% year over year. Much of that growth did come from its diagnostics segment, where sales of $3.3 billion increased by an impressive 63%. However, medical device revenue was higher at $3.7 billion, up more than 51%. The company gives investors the best of both worlds -- its stock can benefit both from an uptick in COVID-19 testing and from a post-pandemic return to normal (as indicated by an increase in medical device sales).
Historically, Abbott has generated solid gross margins of at least 55% in each of the past five years. A strong margin is important to ensure that as the business grows, so too will its bottom line. In 2020, the company's operating profit of $5.4 billion was more than triple the $1.7 billion it earned just three years earlier.
Another reason Abbott is a good buy-and-forget stock is its dividend. Today, it yields 1.4%, which isn't much higher than the S&P 500 average of 1.3%. However, with the company just one more dividend increase away from becoming a Dividend King, it's safe to assume that you'll likely collect more on your initial investment over time. Whether you like recurring income or long-term growth (or both!), odds are you'll love Abbott Laboratories stock.
2. Palantir
Tech company Palantir is another business that has the makings of a solid long-term investment. Not only is it growing at an impressive rate, but the company also has many government customers that rely on its software platform for help with counterterrorism operations, anchoring its financials. One of the company's opportunities for long-term growth is in expanding its commercial customers. Palantir has been doing this, though government-related revenue still makes up more than 60% of its top line.
In its second-quarter results (for the period ending June 30), Palantir reported revenue of $376 million, up 49% from the prior-year period. Particularly impressive was its U.S. commercial revenue, which grew at a rate of 90%. And the number of commercial customers was up 61% from the start of the year. Palantir maintains that its revenue will grow at an annual rate of at least 30% though 2025.
Although the company has continually reported net losses since going public a year ago, its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in Q2 totaled $121 million, making up 32% of revenue. And over the trailing 12 months, Palantir has reported positive free cash flow of $62 million.
With more growth on the horizon and the company already being cash flow positive, this is another promising stock that all growth investors should consider buying shares of.
3. Walmart
Big-box retail chain Walmart is a business you know isn't going anywhere. Like Abbott, it also pays a modest dividend (1.5%), and it is two years away from becoming a Dividend King. For investors who love a boring stock that they can count on for recurring revenue, Walmart's an easy pick.
But that's not to say sales won't continue to grow. The business has been expanding into healthcare, and the launch of subscription service Walmart+ last year suggests that it is willing to take on e-commerce giant Amazon head-on for growth opportunities online.
A company the size of Walmart, which generated nearly $26 billion in free cash flow in its most recent fiscal year, can afford to spend money on multiple growth initiatives. While its gross margin of 25% isn't great, Walmart can still do well and turn a profit because of its sheer size; a small 2% net margin on $559 billion in revenue for fiscal 2021 still resulted in more than $13 billion in net income.
And while the surge in e-commerce sales may be slowing down from a year ago when consumers were stuck at home, the retailer still reported that U.S. e-commerce sales grew 6% year over year in its latest quarter, for the period ending July 31. Despite reopenings and more shopping options available to consumers, the company's sales growth remained positive, up 2.4% from the same period last year.
Walmart is the ultimate safe stock to buy for investors who just want an investment they won't have to worry about over the years.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon and Palantir Technologies Inc. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). Although the company has continually reported net losses since going public a year ago, its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in Q2 totaled $121 million, making up 32% of revenue. The business has been expanding into healthcare, and the launch of subscription service Walmart+ last year suggests that it is willing to take on e-commerce giant Amazon head-on for growth opportunities online. | Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). When Abbott last reported earnings on July 22, its sales for the period ending June 30 topped $10.2 billion, up by nearly 40% year over year. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. | Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). When Abbott last reported earnings on July 22, its sales for the period ending June 30 topped $10.2 billion, up by nearly 40% year over year. And while the surge in e-commerce sales may be slowing down from a year ago when consumers were stuck at home, the retailer still reported that U.S. e-commerce sales grew 6% year over year in its latest quarter, for the period ending July 31. | Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). These businesses have been generating strong results and make for safe long-term investments. With more growth on the horizon and the company already being cash flow positive, this is another promising stock that all growth investors should consider buying shares of. |
31984.0 | 2021-09-15 00:00:00 UTC | 2 Sizzling Hot Stocks to Buy Right Now | ABT | https://www.nasdaq.com/articles/2-sizzling-hot-stocks-to-buy-right-now-2021-09-15 | nan | nan | Hot stocks can be found across all industries and sectors, but whether or not these high-flying companies are worth the price of admission is often another story. If you're a long-term investor searching for stocks that can lend some serious growth to your portfolio in the coming years and also demonstrate resilience in a variety of market environments, keep on reading.
The following two stocks are absolutely sizzling right now, but they also both boast superior businesses with strong competitive advantages that generate and sustain consistent demand and robust profits.
Let's take a closer look.
Image source: Getty Images.
1. DexCom
Medical device maker DexCom (NASDAQ: DXCM) may not be a household name for many investors, but it should be. The company has a track record of generating notable cash flow growth year after year, and its shares have appreciated swiftly in kind. Over the past six months alone, the stock has shot up by about 50%. And over the past five years ago, it has popped an incredible 480%.
That's because DexCom is one of a very small handful of companies with an FDA-approved continuous glucose monitoring (CGM) device on the market. The company's sole and flagship product is its G6 CGM system. It's also currently working on the next-generation G7 system, which should be launched later this year. According to the latest stats from Grand View Research, the global CGM device market is on track to reach more than $10 billion in size by 2028.
The company certainly isn't without competition. Its most notable rival is Abbott Laboratories' FreeStyle Libre system. However, this industry is far from overcrowded and demand is constant. DexCom has managed to carve out and maintain a substantial piece of the pie for itself and has proven its staying power in this industry time and time again with consistent, above-average earnings growth.
In its most recent quarter ended June 30, the company grew revenue by 32% and net income by 36% over the same period last year.
Despite DexCom's rapid growth, the company continues to build up its liquidity while keeping its debt levels manageable. At the end of the second quarter, the company boasted $2.6 billion in cash, cash equivalents, and marketable securities compared to about $601 million in short-term liabilities.
Admittedly, the stock has had a good run of late. But if you're looking for a super-charged healthcare stock that can lend substantial growth to your portfolio over a period of years, DexCom is a pick that continues to hit the bullseye.
2. Nvidia
Semiconductor stock Nvidia (NASDAQ: NVDA) is known for its computer-graphics processors used by companies of all sizes across a broad spectrum of industries. In fact, it is one of the world's top manufacturers of these processors (known as GPUs) -- ranking third at just a little over 15% of the global PC GPU market, according to Statista. The company boasts some pretty big names on its client list, including the likes of Microsoft and Facebook.
It's no wonder then that Nvidia delivered another series of record results in its most recent quarter. Not only did the company's total revenue spike 68% year over year, but its net income jumped by an eye-popping 282% from the year-ago quarter. Nvidia's four divisions -- automotive, professional visualization, data center, and gaming -- generated respective year-over-year revenue increases of 37%, 156%, 35%, and 85%.
Shares of Nvidia have picked up some serious steam in recent months. The stock is trading about 66% higher than it was just six months ago -- and over the trailing five years, the stock has appreciated by a whopping 1,300%.
Yet, the stock may still have considerable runway. From autonomous vehicles to artificial intelligence, Nvidia's products are an ideal solution for companies operating in both established and emerging industries. The stock may be sizzling now, but there's no reason to think it can't explode even higher in the coming years.
10 stocks we like better than Nvidia
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Nvidia wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Rachel Warren owns shares of DexCom. The Motley Fool owns shares of and recommends Facebook, Microsoft, and Nvidia. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you're a long-term investor searching for stocks that can lend some serious growth to your portfolio in the coming years and also demonstrate resilience in a variety of market environments, keep on reading. The following two stocks are absolutely sizzling right now, but they also both boast superior businesses with strong competitive advantages that generate and sustain consistent demand and robust profits. But if you're looking for a super-charged healthcare stock that can lend substantial growth to your portfolio over a period of years, DexCom is a pick that continues to hit the bullseye. | The company has a track record of generating notable cash flow growth year after year, and its shares have appreciated swiftly in kind. But if you're looking for a super-charged healthcare stock that can lend substantial growth to your portfolio over a period of years, DexCom is a pick that continues to hit the bullseye. The Motley Fool owns shares of and recommends Facebook, Microsoft, and Nvidia. | Nvidia Semiconductor stock Nvidia (NASDAQ: NVDA) is known for its computer-graphics processors used by companies of all sizes across a broad spectrum of industries. The stock is trading about 66% higher than it was just six months ago -- and over the trailing five years, the stock has appreciated by a whopping 1,300%. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. | But if you're looking for a super-charged healthcare stock that can lend substantial growth to your portfolio over a period of years, DexCom is a pick that continues to hit the bullseye. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Nvidia wasn't one of them! The Motley Fool owns shares of and recommends Facebook, Microsoft, and Nvidia. |
31985.0 | 2021-09-13 00:00:00 UTC | January 2024 Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/january-2024-options-now-available-for-abbott-laboratories-abt-2021-09-13 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $115.00 strike price has a current bid of $12.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $115.00, but will also collect the premium, putting the cost basis of the shares at $103.00 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $125.34/share today.
Because the $115.00 strike represents an approximate 8% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 65%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 10.43% return on the cash commitment, or 4.44% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $115.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $130.00 strike price has a current bid of $12.50. If an investor was to purchase shares of ABT stock at the current price level of $125.34/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $130.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 13.69% if the stock gets called away at the January 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red:
Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 50%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 9.97% boost of extra return to the investor, or 4.24% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 30%, while the implied volatility in the call contract example is 25%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $125.34) to be 22%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2024 contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2024 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2024 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2024 expiration. |
31986.0 | 2021-09-13 00:00:00 UTC | Got $3,000? Keep It Safe With These 3 Healthcare Stocks | ABT | https://www.nasdaq.com/articles/got-%243000-keep-it-safe-with-these-3-healthcare-stocks-2021-09-13 | nan | nan | As silly as it may sound, there's truth to the old saying that the best way to make money is to stop losing money. Even in our present age of meme-stock mania, there should always be a home in your portfolio for less risky investments that you can count on no matter the economic conditions.
The trio of stocks I'll discuss today are stable because they offer products and services that companies in the healthcare sector need to succeed. And they each pay a tidy dividend, so their share prices aren't as volatile as they might otherwise be. While there's no guarantee that they'll beat the market 100% of the time, all three are worthy picks for the defensive section of your diversified portfolio, so let's dive in.
Image source: Getty Images.
1. Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies on the planet, and it makes a massive variety of products. Whether it's with surgical tools, coronavirus tests, baby formula, or antibiotics, Abbott Labs serves the market. And because people and hospitals simply can't go without the goods that it makes, its business is quite steady.
Importantly, Abbott Labs continues to grow by launching new product lines, like its FreeStyle Libre glucose monitor. Since the second quarter of 2016, its quarterly revenue has risen by 92.8%, thanks to steady expansions of its product portfolio.
While it isn't exactly a growth stock, its rising revenue does provide for substantial shareholder returns over time in the form of dividends. For nearly the last 50 years, Abbott Labs has increased its dividend on an annual basis, making it a Dividend Aristocrat, one of the most reliable dividend-paying stocks. In other words, investors can have confidence in the stability of this company's cash flow, as management wouldn't approve raising the dividend so often over such a long period if they didn't think it were sustainable. But, its forward dividend yield is only around 1.4% right now, so it probably won't make you rich anytime soon. Still, that's a bit more than the market's average yield of 1.29% this year.
2. AstraZeneca
AstraZeneca (NASDAQ: AZN) has been in the headlines since 2020 thanks to its coronavirus vaccine, but there's a lot more to the company than just that. With a massive portfolio of drugs on the market and about 160 projects in its development pipeline, it's constantly churning out opportunities to grow future revenue.
AstraZeneca is a relatively safe investment because healthcare systems around the world need a constant supply of its oncology, respiratory, and gastrointestinal medications to treat their patients. And, as a result of its long and successful history of developing new drugs and commercializing them worldwide, there's little reason to suspect any major unforeseen drop-offs in revenue.
While the company does face consistent pressure from competitors, as well as the future expiration of intellectual property (IP) protections for its drugs on the market, its annual profit margin has grown over the past three years to reach nearly 13%. Over the same period, quarterly revenue was up by nearly 54%.
Since it's one of the world's largest pharmaceutical companies, AstraZeneca's comfortable position is no surprise. That's what allows it to pay a quarterly dividend, which has a forward yield of 2.49% at the moment. But, investors should be aware that AstraZeneca's dividend payment has a history of increasing and decreasing from quarter to quarter.
^SPX data by YCharts.
3. Alexandria Real Estate Equities
Unlike AstraZeneca and Abbott Laboratories, Alexandria Real Estate Equities (NYSE: ARE) is a real estate investment trust (REIT). Its business model is to lease and manage life-sciences laboratory space to biotechs and pharmaceutical companies in industry hubs such as Boston.
That means its income is highly predictable, and also that its revenue base is highly resilient against external economic conditions. After all, its tenants need to pay the rent every month if they have any aspirations to keep performing the research and development (R&D) work that's necessary to have a shot at commercializing medicines.
What's more, as a landlord, Alexandria sets the terms of its leases such that the rent will rise by predictable amounts over time. So even though it continues to build out new laboratory space to lease to new customers, it can rely on significantly higher revenue in the future solely from its existing clientele. In other words, this stock's low risk profile is practically encoded in its leasing contracts.
And those contracts are long-lived, so investors can count on the dividend to remain secure. On average, the company's tenants have a remaining lease length of 7.5 years. Of course, buying new buildings and converting them to laboratory space is capital-intensive, so investors shouldn't necessarily expect Alexandria's top line to explode over time. But shareholders can expect management to raise the dividend payment again in the future. Though its forward yield is only 2.24%, the dividend itself has increased steadily with each quarter since its inception in 1998.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
Alex Carchidi owns shares of Abbott Laboratories and AstraZeneca. The Motley Fool recommends Alexandria Real Estate Equities. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies on the planet, and it makes a massive variety of products. AstraZeneca is a relatively safe investment because healthcare systems around the world need a constant supply of its oncology, respiratory, and gastrointestinal medications to treat their patients. While the company does face consistent pressure from competitors, as well as the future expiration of intellectual property (IP) protections for its drugs on the market, its annual profit margin has grown over the past three years to reach nearly 13%. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies on the planet, and it makes a massive variety of products. Alexandria Real Estate Equities Unlike AstraZeneca and Abbott Laboratories, Alexandria Real Estate Equities (NYSE: ARE) is a real estate investment trust (REIT). The Motley Fool recommends Alexandria Real Estate Equities. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies on the planet, and it makes a massive variety of products. For nearly the last 50 years, Abbott Labs has increased its dividend on an annual basis, making it a Dividend Aristocrat, one of the most reliable dividend-paying stocks. Alexandria Real Estate Equities Unlike AstraZeneca and Abbott Laboratories, Alexandria Real Estate Equities (NYSE: ARE) is a real estate investment trust (REIT). | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies on the planet, and it makes a massive variety of products. For nearly the last 50 years, Abbott Labs has increased its dividend on an annual basis, making it a Dividend Aristocrat, one of the most reliable dividend-paying stocks. But, investors should be aware that AstraZeneca's dividend payment has a history of increasing and decreasing from quarter to quarter. |
31987.0 | 2021-09-12 00:00:00 UTC | 3 Dividend Stocks to Buy and Hold Forever | ABT | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-and-hold-forever-2021-09-12 | nan | nan | What's the easiest way to increase your investment returns? Stretch out how long you hold onto your stocks. That's especially the case with dividend stocks. Reinvesting dividends over a long period of time can significantly boost your total returns.
If you intend to hold for a long time, though, it means that you'll want to be more selective about the stocks you buy in the first place. Here are three dividend stocks you can buy and hold forever.
Image source: Getty Images.
Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a Dividend Aristocrat with 49 consecutive years of dividend increases. The company ranks among Fortune's Top 50 Most Admired Companies. It's held the No. 1 spot in its industry for the last eight years.
Those are certainly impressive accolades. However, it's even more important that Abbott commands the market-leading position in all of its businesses. Cardiovascular care, diabetes care, diagnostics, nutrition -- you name it, and Abbott sits at the top.
Granted, Abbott's dividend yield of 1.4% probably won't make your mouth water. But the dividend will almost certainly grow over time. Even better, Abbott should deliver strong revenue and earnings growth that's a precursor to strong share price appreciation.
The company's FreeStyle Libre continuous glucose monitoring device and MitraClip mitral valve continue to serve as key growth drivers. Its COVID-19 testing sales could decline but should remain an important revenue source even after the pandemic ends. Abbott's commitment to innovation will likely translate to new products and new markets over the next decade and beyond.
Brookfield Renewable
Brookfield Renewable (NYSE: BEP) (NYSE: BEPC) can't claim the track record of dividend hikes that Abbott can. However, the company has increased its dividend distribution by a compound annual growth rate of 6% over the last two decades. And most investors will probably like its yield of close to 3%.
There's one thing that Brookfield Renewable has in common with Abbott, though. Its growth prospects are even more attractive than its dividend.
Nearly 130 governments have established net-zero carbon emission targets. Close to 3,100 businesses have committed to slashing their carbon emissions by 50% by 2030. This presents a huge opportunity for Brookfield Renewable, which stands out as one of the world's leading renewable energy providers.
Brookfield Renewable expects to generate total returns of between 12% and 15% over the long term. With the expanding demand for renewable energy and its massive development pipeline poised to provide significantly more capacity, the company should be in a strong position to achieve that goal.
Johnson & Johnson
Few companies can boast as impressive a pedigree as Johnson & Johnson (NYSE: JNJ). It's a Dividend King with 59 consecutive years of dividend increases. J&J ranks No. 1 among pharmaceutical companies on Fortune's Most Admired Companies list. It's the largest healthcare company in the world.
Johnson & Johnson is about as steady as they come. Roughly 70% of its sales come from products that are either No. 1 or No. 2 in their respective markets. The company has 28 products or platforms that generate annual sales of more than $1 billion.
It's also a surprisingly nimble giant. The company has delivered an annualized total return of 13.1% over the last 10 years. Around one-fourth of its total revenue stems from products that have been launched in the past five years.
J&J should be able to generate solid long-term earnings growth. Add to that the company's attractive dividend, which currently yields close to 2.8%. This blue-chip dividend stock is one that you'll probably never regret buying.
10 stocks we like better than Johnson & Johnson
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
Keith Speights owns shares of Brookfield Renewable Corporation Inc. and Brookfield Renewable Partners L.P. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a Dividend Aristocrat with 49 consecutive years of dividend increases. Reinvesting dividends over a long period of time can significantly boost your total returns. Its COVID-19 testing sales could decline but should remain an important revenue source even after the pandemic ends. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a Dividend Aristocrat with 49 consecutive years of dividend increases. The company ranks among Fortune's Top 50 Most Admired Companies. Brookfield Renewable Brookfield Renewable (NYSE: BEP) (NYSE: BEPC) can't claim the track record of dividend hikes that Abbott can. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a Dividend Aristocrat with 49 consecutive years of dividend increases. Brookfield Renewable Brookfield Renewable (NYSE: BEP) (NYSE: BEPC) can't claim the track record of dividend hikes that Abbott can. Johnson & Johnson Few companies can boast as impressive a pedigree as Johnson & Johnson (NYSE: JNJ). | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a Dividend Aristocrat with 49 consecutive years of dividend increases. The company ranks among Fortune's Top 50 Most Admired Companies. It's a Dividend King with 59 consecutive years of dividend increases. |
31988.0 | 2021-09-11 00:00:00 UTC | 3 Dividend Investing Tips That Could Earn You Thousands | ABT | https://www.nasdaq.com/articles/3-dividend-investing-tips-that-could-earn-you-thousands-2021-09-11 | nan | nan | It's always fun to get paid for being a shareholder. Under the best conditions, dividend stocks provide regular income that you can count on for years. But if you pick a weak contender, you might not even have an opportunity to make your money back.
So, if you want to supercharge your returns, you'll need to pick dividend-bearing investments quite prudently. Today, I'll be sharing three tips that should get you on your way to building a robust income stream from your holdings.
Image source: Getty Images.
1. High yields can be a warning sign
One mistake that dividend investors may be tempted to make is buying a stock on the basis of its spectacularly high dividend yield. When you see a high yield, it's important to proceed with caution, because the yield may be the result of a larger story that's relevant to the stock's merit as a part of your portfolio.
There are a couple of ways that the dividend yield of a stock can rise, and they're both rooted in simple algebra. One way is when management decides to increase the size of the dividend payment, which makes it larger in comparison to the stock's price.
Another way is for the stock's price to fall while the dividend payment remains constant. And for dividend yields in excess of 10%, especially when you're looking at a company that isn't a real estate investment trust (REIT), it's the second of the two options that is often the explanation for the attractive yield.
Thus, stocks with very high yields are commonly stocks that recently lost a lot of their value as a result of poor earnings or some other unfavorable development. That doesn't mean you should never buy them, but it does mean that you will need to identify and understand what's going on and how it relates to the company's ability to be a good investment over time.
Of course, if you find that there's actually nothing wrong and there's just been a large hike in the payment or the announcement of a special dividend, it's a positive sign rather than a warning.
Finally, it's worth noting that some of the all-time great dividend stocks have relatively low dividend yields -- like Abbott Laboratories (NYSE: ABT), currently clocking in at around 1.4%. So, don't let a low yield dissuade you in the same way a high yield might.
2. Look for consistency and growth
There's not much point in buying a stock for its dividend if it only pays erratically. Likewise, if you buy dividend stocks that don't ever raise the size of their payments, in the long run the dividend's value will get eroded by inflation.
One way to filter out stocks that don't meet the cut is to look at the history of the business' dividends, which you can usually find on the investor website. A payout that rises one quarter only to fall or be absent in the next quarter isn't one that you should be counting on.
A great way to screen for both the consistency and growth of dividends is to look at a list of the Dividend Aristocrats. The Aristocrats are major companies (like Abbott Laboratories) that have increased their dividend payments each year for at least 25 years consecutively.
So, you can likely count on them to keep paying out -- and increasing those payouts over time. If you're willing to invest in a company with a shorter payout history, there are less stringent categories of dividend royalty, like the Dividend Contenders, which have between 10 and 24 years of consecutive increases.
If you're a conservative investor, there are also stocks that are part of the even more exclusive Dividend Kings list, such as Johnson & Johnson (NYSE: JNJ). These stocks have more than 50 years of dividend growth.
3. Sustainability is key
Even with Dividend Kings, you need to be vetting the sustainability of the dividend -- that is, the ability of a company to successfully compete in its markets and grow while at the same time reward its shareholders with a dividend. For highly ranked dividend-paying businesses like Abbott Laboratories and Johnson & Johnson, investors tend to have a great deal of confidence in their sustainability.
ABT Dividend data by YCharts
Simply being able to pay a dividend through the next year or so does not guarantee that shareholders will continue to get what's due. Declining companies can theoretically liquidate productive assets or take out debt to avoid cutting the dividend, for a time. But robust and growing businesses can expand their balance sheet while increasing their dividends too.
For me, the biggest metric to look at regarding dividend sustainability is growth in a company's free cash flow (FCF) over time, which both Abbott and Johnson & Johnson have in spades. Rising free cash flow is usually the product of diligent management and an effective business model, generally speaking. If over the years there's a steady trend of having more free cash flow with each quarter that passes, the company is probably healthy enough to keep paying out its dividend. On the other hand, a downward trend could point to cuts in the future, so it might be worth avoiding.
It's also not a good look when companies prioritize investor returns over the long-term health of the company. Remember, every dollar paid out in the form of dividends is a dollar that management doesn't have the opportunity to deploy at an attractive rate of return to grow the business.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
Alex Carchidi owns shares of Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Finally, it's worth noting that some of the all-time great dividend stocks have relatively low dividend yields -- like Abbott Laboratories (NYSE: ABT), currently clocking in at around 1.4%. ABT Dividend data by YCharts Simply being able to pay a dividend through the next year or so does not guarantee that shareholders will continue to get what's due. One way to filter out stocks that don't meet the cut is to look at the history of the business' dividends, which you can usually find on the investor website. | Finally, it's worth noting that some of the all-time great dividend stocks have relatively low dividend yields -- like Abbott Laboratories (NYSE: ABT), currently clocking in at around 1.4%. ABT Dividend data by YCharts Simply being able to pay a dividend through the next year or so does not guarantee that shareholders will continue to get what's due. The Aristocrats are major companies (like Abbott Laboratories) that have increased their dividend payments each year for at least 25 years consecutively. | Finally, it's worth noting that some of the all-time great dividend stocks have relatively low dividend yields -- like Abbott Laboratories (NYSE: ABT), currently clocking in at around 1.4%. ABT Dividend data by YCharts Simply being able to pay a dividend through the next year or so does not guarantee that shareholders will continue to get what's due. High yields can be a warning sign One mistake that dividend investors may be tempted to make is buying a stock on the basis of its spectacularly high dividend yield. | Finally, it's worth noting that some of the all-time great dividend stocks have relatively low dividend yields -- like Abbott Laboratories (NYSE: ABT), currently clocking in at around 1.4%. ABT Dividend data by YCharts Simply being able to pay a dividend through the next year or so does not guarantee that shareholders will continue to get what's due. High yields can be a warning sign One mistake that dividend investors may be tempted to make is buying a stock on the basis of its spectacularly high dividend yield. |
31989.0 | 2021-09-10 00:00:00 UTC | 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate | ABT | https://www.nasdaq.com/articles/3m-qiagen-to-comply-with-bidens-covid-19-vaccination-test-mandate-2021-09-10 | nan | nan | Adds 3M's statement
Sept. 10 (Reuters) - 3M Co MMM.N, the biggest U.S. producer of N95 masks, and German genetic testing specialist Qiagen QIA.DE said separately on Friday that they will comply with the Biden administration's new COVID-19 vaccination and testing mandate for workplaces.
"We strongly support all initiatives aiming to increase vaccination rates especially at the workplace," Qiagen told Reuters in an email.
Qiagen said it had already updated its policies to make vaccination compulsory for certain employee groups at its U.S. locations.
3M, the diversified manufacturer which makes everything from Post-It notes and adhesives to industrial sandpaper, said it will comply with the mandate while also adding that it was strongly encouraging its employees to get vaccinated.
U.S. President Joe Biden on Thursday announced policies requiring most federal employees to get COVID-19 vaccinations and pushing large and small private employers to have their workers inoculated or tested weekly.
The White House said it will spend nearly $2 billion on 280 million rapid COVID-19 tests to support the drive.
Abbott Laboratories ABT.N, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees.
Increased capacity will ensure availability of tens of millions more tests in the coming weeks and months, the medical device maker said.
The new vaccination mandate could apply to as many as 100 million Americans - close to two-thirds of the country's workforce - and amount to Biden's strongest push yet for inoculation.
Southwest Airlines Co LUV.N, which has more than 54,000 employees, said it was prepared to move toward compliance with the mandate.
"We continue to strongly encourage our Employees to seek and obtain vaccination, and to share their vaccination status with us," the company said.
(Reporting by Mrinalika Roy, Sanjana Shivdas in Bengaluru; Additional reporting by Shubham Kalia; Editing by Shinjini Ganguli and Shailesh Kuber)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees. 3M, the diversified manufacturer which makes everything from Post-It notes and adhesives to industrial sandpaper, said it will comply with the mandate while also adding that it was strongly encouraging its employees to get vaccinated. U.S. President Joe Biden on Thursday announced policies requiring most federal employees to get COVID-19 vaccinations and pushing large and small private employers to have their workers inoculated or tested weekly. | Abbott Laboratories ABT.N, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees. Adds 3M's statement Sept. 10 (Reuters) - 3M Co MMM.N, the biggest U.S. producer of N95 masks, and German genetic testing specialist Qiagen QIA.DE said separately on Friday that they will comply with the Biden administration's new COVID-19 vaccination and testing mandate for workplaces. 3M, the diversified manufacturer which makes everything from Post-It notes and adhesives to industrial sandpaper, said it will comply with the mandate while also adding that it was strongly encouraging its employees to get vaccinated. | Abbott Laboratories ABT.N, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees. Adds 3M's statement Sept. 10 (Reuters) - 3M Co MMM.N, the biggest U.S. producer of N95 masks, and German genetic testing specialist Qiagen QIA.DE said separately on Friday that they will comply with the Biden administration's new COVID-19 vaccination and testing mandate for workplaces. U.S. President Joe Biden on Thursday announced policies requiring most federal employees to get COVID-19 vaccinations and pushing large and small private employers to have their workers inoculated or tested weekly. | Abbott Laboratories ABT.N, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees. Adds 3M's statement Sept. 10 (Reuters) - 3M Co MMM.N, the biggest U.S. producer of N95 masks, and German genetic testing specialist Qiagen QIA.DE said separately on Friday that they will comply with the Biden administration's new COVID-19 vaccination and testing mandate for workplaces. 3M, the diversified manufacturer which makes everything from Post-It notes and adhesives to industrial sandpaper, said it will comply with the mandate while also adding that it was strongly encouraging its employees to get vaccinated. |
31990.0 | 2021-09-09 00:00:00 UTC | Noteworthy ETF Inflows: SPLG, BRK.B, ABT, VZ | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-splg-brk.b-abt-vz-2021-09-09 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $135.2 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 232,800,000 to 235,350,000). Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is trading flat, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Verizon Communications Inc (Symbol: VZ) is lower by about 0.4%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average:
Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.385 as the 52 week high point — that compares with a last trade of $53.17. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 7%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is trading flat, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Verizon Communications Inc (Symbol: VZ) is lower by about 0.4%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.385 as the 52 week high point — that compares with a last trade of $53.17. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is trading flat, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Verizon Communications Inc (Symbol: VZ) is lower by about 0.4%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.385 as the 52 week high point — that compares with a last trade of $53.17. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is trading flat, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Verizon Communications Inc (Symbol: VZ) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $135.2 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 232,800,000 to 235,350,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.385 as the 52 week high point — that compares with a last trade of $53.17. | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is trading flat, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Verizon Communications Inc (Symbol: VZ) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $135.2 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 232,800,000 to 235,350,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.385 as the 52 week high point — that compares with a last trade of $53.17. |
31991.0 | 2021-09-09 00:00:00 UTC | Biden to lay out 'path ahead' in COVID-19 fight | ABT | https://www.nasdaq.com/articles/biden-to-lay-out-path-ahead-in-covid-19-fight-2021-09-09 | nan | nan | Adds White House comment, quotes
WASHINGTON, Sept 9 (Reuters) - President Joe Biden on Thursday will press for new approaches to control the COVID-19 pandemic in the United States, which rages on despite the wide availability of vaccines, with surging cases in some U.S. statesoverwhelming local hospitals.
In a speech, Biden will focus on new plans to get more people vaccinated, enhancing protection for those who already have had shots and keeping schools open, White House spokeswoman Jen Psaki said.
The speech will also cover increasing testing and mask-wearing, protecting the economic recovery from the pandemic-induced recession, and improving healthcare for people infected with the disease, she saidin television interviews.
"He ... really wants to lay out the path ahead," Psaki told MSNBC on Thursday ahead of Biden's remarks, scheduled for 5 p.m. (2100 GMT).
"He's going to speak directly to vaccinated people and their frustration, and he wants them to hear how we're going to build on what we've done to date to get the virus under control and to return to some version of normal in this country," she added.
Increasing infections have raised concerns as children head back to school, while also rattling investors and upending company return-to-office plans.
Just over 53% of Americans are fully vaccinated, including almost two-thirds of the adult population, according to CDC data. The disease has killed more than 651,000 Americans. https://tmsnrt.rs/3A1KHg3
With 160,000 new infections a day, the country is "still in pandemic mode ... That's not even modestly good control," Biden's chief medical adviser Dr. Anthony Fauci told Axios, adding: "You've got to get well below 10,000 before you start feeling comfortable."
With many Americans still skeptical of the shots, the White House has already planned to offerbooster shots to give additional protection to those who are fully vaccinated. That amounts to a rejection of arguments from the World Health Organization and other advocates that with global vaccine supplies limited, rich countries should pause booster shots until more people worldwide are inoculated.
Psaki also told MSNBC the White House wants to see COVID-19 tests easier to obtain.
Abbott Laboratories ABT.N and other test manufacturers are trying to boost production as cases soar, after having scaled back in recent months. CVS Health Corp CVS.N also recently imposed limits on the number of at-home tests customers can buy.
"It's hard to find a test... they should be more available and accessible to people across the country," Psaki said.
The White House says the federal government cannot mandate vaccines nationwide, but it has encouraged school districts, businesses and other entities to require shots.
"We know it works," Psaki said of inoculations, adding that the administration would build on the push for mandates, offering no further details.
Many school districts have mandated masks, despite heated controversy in some areas, and some have required teachers to be vaccinated or face regular testing. Later on Thursday, the Los Angeles County School Board, the nation's second largest school district behind New York City, is scheduled to weigh a COVID-19 vaccine requirement for youth 12 and older.
(Reporting by Trevor Hunnicutt; additional reporting by Susan Heavey Editing by Robert Birsel and Peter Graff)
((trevor.hunnicutt@tr.com; +1 646 223 7914; twitter.com/trhunnicutt; Reuters Messaging: trevor.hunnicutt.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N and other test manufacturers are trying to boost production as cases soar, after having scaled back in recent months. Adds White House comment, quotes WASHINGTON, Sept 9 (Reuters) - President Joe Biden on Thursday will press for new approaches to control the COVID-19 pandemic in the United States, which rages on despite the wide availability of vaccines, with surging cases in some U.S. statesoverwhelming local hospitals. https://tmsnrt.rs/3A1KHg3 With 160,000 new infections a day, the country is "still in pandemic mode ... That's not even modestly good control," Biden's chief medical adviser Dr. Anthony Fauci told Axios, adding: "You've got to get well below 10,000 before you start feeling comfortable." | Abbott Laboratories ABT.N and other test manufacturers are trying to boost production as cases soar, after having scaled back in recent months. "He ... really wants to lay out the path ahead," Psaki told MSNBC on Thursday ahead of Biden's remarks, scheduled for 5 p.m. (2100 GMT). With many Americans still skeptical of the shots, the White House has already planned to offerbooster shots to give additional protection to those who are fully vaccinated. | Abbott Laboratories ABT.N and other test manufacturers are trying to boost production as cases soar, after having scaled back in recent months. Adds White House comment, quotes WASHINGTON, Sept 9 (Reuters) - President Joe Biden on Thursday will press for new approaches to control the COVID-19 pandemic in the United States, which rages on despite the wide availability of vaccines, with surging cases in some U.S. statesoverwhelming local hospitals. In a speech, Biden will focus on new plans to get more people vaccinated, enhancing protection for those who already have had shots and keeping schools open, White House spokeswoman Jen Psaki said. | Abbott Laboratories ABT.N and other test manufacturers are trying to boost production as cases soar, after having scaled back in recent months. In a speech, Biden will focus on new plans to get more people vaccinated, enhancing protection for those who already have had shots and keeping schools open, White House spokeswoman Jen Psaki said. Psaki also told MSNBC the White House wants to see COVID-19 tests easier to obtain. |
31992.0 | 2021-09-09 00:00:00 UTC | What's Next For Baxter Stock After An 11% Rise In A Month? | ABT | https://www.nasdaq.com/articles/whats-next-for-baxter-stock-after-an-11-rise-in-a-month-2021-09-09 | nan | nan | [Updated: Sep 7, 2021] Baxter Stock Rise
The stock price of Baxter International (NYSE:BAX), a medical supplies company, has seen a rise of around 11% over the last twenty-one trading days, and it is up just 1% over the last twelve-month period. The rally in BAX stock over the recent past has been propelled by Hill-Rom accepting Baxter’s acquisition bid of $156 per share. The Hill-Rom acquisition appears to be good for Baxter in the long run, as it offers the addition of connected care offerings to Baxter’s existing portfolio. The transaction is expected to be low double-digit EPS accretive by 2023 and even higher over the subsequent years.
But now that BAX stock has seen an 11% move over the last month or so, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a decline in BAX stock over the next month. Out of 66 instances in the last ten years that BAX stock saw a twenty-one day rise of 11% or more, 35 of them resulted in BAX stock falling over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 35 out of 66, or about a 53% chance of a decline in BAX stock over the coming month. See our analysis on Baxter Stock Chances of Decline for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
After moving 10% or more over a ten-day period, the stock rose in the next ten days only on 39% of the occasions
After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days only on 47% of the occasions.
Baxter International (BAX) Stock Return (Recent) Comparison With Peers
Five-Day Return: BAX highest at 12%; BSX lowest at 0.3%
Ten-Day Return: BAX highest at 10%; BSX lowest at 1.1%
Twenty-One Day Return: BAX highest at 11%; BSX lowest at 0.6%
[Updated: Aug 3, 2021] Baxter Stock Decline
The stock price of medical supplies company Baxter (NYSE: BAX) has seen a fall of 4% over the last five trading days, while it is also down over 7% in the last year. The recent fall came after the company announced its Q2 results and reports of it planning to acquire another medical devices company – Hill-Rom.
Baxter’s total revenues of $3.1 billion in Q2 2021 were in-line, while its EPS of $0.80 was better than the $0.75 consensus estimate. The company’s top-line expanded 14% and the bottom-line 22% on a y-o-y basis. The company has guided for sales growth of 8%, compared to a range of 8% to 9% per the earlier guidance in Q1 2021. Looking at the bottom-line, Baxter now expects adjusted EPS to be $3.52 for the full-year 2021, compared to $3.51 per the earlier guidance, at the mid-point of the range.
Another factor that impacted BAX stock was a report of it planning to acquire Hill-Rom. As per the report, Hill-Rom rejected a $144-per-share bid from Baxter. Hill-Rom was trading at levels of around $128 before this news broke, and it has since rallied 14%. If Baxter wants a deal, it may have to bid at a higher price, and this has likely weighed on its stock.
Now, after a 4.4% fall in a week, will BAX stock continue its downward trajectory over the coming weeks, or is a recovery in the stock imminent? According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BAX stock average 2.6% in the next one-month (twenty-one trading days) period after experiencing an 4.4% drop over the previous week (five trading days), implying that BAX stock may rebound in the near term. That said, the movement in BAX stock will also depend on any development around its Hill-Rom acquisition plans.
But how would these numbers change if you are interested in holding BAX stock for a shorter or a longer time period? You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Baxter stock chances of a rise after a fall. You can test the chance of recovery over different time intervals of a quarter, month, or even just 1 day!
MACHINE LEARNING ENGINE – try it yourself:
IF BAX stock moved by -5% over five trading days, THEN over the next twenty-one trading days BAX stock moves an average of 2.9%, with a good 72% probability of a positive return over this period.
Some Fun Scenarios, FAQs & Making Sense of Baxter International Stock Movements:
Question 1: Is the average return for Baxter International stock higher after a drop?
Answer: Consider two situations,
Case 1: Baxter International stock drops by -5% or more in a week
Case 2: Baxter International stock rises by 5% or more in a week
Is the average return for Baxter International stock higher over the subsequent month after Case 1 or Case 2?
BAX stock fares better after Case 1, with an average return of 2.9% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 0.4% for Case 2.
In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise.
Try the Trefis machine learning engine above to see for yourself how Baxter International stock is likely to behave after any specific gain or loss over a period.
Question 2: Does patience pay?
Answer: If you buy and hold Baxter International stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong.
Overall, according to data and Trefis machine learning engine’s calculations, patience absolutely pays for most stocks!
For BAX stock, the returns over the next N days after a -5% change over the last five trading days is detailed in the table below, along with the returns for the S&P500:
You can try the engine to see what this table looks like for Baxter International after a larger loss over the last week, month, or quarter.
Question 3: What about the average return after a rise if you wait for a while?
Answer: The average return after a rise is understandably lower than after a fall as detailed in the previous question. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks.
It’s pretty powerful to test the trend for yourself for Baxter International stock by changing the inputs in the charts above.
While BAX stock may rise in the near term, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Freeport vs. Baxter.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The rally in BAX stock over the recent past has been propelled by Hill-Rom accepting Baxter’s acquisition bid of $156 per share. Try the Trefis machine learning engine above to see for yourself how Baxter International stock is likely to behave after any specific gain or loss over a period. Answer: If you buy and hold Baxter International stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong. | [Updated: Sep 7, 2021] Baxter Stock Rise The stock price of Baxter International (NYSE:BAX), a medical supplies company, has seen a rise of around 11% over the last twenty-one trading days, and it is up just 1% over the last twelve-month period. Baxter International (BAX) Stock Return (Recent) Comparison With Peers Five-Day Return: BAX highest at 12%; BSX lowest at 0.3% Ten-Day Return: BAX highest at 10%; BSX lowest at 1.1% Twenty-One Day Return: BAX highest at 11%; BSX lowest at 0.6% [Updated: Aug 3, 2021] Baxter Stock Decline The stock price of medical supplies company Baxter (NYSE: BAX) has seen a fall of 4% over the last five trading days, while it is also down over 7% in the last year. According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BAX stock average 2.6% in the next one-month (twenty-one trading days) period after experiencing an 4.4% drop over the previous week (five trading days), implying that BAX stock may rebound in the near term. | Baxter International (BAX) Stock Return (Recent) Comparison With Peers Five-Day Return: BAX highest at 12%; BSX lowest at 0.3% Ten-Day Return: BAX highest at 10%; BSX lowest at 1.1% Twenty-One Day Return: BAX highest at 11%; BSX lowest at 0.6% [Updated: Aug 3, 2021] Baxter Stock Decline The stock price of medical supplies company Baxter (NYSE: BAX) has seen a fall of 4% over the last five trading days, while it is also down over 7% in the last year. According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BAX stock average 2.6% in the next one-month (twenty-one trading days) period after experiencing an 4.4% drop over the previous week (five trading days), implying that BAX stock may rebound in the near term. Answer: Consider two situations, Case 1: Baxter International stock drops by -5% or more in a week Case 2: Baxter International stock rises by 5% or more in a week Is the average return for Baxter International stock higher over the subsequent month after Case 1 or Case 2? | The rally in BAX stock over the recent past has been propelled by Hill-Rom accepting Baxter’s acquisition bid of $156 per share. Looking at the bottom-line, Baxter now expects adjusted EPS to be $3.52 for the full-year 2021, compared to $3.51 per the earlier guidance, at the mid-point of the range. According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BAX stock average 2.6% in the next one-month (twenty-one trading days) period after experiencing an 4.4% drop over the previous week (five trading days), implying that BAX stock may rebound in the near term. |
31993.0 | 2021-09-08 00:00:00 UTC | Validea Martin Zweig Strategy Daily Upgrade Report - 9/8/2021 | ABT | https://www.nasdaq.com/articles/validea-martin-zweig-strategy-daily-upgrade-report-9-8-2021-2021-09-08 | nan | nan | The following are today's upgrades for Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT
Full Factor Report for ABT
JPMORGAN CHASE & CO. (JPM) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: JPMorgan Chase & Co. is a financial holding company. The Company is engaged in investment banking, financial services and asset management. It operates in four segments, as well as a Corporate segment. Its segments are Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking and Asset Management. The Consumer & Community Banking segment offers services to consumers and businesses through bank branches, automatic teller machines, online, mobile and telephone banking. The Corporate & Investment Bank segment, comprising Banking and Markets and Investor Services, offers investment banking, market-making, prime brokerage, and treasury and securities products and services to corporations, investors, financial institutions, and government and municipal entities. The Commercial Banking segment provides financial solutions, including lending, treasury services, investment banking and asset management. The Asset Management segment comprises investment and wealth management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of JPMORGAN CHASE & CO.
Full Guru Analysis for JPM
Full Factor Report for JPM
KULICKE AND SOFFA INDUSTRIES INC. (KLIC) is a mid-cap growth stock in the Semiconductors industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Kulicke and Soffa Industries, Inc. designs, manufactures and sells capital equipment and expendable tools used to assemble semiconductor devices, including integrated circuits (ICs), high and low powered discrete devices, light-emitting diodes (LEDs) and power modules. The Company also services, maintains, repairs and upgrades equipment, all used to assemble semiconductor devices. The Company supplies a range of bonding equipment. It operates through two segments: Capital Equipment and Aftermarket Products and Services (APS). The Capital Equipment segment manufactures and sells a line of ball bonders, wedge bonders, advanced packaging and surface mount technology solutions. The APS segment manufactures and sells expendable tools for a range of semiconductor packaging applications. Its customers primarily consist of semiconductor device manufacturers, outsourced semiconductor assembly and test providers (OSATs), other electronics manufacturers and automotive electronics suppliers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of KULICKE AND SOFFA INDUSTRIES INC.
Full Guru Analysis for KLIC
Full Factor Report for KLIC
QCR HOLDINGS, INC. (QCRH) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: QCR Holdings, Inc. is a multi-bank holding company. The Company serves the Quad Cities, Cedar Rapids, Waterloo/Cedar Falls, Des Moines/Ankeny and Rockford communities through its banking subsidiaries, Quad City Bank and Trust Company (QCBT), Cedar Rapids Bank and Trust Company (CRBT), Community State Bank (CSB), and Guaranty Bank and Trust Company, which provide full-service commercial and consumer banking and trust and asset management services. It is also engaged in direct financing lease contracts through m2 Lease Funds, LLC (m2), a subsidiary of QCBT. Its principal business consists of attracting deposits and investing those deposits in loans/leases and securities. The Company and its subsidiaries provide a range of commercial and retail lending/leasing, and investment services to corporations, partnerships, individuals and government agencies. It offers a range of loans, including one-to four-family residential loans and multi-family loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of QCR HOLDINGS, INC.
Full Guru Analysis for QCRH
Full Factor Report for QCRH
RBB BANCORP (RBB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: RBB Bancorp (the Bank) is a bank holding company with the principal business to serve as the holding company for its wholly-owned banking subsidiaries, including Royal Business Bank (Bank) and RBB Asset Management Company (RAM). The Company operates Royal Business Bank, which is a California state-chartered commercial bank. The Bank is focused on providing commercial banking services. The Bank's offerings include traditional commercial real estate loans, secured commercial and industrial loans, and trade finance services for companies doing business in China, Taiwan and other Asian countries. The non-qualified single-family residential mortgage loans, small business administration loans. As of March 31, 2017, the Company had total consolidated assets of $1.5 billion, total consolidated deposits of $1.2 billion and total consolidated shareholders equity of $183.5 million.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of RBB BANCORP
Full Guru Analysis for RBB
Full Factor Report for RBB
FREEDOM HOLDING CORP (FRHC) is a mid-cap growth stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Freedom Holding Corp, through its subsidiaries, provides financial services including retail securities brokerage, research, investment counseling, securities trading, market making, corporate investment banking and underwriting services in Eastern Europe and Central Asia. The Company has retail locations in Russia, Kazakhstan, Ukraine, Uzbekistan, Kyrgyzstan and Germany. Its subsidiaries include LLC Investment Company Freedom Finance (Freedom RU), a securities broker-dealer; LLC FFIN Bank (FFIN Bank); JSC Freedom Finance (Freedom KZ), a securities broker-dealer; Freedom Finance Cyprus Limited (Freedom CY), a broker-dealer; Freedom Finance Germany TT GmbH (Freedom GE), a tied agent of Freedom CY; LLC Freedom Finance Uzbekistan (Freedom UZ), a broker-dealer and FFIN Securities, Inc. (FFIN). The Company's retail brokerage services include full-service brokerage, margin lending, investor education andinvestment research
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FREEDOM HOLDING CORP
Full Guru Analysis for FRHC
Full Factor Report for FRHC
ALLY FINANCIAL INC (ALLY) is a large-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ally Financial Inc. is a digital financial services company. The Company is a bank and financial holding company. Its segments include Automotive Finance operations, Insurance operations, Mortgage Finance operations, Corporate Finance operations, and Corporate and Other. The Automotive Finance operations segment provides the United States-based automotive financing services to consumers and automotive dealers, and automotive and equipment financing services to companies and municipalities. The Insurance operations segment offers both consumer finance protection and insurance products sold through the automotive dealer channel, and commercial insurance products sold directly to dealers. The Mortgage Finance operations segment consists of the management of a held-for-investment consumer mortgage finance loan portfolio. The Corporate Finance operations segment provides senior secured leveraged cash flow and asset-based loans to mostly the United States-based middle market companies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ALLY FINANCIAL INC
Full Guru Analysis for ALLY
Full Factor Report for ALLY
INVESTORS BANCORP INC (ISBC) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Investors Bancorp, Inc. is the holding company for Investors Bank (the Bank). The Bank is a New Jersey-chartered savings bank. The Bank is in the business of attracting deposits from the public through its branch network and borrowing funds in the wholesale markets to originate loans and to invest in securities. The Bank originates multi-family loans, commercial real estate loans, commercial and industrial (C&I) loans, one- to four-family residential mortgage loans secured by one- to four-family residential real estate, construction loans and consumer loans, the majority of which are home equity loans, home equity lines of credit and cash surrender value lending on life insurance contracts. Its securities primarily include mortgage-backed securities, the United States Government and Federal Agency obligations, and other securities. Deposits are the primary source of funds used for its lending and investment activities. In addition, it uses a significant amount of borrowings.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of INVESTORS BANCORP INC
Full Guru Analysis for ISBC
Full Factor Report for ISBC
BANK FIRST CORP (BFC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 89% to 97% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bank First Corp, formerly Bank First National Corp, is the holding company for Bank First (the Bank). The Company provides a range of financial services to individual and business customers. The Bank is an independent community bank. It offers personal and business banking services. Its personal banking services include savings, checking, loans and electronic banking. Its personal savings accounts include certificates of deposit (CD), individual retirement account (IRA) savings account and health savings accounts. Its business banking services include savings, checking, credit cards and treasury management. It offers deposit accounts, CD account registry service (CDARS) and health savings accounts. The Bank offers real estate loans, home equity loans, installment and consumer loans, working capital lines of credit, equipment loans, loans for business expansion, real estate loans, construction/development loans, small business administration loans and farm/crop/livestock loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BANK FIRST CORP
Full Guru Analysis for BFC
Full Factor Report for BFC
LKQ CORPORATION (LKQ) is a large-cap growth stock in the Auto & Truck Parts industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: LKQ Corporation (LKQ) is a holding company, which distributes vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, as well as specialty vehicle products and accessories, and automotive glass products. The Company's segments include Wholesale- North America, Europe and Specialty. It offers its customers a range of replacement systems, components, equipment and parts to repair and accessorize automobiles, trucks, and recreational and performance vehicles. It distributes a range of products to collision and mechanical repair shops, including aftermarket collision and mechanical products, recycled collision and mechanical products, refurbished collision products, such as wheels, bumper covers and lights, and re-manufactured engines. It also has operations in North America, Europe and Taiwan.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of LKQ CORPORATION
Full Guru Analysis for LKQ
Full Factor Report for LKQ
NEXSTAR MEDIA GROUP INC (NXST) is a mid-cap value stock in the Broadcasting & Cable TV industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Nexstar Media Group, Inc., formerly Nexstar Broadcasting Group, Inc., is a television broadcasting and digital media company. The Company is focused on the acquisition, development and operation of television stations and interactive community Websites, and digital media services in medium-sized markets in the United States. The Company's segments include Broadcasting and Other. The Company's broadcast segment includes television stations and related community-focused Websites that it owns, operates, programs or provides sales and other services to in various markets across the United States. The other activities of the Company include corporate functions, eliminations and other operations. As of December 31, 2016, it owned, operated, programmed or provided sales and other services to 104 full power television stations in 62 markets in the states of Alabama, Arizona, Arkansas, California, Colorado, Florida, New York, Utah, Vermont, Virginia, West Virginia and Wisconsin, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of NEXSTAR MEDIA GROUP INC
Full Guru Analysis for NXST
Full Factor Report for NXST
SYNNEX CORPORATION (SNX) is a large-cap value stock in the Computer Hardware industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Synnex Corporation provides a range of distribution, logistics and integration services for the technology industry. The Company operates through Technology Solutions segment. The Company's Technology Solutions segment distributes peripherals, information technology (IT) systems, including data center server and storage solutions, system components, software, networking/communications/security equipment, and consumer electronics (CE) and complementary products. Within its Technology Solutions segment, the Company also provides systems design and integration solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SYNNEX CORPORATION
Full Guru Analysis for SNX
Full Factor Report for SNX
WESTERN ALLIANCE BANCORPORATION (WAL) is a large-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Western Alliance Bancorporation is a bank holding company. The Company provides a range of deposit, lending, treasury management, international banking and online banking products and services through its banking subsidiary, Western Alliance Bank (WAB). The Company's regional segments include Arizona, Nevada, Southern California and Northern California, which provide banking and related services to their respective markets. The operations from the regional segments correspond to the banking divisions, which include Alliance Bank of Arizona (ABA) in Arizona, Bank of Nevada (BON) and First Independent Bank (FIB) in Nevada, Torrey Pines Bank (TPB) in Southern California, and Bridge Bank in Northern California. The Company's specialized financial services include Alliance Association Bank, Corporate Finance, Mortgage Warehouse Lending, Equity Fund Resources, Hotel Franchise Finance (HFF), Public & Nonprofit Finance, Renewable Resource Group, Resort Finance, and Technology Finance.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of WESTERN ALLIANCE BANCORPORATION
Full Guru Analysis for WAL
Full Factor Report for WAL
ARES CAPITAL CORPORATION (ARCC) is a mid-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ares Capital Corporation is a specialty finance company. The Company operates as a closed-end, non-diversified management investment company. The Company's investment objective is to generate both current income and capital appreciation through debt and equity investments. It invests primarily in the United States middle-market companies. It may from time to time invest in larger or smaller (in particular, for investments in early-stage and/or venture capital-backed) companies. It invests primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position), second lien senior secured loans, and mezzanine debt, which in some cases includes an equity component. It invests in various industries, such as automotive services, business services, consumer products, and containers and packaging. Ares Capital Management LLC serves as its investment advisor.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ARES CAPITAL CORPORATION
Full Guru Analysis for ARCC
Full Factor Report for ARCC
AMERIS BANCORP (ABCB) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ameris Bancorp is a financial holding company. The Company's business is conducted through its banking subsidiary, Ameris Bank (the Bank), which provides a range of banking services to its retail and commercial customers. The Company operates through four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the SBA Division. The Banking Division is engaged in the delivery of financial services, which include commercial loans, consumer loans and deposit accounts. The Retail Mortgage Division is engaged in the origination, sales and servicing of one- to four-family residential mortgage loans. The Warehouse Lending Division is engaged in the origination and servicing of warehouse lines to other businesses that are secured by underlying one- to four-family residential mortgage loans. The SBA Division is engaged in the origination, sales and servicing of small business administration (SBA) loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AMERIS BANCORP
Full Guru Analysis for ABCB
Full Factor Report for ABCB
BCB BANCORP, INC. (BCBP) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BCB Bancorp, Inc. is the holding company parent of BCB Community Bank (the Bank). The Bank is a community-oriented financial institution. The Bank's business is to offer Federal Deposit Insurance Corporation (FDIC)-insured deposit products and to invest funds held in deposit accounts at the Bank, together with funds generated from operations, in loans and investment securities. The Bank offers loans, including commercial and multi-family real estate loans, one-to four-family mortgage loans, home equity loans, construction loans, consumer loans and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, mobile banking, gift cards and fraud detection (positive pay).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BCB BANCORP, INC.
Full Guru Analysis for BCBP
Full Factor Report for BCBP
DORMAN PRODUCTS INC. (DORM) is a mid-cap growth stock in the Auto & Truck Parts industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Dorman Products, Inc. is a supplier of replacement parts and fasteners for passenger cars, light trucks and heavy duty trucks in the automotive aftermarket. As of December 31, 2016, the Company distributed and marketed approximately 155,000 different stock keeping units (SKU's) of automotive replacement parts and fasteners. As of December 31, 2016, approximately 83% of its products were sold under brands that it owned and the remainder of its products were sold for resale under customers' private labels, other brands or in bulk. Its products are sold in the United States through automotive aftermarket retailers, national, regional and local warehouse distributors, and specialty markets, and salvage yards. It also distributes automotive replacement parts outside the United States, with sales primarily into Canada, Mexico, Europe, the Middle East, and Australia. Its parts are marketed under the OE Solutions, TECHoice, AutoGrade, Conduct-Tite, FirstStop and HD Solutions brand names.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of DORMAN PRODUCTS INC.
Full Guru Analysis for DORM
Full Factor Report for DORM
ROCKY BRANDS INC (RCKY) is a small-cap value stock in the Footwear industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Rocky Brands, Inc. is a designer, manufacturer and marketer of footwear and apparel marketed under a portfolio of brand names, including Rocky, Georgia Boot, Durango, Lehigh and the licensed brand Michelin. The Company operates its business through three segments: wholesale, retail and military. In its wholesale segment, the Company distributes its products through a range of distribution channels representing over 10,000 retail store locations in the United States and Canada, as well as in other international markets. Its wholesale channels vary by product line and include sporting goods stores, outdoor retailers, independent shoe retailers, hardware stores, catalogs, mass merchants and uniform stores. In its retail segment, the Company sells its products directly to consumers through its consumer and business direct Websites and its Rocky outlet store. In its military segment, the Company sells footwear under the Rocky label to the United States military.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ROCKY BRANDS INC
Full Guru Analysis for RCKY
Full Factor Report for RCKY
SAIA INC (SAIA) is a mid-cap growth stock in the Trucking industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Saia, Inc., is a transportation company. The Company provides regional and interregional less-than-truckload (LTL) services. The Company also offers a range of other value-added services, including non-asset truckload, expedited and logistics services across North America. The Company's subsidiary Saia Motor Freight Line, LLC (Saia LTL Freight) is a LTL carrier. Saia LTL Freight serves approximately 34 states in the South, Southwest, Midwest, Pacific Northwest and West and portions of the Northeast. Saia LTL Freight specializes in offering its customers a range of regional and interregional LTL services, including time-definite and expedited options. Saia LTL Freight primarily provides its customers with solutions for shipments approximately between 100 and 10,000 pounds, but also provides truckload services. It operated a network consisting of approximately 166 owned and leased locations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SAIA INC
Full Guru Analysis for SAIA
Full Factor Report for SAIA
BLACKROCK MUNIHOLDINGS QUALITYFND II INC (MUE) is a small-cap growth stock in the Misc. Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BlackRock MuniHoldings Quality Fund II, Inc. (the Fund) is a non-diversified, closed-end management investment company. The Fund's investment objective is to provide shareholders with current income exempt from federal income taxes. The Fund seeks to achieve its investment objective by investing primarily in long-term, investment grade municipal obligations exempt from federal income taxes (except that the interest may be subject to the federal alternative minimum tax). Under normal market conditions, the Fund invests at least 80% of its assets in municipal obligations with remaining maturities of one year or more at the time of investment. The Fund may invest directly in such securities or synthetically through the use of derivatives. The Fund's portfolio includes its investments in various sectors, including transportation, utilities, health, education, housing and tobacco. The Fund's investment advisor is BlackRock Advisors, LLC.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BLACKROCK MUNIHOLDINGS QUALITYFND II INC
Full Guru Analysis for MUE
Full Factor Report for MUE
MAIN STREET CAPITAL CORPORATION (MAIN) is a mid-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Main Street Capital Corporation (MSCC) is a principal investment firm. MSCC's principal investment objective is to maximize its portfolio's total return by generating current income from the Company's debt investments and capital appreciation from its equity and equity related investments, including warrants, convertible securities and other rights to acquire equity securities in a portfolio company. It is primarily focused on providing customized debt and equity financing to lower middle market (LMM) companies and debt capital to middle market (Middle Market) companies. It invests primarily in secured debt investments, equity investments, warrants and other securities of LMM companies and in secured debt investments of Middle Market companies. Its investment portfolio includes its investments in LMM portfolio companies, investments in Middle Market portfolio companies and Other Portfolio investments, among others. MSC Adviser I, LLC is the External Investment Manager.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MAIN STREET CAPITAL CORPORATION
Full Guru Analysis for MAIN
Full Factor Report for MAIN
TEXTAINER GROUP HOLDINGS LIMITED (TGH) is a small-cap value stock in the Rental & Leasing industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Textainer Group Holdings Limited is a holding company. The Company is involved in the purchase, ownership, management, leasing and disposal of a fleet of intermodal containers. The Company operates in three segments: Container Ownership, which owns containers; Container Management, which manages containers on behalf of affiliated and unaffiliated container investors, and provides acquisition, management and disposal services, and total managed containers, and Container Resale, which sells containers from its fleet when they reach the end of their useful lives in marine service, and also purchases and leases or resells containers from shipping line customers, container traders and other sellers of containers. The Company is a lessor of intermodal containers based on fleet size. The Company is also a seller of used containers. The Company's subsidiaries include Textainer Equipment Management Limited (TEML) and Textainer Limited (TL).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of TEXTAINER GROUP HOLDINGS LIMITED
Full Guru Analysis for TGH
Full Factor Report for TGH
AMES NATIONAL CORPORATION (ATLO) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ames National Corporation is a bank holding company. The Company operates through banking segment. The Company owns banking subsidiaries, including First National Bank, Ames; Boone Bank & Trust Co., Boone; Iowa State Savings Bank, Creston; State Bank & Trust Co., Nevada; Reliance State Bank, Story City; and United Bank & Trust, Marshalltown. All of its operations are conducted in the State of Iowa and primarily within the central and north central Iowa counties of Boone, Hancock, Marshall, Polk and Story where the Company's banking subsidiaries are located. The Banks offer a range of deposit services, including checking accounts, savings accounts and time deposits of various types, ranging from money market accounts to longer-term certificates of deposit. The Banks also offer retirement accounts, such as individual retirement accounts (IRAs). It provides financial products, such as Internet banking and trust services for customers and communities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AMES NATIONAL CORPORATION
Full Guru Analysis for ATLO
Full Factor Report for ATLO
PINNACLE FINANCIAL PARTNERS INC (PNFP) is a mid-cap growth stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Pinnacle Financial Partners, Inc. is a bank holding company. The Company operates through its subsidiary, Pinnacle Bank. The Company operates as a community bank primarily in the urban markets of Nashville, Knoxville, Memphis and Chattanooga, Tennessee and other counties. It provides the personalized service associated with small community banks, while seeking to offer the products and services, such as investments and treasury management. Pinnacle Bank offers an array of convenience-centered products and services, including round the clock telephone and Internet banking, mobile banking, debit and credit cards, direct deposit, remote deposit and cash management services for small- to medium-sized businesses. In addition, Pinnacle Bank is associated with a network of automated teller machines of other financial institutions that its clients are able to use throughout Tennessee and other regions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of PINNACLE FINANCIAL PARTNERS INC
Full Guru Analysis for PNFP
Full Factor Report for PNFP
FARMERS NATIONAL BANC CORP (FMNB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Farmers National Banc Corp. is a one-bank holding company. The Company's principal business consists of owning and supervising its subsidiaries. The Company operates through tree segments: the Bank, Trust and Retirement Consulting. The Company operates principally through its subsidiaries, The Farmers National Bank of Canfield (the Bank or Farmers Bank), Farmers Trust Company (Trust or Farmers Trust), National Associates, Inc. (NAI) and Farmers National Captive, Inc. (Captive). The Bank's subsidiaries include Farmers National Insurance, LLC (Farmers Insurance) and Farmers of Canfield Investment Co. (Farmers Investments). The banking operation offers loans, investments and deposits; the trust operations provide trust services, and the retirement consulting operations offer consulting services. The Company and its subsidiaries operate in the domestic banking, trust, retirement consulting, insurance and financial management industries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FARMERS NATIONAL BANC CORP
Full Guru Analysis for FMNB
Full Factor Report for FMNB
MEDIFAST INC (MED) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medifast, Inc. produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company's product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins. Its business units include Optavia, Medifast Direct, Franchise Medifast Weight Control Centers (MWCC) and Medifast Wholesale. Optavia is a personal coaching division of the Company that consists of Optavia Coaches, who provides coaching and support to clients utilizing the Optavia platform. Medifast Direct is its direct-to-consumer business unit that allows customers to order Medifast products directly through its Website or its in-house call center. The MWCC business unit sells product through franchise and reseller locations, which offers structured programs and a team of professionals to help customers achieve weight-loss and weight-management success at center locations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MEDIFAST INC
Full Guru Analysis for MED
Full Factor Report for MED
BROWN & BROWN, INC. (BRO) is a large-cap growth stock in the Insurance (Miscellaneous) industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Brown & Brown, Inc. is a diversified insurance agency, wholesale brokerage, insurance programs and service company. The Company markets and sells insurance products and services, in the property, casualty and employee benefits areas. The Company provides its customers with non-investment insurance contracts, as well as other customized risk management products and services. It operates through four segments: the Retail Segment, which provides a range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers; the National Programs Segment, which acts as a managing general agent, provides professional liability and related package products; the Wholesale Brokerage Segment, which markets and sells excess and surplus commercial and personal lines insurance, and the Services Segment, which provides insurance-related services, including third-party claims administration and medical utilization management services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BROWN & BROWN, INC.
Full Guru Analysis for BRO
Full Factor Report for BRO
TRUSTMARK CORP (TRMK) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Trustmark Corporation is a bank holding company. The Company's principal subsidiary is Trustmark National Bank (TNB). Through TNB and its subsidiaries, the Company operates as a financial services company providing banking and other financial solutions. It operates through three segments: General Banking, Wealth Management and Insurance. The General Banking Segment is responsible for all traditional banking products and services, including loans and deposits. The Wealth Management Segment provides customized solutions for customers by integrating financial services with traditional banking products and services, such as money management, full-service brokerage, financial planning, personal and institutional trust and retirement services. Through Fisher Brown Bottrell Insurance, Inc. (FBBI), a subsidiary of TNB, the Insurance Segment provides a range of retail insurance products, including commercial risk management products, bonding, group benefits and personal lines coverage.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of TRUSTMARK CORP
Full Guru Analysis for TRMK
Full Factor Report for TRMK
UMB FINANCIAL CORP (UMBF) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UMB Financial Corporation is a diversified financial holding company. The Company supplies banking services, institutional investment management, asset servicing and payment solutions to its customers in the United States and around the globe. The Company's segments include Bank, which provides a range of banking services to commercial, retail, government and correspondent bank customers through the Company's branches, call center, Internet banking and automated teller machine network; Institutional Investment Management, which provides equity and fixed income investment strategies in the intermediary and institutional markets, and Asset Servicing, which provides services to the asset management industry, supporting a range of investment products, including mutual funds, alternative investments and managed accounts. The Company's subsidiary includes UMB Fund Services, Inc. (UMBFS).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of UMB FINANCIAL CORP
Full Guru Analysis for UMBF
Full Factor Report for UMBF
CAMDEN NATIONAL CORPORATION (CAC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 89% to 97% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Camden National Corporation is a bank holding company. The Company is a diversified financial services provider. The primary business of the Company and its subsidiary, Camden National Bank (the Bank), is to attract deposits from, and to extend loans to, consumer, institutional, municipal, non-profit and commercial customers. The Company, through the Bank, offers commercial and consumer banking products and services, and through Camden Financial Consultants and Camden National Wealth Management, divisions of the Bank, brokerage and insurance services, as well as investment management and fiduciary services. The Bank is a national banking association. The Company had 61 banking centers, 84 automated teller machines and three lending offices as of December 31, 2016. The Company operates and manages the Bank's business within Maine's various regions, including Mid Coast, Southern, Central, Bangor and Downeast. Healthcare Professional Funding Corporation is a subsidiary of the Bank.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CAMDEN NATIONAL CORPORATION
Full Guru Analysis for CAC
Full Factor Report for CAC
QUANTA SERVICES INC (PWR) is a large-cap growth stock in the Construction Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quanta Services, Inc. is a provider of specialty contracting services, offering infrastructure solutions primarily to the electric power and oil and gas industries in the United States, Canada and Australia and selected other international markets. The Company operates through two segments: Electric Power Infrastructure Services, which provides network solutions to customers in the electric power industry, and Oil and Gas Infrastructure Services, which provides network solutions to customers involved in the development and transportation of natural gas, oil and other pipeline products. The services it provides include the design, installation, upgrade, repair and maintenance of infrastructure within each of the industries it serves, such as electric power transmission and distribution networks, substation facilities, renewable energy facilities, pipeline transmission and distribution systems and facilities, and infrastructure services for the offshore and inland water energy markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of QUANTA SERVICES INC
Full Guru Analysis for PWR
Full Factor Report for PWR
GUARANTY BANCSHARES, INC. (GNTY) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Guaranty Bancshares, Inc. is the holding company for Guaranty Bank & Trust (Guaranty). Guaranty offers various solutions, such as personal banking, business banking, mortgage and wealth management. Its personal banking solutions include checking accounts, which include compare accounts, green checking, student checking, choice checking, guaranty interest checking, order checks and debit cards; savings accounts, which include regular savings, premier money market, certificate of deposit, individual retirement account (IRA) options and health savings account, and online banking, which includes money desktop and e-statements. Guaranty offers various loans, including line of credit, small business administration loans and real estate loans. Guaranty also offers mobile banking solutions, mortgage warehouse lending solutions and treasury management solutions. It has approximately 30 bank locations in over 20 Texas communities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of GUARANTY BANCSHARES, INC.
Full Guru Analysis for GNTY
Full Factor Report for GNTY
HORIZON BANCORP INC (HBNC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Horizon Bancorp Inc, formerly Horizon Bancorp, is a bank holding company. The Company provides a range of banking services in Northern and Central Indiana and Southwestern and Central Michigan through its bank subsidiary, Horizon Bank, N.A. (the Bank) and other affiliated entities and Horizon Risk Management, Inc. The Company operates through commercial banking segment. The Bank is a full-service commercial bank offering commercial and retail banking services, corporate and individual trust and agency services and other services incident to banking. Horizon Risk Management, Inc. is a captive insurance company. LSB Risk Management, Inc. is a captive insurance company. As of September 1, 2017, the Bank operated through 60 offices throughout northern and central Indiana and southern Michigan and Ohio. The Bank's loan portfolio consists of commercial loans, real estate loans, mortgage warehouse loans and consumer loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HORIZON BANCORP INC
Full Guru Analysis for HBNC
Full Factor Report for HBNC
WILLIAMS-SONOMA, INC. (WSM) is a large-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Williams-Sonoma, Inc. is a specialty retailer of sustainable products for the home. The Company operates in the United States, Puerto Rico, Canada, Australia, and the United Kingdom. The Company offers international shipping worldwide and has franchisees stores in the Middle East, the Philippines, Mexico, South Korea, and India as well as e-commerce Websites. The Company's merchandise includes Williams Sonoma, Pottery Barn, Pottery Barn Kids, Pottery Barn Teen, West Elm, Williams Sonoma Home, Rejuvenation, and Mark and Graham, which sell its products through the Company's e-commerce Websites, direct-mail catalogs, and retail stores.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of WILLIAMS-SONOMA, INC.
Full Guru Analysis for WSM
Full Factor Report for WSM
SIMPSON MANUFACTURING CO, INC. (SSD) is a mid-cap growth stock in the Misc. Fabricated Products industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Simpson Manufacturing Co., Inc., through its subsidiary, Simpson Strong-Tie Company Inc. (SST), designs, engineers and manufactures wood construction products, including connectors, truss plates, fastening systems, fasteners and pre-fabricated lateral systems used in light-frame construction. The Company's segments are North America, Europe, Asia/Pacific, and Administrative & All Other. The North America segment includes operations primarily in the United States and Canada. The Europe segment includes operations primarily in France, the United Kingdom, Germany, Denmark, Switzerland, Portugal, Poland, the Netherlands and Belgium. The Asia/Pacific segment includes operations primarily in Australia, New Zealand, South Africa, China, Taiwan and Vietnam. The Company manufactures concrete construction products used for concrete, masonry, steel construction and for concrete repair, protection and strengthening, including adhesives, chemicals and mechanical anchors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SIMPSON MANUFACTURING CO, INC.
Full Guru Analysis for SSD
Full Factor Report for SSD
TORONTO-DOMINION BANK (TD) is a large-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 54% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Toronto-Dominion Bank (the Bank) operates as a bank in North America. The Company's segments include Canadian Retail, U.S. Retail, Wholesale Banking and corporate. Canadian Retail segment serves customers in the Canadian personal and commercial banking, wealth, and insurance businesses. Personal Banking provides financial products and advice through its network of automated teller machines (ATM), telephone, digital and mobile banking. U.S. Retail comprises the Bank's personal and business banking operations under the brand TD Bank and wealth management in the United States. Wholesale Banking offers a range of capital markets and corporate and investment banking services, including underwriting and distribution of new debt and equity issues, providing advice on strategic acquisitions and divestitures, and meeting the daily trading, funding, and investment needs of its clients.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of TORONTO-DOMINION BANK
Full Guru Analysis for TD
Full Factor Report for TD
ENCORE WIRE CORPORATION (WIRE) is a small-cap value stock in the Misc. Fabricated Products industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Encore Wire Corporation is a manufacturer of electrical building wire and cable. The Company is a supplier of building wire for interior electrical wiring in commercial and industrial buildings, homes, apartments, and manufactured housing. The Company manufactures electric building wire, principally NM-B cable, for use primarily as interior wiring in homes, apartments and manufactured housing, and THHN/THWN-2 cable and metal-clad and armored cable for use primarily as wiring in commercial and industrial buildings. It offers an electrical building wire product line that consists primarily of UF-B cable and other types of wire products, including metal-clad and armored cable. All of these products are manufactured with copper or aluminum as the conductor. NM-B cable consists of either two or three insulated copper wire conductors, with an uninsulated ground wire, all sheathed in a polyvinyl chloride (PVC) jacket.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ENCORE WIRE CORPORATION
Full Guru Analysis for WIRE
Full Factor Report for WIRE
FIRST FINANCIAL CORP (THFF) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Financial Corporation is a financial holding company. The Company, through its subsidiaries, offers financial services, including commercial, mortgage and consumer lending, lease financing, trust account services, depositor services and insurance services. The Company's subsidiaries include First Financial Bank, N.A. (the Bank), The Morris Plan Company of Terre Haute (Morris Plan), First Chanticleer Corporation and FFB Risk Management Co., Inc. The Bank has two investment subsidiaries, Portfolio Management Specialists A (Specialists A) and Portfolio Management Specialists B (Specialists B), which holds and manages certain assets to manage various income streams and provides opportunities for capital creation as needed. The Bank's loan portfolio includes commercial loans, residential loans and consumer loans. Its deposits include non-interest-bearing demand deposits, interest-bearing demand deposits, savings deposits, time deposits: $100,000 or more, and other time deposits.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FIRST FINANCIAL CORP
Full Guru Analysis for THFF
Full Factor Report for THFF
GERMAN AMERICAN BANCORP., INC. (GABC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: German American Bancorp, Inc. is a bank holding company. The Company, through its banking subsidiary German American Bank, operates approximately 74 banking offices in 20 contiguous southern Indiana counties and six counties in Kentucky. Its segments are core banking, trust and investment advisory services, insurance, and other. The core banking segment involves attracting deposits from the general public and using such funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans, primarily in its local markets. The core banking segment also involves the sale of residential mortgage loans in the secondary market. The trust and investment advisory services segment involves providing trust, investment advisory, and brokerage services to customers. The insurance segment offers a range of personal and corporate property and casualty insurance products, in its banking subsidiary's local markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of GERMAN AMERICAN BANCORP., INC.
Full Guru Analysis for GABC
Full Factor Report for GABC
HAVERTY FURNITURE COMPANIES, INC. (HVT) is a small-cap value stock in the Furniture & Fixtures industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Haverty Furniture Companies, Inc. is a retailer of residential furniture and accessories. The Company sells home furnishings in its retail stores and through its Website, havertys.com. As of December 31, 2016, the Company had 124 stores in 16 states in the Southern and Midwest regions. As of December 31, 2016, the Company's retail store space totaled approximately 4.5 million square feet for 124 stores. It also offers financing through a third-party finance company, as well as an internal revolving charge credit plan. The Company's retail locations are operated using the Havertys name. It offers mattress product lines, such as Sealy, Tempur-Pedic, Serta, Stearns & Foster and Beautyrest Black. The Company's customers are college educated women in middle to upper-middle income households. The Company stores are located in areas, including Florida, Texas, North Carolina, Tennessee and Maryland.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HAVERTY FURNITURE COMPANIES, INC.
Full Guru Analysis for HVT
Full Factor Report for HVT
HORACE MANN EDUCATORS CORPORATION (HMN) is a small-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Horace Mann Educators Corporation (HMEC) is an insurance holding company. Through its subsidiaries, HMEC markets and underwrites personal lines of property and casualty (primarily personal lines automobile and homeowners) insurance, retirement annuities (primarily tax-qualified products) and life insurance in the United States. The Company's operating segments include Property and Casualty segment, comprising primarily personal lines automobile and homeowners products; Retirement segment, comprising primarily tax-qualified fixed and variable annuities; Life segment life insurance, and Corporate and Other. It markets and services its products through a sales force of full-time agents supported by its Customer Contact Center. These agents sell HMEC's products and limited additional third-party vendor products. As of December 31, 2016, its property and casualty subsidiaries and its life insurance subsidiary were licensed to write business in over 48 states and the District of Columbia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HORACE MANN EDUCATORS CORPORATION
Full Guru Analysis for HMN
Full Factor Report for HMN
CAPITAL SOUTHWEST CORPORATION (CSWC) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Capital Southwest Corporation is an investment company that specializes in providing customized financing to middle market companies in a range of industry segments located primarily in the United States. The Company is a specialty lending company. Its principal investment objective is to produce risk-adjusted returns by generating current income from debt investments and capital appreciation from its equity and equity related investments. It focuses on partnering with business owners, management teams and financial sponsors to provide financing solutions to fund growth, changes of control, or other corporate events. In allocating future investments, it focuses on investing in senior and subordinated debt securities secured by security interests in portfolio company assets, coupled with equity interests. It targets senior and subordinated investments in the lower middle market and private loan transactions, as well as first and second lien syndicated loans in middle market companies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CAPITAL SOUTHWEST CORPORATION
Full Guru Analysis for CSWC
Full Factor Report for CSWC
CLEAN HARBORS INC (CLH) is a mid-cap growth stock in the Waste Management Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Clean Harbors, Inc. is a provider of environmental, energy and industrial services throughout North America. The Company is also a re-refiner and recycler of used oil in the world and a provider of parts cleaning and related environmental services to commercial, industrial and automotive customers in North America. The Company operates in six segments: Technical Services, Industrial Services, Field Services, Safety-Kleen, Oil and Gas Field Services, and Lodging Services. The Company is also a service provider in the recovery and decontamination of pollutants. The Company provides services to protect the ozone layer from the effects of chlorofluorocarbons (CFCs). It offers brands, such as Performance Plus brand and green brand EcoPower. The Company also offers CleanPack services, which include the collection, identification and categorization, packaging, transportation and disposal of laboratory chemicals and household hazardous waste. It also provides hydro excavation services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CLEAN HARBORS INC
Full Guru Analysis for CLH
Full Factor Report for CLH
CREDIT ACCEPTANCE CORP. (CACC) is a large-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Credit Acceptance Corporation offers financing programs that enable automobile dealers to sell vehicles to consumers. The Company's financing programs are offered through a network of automobile dealers. The Company has two Dealers financing programs: the Portfolio Program and the Purchase Program. Under the Portfolio Program, the Company advances money to dealers (Dealer Loan) in exchange for the right to service the underlying consumer loans. Under the Purchase Program, the Company buys the consumer loans from the dealers (Purchased Loan) and keeps the amounts collected from the consumer. Dealer Loans and Purchased Loans are collectively referred to as Loans. As of December 31, 2016, the Company's target market included approximately 60,000 independent and franchised automobile dealers in the United States. The Company has market area managers located throughout the United States that market its programs to dealers, enroll new dealers and support active dealers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CREDIT ACCEPTANCE CORP.
Full Guru Analysis for CACC
Full Factor Report for CACC
AFLAC INCORPORATED (AFL) is a large-cap value stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Aflac Incorporated is a holding company. The Company is involved in supplemental health and life insurance, which is marketed and administered through its subsidiary, American Family Life Assurance Company of Columbus (Aflac). The Company's insurance business consists of two segments: Aflac Japan and Aflac U.S. Aflac Japan are designed to help consumers pay for medical and non-medical costs that are not reimbursed under Japan's national health insurance system. It offers insurance products, such as cancer, medical, and income support insurance. Its protection products include whole life, GIFT, and WAYS and Child Endowment. The Company designs the United States insurance products to provide supplemental coverage for people having medical or primary insurance coverage. Aflac U.S. offers accident coverage on both an individual and group basis. It offers cancer plans, critical illness plans, and critical care and recovery plans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AFLAC INCORPORATED
Full Guru Analysis for AFL
Full Factor Report for AFL
ALLEGHANY CORPORATION (Y) is a mid-cap value stock in the Insurance (Life) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Alleghany Corporation is an insurance holding company. The Company, through its subsidiary Alleghany Insurance Holdings LLC (AIHL) and its subsidiaries, is engaged in the property and casualty insurance business. AIHL's insurance operations are conducted by its subsidiaries RSUI Group, Inc. (RSUI), CapSpecialty, Inc. (CapSpecialty) and Pacific Compensation Corporation (PacificComp). Its segments include reinsurance and insurance. Its reinsurance segment consists of property and casualty reinsurance operations conducted by Transatlantic Holdings, Inc. reinsurance operating subsidiaries. Its insurance segment consists of property and casualty insurance operations conducted by AIHL through its insurance operating subsidiaries RSUI, CapSpecialty and PacificComp. AIHL Re LLC, which is a captive reinsurance company, provides reinsurance to its insurance operating subsidiaries and affiliates.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ALLEGHANY CORPORATION
Full Guru Analysis for Y
Full Factor Report for Y
AMEDISYS INC (AMED) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Amedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. The Company owns and operates approximately 524 centers in 39 states and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness, such as heart disease, pulmonary disease, Alzheimer's and Human Immunodeficiency Virus (HIV)/Acquired Immuno Deficiency Syndrome (AIDS). The Personal care segment provides patients with assistance with the essential activities of daily living.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AMEDISYS INC
Full Guru Analysis for AMED
Full Factor Report for AMED
ARROW FINANCIAL CORPORATION (AROW) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Arrow Financial Corporation (Arrow) is a bank holding company. The Company's banking subsidiaries are Glens Falls National Bank and Trust Company (Glens Falls National) and Saratoga National Bank and Trust Company (Saratoga National). It operates in community banking industry segment. The Company's business consists primarily of the ownership, supervision and control of its two banks. It provides advisory and administrative services and coordinates the general policies and operation of the banks. The Company offers a range of commercial and consumer banking, and financial products. Its deposit base consists of deposits derived from the communities it serves. Through its banks' trust operations, the Company provides retirement planning, trust and estate administration services for individuals, and pension, profit-sharing and employee benefit plan administration for corporations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ARROW FINANCIAL CORPORATION
Full Guru Analysis for AROW
Full Factor Report for AROW
BALL CORPORATION (BLL) is a large-cap growth stock in the Containers & Packaging industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ball Corporation is focused on suppling aluminum packaging for the beverage, personal care and household products industries. The Company's sustainable and aluminum packaging products are produced for a various of end uses and are manufactured in facilities worldwide. It also provides aerospace and other technologies and services to governmental and commercial customers within its aerospace segment. The Company's segments include beverage packaging, North and Central America; beverage packaging, Europe, Middle East and Africa (beverage packaging, EMEA); beverage packaging, South America and aerospace. The Company produces spacecraft, instruments and sensors, radio frequency systems and components, data exploitation solutions and a range of advanced technologies and products that enable weather prediction and climate change monitoring.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BALL CORPORATION
Full Guru Analysis for BLL
Full Factor Report for BLL
SELECTIVE INSURANCE GROUP INC (SIGI) is a mid-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Selective Insurance Group, Inc. is a holding company. As of December 31, 2016, the Company had 10 insurance subsidiaries, nine of which were licensed by various state departments of insurance to write specific lines of property and casualty insurance business. The remaining subsidiary is authorized by various state insurance departments to write property and casualty insurance in the excess and surplus lines (E&S) market. Its segments include Standard Commercial Lines, which consists of insurance products and services provided in the standard marketplace; Standard Personal Lines, which consists of insurance products and services, including flood insurance coverage that it writes through the National Flood Insurance Program (NFIP); E&S Lines, which consists of insurance products and services provided to customers not obtaining coverage in the standard marketplace, and investment segment invests insurance premiums, as well as amounts generated through its capital management strategies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SELECTIVE INSURANCE GROUP INC
Full Guru Analysis for SIGI
Full Factor Report for SIGI
MICROSOFT CORPORATION (MSFT) is a large-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Microsoft Corporation is a technology company. The Company develops and supports a range of software products, services, devices, and solutions. The Company's segments include Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Company's products include operating systems; cross-device productivity applications; server applications; business solution applications; desktop and server management tools; software development tools; and video games. It also designs, manufactures, and sells devices, including personal computers (PCs), tablets, gaming and entertainment consoles, other intelligent devices, and related accessories. It offers an array of services, including cloud-based solutions that provide customers with software, services, platforms, and content, and it provides solution support and consulting services. It markets and distributes its products and services through original equipment manufacturers, direct, and distributors and resellers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MICROSOFT CORPORATION
Full Guru Analysis for MSFT
Full Factor Report for MSFT
ORACLE CORPORATION (ORCL) is a large-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Oracle Corporation (Oracle) provides products and services that address enterprise information technology (IT) environments. The Company's businesses include cloud and license, hardware and services. Its products and services include applications and infrastructure offerings that are delivered through a variety of IT deployment models. Its customers include government agencies, educational institutions and resellers. Using Oracle technologies, its customers build, deploy, run, manage and support their internal and external products, services and business operations. Its Oracle Cloud Services offerings includes Oracle Software as a Service (SaaS) and Oracle infrastructure as a service (IaaS) offering, which provides a stack of applications and infrastructure services delivered via cloud-based deployment models. Oracle Cloud Services integrate the software, hardware and services on a customer's behalf in a cloud-based IT environment.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ORACLE CORPORATION
Full Guru Analysis for ORCL
Full Factor Report for ORCL
T ROWE PRICE GROUP INC (TROW) is a large-cap growth stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: T. Rowe Price Group, Inc. is a financial services holding company. The Company provides global investment management services through its subsidiaries to investors across the world. It provides a range of United States mutual funds, sub advised funds, separately managed accounts, collective investment trusts, and other products, which include open-ended investment products offered to investors outside the United States and products offered through variable annuity life insurance plans in the United States. The Company distributes its products in countries located within three geographical regions: Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). It also offers specialized advisory services, including management of stable value investment contracts and a distribution management service for the disposition of equity securities its clients receive from third-party venture capital investment pools. It serves clients in approximately 51 countries across the world.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of T ROWE PRICE GROUP INC
Full Guru Analysis for TROW
Full Factor Report for TROW
SOUTH PLAINS FINANCIAL INC (SPFI) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: South Plains Financial Inc. is a bank holding company for City bank (the Bank). The Bank provides wide range of commercial and consumer financial services to small and medium-sized businesses and individuals in its market areas. Its principal business activities include commercial and retail banking, along with insurance, investment, trust and mortgage services. The Bank operates 26 branch offices and 13 production offices both in banking markets and in certain areas that primarily focus on mortgage loan production. The Bank operates through two reportable segments: banking and insurance.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SOUTH PLAINS FINANCIAL INC
Full Guru Analysis for SPFI
Full Factor Report for SPFI
BAIN CAPITAL SPECIALTY FINANCE INC (BCSF) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bain Capital Specialty Finance, Inc. is a managed specialty finance company focused on lending to middle market companies. The fund seeks to invest in senior investments with a first or second lien on collateral, senior first lien, stretch senior, senior second lien, unitranche, mezzanine debt, junior securities, other junior investments, and secondary purchases of assets or portfolios that primarily consist of middle-market corporate debt. The Company's investment portfolio also includes corporate bonds, investment vehicles, equity interest, and preferred equity. It focuses on structuring, monitoring, and managing each of its current and prospective portfolio company investments. The Company also draws on the broader capabilities within Bain Capital's platform of investment professionals around the world.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BAIN CAPITAL SPECIALTY FINANCE INC
Full Guru Analysis for BCSF
Full Factor Report for BCSF
UFP INDUSTRIES INC (UFPI) is a mid-cap value stock in the Forestry & Wood Products industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UFP Industries, Inc., formerly Universal Forest Products, Inc., is a holding company. The Company, through its subsidiaries, supplies wood, wood composite and other products to three primary markets, such as retail, construction and industrial. Its segments include North, South, West, Alternative Materials, International, idX Holdings, Inc. (idX) and Corporate divisions. idX is a designer, manufacturer and installer of in-store environments. It designs, manufactures and markets wood and wood-alternative products for national home centers and other retailers; structural lumber and other products for the manufactured housing industry; engineered wood components for residential and commercial construction; specialty wood packaging, components and packing materials for various industries, and customized interior fixtures used in a range of retail stores, commercial and other structures.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of UFP INDUSTRIES INC
Full Guru Analysis for UFPI
Full Factor Report for UFPI
RATTLER MIDSTREAM LP (RTLR) is a small-cap value stock in the Oil Well Services & Equipment industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Rattler Midstream LP provides crude oil, natural gas and water-related midstream services to Diamondback Energy, Inc. (Diamondback). The Company's services include fresh water services, saltwater disposal services, crude oil gathering, natural gas gathering and real estate contracts. The Company owns, operates, develops and acquires midstream infrastructure assets in the Midland and Delaware Basins of the Permian. The Company operates through two segments: midstream services and real estate operations. The Company owned and operated 781 miles of pipeline across the Midland and Delaware Basins with approximately 232,000 barrels per day (Bbl/d) of crude oil gathering capacity, 2.720 million Bbl/d of saltwater disposal, or SWD, capacity, 575,000 Bbl/d of fresh water gathering capacity, 80,000 thousand cubic feet per day (Mcf/d) of natural gas compression capability and 150,000 Mcf/d of natural gas gathering capacity.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of RATTLER MIDSTREAM LP
Full Guru Analysis for RTLR
Full Factor Report for RTLR
IAA INC (IAA) is a mid-cap growth stock in the Retail (Specialty) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: IAA, Inc. is a provider of auction solutions for total loss, damaged and low-value vehicles. The Company facilitates the sale of total loss, damaged and low-value vehicles for a range of sellers, including insurance companies, dealerships, rental car companies, fleet lease companies and charitable organizations. Its solutions provide buyers with the vehicles they need to fulfill their vehicle rebuild requirements, replacement part inventory or scrap demand. Its services include CSAToday, IAA Market Value, Mobile Vehicle Assignment, BidFast, Catastrophe (CAT) Services, Multi-Channel Auction Model, i-Bid LIVE, IAA Buy Now and IAA Screen Sale. The Company operates as Insurance Auto Auctions, Inc. (IAA) in the United States, Impact Auto Auctions Ltd in Canada and HBC Vehicle Services Limited (HBC) in the United Kingdom.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of IAA INC
Full Guru Analysis for IAA
Full Factor Report for IAA
HARBORONE BANCORP INC (HONE) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: HarborOne Bancorp, Inc is the bank holding company for HarborOne Bank. The Bank serves the financial needs of consumers, businesses, and municipalities throughout Eastern Massachusetts and Rhode Island through a network of over 26 full-service branches located in Massachusetts and Rhode Island, and a commercial lending office in each of Boston, Massachusetts and Providence, Rhode Island. The Bank also provides a range of educational services through HarborOne U, with classes on small business, financial literacy and personal enrichment at two campuses located adjacent to its Brockton and Mansfield locations. HarborOne Mortgage, LLC, a subsidiary of HarborOne Bank, is a full-service mortgage lender with more than 30 offices in Massachusetts, Rhode Island, New Hampshire, Maine, New Jersey and Florida.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HARBORONE BANCORP INC
Full Guru Analysis for HONE
Full Factor Report for HONE
BANCO BBVA ARGENTINA SA (ADR) (BBAR) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 69% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Banco Bbva Argentina SA, formerly known as BBVA French Bank, is an Argentina-based banking institution. Through its banking platform, the Bank provides a broad range of financial and non-financial services to both individuals and companies. It manages three business lines: Retail Banking, Small and Medium-Sized Companies and Corporate and Investment Banking (C&IB). Retail Banking offers checking and savings accounts, time deposits, credit cards, loans, mortgages, insurance and investment products, among others. Small and Medium-Sized Companies targets local private-sector companies providing financing products, factoring, checking accounts, time deposits, transactional and payroll services, insurance and investment products, among others. C&IB offers financial services to corporations and multinational companies, as well as global transaction services, global markets solutions, long term financing, among others. The Bank is active locally, mostly.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BANCO BBVA ARGENTINA SA (ADR)
Full Guru Analysis for BBAR
Full Factor Report for BBAR
CARLYLE GROUP INC (CG) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Carlyle Group Inc., formerly The Carlyle Group L.P., is a diversified multi-product global alternative asset management firm. The Company advises on various investment funds and other investment vehicles that invests across a range of industries, geographies, asset classes and investment strategies, and seeks to deliver returns for its fund investors. The Company operates in four segments: Corporate Private Equity (CPE), Real Assets, Global Credit and Investment Solutions. The Corporate Private Equity segment is comprised of the operations that advise a diverse group of funds that invest in buyout, middle market and growth capital transactions that focus on either a geography or a particular industry. The Real Assets segment is comprised of the operations that advise United States and international funds focused on real estate, infrastructure, energy and renewable energy transactions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CARLYLE GROUP INC
Full Guru Analysis for CG
Full Factor Report for CG
FIRST REPUBLIC BANK (FRC) is a large-cap growth stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Republic Bank (the Bank) is a commercial bank and trust company. The Bank specializes in providing services, including private banking, private business banking, real estate lending and wealth management services, including trust and custody services, to clients in selected metropolitan areas in the United States. It operates through two segments: Commercial Banking and Wealth Management. The principal business activities of the Commercial Banking segment are gathering deposits, originating and servicing loans and investing in investment securities. The principal business activities of the Wealth Management segment include the investment management activities of First Republic Investment Management, Inc. (FRIM), which manages investments for individuals and institutions; money market mutual fund activities through third-party providers and the brokerage activities of First Republic Securities Company, LLC (FRSC) and its foreign exchange activities conducted on behalf of clients.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FIRST REPUBLIC BANK
Full Guru Analysis for FRC
Full Factor Report for FRC
MANNING AND NAPIER INC (MN) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Manning & Napier, Inc. (Manning & Napier) is an independent investment management firm. The Company provides its clients with a range of financial solutions and investment strategies, including wealth management services. The Company's investment strategies are powered by multiple research engines, employing fundamental and quantitative approaches, and are offered as both single- and multi-asset class portfolios. The Company provides investment management services to separately managed accounts, mutual funds and collective investment trust funds. The Company's separate accounts are primarily distributed through wealth management sales channel, where its financial consultants form relationships with high-net-worth individuals, endowments, foundations, and retirement plans. Its mutual funds and collective investment trusts are primarily distributed through financial intermediaries, including brokers, financial advisors, retirement plan advisors and platform relationships.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MANNING AND NAPIER INC
Full Guru Analysis for MN
Full Factor Report for MN
HANMI FINANCIAL CORP (HAFC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Hanmi Financial Corporation is the holding company for Hanmi Bank (the Bank). The Bank is a community bank conducting general business banking, with its primary market encompassing the Korean-American community, as well as other ethnic communities across California, Colorado, Georgia, Illinois, New York, Texas, Virginia and Washington. The Bank's client base reflects the multi-ethnic composition of these communities. The Bank maintains a branch network of full-service branch offices in California, Illinois, New Jersey, New York, Texas and Virginia, and loan production offices in California, Colorado, Texas, Virginia and Washington State. Its lending activities include real estate loans (commercial property, construction and residential property), commercial and industrial loans (commercial term loans, commercial lines of credit and international), and consumer loans and small business administration (SBA) loans. Its revenues are derived from interest and fees on its loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HANMI FINANCIAL CORP
Full Guru Analysis for HAFC
Full Factor Report for HAFC
HOMESTREET INC (HMST) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: HomeStreet, Inc. is a financial services company serving customers primarily in the western United States, including Hawaii. The Company is principally engaged in real estate lending, including mortgage banking activities, and commercial and consumer banking. The Company's operating segments include Commercial and Consumer Banking, and Mortgage Banking. It provides financial products and services to its commercial and consumer customers through retail deposit branches and commercial lending centers, automated teller machines (ATMs), and online, mobile and telephone banking. The Company originates single family residential mortgage loans for sale in the secondary markets. Its mortgage loans are sold to or securitized by Fannie Mae, The Federal Home Loan Mortgage Corporation (Freddie Mac) or The Government National Mortgage Association (Ginnie Mae), while it retains the right to service these loans. It also provides insurance products and services for consumers and businesses.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HOMESTREET INC
Full Guru Analysis for HMST
Full Factor Report for HMST
ARES COMMERCIAL REAL ESTATE CORP (ACRE) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ares Commercial Real Estate Corporation is a specialty finance company. The Company is primarily engaged in originating and investing in commercial real estate (CRE) loans and related investments. The Company operates through principal lending segment. Its target investments include senior mortgage loans, subordinated debt, preferred equity, mezzanine loans and other CRE investment opportunities, including commercial mortgage-backed securities. These investments are generally held for investment and are secured, directly or indirectly, by office, multifamily, retail, industrial, lodging, senior-living, self-storage and other commercial real estate properties, or by ownership interests therein. Through the Company's manager, Ares Commercial Real Estate Management LLC, it has investment professionals located across the United States and Europe who directly source loan opportunities for the Company with owners, operators and sponsors of CRE properties.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ARES COMMERCIAL REAL ESTATE CORP
Full Guru Analysis for ACRE
Full Factor Report for ACRE
FACEBOOK INC (FB) is a large-cap growth stock in the Computer Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Facebook, Inc. is focused on building products that enable people to connect and share through mobile devices, personal computers virtual reality headsets, and in-home devices. The Company's products include Facebook, Instagram, Messenger, WhatsApp and Facebook Reality Labs. Facebook enables people to connect, share, discover and communicate with each other on mobile devices and personal computers. Instagram is a place where people can express themselves through photos, videos, and private messaging, and connect with and shop from their favorite businesses and creators. Messenger is a messaging application for people to connect with friends, family, groups, and businesses across platforms and devices. WhatsApp is a messaging application that is used by people around the world to communicate and transact in a private way. Its Facebook Reality Labs offers augmented and virtual reality products, which include Oculus virtual reality technology and content platform.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FACEBOOK INC
Full Guru Analysis for FB
Full Factor Report for FB
POPULAR INC (BPOP) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Popular, Inc. (Popular) is a financial holding company. The Company operates in two segments: Banco Popular de Puerto Rico (BPPR), which includes its Puerto Rico business, and Banco Popular North America (BPNA), which includes its the United States mainland business. The Company has operations in Puerto Rico, the United States and the Caribbean. The Company's BPPR segment provides retail, mortgage and commercial banking services through its banking subsidiary, Banco Popular de Puerto Rico, as well as auto and equipment leasing and financing, investment banking, broker-dealer and insurance services through specialized subsidiaries. The Company's BPNA segment consists of Popular North America, Inc. (PNA) functioning as the holding company for its operations in the United States. It also operates PNA's subsidiary, E-LOAN, Inc. The banking operations of BPNA in the United States mainland are based in New York, Florida and New Jersey, conducted under the name of Popular Community Bank.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of POPULAR INC
Full Guru Analysis for BPOP
Full Factor Report for BPOP
NATIONAL BANK HOLDINGS CORP (NBHC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: National Bank Holdings Corporation is a bank holding company. The Company's primary operations are conducted through its subsidiary, NBH Bank (the Bank), through which it provides a range of banking products to both commercial and consumer clients. Through NBH Bank, it operates under the brand names: Bank Midwest in Kansas and Missouri; Community Banks of Colorado in Colorado, and Hillcrest Bank in Texas. In addition to traditional banking activities, it provides an array of treasury management solutions to its clients, including online and mobile banking, wire transfers, automated clearing house services, electronic bill payment, lock box services, remote deposit capture services, merchant processing services, cash vault, controlled disbursements, positive pay and other auxiliary services (including account reconciliation, collections, repurchase accounts, zero balance accounts and sweep accounts).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of NATIONAL BANK HOLDINGS CORP
Full Guru Analysis for NBHC
Full Factor Report for NBHC
SHUTTERSTOCK INC (SSTK) is a mid-cap growth stock in the Motion Pictures industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Shutterstock, Inc. (Shutterstock) is a global technology company that operates a two-sided marketplace for professionals to license content. The Company's library of content includes digital imagery, which consists of licensed photographs, vectors, illustrations and video clips that customers use in their visual communications, such as Websites, digital and print marketing materials, corporate communications, books, publications and video content, and commercial music, which consists of music tracks and sound effects and which is often used to complement digital imagery. It also offers digital asset management services through its cloud-based digital asset management platform (webdam). Its global marketplace brings together users and contributors of content by providing a collection of content its customers can pay to license and incorporate into their work and by compensating contributors as their content is licensed to customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SHUTTERSTOCK INC
Full Guru Analysis for SSTK
Full Factor Report for SSTK
LIVE OAK BANCSHARES INC (LOB) is a mid-cap growth stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Live Oak Bancshares, Inc. is a bank holding company. The Company conducts business operations primarily through its commercial bank subsidiary, Live Oak Banking Company (the Bank). The Bank specializes in providing lending services to small businesses nationwide in targeted industries. The loans originated by the Bank are guaranteed by the small business administration (SBA). The Company's loan portfolio includes commercial and industrial loans; construction and development loans; commercial real estate, and commercial land. The Company's investment securities include the United States Government agencies, residential mortgage-backed securities and mutual fund. The Company's deposits include non-interest-bearing deposits and interest-bearing deposits, such as interest-bearing checking, money market and time deposits.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of LIVE OAK BANCSHARES INC
Full Guru Analysis for LOB
Full Factor Report for LOB
HOULIHAN LOKEY INC (HLI) is a mid-cap growth stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Houlihan Lokey, Inc. is a global independent investment bank that focuses on mergers and acquisitions (M&A), capital markets, financial restructuring, valuation, and strategic consulting. The Company operates through three segments: Corporate Finance, Financial Restructuring and Financial and Valuation Advisory. The Company provides financial professionals with an integrated platform that enables them to deliver advice to its clients. The Corporate Finance activities include two categories: M&A and capital markets advisory. The Financial and Valuation Advisory segment includes financial opinions, and a range of valuation and financial consulting services in the United States. It also provides strategic consulting services to clients. The Financial Restructuring segment provides advice to debtors and creditors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HOULIHAN LOKEY INC
Full Guru Analysis for HLI
Full Factor Report for HLI
ALLEGIANCE BANCSHARES INC (ABTX) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Allegiance Bancshares, Inc. is a bank holding company. Through its subsidiary, Allegiance Bank (the Bank), the Company provides a range of commercial banking services primarily to Houston metropolitan area-based small to medium-sized businesses, professionals and individual customers. In addition to banking during normal business hours, the Company offers extended drive-in hours, automated teller machines (ATMs) and banking by telephone, mail and Internet. The Company also provides debit card services, cash management services and wire transfer services, and offers night depository, direct deposits, cashier's checks, letters of credit and mobile deposits. It also offers safe deposit boxes, automated teller machines, drive-in services and round the clock depository facilities. The Company maintains an Internet banking Website that allows customers to obtain account balances and transfer funds among accounts.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ALLEGIANCE BANCSHARES INC
Full Guru Analysis for ABTX
Full Factor Report for ABTX
ALPHABET INC (GOOGL) is a large-cap growth stock in the Computer Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Alphabet Inc. is a holding company. The Company's segments include Google and Other Bets. The Company's Google segment includes Google Services and Google Cloud. Its Google Services products and platforms include Android, Chrome, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. Its Google Cloud provides enterprise-ready cloud services, including Google Cloud Platform and Google Workspace. Its Google Cloud Platform enables developers to build, test, and deploy applications on its infrastructure. Its Google Workspace collaboration tools include applications like Gmail, Docs, Drive, Calendar, Meet. The Google segment is engaged in advertising, sales of digital content, applications and cloud offerings. Its hardware products include Pixel phones, Chromecast with Google TV and the Google Nest Hub smart display. The Other Bets segment is engaged in the sales of Internet and television services, licensing and research and development (R&D) services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ALPHABET INC
Full Guru Analysis for GOOGL
Full Factor Report for GOOGL
WILLIS TOWERS WATSON PLC (WLTW) is a large-cap growth stock in the Insurance (Miscellaneous) industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Willis Towers Watson Public Limited Company (Willis Towers Watson) is a holding company. The Company operates as a global advisory, broking and solutions company. It is engaged in offering risk management, insurance broking, consulting, technology and solutions, and private exchanges. The Company operates through eight segments: Willis International; Willis North America; Willis Capital, Wholesale & Reinsurance (CWR); Willis GB; Towers Watson Benefits; Towers Watson Exchange Solutions; Towers Watson Risk and Financial Services; and Towers Watson Talent and Rewards. The Willis GB segment comprises four business units: Property and Casualty, Transport, Financial Lines and Retail Networks. The Willis Capital Wholesale and Reinsurance segment includes Willis Re; Willis Capital Markets & Advisory; Willis' wholesale business, and Willis Portfolio Underwriting Services. The Willis North America segment provides risk management, insurance brokerage and related risk services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of WILLIS TOWERS WATSON PLC
Full Guru Analysis for WLTW
Full Factor Report for WLTW
ATKORE INC (ATKR) is a mid-cap value stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Atkore Inc., formerly Atkore International Group Inc., is a manufacturer of electrical raceway products. The Company operates in two segments: Electrical segment and Safety and Infrastructure segment. Through the electrical segment, it manufactures products that deploy, isolate and protect a structure's electrical circuitry from the original power source to the final outlet. The Company's electrical segment products are used in the construction of electrical power systems including conduit, cable, and installation accessories. Its Safety and Infrastructure segment designs and manufactures solutions, including metal framing, mechanical pipe, perimeter security and cable management for the protection and reliability of critical infrastructure. The Company's products are primarily offered for non-residential construction and renovation markets, and safety and infrastructure solutions for the construction and industrial markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ATKORE INC
Full Guru Analysis for ATKR
Full Factor Report for ATKR
MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MEDPACE HOLDINGS INC
Full Guru Analysis for MEDP
Full Factor Report for MEDP
FNCB BANCORP INC (FNCB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FNCB Bancorp Inc. is a bank holding company for First National Community Bank (the Bank). The Company's primary activity consists of owning and operating the Bank, which provides customary retail and commercial banking services to individuals and businesses. The Bank's operations are conducted from over 17 full-service branch offices. The Bank provides a range of traditional banking products and services to individuals and businesses, including online, mobile and telephone banking, debit cards, check imaging and electronic statements. Deposit products include various checking, savings and certificate of deposit products, as well as a line of preferred products for higher-balance customers. The Bank offers its retail and business customers several overdraft protection products including bounce protection, instant money and transfers from another FNCB checking or savings account.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FNCB BANCORP INC
Full Guru Analysis for FNCB
Full Factor Report for FNCB
JANUS HENDERSON GROUP PLC (JHG) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Janus Henderson Group PLC is an independent global asset manager. The Company specializes in active investment across all asset classes. It operates through the investment management business segment. It manages a broad range of investment products for institutional and retail investors across five capabilities: Equities, Quantitative Equities, Fixed Income, Multi-Asset and Alternatives. It operates across various product lines, distribution channels and geographic regions. Its regional focus includes United States, Europe, Asia and Australia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of JANUS HENDERSON GROUP PLC
Full Guru Analysis for JHG
Full Factor Report for JHG
KNIGHT-SWIFT TRANSPORTATION HOLDINGS INC (KNX) is a mid-cap growth stock in the Trucking industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Knight-Swift Transportation Holdings Inc., formerly Swift Transportation Company, provides truckload services in North America. The Company also provides rail intermodal and non-asset based freight brokerage and logistics management services. The Company provides its services across United States, Mexico and Canada using its dry van, refrigerated, flatbed and specialized trailers, and intermodal containers. As of September 10, 2017, the Company had a fleet of approximately 23,000 tractors and 77,000 trailers. It operates through its Knight Transportation, Swift Transportation, and Barr-Nunn branded subsidiaries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of KNIGHT-SWIFT TRANSPORTATION HOLDINGS INC
Full Guru Analysis for KNX
Full Factor Report for KNX
METROPOLITAN BANK HOLDING CORP (MCB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Metropolitan Bank Holding Corp. is a bank holding company. Through its subsidiary, Metropolitan Commercial Bank, the Bank provides a range of business, commercial and retail banking products and services to small businesses, middle-market enterprises, public entities and affluent individuals in the New York metropolitan area. In addition to the traditional commercial banking products, it offers cash management and retail banking services. The Bank also serve as an issuing bank for debit card programs nationwide. The Bank's products and services include lending products and services and retail product and services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of METROPOLITAN BANK HOLDING CORP
Full Guru Analysis for MCB
Full Factor Report for MCB
RELIANT BANCORP INC (RBNC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Reliant Bancorp, Inc., formerly Commerce Union Bancshares, Inc., serves as the bank holding company for Reliant Bank. The Company has two segments: Retail Banking and Residential Mortgage Banking. Retail Banking provides deposit and lending services to consumer and business customers within its primary geographic markets. Its customers are serviced through branch locations, automated teller machines (ATMs), online banking and mobile banking. Residential Mortgage Banking originates first lien residential mortgage loans throughout the United States. These loans are typically underwritten to government agency standards and sold to third-party secondary market mortgage investors. Reliant Bank provides a range of traditional banking services throughout the Middle Tennessee Region and the Nashville-Davidson-Murfreesboro-Franklin Metropolitan Statistical Area. Reliant Bank provides commercial banking services for businesses and individuals.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of RELIANT BANCORP INC
Full Guru Analysis for RBNC
Full Factor Report for RBNC
LEVEL ONE BANCORP INC (LEVL) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Level One Bancorp, Inc is a bank holding company operating through its wholly owned subsidiary, Level One Bank. The Bank offers a comprehensive range of loan products to residential and commercial markets, as well as retail and business banking services. The Bank operates over 17 offices, including 11 full-service banking centers in Metro Detroit, one banking center in Grand Rapids, one banking center in Jackson, three banking centers in Ann Arbor and one mortgage loan production office in Ann Arbor. The Bank provides a wide range of business and consumer financial services in southeastern Michigan and west Michigan. Its primary deposit products are checking, interest-bearing demand, money market and savings, and term certificate accounts, and its primary lending products are commercial real estate, commercial and industrial, residential real estate and consumer loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of LEVEL ONE BANCORP INC
Full Guru Analysis for LEVL
Full Factor Report for LEVL
SPIRIT OF TEXAS BANCSHARES INC (STXB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Spirit of Texas Bancshares, Inc. is a bank holding company. Through its subsidiary, Spirit of Texas Bank SSB, offers a range of commercial and retail banking services. The Company primarily operates through Community Banking. It operates through 36 full-service branches located primarily in the Houston and Dallas/Fort Worth, Bryan/College Station, Corpus Christi and Tyler metropolitan areas, along with offices in North Central Texas. It delivers relationship-driven financial services to small and medium sized businesses, as well as individuals. It offers a range of loans, including commercial and industrial loans, small business administration loans, construction, land and development real estate loans, commercial real estate loans (including multifamily) and municipal loans. It also offers various loans and leases to individuals and professionals including residential real estate loans, home equity loans, installment loans, personal lines of credit, and standby letters of credit.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SPIRIT OF TEXAS BANCSHARES INC
Full Guru Analysis for STXB
Full Factor Report for STXB
KKR & CO INC (KKR) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: KKR & Co. Inc is a global investment company. The Company offers alternative asset management and capital markets and insurance solutions. The Company manages investments funds that invest in private equity, credit and real assets and hedge funds. It offers a range of investment management services to its fund investors, and provides capital markets services to its firm, its portfolio companies and third parties. The Company conducts its business with offices across the world, providing it with a global platform for sourcing transactions, raising capital and carrying out capital markets activities. The Company operates through four business lines: Private Markets, Public Markets, Capital Markets and Principal Activities. The Company also offers annuities for individuals through a network of banks, broker-dealers, and insurance agencies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of KKR & CO INC
Full Guru Analysis for KKR
Full Factor Report for KKR
BANK OZK (OZK) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bank Ozk, formerly Bank of the Ozarks, Inc., is a state chartered bank that provides retail and commercial banking services. Its deposit services include checking, savings, money market, time deposit and individual retirement accounts. Its loan services include various types of real estate, consumer, commercial, industrial and agricultural loans and various leasing services. It also provides mortgage lending; treasury management services for businesses, individuals and non-profit and governmental entities, including wholesale lock box services; remote deposit capture services; trust and wealth management services for businesses, individuals and non-profit and governmental entities, including financial planning, money management, custodial services and corporate trust services; real estate appraisals; ATMs; telephone banking; online and mobile banking services, including electronic bill pay and consumer mobile deposits, and debit cards, gift cards and safe deposit boxes.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BANK OZK
Full Guru Analysis for OZK
Full Factor Report for OZK
CAPITAL BANCORP INC (CBNK) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Capital Bancorp, Inc. is a bank holding company. The Company operates through its wholly owned subsidiary, Capital Bank, N.A., a commercial-focused community bank. The Company serves financial solutions to businesses, not-for-profit associations and entrepreneurs. The Company operates through three divisions: Commercial Banking; Church Street Mortgage, its residential mortgage banking platform, and OpenSky, credit card platform. Its Commercial Banking division provides advices and solutions to commercial clients. The Church Street Mortgage division originates residential mortgage loans for sale into the secondary market. The OpenSky division provides credit cards to under-banked populations. OpenSky's cards operate on a digital and mobile enabled platform with all marketing and application procedures conducted through its Website and mobile applications.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CAPITAL BANCORP INC
Full Guru Analysis for CBNK
Full Factor Report for CBNK
INDEPENDENT BANK GROUP INC (IBTX) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Independent Bank Group, Inc. is a bank holding company. Through the Company's subsidiary, Independent Bank (the Bank), the Company provides a range of commercial banking products and services tailored to meet the needs of businesses, professionals and individuals. As of December 31, 2016, the Company operated 41 banking offices in the Dallas/North Texas area, the Austin/Central Texas area, and the Houston metropolitan area. The Company offers residential mortgages through its mortgage brokerage division. As a mortgage broker, the Company originates residential mortgages, which are sold into the secondary market shortly after closing. The Company also provides wealth management services to its customers, including investment advisory and other related services. The Company offers a range of commercial and retail lending products to businesses, professionals and individuals. Deposits are the Company's principal source of funds for use in lending and other general banking purposes.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of INDEPENDENT BANK GROUP INC
Full Guru Analysis for IBTX
Full Factor Report for IBTX
FIRST INTERNET BANCORP (INBK) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Internet Bancorp is a bank holding company that conducts its business activities through its subsidiary, First Internet Bank of Indiana (the Bank). The Company offers a complement of products and services on a nationwide basis. The Company conducts its deposit operations primarily over the Internet. The Company also offers commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking/treasury management services. The Bank provides commercial and retail banking services, with operations conducted on the Internet at www.firstib.com. It offers residential real estate loans, home equity loans and lines of credit, and consumer loans, and loans to commercial clients, which include commercial loans, commercial real estate loans, letters of credit and single tenant lease financing. The Bank's subsidiary, JKH Realty Services, LLC manages real estate owned properties.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of FIRST INTERNET BANCORP
Full Guru Analysis for INBK
Full Factor Report for INBK
STERLING BANCORP (STL) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sterling Bancorp is a financial holding company. The Company is a bank holding company that owns the Sterling National Bank (the Bank). The Bank specializes in the delivery of services and solutions to business owners, their families and consumers within the communities it serves. The Bank offers a line of commercial, business, and consumer banking products and services. The Bank is engaged in the origination of commercial loans and commercial mortgage loans. The Company also originates residential mortgage loans and consumer loans. The Bank offers services in the New York Metro Market, which includes Manhattan and Long Island, and the New York Suburban Market, which consists of Rockland, Orange, Sullivan, Ulster, Putnam and Westchester counties in New York and Bergen County in New Jersey. Its deposit products include non-interest bearing demand deposits, interest bearing demand deposits, savings, money market and certificate of deposits.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of STERLING BANCORP
Full Guru Analysis for STL
Full Factor Report for STL
LGI HOMES INC (LGIH) is a mid-cap value stock in the Construction Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: LGI Homes, Inc is a homebuilder and developer. The Company is engaged in the design, construction, and sale of new homes in markets in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia and Pennsylvania. It operates through segments such as the Central division, the Southeast division, the Northwest division, the West division and the Florida divisions. The Company's product offerings include entry-level homes, including both detached and attached homes, and move-up homes, which are sold under its LGI Homes brand, and its luxury series homes, which are sold under its Terrata Homes brand. The Company provides information regarding floor plans and pricing and conduct tours of its homes based on the customer's needs and budget.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of LGI HOMES INC
Full Guru Analysis for LGIH
Full Factor Report for LGIH
NMI HOLDINGS INC (NMIH) is a small-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: NMI Holdings, Inc. (NMIH) provides private mortgage guaranty insurance through its insurance subsidiaries. The Company's primary insurance subsidiary, National Mortgage Insurance Corporation (NMIC), is a mortgage insurance (MI) provider on loans purchased by the Government-sponsored enterprises (GSEs). Its reinsurance subsidiary, National Mortgage Reinsurance Inc One (Re One), provides reinsurance to NMIC on certain loans insured by NMIC. NMIH's subsidiary, NMI Services, Inc. (NMIS), provides outsourced loan review services to mortgage loan originators. Its Primary mortgage insurance provides mortgage default protection on individual loans at specified coverage percentages. Primary insurance may be written on a flow basis, in which loans are insured as loan originations occur in individual, loan-by-loan transactions, or an aggregated basis, in which each loan in a portfolio of loans is individually insured in a single transaction, typically after the loans have been originated.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of NMI HOLDINGS INC
Full Guru Analysis for NMIH
Full Factor Report for NMIH
ARTISAN PARTNERS ASSET MANAGEMENT INC (APAM) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Artisan Partners Asset Management Inc. is an investment management company. The Company provides a range of the United States, non-United States and global investment strategies, each of which is managed by one of its investment teams. The Company provides investment management services to separate accounts, mutual funds and other pooled investment vehicles. The Company offers its investment management services primarily to institutions and through intermediaries that operate with institutional-like decision-making processes and have long-term investment horizons. The Company provides clients with multiple equity investment strategies spanning market capitalization segments and investing styles in both the United States and non-United States markets. The Company also offers one fixed income strategy, the Artisan High Income strategy. Each strategy is managed by one of the investment teams.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ARTISAN PARTNERS ASSET MANAGEMENT INC
Full Guru Analysis for APAM
Full Factor Report for APAM
INVESCO LTD. (IVZ) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Invesco Ltd. (Invesco) is an independent investment management company. The Company provides a range of investment capabilities and outcomes, which are delivered through a set of investment vehicles, to help clients achieve their investment objectives. It has a presence in the retail and institutional markets within the investment management industry in North America; Europe, Middle East and Africa (EMEA), and Asia-Pacific. Its Jemstep solution provides wealth management home offices and their advisors with a suite of technology solutions that are customizable and are integrated into existing systems. The solution offers advisors an open architecture platform that includes Invesco's fundamental and factor-based investment strategies. It offers retail products within various asset classes. It offers a suite of domestic and global strategies, including traditional and quantitative equities, fixed income and absolute return strategies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of INVESCO LTD.
Full Guru Analysis for IVZ
Full Factor Report for IVZ
CLEARFIELD INC (CLFD) is a small-cap growth stock in the Communications Equipment industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Clearfield, Inc. manufactures, markets and sells fiber management and enclosure platform that consolidates, distributes and protects fiber as it moves from the inside plant to the outside plant and all the way to the home, business and cell site. The Company's products include Clearview Cassette, which is the building block of its product platform; Connectivity and Optical Components; FieldSmart, which is a series of panels, cabinets, wall boxes and other enclosures that house the Clearview components; FieldShield, which is a fiber delivery method for broadband deployment; CraftSmart, which is a line of optical protection field enclosures, and Cable Assemblies. Its products are sold across broadband service providers, including traditional telephone companies, competitive local exchange carriers, multiple service operators (cable television), wireless service providers, and municipal-owned utilities that utilize fiber in their service offerings to businesses and consumers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of CLEARFIELD INC
Full Guru Analysis for CLFD
Full Factor Report for CLFD
VIRTUS INVESTMENT PARTNERS INC (VRTS) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Virtus Investment Partners, Inc. (Virtus) is a provider of investment management and related services to individuals and institutions. The Company provides its products in various forms and through multiple distribution channels. Its retail products include open-end mutual funds, closed-end funds, exchange traded funds, variable insurance funds, undertakings for collective investments in transferable securities (UCITS) and separately managed accounts. Its open-end mutual funds are distributed through intermediaries. Its closed-end funds trade on the New York Stock Exchange. Its variable insurance funds are available as investment options in variable annuities and life insurance products distributed by life insurance companies. Separately managed accounts consists of intermediary programs, sponsored and distributed by unaffiliated brokerage firms, and private client accounts, which are offered to the high net-worth clients of its affiliated managers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of VIRTUS INVESTMENT PARTNERS INC
Full Guru Analysis for VRTS
Full Factor Report for VRTS
APOLLO COMMERCIAL REAL EST. FINANCE INC (ARI) is a mid-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust. The Company primarily originates, acquires, invests in and manages performing commercial first mortgage loans, subordinate financings, commercial mortgage-backed securities (CMBS) and other commercial real estate-related debt investments. The Company targets investments that are secured by institutional quality real estate. The Company's principal business objective is to make investments in its target assets in order to provide attractive risk adjusted returns to its stockholders over the long term, primarily through dividends and secondarily through capital appreciation. The Company is externally managed and advised by ACREFI Management, LLC.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of APOLLO COMMERCIAL REAL EST. FINANCE INC
Full Guru Analysis for ARI
Full Factor Report for ARI
PZENA INVESTMENT MANAGEMENT, INC. (PZN) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Pzena Investment Management, Inc. is a holding company. The Company is the sole managing member of Pzena Investment Management, LLC. Pzena Investment Management, LLC is an investment management company. The Company also serves as the general partner of Pzena Investment Management, LP. The Company offers institutional investment products to public and corporate pension funds, endowments, foundations and certain commingled vehicles geared toward institutional investors. The Company also offers access to certain of its global and non-United States strategies through private placement vehicles and collective investment trusts. Pzena Investment Management, LLC is its operating company. Pzena Investment Management, LLC consists of Class A and Class B membership units.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of PZENA INVESTMENT MANAGEMENT, INC.
Full Guru Analysis for PZN
Full Factor Report for PZN
GRUPO FINANCIERO GALICIA S.A. (ADR) (GGAL) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Grupo Financiero Galicia SA is an Argentina-based financial services holding company. The Company does not have operations of its own and conduct its business through its subsidiaries. Banco Galicia is the Company's main subsidiary and one of Argentina's service banks. The Company's goal is to consolidate its position as one of Argentina's comprehensive financial services providers while continuing to strengthen Banco Galicia's position as one of Argentina's banks. The Company seeks to broaden and complement the operations and businesses of Banco Galicia, through holdings in companies and undertakings whose objectives are related to and/or can produce synergies with financial activities. The Company's non-banking subsidiaries operate in financial and related activities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of GRUPO FINANCIERO GALICIA S.A. (ADR)
Full Guru Analysis for GGAL
Full Factor Report for GGAL
META FINANCIAL GROUP INC. (CASH) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Meta Financial Group, Inc. is a unitary savings and loan holding company. The Company operates through its banking subsidiary, MetaBank (the Bank). Its segments include Payments, Banking, and Corporate Services/Other. MetaBank is both a community-oriented financial institution offering a range of financial services to meet the needs of the communities it serves and a payments company providing services on a nationwide basis. It operates in both the banking and payments industries through MetaBank, its retail banking operation; Meta Payment Systems (MPS), its electronic payments division; AFS/IBEX Financial Services Inc. (AFS/IBEX), its insurance premium financing division, and Refund Advantage, EPS Financial, LLC (EPS) Financial and Specialty Consumer Services, its tax-related financial solutions divisions. The Company, through its Meta Commercial Finance Division, which includes its state-chartered bank subsidiary, Crestmark Bank, provides business-to-business commercial financing.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of META FINANCIAL GROUP INC.
Full Guru Analysis for CASH
Full Factor Report for CASH
TOWNEBANK (TOWN) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: TowneBank is a community bank. The Bank offers personal banking services and business banking services. The Bank operates through three segments: Banking, Realty and Insurance. The Banking segment provides loan and deposit services to retail and commercial customers. The Realty segment provides residential real estate services, originations of a range of mortgage loans, resort property management, and residential and commercial title insurance. The Insurance segment provides property and casualty insurance, as well as employee and group benefits. The Bank provides checking accounts, cards, savings, money markets and certificate of deposits (CDs), mobile banking, financial management software, private banking and switch kit. The Bank also offers auto loans, home equity loans, construction loans, lot loans, recreational vehicles, mortgage loans, land acquisition loans, construction loans, development Loans, and personal loans and lines of credit.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of TOWNEBANK
Full Guru Analysis for TOWN
Full Factor Report for TOWN
LAZARD LTD (LAZ) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Lazard Ltd (Lazard) is a financial advisory and asset management company. The Company operates through two segments: Financial Advisory and Asset Management. It serves a range of clients around the world, including corporations, governments, institutions, partnerships and individuals. The Financial Advisory business segment offers corporate, partnership, institutional, government, sovereign and individual clients across the globe a range of financial advisory services regarding mergers and acquisitions (M&A) and other strategic matters, restructurings, capital structure, capital raising and various other financial matters to corporate, partnership, institutional, government, sovereign and individual clients. The Asset Management business provides investment solutions and investment management services in equity and fixed income strategies, alternative investments and private equity funds to corporations, public funds and sovereign entities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of LAZARD LTD
Full Guru Analysis for LAZ
Full Factor Report for LAZ
SVB FINANCIAL GROUP (SIVB) is a large-cap growth stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: SVB Financial Group is a financial services company, as well as a bank holding and a financial holding company. Its segments include Global Commercial Bank (GCB), SVB Private Bank, SVB Capital and SVB Leerink. The GCB segment consists of the operations of its Commercial Bank, its Global Fund Banking, SVB Wine and its Debt Fund Investments. SVB Private Bank is the private banking and wealth management division of the Bank, which provides personal financial solutions for its clients. SVB Capital is the venture capital investment arm of SVB Financial Group, which focuses on funds management. The Company, through its subsidiaries and divisions, offers a range of banking and financial products and services to clients across the United States. It offers services in the technology, life science/healthcare, private equity/venture capital and wine industries. The Bank and its subsidiaries, also offer asset management, private wealth management, brokerage and other investment services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SVB FINANCIAL GROUP
Full Guru Analysis for SIVB
Full Factor Report for SIVB
PARKE BANCORP, INC. (PKBK) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Parke Bancorp, Inc. is a bank holding company of Parke Bank (the Bank). The Bank is a full commercial service bank, with focus on providing personal and business financial services to individuals and small to mid-sized businesses in Gloucester, Atlantic and Cape May Counties in New Jersey and the Philadelphia area in Pennsylvania. It focuses its commercial loan originations on small and mid-sized businesses. Its commercial loan products include residential and commercial real estate construction loans; working capital loans and lines of credit; demand, term and time loans, and equipment, inventory and accounts receivable financing. It also offers a range of deposit products to its commercial customers. It offers contemporary products and services, such as debit cards, Internet banking and online bill payment. Its retail lending activities include residential mortgage loans, home equity lines of credit, fixed rate second mortgages, new and used auto loans and overdraft protection.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of PARKE BANCORP, INC.
Full Guru Analysis for PKBK
Full Factor Report for PKBK
PRIMERICA, INC. (PRI) is a mid-cap value stock in the Insurance (Life) industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Primerica Inc. (Primerica) is a distributor of financial products to middle-income households in the United States and Canada. The Company operates through three segments: Term Life Insurance, Investment and Savings Products, and Corporate and Other Distributed Products. The Term Life Insurance segment includes underwriting profits on its in-force book of term life insurance policies, net of reinsurance, which are underwritten by its life insurance company subsidiaries. The Investment and Savings Products segment includes retail and managed mutual funds, and annuities distributed through licensed broker-dealer subsidiaries and includes segregated funds, an individual annuity savings product that it underwrites in Canada through Primerica Life Insurance Company of Canada (Primerica Life Canada). In the United States, it distributes mutual fund and annuity products of various third-party companies. It also earns fees for account servicing on a subset of the mutual funds it distributes.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of PRIMERICA, INC.
Full Guru Analysis for PRI
Full Factor Report for PRI
VALLEY NATIONAL BANCORP (VLY) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Valley National Bancorp is the bank holding company for Valley National Bank (the Bank). The Bank provides a range of commercial, retail, insurance and wealth management financial services products. The Company's segments include Consumer Lending, Commercial Lending, Investment Management, and Corporate and Other Adjustments. The Consumer Lending segment primarily includes residential mortgages, home equity loans and automobile loans. The Commercial Lending segment primarily includes floating rate and adjustable rate commercial and industrial loans, as well as fixed rate owner occupied and commercial real estate loans. The Investment Management segment includes the Company's investments in various types of securities. As of July 26, 2017, the Bank operated 200 branch locations serving northern and central New Jersey, the New York City boroughs of Manhattan, Brooklyn, Queens and Long Island, and Florida.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of VALLEY NATIONAL BANCORP
Full Guru Analysis for VLY
Full Factor Report for VLY
WERNER ENTERPRISES, INC. (WERN) is a mid-cap value stock in the Trucking industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Werner Enterprises, Inc. is a transportation and logistics company. The Company is engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. It operates through two segments: Truckload and Werner Logistics. It provides logistics services through its Werner Logistics division. As of December 31, 2016, it had a fleet of approximately 7,100 trucks, of which 6,305 were company-operated and 795 were owned and operated by independent contractors. Its Werner Logistics division operated 74 intermodal drayage trucks as of December 31, 2016. Its Truckload segment comprises the One-Way Truckload and Specialized Services units. It operates in several provinces of Canada to provide through-trailer service into and out of Mexico. Its Werner Logistic segment is a non-asset-based transportation and logistics provider and comprises four operating units: truck brokerage, freight management, the intermodal and Werner Global Logistics international.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of WERNER ENTERPRISES, INC.
Full Guru Analysis for WERN
Full Factor Report for WERN
BANK OF MONTREAL (USA) (BMO) is a large-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bank of Montreal (the Bank) is a financial services provider. The Bank provides a range of personal and commercial banking, wealth management and investment banking products and services. The Bank conducts its business through three operating groups: Personal and Commercial Banking (P&C), Wealth Management and BMO Capital Markets. The P&C business includes two retail and business banking operating segments, such as Canadian Personal and Commercial Banking (Canadian P&C), and the United States Personal and Commercial Banking (U.S. P&C). The Bank's Wealth Management business serves a range of client segments, from mainstream to ultra-high net worth and institutional, with an offering of wealth management products and services, including insurance. BMO Capital Markets is a North American-based financial services provider offering a range of products and services to corporate, institutional and government clients. The Bank has over 900 bank branches in Canada and the United States.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BANK OF MONTREAL (USA)
Full Guru Analysis for BMO
Full Factor Report for BMO
HINGHAM INSTITUTION FOR SAVINGS (HIFS) is a small-cap value stock in the S&Ls/Savings Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Hingham Institution for Savings (the Bank) is a Massachusetts-chartered savings bank (the Bank). The Bank is principally engaged in the business of residential and commercial real estate mortgage lending, funded by a retail deposit network and borrowings. The Bank provides a range of financial services to individuals and small businesses through its approximately 10 offices in Boston and southeastern Massachusetts. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in Eastern Massachusetts. The Bank offers personal checking accounts, money market and savings accounts, as well as longer term certificates of deposit for individuals, businesses, non-profits, cities and towns. The Bank's loan portfolio includes residential real estate, commercial real estate, construction, home equity, commercial and consumer segments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of HINGHAM INSTITUTION FOR SAVINGS
Full Guru Analysis for HIFS
Full Factor Report for HIFS
SIMMONS FIRST NATIONAL CORPORATION (SFNC) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Simmons First National Corporation is a financial holding company. The Company, through its subsidiary bank, Simmons Bank, provides financial services to individuals and businesses throughout the market areas they serve. As of December 31, 2016, Simmons Bank conducted banking operations through 150 financial centers located in communities throughout Arkansas, Kansas, Missouri, Tennessee, Colorado, Oklahoma and Texas. Simmons Bank offers consumer, real estate and commercial loans, checking and savings deposits. Simmons Bank and its subsidiaries have also developed products and services, which include credit cards, investments, agricultural finance lending, equipment lending, insurance and small business administration lending. The securities within the portfolio are classified as either held-to-maturity, available-for-sale or trading. The Company offers deposits, including non-interest bearing transaction accounts; interest bearing transaction accounts, and time deposits.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of SIMMONS FIRST NATIONAL CORPORATION
Full Guru Analysis for SFNC
Full Factor Report for SFNC
STIFEL FINANCIAL CORP (SF) is a mid-cap value stock in the Investment Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Stifel Financial Corp. is a financial holding company. Its principal subsidiary is Stifel, Nicolaus & Company, Incorporated, a retail and institutional wealth management and investment banking firm. It operates through three segments: Global Wealth Management, Institutional Group and Other. The Global Wealth Management segment consists of the Private Client Group and Stifel Bank businesses. The Institutional Group segment includes research, equity and fixed income institutional sales and trading, investment banking, public finance and syndicate. The Other segment includes interest income from stock borrow activities and interest income. Its principal activities are private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading, research and municipal finance; investment banking services, and retail and commercial banking, including personal and commercial lending programs.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of STIFEL FINANCIAL CORP
Full Guru Analysis for SF
Full Factor Report for SF
STURM RUGER & COMPANY INC (RGR) is a small-cap value stock in the Recreational Products industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sturm, Ruger & Company, Inc. is engaged in the design, manufacture, and sale of firearms to domestic customers. The Company operates through two segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a range of federally licensed, independent wholesale distributors primarily located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding (MIM) parts. The Company's design and manufacturing operations are located in the United States. The Company primarily offers products in three industry product categories: rifles, pistols, and revolvers. The Company's firearms are sold through independent wholesale distributors, principally to the commercial sporting market. The Company manufactures firearm products under the Ruger name. The Company also manufactures and sells accessories and replacement parts for its firearms.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of STURM RUGER & COMPANY INC
Full Guru Analysis for RGR
Full Factor Report for RGR
NVR, INC. (NVR) is a large-cap growth stock in the Construction Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: NVR, Inc. is engaged in the construction and sale of single-family detached homes, townhomes and condominium buildings. The Company's segments are Homebuilding Mid Atlantic, Homebuilding North East, Homebuilding Mid East, Homebuilding South East and Mortgage Banking. Its Homebuilding Mid Atlantic segment operates in various geographic regions, which include Maryland, Virginia, West Virginia, Delaware and Washington, District of Columbia (D.C.). Its Homebuilding North East segment operates in various geographic regions, which include New Jersey and Eastern Pennsylvania. Its Homebuilding Mid East segment operates in various geographic regions, which include New York, Ohio, Indiana and Illinois, The Homebuilding South East segment operates in various geographic regions, which include North Carolina, South Carolina, Florida and Tennessee. The Mortgage Banking segment provides mortgage-related services to home building customers through its mortgage banking operations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of NVR, INC.
Full Guru Analysis for NVR
Full Factor Report for NVR
OLD DOMINION FREIGHT LINE INC (ODFL) is a large-cap growth stock in the Trucking industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Old Dominion Freight Line, Inc. is a North American less-than-truckload (LTL) motor carrier's company. The Company provide regional, inter-regional and national LTL services through a single integrated, union-free organization union-free motor carrier. Its service offerings include expedited transportation, which are provided through a network of service centers located throughout the continental United States. It also provides LTL services throughout North America. In addition to its core LTL services, it offers a range of value-added services including container drayage, truckload brokerage and supply chain consulting. Its service centers are responsible for the pickup and delivery of freight within their local service area. Its network includes breakbulk facilities located in Atlanta, Georgia; Columbus, Ohio; Indianapolis, Indiana; Greensboro, North Carolina; Harrisburg, Pennsylvania; Memphis and Morristown, Tennessee; Dallas, Texas; and Salt Lake City, Utah.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of OLD DOMINION FREIGHT LINE INC
Full Guru Analysis for ODFL
Full Factor Report for ODFL
PULTEGROUP, INC. (PHM) is a large-cap value stock in the Construction Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: PulteGroup, Inc. is a homebuilder in the United States. The Company's segments include Homebuilding and Financial Services. Its Homebuilding operations are engaged in the acquisition and development of land primarily for residential purposes within the United States and the construction of housing on such land. Its Financial Services operations consist principally of mortgage banking and title operations. The Company conducts its financial services business, through Pulte Mortgage LLC (Pulte Mortgage) and other subsidiaries. Pulte Mortgage arranges financing through the origination of mortgage loans. The Company's subsidiaries are engaged in the homebuilding business. It offers a product line to meet the needs of homebuyers in its focused markets. Through its brands, which include Centex, Pulte Homes, Del Webb, DiVosta Homes, and John Wieland Homes and Neighborhoods, the Company offers a range of home designs, including single-family detached, townhouses, condominiums and duplexes.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of PULTEGROUP, INC.
Full Guru Analysis for PHM
Full Factor Report for PHM
MERITAGE HOMES CORP (MTH) is a mid-cap value stock in the Construction Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Meritage Homes Corporation operates as a holding company. The Company is a designer and builder of single-family homes. The Company operates through two segments: homebuilding and financial services. The homebuilding segment is engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services. It builds homes in the regions of the United States and offers a range of homes that are designed for a range of homebuyers, including first-time, move-up, active adult and luxury. As of December 31, 2016, it had homebuilding operations in three regions: West, Central and East, which were consisted of nine states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina and Tennessee. It also operates Carefree Title Agency, Inc. (Carefree Title) company. Carefree Title's core business includes title insurance and closing/settlement services it offers to its homebuyers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of MERITAGE HOMES CORP
Full Guru Analysis for MTH
Full Factor Report for MTH
M.D.C. HOLDINGS, INC. (MDC) is a mid-cap value stock in the Construction Services industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: M.D.C. Holdings, Inc. is engaged in two primary operations, including homebuilding and financial services. The Company's segments include West, including segments located in Arizona, California, Nevada and Washington; Mountain, including segments located in Colorado and Utah; East, including segments located in Virginia, Florida and Maryland, which includes Pennsylvania and New Jersey; mortgage operations, including HomeAmerican Mortgage Corporation, and Other, which includes Allegiant Insurance Company, Inc., StarAmerican Insurance Ltd., American Home Insurance Agency, Inc. and American Home Title and Escrow Company. The homebuilding operations consist of subsidiary companies that purchases finished lots or develop lots necessary for the construction and sale of single-family detached homes to first-time and first-time move-up homebuyers under the name Richmond American Homes. It also includes land acquisition and development, home construction, and sales and marketing.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
INSIDER TRANSACTIONS: PASS
Detailed Analysis of M.D.C. HOLDINGS, INC.
Full Guru Analysis for MDC
Full Factor Report for MDC
JOHNSON OUTDOORS INC. (JOUT) is a small-cap value stock in the Recreational Products industry. The rating according to our strategy based on Martin Zweig changed from 85% to 92% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Johnson Outdoors Inc. is a manufacturer and marketer of branded seasonal, outdoor recreation products. The Company operates through four segments: Marine Electronics, Outdoor Equipment, Watercraft and Diving. Its Marine Electronics segment's brands are Minn Kota, Humminbird and Cannon. Its Outdoor Equipment segment's brands are Eureka!, Jetboil and Silva. Its Watercraft segment designs and markets Necky sea touring kayaks; sit on top Ocean Kayaks, and Old Town canoes and kayaks for family recreation, touring, angling and tripping. The Company manufactures and markets underwater diving products for recreational divers, which it sells and distributes under the SCUBAPRO brand name. It markets a line of underwater diving and snorkeling equipment, including regulators, buoyancy compensators, dive computers and gauges, wetsuits, masks, fins, snorkels and accessories. The Company's products are used for fishing from a boat, diving, paddling, hiking and camping.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of JOHNSON OUTDOORS INC.
Full Guru Analysis for JOUT
Full Factor Report for JOUT
INSTEEL INDUSTRIES INC (IIIN) is a small-cap value stock in the Misc. Fabricated Products industry. The rating according to our strategy based on Martin Zweig changed from 77% to 85% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Insteel Industries, Inc. is a manufacturer of steel wire reinforcing products for concrete construction applications. The Company's operations are focused on the manufacture and marketing of steel wire reinforcing products for concrete construction applications. Its concrete reinforcing products consist of two product lines: prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand is a seven-wire strand that is used to impart compression forces into precast concrete elements and structures, providing reinforcement for bridges, parking decks, buildings and other concrete structures. WWR is produced as an engineered reinforcing product for use in nonresidential and residential construction. Its products are sold primarily to manufacturers of concrete products that are used in nonresidential construction. The Company sells its products nationwide across the United States, Canada, Mexico, and Central and South America.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of INSTEEL INDUSTRIES INC
Full Guru Analysis for IIIN
Full Factor Report for IIIN
INVESTORS TITLE COMPANY (ITIC) is a small-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Martin Zweig changed from 82% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Investors Title Company is an insurance holding company. The Company, through its subsidiaries, Investors Title Insurance Company (ITIC) and National Investors Title Insurance Company (NITIC), is engaged in issuance of residential and commercial title insurance, Investors Title Insurance Company (ITIC) and National Investors Title Insurance Company (NITIC). The Company also provides tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC); investment management and trust services to individuals, trusts and other entities through its subsidiary, Investors Trust Company (Investors Trust), and management services to title insurance agencies through its subsidiary, Investors Title Management Services (ITMS). In addition, the Company operates in the issuance of residential and commercial title insurance through ITIC and NITIC segment.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of INVESTORS TITLE COMPANY
Full Guru Analysis for ITIC
Full Factor Report for ITIC
More details on Validea's Martin Zweig strategy
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT JPMORGAN CHASE & CO. (JPM) is a large-cap value stock in the Investment Services industry. Detailed Analysis of HOULIHAN LOKEY INC Full Guru Analysis for HLI Full Factor Report for HLI ALLEGIANCE BANCSHARES INC (ABTX) is a small-cap value stock in the Regional Banks industry. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT JPMORGAN CHASE & CO. (JPM) is a large-cap value stock in the Investment Services industry. Detailed Analysis of HOULIHAN LOKEY INC Full Guru Analysis for HLI Full Factor Report for HLI ALLEGIANCE BANCSHARES INC (ABTX) is a small-cap value stock in the Regional Banks industry. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT JPMORGAN CHASE & CO. (JPM) is a large-cap value stock in the Investment Services industry. Detailed Analysis of HOULIHAN LOKEY INC Full Guru Analysis for HLI Full Factor Report for HLI ALLEGIANCE BANCSHARES INC (ABTX) is a small-cap value stock in the Regional Banks industry. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT JPMORGAN CHASE & CO. (JPM) is a large-cap value stock in the Investment Services industry. Detailed Analysis of HOULIHAN LOKEY INC Full Guru Analysis for HLI Full Factor Report for HLI ALLEGIANCE BANCSHARES INC (ABTX) is a small-cap value stock in the Regional Banks industry. |
31994.0 | 2021-09-08 00:00:00 UTC | How Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008? | ABT | https://www.nasdaq.com/articles/how-does-sareptas-stock-performance-in-the-current-crisis-compare-with-that-in-2008-2021 | nan | nan | We believe that Sarepta Therapeutics stock (NASDAQ: SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying opportunity at the present time. SRPT stock trades under $80 levels currently and it is, in fact, down 37% from its pre-Covid high of around $125 in February 2020 – before the coronavirus pandemic hit the world.
Sarepta hasn’t had a great year thus far with its stock plummeting over 52% from levels of around $165 toward the beginning of the year to $79 now. Much of this fall came in early January following an unfavorable outcome from clinical trials for one of its drugs, SRP-9001, used for treating Duchenne muscular dystrophy (DMD). However, we continue to believe that SRPT stock is oversold now, and it is likely to see higher levels going forward. The selling now appears to be overdone. While the development around SRP-9001 was surely negative, the company has a solid pipeline of over 40 programs, most of which are focused on gene therapies.
While SRPT stock has seen lower levels during the current Covid-19 crisis, how did it fare in the 2008 crisis? In this note we focus on a comparative analysis of Sarepta stock during the 2008 recession vs now in our interactive dashboard.
Timeline of 2020 Coronavirus Crisis:
12/12/2019: Coronavirus cases first reported in China
1/31/2020: WHO declares a global health emergency.
2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high
3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, 2020, as Covid-19 cases accelerate outside China. Doesn’t help that oil prices crash in mid-March amid Saudi-led price war
Since 3/24/2020: S&P 500 rallies 103% from the lows seen on Mar 23, 2020, as the Fed’s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system.
In contrast, here is how SRPT stock and the broader market fared during the 2007-08 crisis
Timeline of 2007-08 Crisis
10/1/2007: Approximate pre-crisis peak in S&P 500 index
9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08)
3/1/2009: Approximate bottoming out of S&P 500 index
12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008)
SRPT and S&P 500 Performance Over 2007-08 Financial Crisis
SRPT stock plummeted from from levels of about $15 in October 2007 (pre-crisis peak for the broader markets) to levels of under $7 in September 2008 before plunging to around $4 in March 2009 (as the markets bottomed out), implying SRPT stock lost 73% from its peak. It staged a strong recovery immediately post the 2008 crisis, to levels of around $9 by January 2010, reflecting a large 116% rise. In comparison, the S&P 500 Index saw a decline of 51% from its peak in September 2007 to its bottom in March 2009, followed by a sharp recovery of 48% by January 2010.
Sarepta’s Top Line Has Expanded While It Is Still Not Profitable
Sarepta’s revenues increased from $155 million in 2017 to $600 million over the last twelve-month period, led by increased sales of its DMD drugs. The company is currently running into losses, primarily due to higher R&D investments. The company reported a loss of $8.03 per share for the last twelve-month period, compared to a loss of $0.86 per share in 2017. Note that most of the company’s drugs are still in early stages of clinical trials.
Does SRPT Have Sufficient Cash Cushion To Meet Its Obligations?
Sarepta has seen its total debt increase from $431 million in 2017 to $1.2 billion currently, while its total cash increased from $1.1 billion to $1.7 billion over the same period. The company spent $702 million cash for its operations over the last twelve-month period. The company has a sufficient liquidity cushion to meet its near term obligations.
Conclusion
Phases of Covid-19 Crisis:
Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally
Late-March 2020 onward: Social distancing measures + lockdowns
April 2020: Fed stimulus suppresses near-term survival anxiety
May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases
Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. Multiple countries have undertaken large-scale vaccine programs for Covid-19, though new variants of coronavirus resulted in an uptick in active cases.
Overall, SRPT stock looks oversold and it is likely to see a rebound in the near term. Even if we look at the average of analysts price estimates of $120, it reflects over 50% upside from the current levels.
While SRPT stock can see a rebound, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for AMD vs Etsy.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SRPT stock trades under $80 levels currently and it is, in fact, down 37% from its pre-Covid high of around $125 in February 2020 – before the coronavirus pandemic hit the world. Much of this fall came in early January following an unfavorable outcome from clinical trials for one of its drugs, SRP-9001, used for treating Duchenne muscular dystrophy (DMD). Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. | In contrast, here is how SRPT stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) SRPT and S&P 500 Performance Over 2007-08 Financial Crisis SRPT stock plummeted from from levels of about $15 in October 2007 (pre-crisis peak for the broader markets) to levels of under $7 in September 2008 before plunging to around $4 in March 2009 (as the markets bottomed out), implying SRPT stock lost 73% from its peak. Sarepta has seen its total debt increase from $431 million in 2017 to $1.2 billion currently, while its total cash increased from $1.1 billion to $1.7 billion over the same period. Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. | We believe that Sarepta Therapeutics stock (NASDAQ: SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying opportunity at the present time. In contrast, here is how SRPT stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) SRPT and S&P 500 Performance Over 2007-08 Financial Crisis SRPT stock plummeted from from levels of about $15 in October 2007 (pre-crisis peak for the broader markets) to levels of under $7 in September 2008 before plunging to around $4 in March 2009 (as the markets bottomed out), implying SRPT stock lost 73% from its peak. Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. | Timeline of 2020 Coronavirus Crisis: 12/12/2019: Coronavirus cases first reported in China 1/31/2020: WHO declares a global health emergency. Note that most of the company’s drugs are still in early stages of clinical trials. The company spent $702 million cash for its operations over the last twelve-month period. |
31995.0 | 2021-09-08 00:00:00 UTC | What's Happening With Abbott Stock? | ABT | https://www.nasdaq.com/articles/whats-happening-with-abbott-stock-2021-09-08 | nan | nan | [Updated: Sep 3, 2021] Abbott Stock Update
The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. The company’s Q2 results were comfortably above our as well as the consensus estimates driven by continued demand for Covid-19 testing. In fact, the company garnered $1.3 billion in sales from the Covid-19 testing in Q2. Now, there has been a rise of Covid-19 cases in the U.S. due to the spread of the delta variant. The seven-day average of new Covid-19 cases rose from around 12,000 cases toward the end of June this year to over 160,000 currently. This has again resulted a sharp increase in demand for Covid-19 testing, especially the at-home testing kits, including Abbott’s BinaxNOW. This will result in an increased contribution to Abbott’s top-line in the near term.
Furthermore, the company’s other businesses also have seen a rebound with 12% growth in businesses other than the Covid-19 testing. With a rise in vaccination rates, the total procedure volume is expected to see higher levels going forward, boding well for Abbott’s medical devices business. The company yesterday announced the acquisition of Walk Vascular to strengthen its peripheral vascular offerings. Walk Vascular’s JETi Peripheral Thrombectomy System and JETi AIO Peripheral Thrombectomy System are unique aspiration systems for the removal of intravascular clots, and both of them are approved by the U.S. FDA and they have also received the CE Mark in Europe..
Although there are multiple positive triggers for ABT stock, going by our Abbott Valuation of $130 per share based on $4.42 EPS and 29x P/E multiple, it appears that ABT stock is fully valued at its current levels. Now, with the recent rise in demand for at-home Covid-19 testing kits, Abbott may see better earnings growth for the full-year. That said, we believe it will be better for investors willing to buy Abbott stock to wait for a dip to enter. Also, the average of analysts’ price estimates for Abbott currently stands at $132, marginally ahead of its current market price of $128.
[Updated: Jul 20, 2021] Abbott Q2 Earnings Preview
Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. We expect Abbott to report revenues and earnings above the consensus estimates, driven by continued growth in diagnostics business, along with a rebound in demand for medical devices. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. Trefis’ forecast indicates that Abbott’s valuation is $132 per share, which is 11% higher than the current market price of around $119. Our interactive dashboard analysis on Abbott’s Pre-Earnings has additional details.
(1) Revenues expected to be above the consensus estimates
Trefis estimates Abbott’s Q2 2021 revenues to be around $9.85 Bil, compared to the $9.69 Bil consensus estimate. Abbott in Q2 2020 saw a significant decline in medical devices revenue, due to deferment of elective surgeries given the spread of Covid-19. Now that nearly half of the U.S. population is fully vaccinated, and on the international front, most of the countries have undertaken large-scale vaccination programs, the healthcare institutions now have more resources to address the surgeries that were postponed earlier, and people are also more confident heading out, compared to the lockdowns in Q2 last year, implying a rebound for Abbott’s medical devices business. In fact, Abbott’s medical devices sales were also up 13% in Q1 this year.
Looking at the company’s diagnostics business, the sales are expected to continue to remain very high in Q2 as well, after seeing a massive 120% rise in Q1 of this year. This can be attributed to high demand for Covid-19 testing. However, now that the Covid-19 vaccination rate is on a rise, the overall demand for testing is expected to come down over the coming quarters, and it will impact the overall sales growth of the company’s diagnostics business in the quarters to come. This factor was also responsible for a 10% drop in ABT stock a couple of months back. Our dashboard on Abbott Revenues offers more details on the company’s segments.
2) EPS likely to top the consensus estimates
Abbott’s Q2 2021 adjusted earnings per share (EPS) is expected to be $1.07 per Trefis analysis, 5% above the consensus estimate of $1.02. Abbott’s adjusted net income of $2.4 Bil in Q1 2021 reflected a large 2x growth from its $1.2 Bil figure in the prior-year quarter. This can be attributed to higher revenues and over 750 bps rise in net margins. The company’s operating expenses, including R&D and SG&A grew at a slower pace compared to the revenue growth. This trend is expected to continue in Q2 as well, bolstering the overall earnings growth. For the full-year, we expect the adjusted EPS to be higher at $4.55 compared to $3.67 in 2020.
(3) Stock price estimate 11% higher than the current market price
Going by our Abbott’s Valuation, with an EPS estimate of around $4.55 and a P/E multiple of around 29x in 2021, this translates into a price of $132, which is 11% above the current market price of around $119. At current levels of $119, Abbott is trading at 26x its expected EPS of $4.55 in 2021, and the 26x figure compares with levels of 30x seen as recently as late 2020, and 27x seen in late 2019, implying there is more room for growth for ABT stock.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While ABT stock may be undervalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | [Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. Although there are multiple positive triggers for ABT stock, going by our Abbott Valuation of $130 per share based on $4.42 EPS and 29x P/E multiple, it appears that ABT stock is fully valued at its current levels. [Updated: Jul 20, 2021] Abbott Q2 Earnings Preview Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. | [Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. Although there are multiple positive triggers for ABT stock, going by our Abbott Valuation of $130 per share based on $4.42 EPS and 29x P/E multiple, it appears that ABT stock is fully valued at its current levels. [Updated: Jul 20, 2021] Abbott Q2 Earnings Preview Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. | [Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. Although there are multiple positive triggers for ABT stock, going by our Abbott Valuation of $130 per share based on $4.42 EPS and 29x P/E multiple, it appears that ABT stock is fully valued at its current levels. [Updated: Jul 20, 2021] Abbott Q2 Earnings Preview Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. | Although there are multiple positive triggers for ABT stock, going by our Abbott Valuation of $130 per share based on $4.42 EPS and 29x P/E multiple, it appears that ABT stock is fully valued at its current levels. [Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. [Updated: Jul 20, 2021] Abbott Q2 Earnings Preview Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. |
31996.0 | 2021-09-07 00:00:00 UTC | Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT) | ABT | https://www.nasdaq.com/articles/calculating-the-fair-value-of-abbott-laboratories-nyse%3Aabt-2021-09-07 | nan | nan | Does the September share price for Abbott Laboratories (NYSE:ABT) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
Step by step through the calculation
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Levered FCF ($, Millions) US$8.44b US$8.85b US$10.3b US$10.6b US$10.8b US$11.0b US$11.2b US$11.4b US$11.7b US$11.9b
Growth Rate Estimate Source Analyst x7 Analyst x7 Analyst x3 Analyst x2 Est @ 2.02% Est @ 2.01% Est @ 2% Est @ 2% Est @ 2% Est @ 1.99%
Present Value ($, Millions) Discounted @ 6.3% US$7.9k US$7.8k US$8.6k US$8.3k US$7.9k US$7.6k US$7.3k US$7.0k US$6.7k US$6.5k
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$76b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.3%.
Terminal Value (TV)= FCF2031 × (1 + g) ÷ (r – g) = US$12b× (1 + 2.0%) ÷ (6.3%– 2.0%) = US$281b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$281b÷ ( 1 + 6.3%)10= US$152b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$228b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$129, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
NYSE:ABT Discounted Cash Flow September 7th 2021
Important assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Abbott Laboratories as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.3%, which is based on a levered beta of 0.915. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
Moving On:
Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Abbott Laboratories, we've compiled three essential factors you should explore:
Risks: For example, we've discovered 2 warning signs for Abbott Laboratories that you should be aware of before investing here.
Future Earnings: How does ABT's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Does the September share price for Abbott Laboratories (NYSE:ABT) reflect what it's really worth? NYSE:ABT Discounted Cash Flow September 7th 2021 Important assumptions The calculation above is very dependent on two assumptions. Future Earnings: How does ABT's growth rate compare to its peers and the wider market? | Does the September share price for Abbott Laboratories (NYSE:ABT) reflect what it's really worth? NYSE:ABT Discounted Cash Flow September 7th 2021 Important assumptions The calculation above is very dependent on two assumptions. Future Earnings: How does ABT's growth rate compare to its peers and the wider market? | Does the September share price for Abbott Laboratories (NYSE:ABT) reflect what it's really worth? NYSE:ABT Discounted Cash Flow September 7th 2021 Important assumptions The calculation above is very dependent on two assumptions. Future Earnings: How does ABT's growth rate compare to its peers and the wider market? | Does the September share price for Abbott Laboratories (NYSE:ABT) reflect what it's really worth? NYSE:ABT Discounted Cash Flow September 7th 2021 Important assumptions The calculation above is very dependent on two assumptions. Future Earnings: How does ABT's growth rate compare to its peers and the wider market? |
31997.0 | 2021-09-02 00:00:00 UTC | Why Shares of Quidel Surged 10% This Week | ABT | https://www.nasdaq.com/articles/why-shares-of-quidel-surged-10-this-week-2021-09-02 | nan | nan | What happened
Shares of Quidel Corporation (NASDAQ: QDEL) climbed 10% this week as of Thursday's close. Demand for at-home COVID testing is outstripping supply, with the delta variant pushing infections back to levels last seen in January.
Image source: Getty Images.
So what
Early last month, Quidel said sales in its fiscal second quarter declined 12% from the year earlier due in part to a drop-off in its COVID testing business. It doesn't appear that will be a problem next quarter as cases in the U.S. have climbed tenfold in the past two months. A company spokesperson said it is working with retailers to keep the company's QuickVue at-home test in stock.
One way it will do that is offering the test through the more than 7,000 CVS (NYSE: CVS) locations in the U.S. and online. The partnership was announced this Wednesday, and availability is expected within the next week.
Now what
The test maker is leaning into the surge by ramping up manufacturing lines that had been repurposed when COVID waned. Other test makers Abbott Labs (NYSE: ABT) and Becton Dickinson (NYSE: BDX) had also curbed production this summer.
Another driver of demand is the return of students to classrooms and workers to office buildings. With many organizations implementing policies that require constant testing in lieu of vaccination, the surge in sales may remain elevated unless vaccination rates improve.
10 stocks we like better than Quidel
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Quidel wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Quidel. The Motley Fool recommends Becton, Dickinson and CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other test makers Abbott Labs (NYSE: ABT) and Becton Dickinson (NYSE: BDX) had also curbed production this summer. What happened Shares of Quidel Corporation (NASDAQ: QDEL) climbed 10% this week as of Thursday's close. Demand for at-home COVID testing is outstripping supply, with the delta variant pushing infections back to levels last seen in January. | Other test makers Abbott Labs (NYSE: ABT) and Becton Dickinson (NYSE: BDX) had also curbed production this summer. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Jason Hawthorne has no position in any of the stocks mentioned. | Other test makers Abbott Labs (NYSE: ABT) and Becton Dickinson (NYSE: BDX) had also curbed production this summer. So what Early last month, Quidel said sales in its fiscal second quarter declined 12% from the year earlier due in part to a drop-off in its COVID testing business. 10 stocks we like better than Quidel When our award-winning analyst team has a stock tip, it can pay to listen. | Other test makers Abbott Labs (NYSE: ABT) and Becton Dickinson (NYSE: BDX) had also curbed production this summer. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Quidel wasn't one of them! The Motley Fool recommends Becton, Dickinson and CVS Health. |
31998.0 | 2021-09-02 00:00:00 UTC | Abbott Announces Acquisition Of Walk Vascular - Quick Facts | ABT | https://www.nasdaq.com/articles/abbott-announces-acquisition-of-walk-vascular-quick-facts-2021-09-02 | nan | nan | (RTTNews) - Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Walk Vascular's peripheral thrombectomy systems will be incorporated into the company's endovascular product portfolio. Financial terms of the deal were not disclosed.
Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO Peripheral Thrombectomy System are aspiration systems for the removal of intravascular clots. The products have received 510(k) clearance from the FDA for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Walk Vascular's peripheral thrombectomy systems will be incorporated into the company's endovascular product portfolio. The products have received 510(k) clearance from the FDA for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries. | (RTTNews) - Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Walk Vascular's peripheral thrombectomy systems will be incorporated into the company's endovascular product portfolio. Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO Peripheral Thrombectomy System are aspiration systems for the removal of intravascular clots. | (RTTNews) - Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Financial terms of the deal were not disclosed. Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO Peripheral Thrombectomy System are aspiration systems for the removal of intravascular clots. | (RTTNews) - Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Walk Vascular's peripheral thrombectomy systems will be incorporated into the company's endovascular product portfolio. Financial terms of the deal were not disclosed. |
31999.0 | 2021-09-02 00:00:00 UTC | This May Be Abbott's Billion-Dollar Opportunity | ABT | https://www.nasdaq.com/articles/this-may-be-abbotts-billion-dollar-opportunity-2021-09-02 | nan | nan | You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. The company is well diversified -- with medical devices, diagnostics, nutrition, and pharmaceutical businesses. In fact, medical devices usually contribute the most to Abbott's revenue. Still, Abbott became a coronavirus stock after winning authorization for 12 COVID-19 diagnostics last year.
The tests brought in billions of dollars. And Abbott shares climbed. But Abbott stock sank more than 9% in one trading session back in June when the company lowered guidance. The bad news? Demand for coronavirus tests had started to sink. These days, however, the picture has changed. It's changed so much that Abbott may be facing a billion-dollar opportunity...
Image source: Getty Images.
The situation in June
First, let's look back to the situation in June. Coronavirus cases had been dropping since the start of the vaccination rollout. The number of daily new cases for the first time had fallen to as low as the numbers back in March of 2020 -- when the crisis was just starting. As a result, demand for testing declined. States closed some free testing sites, and Abbott cut production of its tests.
Then, only weeks later, coronavirus cases surged once again. The delta variant, which originally wreaked havoc in India, was gaining ground in the U.S. Hospitalizations and deaths also started to rise. States rushed to open testing sites.
Most recently, CVS Health pharmacies limited the number of at-home tests people can buy as demand skyrocketed. CVS' limit applies to Abbott's BinaxNOW test -- currently in short supply.
Demand for laboratory-based COVID-19 tests has soared to 1.5 million per day in mid-August from 250,000 per day six weeks earlier, Reuters reported.
So, what does this mean for Abbott? Initially, it's going to result in costs to ramp up production. But overall, the increase in demand for tests is a billion-dollar opportunity for the company. In the fourth quarter of last year, Abbott generated $2.4 billion in COVID-19 diagnostics sales. It's important to keep in mind that the BinaxNOW laboratory test earned authorization in August 2020 -- and the at-home version of the test won authorization at the end of the year. That timing limited their contribution to full-year earnings.
Elements supporting demand
Moving forward, these rapid tests could add more to Abbott's earnings. Right now, many elements are pushing people to get tested. First and foremost, growth in the delta variant. Experts anticipate other variants to follow. The demand for testing may ebb and flow as cases rise or fall -- but considering the regular emergence of variants, I don't see testing demand dropping permanently anytime soon. And after seeing how quickly the delta variant gained ground, governments may become more proactive about ordering tests to prepare for future strains.
The other elements supporting demand? Testing requirements from schools and workplaces. And requirements for travel. Many of these places/situations now request the presentation of a negative COVID-19 test.
All of this means coronavirus testing wasn't just a temporary boost to Abbott's sales figures in 2020. The laboratory and at-home test kits could become a revenue source for many quarters to come. The main challenge for Abbott will be managing the production of its tests. As mentioned above, demand won't be a steady line higher. In the coming months, though, I would expect strength in testing -- thanks to the various sources of demand I've talked about.
Abbott shares have recovered since their big one-day drop back in June. The stock is now up 15% so far this year. The rest of Abbott's businesses are booming. In the latest earnings report, all four of the company's businesses showed double-digit revenue growth. And total sales rose more than 12% year over year -- that's excluding coronavirus testing sales. Considering the performance of all of Abbott's businesses, I'm optimistic about the shares over the long term. The coronavirus testing opportunity is big -- but for a company as strong as Abbott, it's just the icing on the cake.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 9, 2021
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. The delta variant, which originally wreaked havoc in India, was gaining ground in the U.S. Hospitalizations and deaths also started to rise. Most recently, CVS Health pharmacies limited the number of at-home tests people can buy as demand skyrocketed. | You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. Most recently, CVS Health pharmacies limited the number of at-home tests people can buy as demand skyrocketed. It's important to keep in mind that the BinaxNOW laboratory test earned authorization in August 2020 -- and the at-home version of the test won authorization at the end of the year. | You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. States closed some free testing sites, and Abbott cut production of its tests. It's important to keep in mind that the BinaxNOW laboratory test earned authorization in August 2020 -- and the at-home version of the test won authorization at the end of the year. | You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. Demand for coronavirus tests had started to sink. So, what does this mean for Abbott? |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.